CAPLIN POINT®
Laboratories

Caplin Point Laboratories Limited
Regd. office: Ashvich Tower, 3rd Floor,
No.3, Developed Plots Industrial Estate, Perungudi, Chennai – 600096.
Phone : +91 44 24968000 / +91 80127 72888 / +91 44 71148000
E-mail : info@caplinpoint.net / Website : www.caplinpoint.net
CIN : L24231TN1990PLC019053

September 03, 2021

BSE Limited
Department of Corporate Relationship
1st Floor, New Trade Ring, Rotunda Building
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code: 524742

National Stock Exchange of India Ltd.,
Department of Corporate Services
Exchange Plaza, 5th Floor,
C-1, Block G,Bandra Kurla Complex,
Bandra (E),Mumbai – 400 051
Scrip Code: CAPLIPOINT.

Dear Sir/Madam,

Sub: Annual Report for the Financial Year ended March 31, 2021 – Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

This is further to our letter dated August 5, 2021 wherein the Company had informed that the 30th Annual General Meeting (AGM) of the Company is scheduled to be held on Tuesday, September 28, 2021 through Video Conferencing / Other Audio-Visual Means, in accordance with the relevant circulars issued by Ministry of Corporate Affairs and Securities and Exchange Board of India (SEBI).

In terms of the requirements of Regulation 34(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the Annual Report of the Company, for the financial year 2020-21, which is being sent through electronic mode to the Members.

The Annual Report, also containing the Notice of AGM is enclosed and the same is uploaded on the Company's website at http://www.caplinpoint.net/investor.aspx and on the website of NSDL at www.evoting.nsdl.com.

This is for your kind information and records.

Kindly acknowledge the receipt.

Thanking You,

Sincerely yours,
For **Caplin Point Laboratories Limited**

Dinesh

Dinesh R G
Company Secretary

Encl: A/a

CAPLIN POINT®
Laboratories

CAPLIN POINT LABORATORIES LIMITED

Annual Report 2020-21

Caplin Point Laboratories Limited
Corporate Office, Chennai (India)

Addressing all concerns, of all concerned

> "The pandemic has put a premium on our concern for health (people) and also the health of the concern (Caplin Point)"

A Concern for health

At Caplin we believe that no amount of money can buy a life and no regret can change the past. The pandemic has put a premium on our concern for health (people) and also the health of concern (Caplin Point). Hence the energized focus on our people's safety and business continuity are our astute concerns for health.

- As humans, we are treading on an unchartered path owing to the ongoing pandemic. Consequently, we all are going through a period of deep concern.
- Concern for our health and that of our loved ones.
- Concern for our livelihood and our businesses.
- Concern for the society at large as it battles on.
- At Caplin Point, we are concerned about people who touch our lives and of the lives that we touch every day.
  - Those of our employees.
  - Our customers.
  - Other stakeholders.
- At this point, it gives us immense satisfaction to announce that we have addressed these concerns, rather remarkably.
- While we continue on our mission to provide affordable medicines to the underprivileged by deploying pathbreaking technologies and business models, we have managed to carry on with our operations with minimal disruptions. And all this without compromising the health and safety of our human capital.

After all, we are in this together. And what concerns one, concerns all.

Across the Pages

Scan above code to Download
Caplin Point Laboratories Limited
Annual Report 2020-21

Forward-looking Statement

In this annual report, we have disclosed forward-looking information to enable investors to comprehend our prospects and take informed investment decisions. This report and other statements – written and oral – that we periodically make, contain forward-looking statements that set out anticipated results based on the management's plans and assumptions.

We have tried wherever possible to identify such statements by using words such as 'anticipates', 'estimates', 'expects', 'projects', 'intends', 'plans', 'believes' and words of similar substance in connection with any discussion on future performance.

We cannot guarantee that these forward-looking statements will be realised, although we believe we have been prudent in our assumptions. The achievement of results is subject to risks, uncertainties and even inaccurate assumptions. Should known or unknown risks or uncertainties materialise, or should underlying assumptions prove inaccurate, actual results could vary materially from those anticipated, estimated or projected.

We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

CORPORATE OVERVIEW

MANAGEMENT REPORTS

STANDALONE FINANCIAL STATEMENTS

CONSOLIDATED FINANCIAL STATEMENTS

NOTICE

Design and Purpose

The Covid-19 pandemic is a relevant time to re-design the business model so as to enable Caplin Point to thrive during and after the pandemic. Our business was believed and conceived for the purpose of catering to the Bottom of Pyramid (BoP), Healthier and Happier with quality medicines at affordable cost.

With this context, we set out to create our "Stock and Sale Model" next to customers thereby returning patients to their erstwhile health with speed, economy, convenience and completeness.

At Caplin we responded to the reality with design thinking.

Crisis or mega crisis is another situation to be managed.

Significant Silver Bullets

- When other companies sold generics to importers in LATAM, we replaced the importers and became the importers in smaller geographies of LATAM.
- When the local LATAM companies supplied generics to distributors and wholesalers, we supplied generics directly to semi-wholesalers and retailers to increase the profit and cash flow by selling quality products at affordable price.
- When other companies didn't create any differentiation to the retailers, we made them the digital differentiators with our web portal.
- When others saw crime and violence, we saw opportunity.
- When others looked at poor as poor, we looked poor as customers.
- When other competitors told that we would become part of BoP, we plugged the gaps and became the star performer at the BoP (Bottom of Pyramid).
- When other Companies sold generics for survival in semi-regulated markets, we created sustainable superiority for our generics with business model differentiation.

During the pandemic, we rose to various challenges

- We reinforced our warehousing.
- We stocked larger.
- We worked closer with pharmacies.
- We analysed health trends.
- We customized our portfolio.
- We listened to consumers.
- We widened the concern for health.
- We adopted an IT based AI portal.
- We entered new markets.

Knowing is useless in a world where Google knows everything. But it is doing...

Caplin Point aims to create new niches in the markets of our presence. Looking ahead, we envision implementing our unique business model to ensure that everyone in the market with Caplin's presence has access to quality medicines at affordable prices.

The mission of Caplin Point is to innovate constantly to change the rules of the game and not merely compete in the game as it is innovation that distinguishes a leader from a follower.

HISTORY IS WRITTEN BY THE RULE BREAKERS

Caplin Point was established in 1990. The company set out to manufacture a range of ointments, creams and external applications. The company was listed in 1994, the IPO was oversubscribed by 117 times, proceeds of which were deployed in a manufacturing facility in Pondicherry. The promoters exposed their lives to physical risk when they ventured into war-affected countries to market pharmaceutical products. Caplin Point deepened its presence in the emerging markets of West Africa, Latin America and the Caribbean to market finished formulations, arguably the first Indian company to venture into these markets.



Our business is about making a difference

Caplin markets pharmaceutical products in the emerging markets of Latin America and Africa. The company has state-of-the-art facilities that manufacture a complete range of finished dosage forms. The Company entered regulated markets like US through its subsidiary company Caplin Steriles Limited. The business ranges from the manufacture of formulations at one end and addressing new complex areas in some of the most demanding global markets at the other.

WE ARE DRIVEN BY A COMBINATION OF PROMOTER AND PROFESSIONAL INTERESTS

Caplin Point is stewarded by Mr. C. C. Paarthipan, Non- Executive Chairman and Dr. Sridhar Ganesan, Managing Director, Mr. Vivek Partheeban, Chief Operating Officer, Mr. Ashok Partheeban, Head Latin American Operations, Dr. N Subramanian, Director and Head Research and Development, Caplin Steriles. They are supported by competent technical and managerial professionals. The Board of Directors does not have any member of the promoter's family (apart from the Chairman). The Company has 1675 employees as on 31st March 2021, 20% of which are R&D personnel, comprising scientists, laboratory technicians, clinical research associates, biochemists, chemists, among others.

WE ARE ADDRESSING THE RELATIVELY UNMET NEEDS OF SOCIETY THROUGH A WIDE GEOGRAPHIC PRESENCE

Caplin markets a wide spectrum of pharmaceutical formulations and therapeutic segments in 23 countries. In addition to LATAM and Africa, the Company is now serving the US, European Union and other regulated markets also.

Our manufacturing facilities are state-of-the-art, audited and certified.

The company manufactures products in its state-of-the-art manufacturing facilities one among which is for injectables approved inter-alia by EU-GMP, INVIMA, Colombia, Anvisa, Brazil and US FDA.

WE ARE INVESTING DECISIVELY IN OUR FUTURE

Caplin Point attracted investment in subsidiary Caplin Steriles Limited (CSL) from Eight Roads Ventures India III LP and F-Prime Capital Partners Life Sciences Fund VI LP (proprietary investment arms of Fidelity Group). The Compulsorily Convertible Preference Shares (CCPS) that were issued to the investor will be converted into CSL equity shares on the agreed terms.



Awards and recognition

Ranked #1 in India across industries for average R&D spend as a percentage of revenue in the past 5 years (CNBC-18. Dec 2020)

The Second Largest Wealth Creator among Mid Cap ending 2020 (Source: The Economic Times, 31.12.2020)

Empowering India Awards, 2019 (Category: Pharmaceuticals, healthcare and bio-technology)

The Economic Times Award for Excellence in Business Performance (Rs 100-750 crore standalone revenue category) 2019

Pharmexcil Outstanding Exports Award, 2018

The Economic Times - Family Business of the Year Award, 2018

IPF's Industrial Excellence Award, 2017

Financial Express CFO Awards, 2017, 2019

Nanayam Vikatan's Gold Phoenix Award to Mr. C C Paarthipan, 2017

Forbes Asia Best Under a Billion Award, 2016

Forbes Asia Best Under a Billion Award, 2015

Forbes Asia Best Under a Billion Award, 2014

Caplin addressing a large and growing therapeutic space

~3 billion USD addressable market size of products in the pipeline, under approval and approved in the US

~670 million USD addressable market size of products approved or under approval in the US

CAPLIN FOR LONG WAS A PLAIN VANILLA MANUFACTURER/ EXPORTER

- Market-led company
- Simple generic products
- Presence in two geographies (10 countries in Latin America and Francophone Africa)
- Introduced products that plugged market gaps
- Negative-working capital business

CAPLIN NOW EVOLVING INTO AN END TO END PHARMA COMPANY

- Technology and research-led marketing company
- Mix of generics, branded generics, specialty molecules and injectables
- Launching specialty niche products to create new markets across therapies
- Presence in two geographies (23 countries in Latin America and Francophone Africa)
- Prudent use of credit to enhance market share and remain cash surplus
- Extended to regulated markets like USA (plans for Canada, Australia, China and Brazil)

Caplin caring for patients through a wide product mix

THE BIG NUMBERS

4,000+ Products registered

650+ Pharmaceutical formulations

36 Therapeutic sections

Revenue by business segments



Revenue by channel



Our state-of-the-art facilities and what they produce

CP I PLANT, SUTHUKENY, PUDUCHERRY

Generics and branded generics

- Liquid injections in vials, ampoules, pre-filled syringes and lyophilized injections and emulsion injections.
- Tablets
- Capsules
- Liquid orals (syrup and suspension)
- Soft gelatin capsules
- Suppositories and ovules

CP IV PLANT (CAPLIN STERILES LIMITED), GUMMIDIPOONDI, CHENNAI

Injectables and ophthalmic

- Vials - Liquid, Lyophilized, Emulsions & Suspensions
- Opthlmic Products - Solutions, Emulsions & Suspensions
- Lyophilized vials –under implementation
- Pre-mixed bags-under implementation

ANNUAL PRODUCTION CAPACITY-CURRENT/UNDER IMPLEMENTATION (CP - IV)

Dosage form	Annual Capacity
Liquid in Vials - Line 1	15 million units
Liquid in Vials - Line 2	35 million units
Ophthalmic - Line 3	7 million units
Pre-Mixed Bags - Line 4	4 million units
Liquid & Lyophilized Vials - Line 5	45 million units
Emulsion Vials - Line 6	45 million units
Pre-Filled Syringes - Line 7	16 million units
Total	**167 Mn Units**



CAPACITY-CURRENT/UNDER IMPLEMENTATION

Liquid vials
95 Mn units, (includes Emulsions and Suspension injectables)

Ophthalmic
7 Mn units (includes Emulsions and Suspension ophthalmic)

Pre-filled syringes
16 Mn units

Pre-mixed bags
4 Mn units

Liquid and Lyophilized vials
45 Mn units

Caplin invested in Forward - Looking

Research & Development capabilities

The company ranks #1 in India across industries for average R&D spend as a percentage of revenue in the past 5 years*

5
Numbers of dedicated facilities (three DSIR-approved and two under approval)

₹1.6
billion capital expenditure in these facilities

6%
R&D spend as a % of revenues, 2020-21

25%
Total R&D spend (capital expenditure plus operating expenditure) as % of FY21 PAT

340
Number of R&D professionals, with 27 PhDs

52
Products launched in the three years ended FY 2020-21

22
Number of APIs (to be used in backward integration) for which R&D has been completed

*(source-CNBC-18 -31st Dec 2020)







Our transforming personality

was increasingly visible across every successive quarter of a challenging 2020-21

THE FINANCIAL HEALTH OF OUR BUSINESS

Year, 2020-21	Q1	Q2	Q3	Q4	Total
Revenues (Rs cr)	246.57	269.88	280.21	288.17	1084.83
EBIDTA (Rs cr)	78.09	89.19	89.75	95.15	352.18
Profit after tax (Rs cr)	54.55	62.83	66.14	67.92	251.44
Cash profit (Rs cr)	61.15	69.79	74.37	79.48	284.79

THE FINANCIAL HYGIENE OF OUR BUSINESS

Year, 2020-21	Q1	Q2	Q3	Q4	Annual
EBIDTA margin %	31.67%	33.05%	32.03%	33.02%	32.46%

How we have grown consistently in the last few years



Note: Above mentioned number is Total revenue including Other income.

REVENUES

Definition
Growth in sales net of taxes (if any)

Why is this measured?
It showcases the Company's ability to enhance sales, a number that can be compared with sectoral peers.

What does it mean?
Aggregate sales increased 19.9% to Rs. 1,084.83 crores in FY2020-21 due to various business-strengthening initiatives (detailed in the report)

Value impact
The company grew faster than the sectoral average, which resulted in a growth in market share in FY2020-21



EBITDA

Definition
Earning before the deduction of fixed expenses (interest, depreciation, extraordinary items and tax)

Why is this measured?
It is an index that showcases the Company's ability to generate a surplus following the expensing of operating costs.

What does it mean?
It helps create a robust growth engine, a large part of which could be available for reinvestment

Value impact
The Company generated an attractive growth in EBIDTA despite sectoral challenges



NET PROFIT

Definition
Profit earned during the year after deducting all expenses and provisions

Why is this measured?
This measure highlights the strength of the business model in enhancing shareholder value

What does it mean?
It ensures that adequate surplus is available for reinvestment in the company's operations.

Value impact
The Company reported a 16.9% increase in net profit in FY2020-21 following all-round business-strengthening.



ROCE (%)

Definition
It is a financial ratio that measures a company's profitability and the efficiency with which its capital is employed in the business

Why is this measured?
ROCE is a useful metric for comparing profitability across companies based on the amount of capital they use – especially in capital-intensive sectors.

What does it mean?
Enhanced ROCE can influence valuation and perception.

Value impact
The Company achieved an ROCE of 30% on a higher base of Rs.1,067 Cr Increase of Rs.310 Cr over 2019-20

ROCE for FY 2021 is on a higher base of Rs. 1067 Cr (being the average capital employed) as against Rs. 293 Cr in FY 2018. (3.5 fold increase in Capital employed)



NET WORTH

Definition
This is derived through the accretion of shareholder-owned funds

Why is this measured?
Net worth indicates the financial soundness of the company – the higher the better.

What does it mean?
This indicates the borrowing capacity of the company and influences the gearing (which in turn influenced the cost at which the company can mobilize debt).

Value impact
The Company's net worth strengthened 25.80% during the year under review.

How we will emerge in 2021-22 and beyond

In a span of six years the top line of 2015-16 has become the bottom line of 2020-21.



Presently the Company stands at 39th position among the pharma companies in India.*

Now we plan to achieve the goal to reach one among the top 25 pharma companies in India in the next 6 years.

*(Source: Chronicle PharmaBiz dated 08.07.2021).

EMERGING MARKETS

- The Latin American business continued to report robust growth in sales, cash flows and profitability
- The Company received large tender orders worth $18 million in two markets
- The Company reported 60% revenues from private market sales to distributors, 20% from sales to pharmacies/retail and 20% from institutional sales
- The Company continued to build its cash reserves to fund the next round of capital expenditure (Oncology plant for injectable and OSD; API plant)
- The Company commenced injectable exports to Mexico and Brazil in the last quarter
- The Company has started R&D for API and Oncology formulations in existing and new markets. The registrations for formulations are in progress.
- The Company's e-commerce revenues (through platform QuetenX, part of 10X Healthcare portal) increased 37% when calculated YoY; marketed 440 SKUs to around 1,000+ unique customers in Guatemala, Nicaragua, Honduras and Ecuador.
- The Company's CRO wing Amaris Clinical's US FDA audit is expected shortly; two ANDAs were filed through a partner; Bioequivalence / Bioavailability studies were done from this site.

US AND REGULATED MARKETS

- The Company's US sales increased 31% YoY, despite the pandemic
- The Company received four ANDA approvals since January 2021, increasing approved ANDAs to 15 (ten under Caplin's name and five through partners)
- The Company launched eight products in US; four products are ready for launch and three are likely to be launched before December 2021
- The Company has agreements in place for the registration of products in Canada, Australia and Brazil; revenues are likely to be generated in 18 to 24 months.
- The Pre-Mix Injectable Bag line is ready for installation; Exhibit batches are planned for the second half of FY 2022
- The design /detailed engineering for Phase 2 of Injectable Plant is complete. Overall Project cost is Rs 140 Cr and it will include 2 Vial lines, one Lyophilizer line, one Pre- filled syringe line and provision to add another Pre-mix bag line
- The Company built secondary source APIs for existing ANDAs; seven were completed and 16 were under development (for the primary and secondary source).
- The Company targets a US front-end presence in 2023, by which time 30+ ANDAs are likely to be approved/under review.
- The development pipeline remained robust; 45+ ANDAs were under development with an market of ~$3 Billion.

Chairman's Statement

Perspective – "Rivers Never Go Reverse"

"Looking ahead gives you opportunities, Looking back gives you regrets."

"Chance, Choice and Change made all the difference at Caplin".

OVERVIEW

An effective life is all about learning, listening, evolving and leading life with Self Awareness and Self Belief. The right choices with a dynamic change will lead to success and happiness. If it is left to chance due to cognitive limitations, then you learn little, listen half, understand/ aware a quarter and think zero which creates a competitor in our "Inner Olympic" and the competitor is our own Sub Conscious mind. That is where one sees a Tempest in a Tea Pot or Storm in a Tea Cup. As the negative tenant is already anchored in the subconscious website, the inner competitor attracts negative companions for the doomsday journey. The Solution Thinkers use the right choices to change the life and business to the positive path.

We are still managing the aftermath of Covid 19 pandemic. Vaccination and Covid appropriate discipline are the two key elements of self- care and health care of our people. The only concern for health is the vaccine hesitancy due to a wrong decision supported by false beliefs. However, our concern for health of our people is to help them for vaccination and provide the necessary nutraceuticals for immunity which is almost completed in our work places. For most Companies, the challenging environment has caused significant decrease in revenues and profits, however, we addressed the important priorities and created a framework to manage the end to end supply chain., production network, and also maintained inventories in our warehouses without any stock out situations.

THE ELEMENT OF CHANCE

Our compassion and empathy did not originate one fine morning in a fit of enlightened thinking. It was forged during my years of struggle even before Caplin had been formed. The key elements of chance in my life.

- Born in resource – poor settings
- Low self-esteem issues as a child and adolescent (the intellectual and emotional ambience of the childhood and adolescence in the home is the main missing link)
- Lack of guidance for awareness, leading to false beliefs
- Inherited DNA resulting in mercurial temper.
- Poverty and ignorance led to negative mindset
- In the end, lack of cognitive skills did not help me to understand how to lead a proactive life.

Worked in various places, led an unexamined life, anger and argumentative negative mind-set did not help me to fit into any organization, finally started a business with an amount of Rs.5,000/- by default, rather took a chance for survival.

- Trivial pursuits resulted in random success and repeated failures in business.
- Missing the essential tools in the tool kit except my hammer. (Weakness) "when you have hammer in the hand, everything will look like nails"
- Surrounded by partners and others who could not raise above the status -quo and mediocrity.
- Random success is the completion of the public issue with 117 times over subscription.
- Entire proceeds were deployed in a 51,000 Sq. feet factory in Pondicherry, then the only facility in Tamilnadu and Pondicherry to have all the segments of pharmaceuticals in 1994.
- Did not balance between consolidation and expansion.
- Opinion bias created friction between the promoters and professionals that resulted in huge quality issues.
- Repeated failures led to straitened circumstances and strenuous circumstances.
- Wanted to be the voice of the Bottom of the Pyramid (BoP) but became specialist commentator of poverty.

The Axis of Being was shifted from failure to survival, later the path forward for growth. Learnt the Ropes of Business and positive language, vocabulary, beliefs that led to effective habits and life started moving towards the road well-travelled, supported by the right choices in the form of competent professionals.

- Had a chance to read "Think and Grow Rich"
- First step to change in my thought process and awareness
- Developed the habit of reading self-help books and these books did the hand-holding of the choices of life and business.

Caplin became a NPA, Rs. 10/- per Share quoting less than a rupee.

Understood the responsibility of turn-around in life and business.

Inherited Grit and Handholding (Mentoring) of the books helped me to take the Road less travelled, the toughest parts of Africa (war zones), later to Central America.

Change in mind-set and skill set also slowly changed the Axis of life and business.

The Axis of Being was shifted from failure to survival, later the path forward for growth. Learnt the Ropes of Business and positive language, vocabulary, beliefs that led to effective habits and life started moving towards the road well-travelled, supported by the right choices in the form of competent professionals.

In the meantime my Next-Gen joined me to take the physical risk to change the fortune of the Company, the Inflection point for choice and change.

THE POWER OF CHOICE

When my life does not please me, the choice is to create a new normal. So I created my New Life. The Life and Business based on Choices.

Self-Awareness and Self-Belief are the Key starting points for disciplined mind-set.

Discipline and Determination made the life different to create the differentiation in life and business.

The stock and sale next to the customer

Management Speak

really helped the Company and the Consumers even during the Pandemic.

When others are catering to the creamy layer of the market, our choice is to cater to the middle and bottom of the pyramid. This created a creamy layer to our cash flow. Today our cash & cash equivalents of the company as at June 30, 2021 is Rs 522 Cr.

As an important choice, we chose to outsource formulation from China, when others sourced API from China. Prices of formulation of Pencillin and Cephalosporin are always lesser compared to Indian manufacturers in the international market. This created A RADICAL EDGE to Caplin Point. We also started QC labs in China and Guatemala to maintain / reassure the quality of our products which is the life line of our business.

Our choice of shift in mind-set from "Reactive-victim mode" to "Responsive-creator mode": the road less travelled to see the growth momentum for Caplin Point.

We took the choice of creating an USFDA injectable facility to export products to US which is a rarity among the size of our peer companies.

- Learnt that Nothing happens by chance, by fate, but it is your choice that creates your own actions and fate. That is Karma.

CHANGE DYNAMICS:

If opportunity doesn't knock, be a change agent and build a door. "If you don't know how to handle change and change management by yourself, then you are handling everything else by default". The business that I started by default, has been changed to the business by Design with the help of competent Professionals today.

We are the only company of our size in India, crossed INR 1000 crore exports, by selling Generics in Semi - Regulated Markets of LATAM.

We also have the same distinction of creating an injectable factory with USFDA approval, exporting to USA with our own products, not just being a CMO.

Other Notable changes from the Vulnerable to Valuable Phase as follows,

- 2 API R&D (For Regulated Markets such as USA & Others.)
- 1 Injectable R&D - (For Regulated Markets such as USA & Others).
- 1 Oral Solid Dosage R&D
- 1 Injectable R&D – For ROW Market.
- 1 CRO, is all set for the USFDA virtual Inspection
- Also in the process of establishing front end presence in USA and Consolidation through Backward Integration of API.

TURN AROUND COMPANY.

- The second largest wealth creator in the last Decade –Source: The Economic Times Dec 31st 2020.
- No.1 in R&D Spend – Source: CNBC – TV 18 Dec 31st 2020.

Indifferent set-up of Erstwhile Team to a differentiated new set-up for the path forward in all walks of Caplin Business, creating a "cultural-calendar" for Covid appropriate and Business appropriate behaviours. Hence need to have keen eyes on the all-important disciplined mind-set for Integrity, Quality and Deliverables, attracting the right Talent and Skill sets with ESOP and Freedom to operate for professionals.

Change created a team of honeybees looking for flowers even in the midst of dirt, unlike the insects who prefer dirt.

OUTCOME

The interplay of priorities – chance, choice and change helped Caplin Promoters and professionals to create the differentiated business model. As a result, Caplin may not be the largest in its sector, it is unique. Although small is beautiful, big is necessary. Our choices slip through the cracks when there are too many competing demands for our time, hence our energized focus is on high impact activities to produce highest returns to our shareholders. Caplin always treaded a difficult and different path to unlock maximum value to all our shareholders.

I am optimistic that Caplin is at the bottom-end of a J-curve that enhances value for all the stakeholders of the Company.

C C Paarthipan
Chairman

DR. SRIDHAR GANESAN, MANAGING DIRECTOR SPEAKS ON HOW CAPLIN HAS ENHANCED SHAREHOLDER VALUE

Caplin has created a validated value-accretive model: profitable growth, sustained reinvestment, growing scale, each subsequent project more profitable than the other and attractively short payback tenures

WEALTH CREATOR

759 Rank among 1000 pharma companies of the world (Source: Torreya)

39 Rank among Indian Pharma Companies (Source: Chronicle Pharmabiz dated 18.07.2021)

OUR VALUE-ACCRETIVE BUSINESS MODEL

India is at the cusp of a growth in its knowledge capital, entrepreneurial capability, and encouragement to manufacture within India, global exposure, start-up culture and capital availability.

This is creating an unprecedented opportunity for forward-looking companies like Caplin.

Caplin has created a validated value-accretive model: profitable growth, sustained reinvestment, growing scale, each subsequent project more profitable than the other and attractively short payback tenures.

Caplin's business model is marked by aggressive yet protected growth; rapid scale up has been complemented by near-annuity incomes, resulting in business predictability.

PROMISE MADE

Caplin's 2015 topline would be its 2021 bottom Line

PROMISE DELIVERED

Rs. 254.80 cr, Caplin's top line, 2014-15 became Rs. 251.43 cr, Caplin's bottom line, 2020-21

OUR VALUE-CREATION PRIORITIES

- Focus on niche therapies, products and geographies
- Asset-light or capital-light business approach
- Extend beyond me-too products to complex and high-end products.
- Create marketing as an activity of excellence

OUR VALUE-CREATION OUTCOMES

- Cash corpus 39% of total capital employed as at March 31, 2021
- EBITDA margin in excess of 20% in every single year of the last 9 years
- EBITDA CAGR growth of 41% in the last ten years
- Capital expenditure of Rs. 408 Cr incurred in last 10 years made from internal accruals

HOW OUR VALUATION STRENGTHENED

Capital appreciation

Rs. 2,140 Cr, market capitalization as on 31st March 2020.

Rs.3,052 Cr, market capitalization as on 31st March 2021.

HOW WE INTEND TO ENHANCE VALUE GOING AHEAD

- Focus on cash flows; top line and profit consistency
- Add a new revenue stream every year
- Maintain cost, quality, integrity, safety and security standards
- Prudently recruit specialized competencies
- Disciplined capital allocation for projects
- Fast-track registrations to accelerate viability of new projects
- Adopting to New Normal business practices
- Take advantage of technological communication process to be near the customer, employee and stakeholders

Ashok Partheeban, Head Marketing at LATAM speaks:

You are changing the definition of you." When I read this in a book, I learnt the importance of change. When you change the definition of your life, you are overriding your genetic programming with all its years of ingrained habit. This very thought helped me understand the culture in Latin America. Success came in bits and pieces initially, however, the focus has always been catering to the underprivileged, which created the privilege of being the No.1 Indian company in Central America

Caplin Point entered Latin America to address the under-penetration of affordable, accessible and available pharmaceutical products. We continue to stick true to this philosophy by creating and capturing value at the bottom of the pyramid. Even today, much of Caplin's growth comes from the smaller markets of Latin America, while we gradually move to larger markets such as Mexico, Chile, Colombia and Brazil, as part of our contiguous expansion in the region.

Our business today is de-risked because of our presence in multiple countries and having a wide array of customers. We reach over 14,000 Points Of Sale in Latin America on a daily basis. Why we call this de-risked is because we don't have a handful of customers that we're over-reliant on, and we're also not over-reliant on a single market giving us majority of the revenues.

We're actively working on establishing and promoting QueTenX, which is our healthcare portal that automates Pharmacies and Distributors in the countries of our presence. We're glad to say that we have over 1000 unique customers on our portal generating over 6700 sale orders regularly. We hope to expand QueTenX to all countries of operation within the next couple of years.

Our sales breakup is around 60% to Wholesalers and smaller distributors, 20% to Pharmacies and 20% to Institutions, the latter going up marginally in the last year due to Covid-related emergency procurements from all countries. We're still at around 75/25 breakup when it comes to Generics vs Branded Generics. We expect this trend to continue for the short to mid-term.

Some of the key areas we're focusing on to further augment profitable growth in the current and newer markets of entry are:

- Hospital Injectables
- Psychotropic and Psychiatric products
- Oncology products
- Branded Pharmaceutical Softgels
- Recently off patent niche Oral Solid Dosages.

The R&D works for all the above are under progress and we expect to make significant inroads into these segments in the next 24 months.

"You are changing the definition of you." When I read this in a book, I learnt the importance of change. When you change the definition of your life, you are overriding your genetic programming with all its years of ingrained habit. This very thought helped me understand the culture in Latin America. Success came in bits and pieces initially, however, the focus has always been catering to the underprivileged, which created the privilege of being the No.1 Indian company in Central America.

Vivek Partheeban, C.O.O speaks on our US FDA Injectable Business:

We have completed the design drawings and detail engineering of the plant lay out and we are planning to set up an oncology plant for tablets and capsule in Phase 1 and injectables in Phase 2 for both Regulated and ROW markets.

"Man needs to choose, not just accept his destiny. When you make the choice, you change the future"

I went to China with a differentiated purpose of sourcing formulations, unlike other companies that were sourcing APIs only. When we found generic business as pedestrian in nature, we created a first-mover advantage of exporting formulations from China to LATAM, which made Caplin a fast-mover in our markets.

When it comes to US, we're making consistent progress in terms of product approvals, with 10 ANDAs in Caplin Steriles' name and 5 more through partners. Despite temporary slowdown in equipment qualification for our second Vial line in 2020, we were still able to finish the year with almost 31% higher revenue. With more launches in 2021/22, we expect current year revenues to comfortably pass 2020/21. We're actively drawing up business models and scouting for candidates for our entry into the front end in the US in the near term.

Our API R&D team has already completed lab scale development of 22+ APIs, most of which we're planning to use as backward integration for our ANDAs. While our own API plant is getting ready, we're looking to tie up with existing FDA approved CMOs to file the DMF and start commercials.

Capacity expansion at Caplin Steriles (funded through a loan from parent company Caplin Point)

- Pre-Mix Injectable Bag line ready for installation with Exhibit Batches planned in Jan/Feb 2022
- Plans underway to add 2 more Vial lines, one with high volume Lyophilization capacity and another dedicated line for Injectable Emulsions
- Pre-Filled syringe line to be added in Phase 2 as well

ONCOLOGY ENTRY (FUNDED ENTIRELY FROM INTERNAL ACCRUALS)

Through a bank auction, we had recently acquired buildings measuring 1,52,000 square feet, which was built for a pharmaceutical company. We have completed the design drawings and detail engineering of the plant lay out and we are planning to set up an oncology plant for tablets and capsule in Phase 1 and injectables in Phase 2 for both Regulated and ROW markets. The process machinery ordering has been completed and we are confident of completing and starting the commercials in 2022.

Dr. N Subramanian, Director and Head - R&D for Sterile Formulations, Chennai speaks:

What I like about Caplin: open culture, no visible hierarchy, transparent in people management, quick decision making, excellent work environment, unmatched career prospects and strong management support for research.

"After 20 years in Pharmaceutical R&D sector, I joined Caplin: for its vision for the future through research and its ingenious and unique approach in looking at LATAM and other emerging markets, when every Indian pharma company was looking towards US. What I like about Caplin: open culture, no visible hierarchy, transparent in people management, quick decision making, excellent work environment, unmatched career prospects and strong management support for research. Best of all, we are graduating from research in simple products (solution injections) to complex products that are difficult to develop and manufacture."

"We started working on products in the injectables and ophthalmic spaces through novel delivery systems like emulsion, suspension, liposomes and nano-emulsion products that are difficult to manufacture; few global companies have filed these products in the US. Earlier, we possessed manufacturing capabilities in conventional injections and ophthalmics; now we possess capabilities to handle emulsion and suspension products using sophisticated equipment. We are into the manufacturing of ready-to-use injectables in infusion bags, which is not done by any of the Indian Companies of our size. We are looking to get into the pre-fill syringe product line as well in near future. We are one among the very few Indian companies, who possess the manufacturing frame work for all type of injectables (vials, lyophilized, infusion bag line and pre-fill syringe).

This is what makes Caplin different: an appetite for growth."

Our Products










Management Discussion and Analysis

GLOBAL ECONOMIC OVERVIEW AND OUTLOOK

The COVID-19 pandemic has disrupted lives across the continents and communities and also negatively affected global economic growth in 2020, beyond anything experienced in nearly a century. The COVID-19 pandemic continues to be a highly personal, individual experience that is also an unprecedented globally-shared phenomenon with wide-ranging repercussions. The contraction of activity in 2020 was unprecedented in living memory in its speed and synchronized nature. But it could have been a lot worse, although difficult to pin down precisely, certain estimates suggest that the contraction could have been three times as large if not for extraordinary policy support. Much remains to be done to beat back the pandemic and avoid divergence in income per capita across economies and persistent increases in inequality within countries.

(Source: CRS report dated July 21, 2021)

However, despite the adverse impact seen during year 2020, the world economy is experiencing an exceptionally strong but highly uneven recovery. Global growth is set to reach 5.6 percent in 2021—its strongest post-recession pace in 80 years—in part underpinned by steady but highly unequal vaccine access. Growth is concentrated in a few major economies, with most emerging market and developing economies (EMDEs) lagging behind: while about 90 percent of advanced economies are expected to regain their pre-pandemic per capita income levels by 2022, only about one-third of EMDEs are expected to do so. In low-income countries, the effects of the pandemic are reversing earlier gains in poverty reduction and compounding food insecurity and other long-standing challenges.

The global outlook remains highly uncertain, with major risks around the path of the pandemic and the possibility of financial stress amid large debt loads. Controlling the pandemic at the global level will require more equitable vaccine distribution, especially for low-income countries. In addition to the necessary efforts to pursue widespread vaccination, policy makers face a difficult balancing act as they seek to nurture the recovery through efficiently allocated fiscal support while safeguarding price stability and fiscal sustainability. Policy makers can also help entrench a lasting recovery by undertaking growth enhancing reforms and steering their economies onto a green, resilient, and inclusive development path. Prominently among the necessary policies are efforts to lower trade costs so that trade can once again become a robust engine of growth.

INDIAN ECONOMY

India's Gross Domestic Product (GDP) contracted 7.3% during FY 2020-21 as against growth of 4.2% during FY 2019-20 mainly on account of the impact of the COVID-19 pandemic.

As indicated by provisional estimates released by the National Statistical Office (NSO), India posted a V-shaped recovery in the second half of FY 2020-21. As per these estimates, India registered an increase of 1.1% in the second half of FY 2020-21; this was driven by the gradual and phased unlocking of industrial activities, increased investments and growth in government expenditure.

The economy of India grew 0.4% year-on-year in the last three months of 2020, slightly below market forecasts of a 0.5% gain. Still, it is the first expansion in three quarters as the government opened economic activities in phases from June after a coronavirus lockdown in late-March.

The economy of India grew 0.4% year-on-year in the last three months of 2020, slightly below market forecasts of a 0.5% gain. Still, it is the first expansion in three quarters as the government opened economic activities in phases from June after a coronavirus lockdown in late-March. On the expenditure side, both private (1% vs -8.3% in Q3) and public (7.2% vs -17.5%) spending rebounded. Gross fixed capital formation also returned to growth (5.9% vs -7%) while exports declined 1.7% (vs -0.1% and imports sank 2% (vs -16.9%). On the production side, gross value added surged 1%, boosted by a rebound in manufacturing (1.6% vs -1.5%), construction (6.2% vs -7.2%), financial, real estate and professional services (6.6% vs -9.5%). The contraction for financial year 2020- 2021 was estimated slightly higher at 8% from 7.7% which would be the biggest drop ever.

(Source: Provisional estimates released by the National Statistical Office (NSO)

INDIA : TREND - GROSS DOMESTIC PRODUCT (GDP) GROWTH RATE

The data clearly indicates that India was hit hard by the pandemic, particularly during the second wave of the virus during May - June of 2021. The sharp drop in GDP is one of the largest in the country's history, but this may still underestimate the economic damage experienced by the poorest households.

In the post-independence period, India's national income has declined only four times before 2020 – in 1958, 1966, 1973 and 1980 – with the largest drop being in 1980 (5.2%). This means that 2020-21was the worst year in terms of economic contraction in the country's history, and much worse than the overall contraction in the world.

The decline is solely responsible for reversing the trend in global inequality, which had been falling but has now started to rise again after three decades.

(Source:https://www.economicsobservatory.com/,Deaton,2021; Ferreira, 2021).

OVERVIEW - PHARMACEUTICAL SECTOR

The global pharmaceuticals market is expected to grow from $1228.45 billion in 2020 to $1250.24 billion in 2021 at a compound annual growth rate (CAGR) of 1.8%.

The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $1700.97 billion in 2025 at a CAGR of 8%.

North America was the largest region in the global pharmaceuticals market, accounting for 46% of the market in 2020. Asia Pacific was the second largest region accounting for 26% of the global pharmaceuticals market. Africa was the smallest region in the global pharmaceuticals market.

The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $1700.97 billion in 2025 at a CAGR of 8%.

In spite of the unprecedented disruption created by the COVID-19 pandemic, medicine spending growth will continue to be driven by traditional factors including patent expiries, launches of new medicines as well as changing volume demand particularly in emerging and lower income countries. As per the IQVIA report, the global medicine spending — the amount spent on purchasing medicines from manufacturers before off-invoice discounts and rebates — is expected to reach about USD 1.6 trillion in total market size in 2025, registering 3-6% CAGR. This excludes spending on COVID-19 vaccines. This estimate does not reflect the true spending level net of discounts and rebates; it is more helpful when focused on growth trends or volume metrics.

KEY IMPACTS OF COVID-19 ON PHARMACEUTICAL MARKETS

Economic impact: Pessimism affected pharmaceutical spending in countries with high medical expenditure.

Increase in symptomatic medicine demand: Increase in volume through retail channels for the short-term as people stored cough and cold medicines.

Minimal face-to-face interactions: Reduced face-to-face relationship impacted sales in the short term.

Travel restrictions and medical tourism: Lower number of medical tourists affected pharmaceuticals market growth.

Impact on innovation: Delay in new product launches could impact sales growth during the short term.

US PHARMACEUTICAL SECTOR

United States is the largest pharmaceutical market worth around $490 billion which represents 40.4% of the global sector size of $1.27 trillion. The country had the highest pharmaceutical per capita spending in the world with an average spending per person of $1,200.

Since 1980, US has been the leading player in research & development in the world and is estimated to invest $60 billion annually. The R&D efforts in the country have witnessed a significant surge to USD 71.4 billion in 2017 from USD 2 billion back in 1980. The US has continuously maintained the R&D intensity to the highest level, accounting more than half of the global R&D expenditure by US pharma giants.

(Sources: Pharmaapproach.com, Statista, phrma.org)

OVERVIEW – INDIAN PHARMACEUTICAL SECTOR

India is the largest provider of generic medicines globally, occupying a 20% share in global supply by volume, and also supplies 62% of global demand for vaccines. India ranks 3rd worldwide for production by volume and 14th by value. India has the highest number of US-FDA compliant Pharma plants outside of USA, and is home to more than 3,000 pharma companies with a strong network of over 10,500 manufacturing facilities.

The sector offers 60,000 generic brands across 60 therapeutic categories, The API industry is ranked third largest in the world.

- Expected to reach US$ 65 billion by 2024, and ~US$ 120-130 billion by 2030
- Market growth rate 10-12%
- Cost of manufacturing ~ 33% lower than western markets
- 18.7% year on year export growth

(Source: https://www.investindia.gov.in)

The Indian pharma industry has achieved significant growth in both domestic and global markets during the past five decades. From contributing just 5% of the medicine consumption in 1969 (95% share with the global pharma), the share of "Made in India" medicines in Indian pharma market is now a robust 80% in 2020. More importantly, during the same period, the country has also established leading position in the global generic pharmaceuticals landscape and is now known as the "Pharmacy of the world". Popularly called the "archetype of affordable healthcare," the industry has significantly contributed towards improving public health outcome, both in India and across the globe.

The pharma sector has been contributing significantly to India's economic growth as one of the top 10 sectors in reducing trade deficit and attracting the Foreign Direct Investment (FDI). The drugs and pharmaceuticals sector attracted cumulative FDI inflow worth US$16.54 billion between April 2000 and June 2020. The industry employs over 2.7 million people either directly or indirectly and ranks third in terms of volume and 14th in terms of value globally.

OPPORTUNITY AND THREATS

As per the trends so far, the COVID-19 pandemic is expected to have far-reaching effects globally. While it is difficult to predict with certainty the scale and spread of the Coronavirus disease, let alone its impact on international economics, politics and society, it is possible to systematically identify areas of potential vulnerability.

Policy makers are facing unprecedented challenges in financing health especially in low- and middle-income settings. Many health systems are already stretched and underfunded. They have been further constrained by the increasing number of COVID-19 patients demanding care as a result of the pandemic. It is difficult to predict how international economies will be affected over the coming months, when a so-called saw-toothed recovery is in play. Many geographies are already experiencing the second or third wave of the virus, resulting in new lockdowns and restrictions. Different industries have been differently affected by the virus. Consumer-focused industries like hospitality and travel sectors have been deeply impacted as leisure time is spent at home or closer to home. Technology companies have seen a resurgence given the role 4G and 5G networks, and devices play in connecting individuals when physical distance is a key requirement. Health and life sciences companies, meanwhile, remained relatively less affected by the virus. However, there are now growing signs of sales slowing down and impact of currency exchange. Additionally, certain parts of the value chain, namely research and development (R&D) and the supply chain have been heavily affected.

GLOBAL DISRUPTION IN THE SUPPLY CHAIN

There have been concerns around overdependence on China for active pharmaceutical ingredients (APIs) for quite some time now in India as well in the US and Europe. Last year a representative of the US Defence Health Agency reiterated the national security risks due to increased Chinese dominance of the global API market. During the last few months, most countries have experienced disruption in pharma supply chain because of their dependency on China for APIs and excipients. While this does not indicate an end to the global supply chain, countries and companies do have supply chain resilience as one of the near-term priorities. COVID-19 has accentuated issues like re-shoring, near-shoring and shortening supply chains.

INDIA: PREPARING TO LEAD IN THE POST-PANDEMIC WORLD

COVID-19 has clearly highlighted the importance of a strong health care system, the lack of which can put an entire nation's economy and society at risk. As India continues to fight COVID-19 and stabilize its economic growth trajectory, it is the right time for the country to apply learnings from the challenges and best practices that emerged during the pandemic. There is a need to swiftly develop the required healthcare infrastructure and make it available to the entire population. The Indian pharma industry has been a key contributor in improving the country's healthcare and economic outcomes. The pandemic has accelerated several opportunities and challenges for the industry. While the growing trust deficit with China presents an opportunity for India, there is increasing competition from other countries, such as Vietnam and Malaysia. India is also dependent on China for ~two third of its imports of bulk drugs or drug intermediaries.

To emerge as a winner in the post-pandemic world, the industry needs to continue building on its strength and at the same time make a giant leap towards innovation. New capabilities need to be introduced across the business functions to bring efficiencies and to help industry move up the value chain. Government also needs to provide the right enablers and business environment conducive for growth. This is an opportunity for the Indian pharma industry to consolidate on its advantages and undertake fundamental reforms to reignite innovation-led industrial growth to meet the target of US$130b by 2030.

WAY FORWARD: FOCUSING ON RESEARCH AND INNOVATION TO ACHIEVE GROWTH AMBITION

India is the third-largest manufacturer of drugs worldwide in terms of production volume, accounting for 10% of the global total. However, India accounts for only 1.5% of the total value of drugs produced worldwide, making it 14th ranked among manufacturing nations. This disconnect between India's relatively high share of volume and low share of value will only be bridged if India intensifies efforts in innovative R&D. India needs to develop short- and long-term research and innovation strategies with specific focus areas (such as biosimilars, complex APIs and generics, vaccines, and contract research). These focus areas would play to India's strengths and align with the nation's future ambition of moving up the product value chain to developing NCEs and potentially personalized medicines such as cell & gene therapies in the coming years. Strengthening India's research and innovation capabilities requires interventions across the dimensions.

(Source: EY FICCI Pharma Report 2021)

FINANCIAL OVERVIEW

FINANCIAL HIGHLIGHTS

(Rs. In Lakhs)

Financial Results	Standalone		Consolidated	
Particulars	**2020-21**	**2019-20**	**2020-21**	**2019-20**
Revenue from Operations	48,267.96	52,782.53	1,06,129.04	86,320.17
Other Income	1,861.80	6,597.13	2,354.22	4,133.37
Total Income	**50,129.76**	**59,379.66**	**1,08,483.26**	**90,453.54**
Profit Before Interest, Depreciation and Tax	**23,254.29**	**27,296.37**	**35,217.93**	**30,140.14**
Less: Finance cost	16.67	18.50	158.96	31.97
Less : Depreciation and amortization expenses	2,244.08	1,965.38	3,697.12	3,161.92
Profit Before Tax	**20,993.53**	**25,312.49**	**31,361.85**	**26,946.25**
Less: Tax Expenses	5,371.55	5,548.64	6,218.82	5,437.88
Net Profit	**15,621.98**	**19,763.85**	**25,143.03**	**21,508.37**
Less: Non-controlling Interest	-	-	916.41	7.57
Net profit attributable to the shareholders of the Company	**15,621.98**	**19,763.85**	**24,226.62**	**21,500.80**

- In line with company's commitment, Top line of 2015 becomes bottom line of 2021.
- Consolidated Total Revenue at INR 1085 Cr for 12MFY21, up 20% YoY, as compared to INR 905 Cr in 12MFY20
- Cash and Cash Equivalent at Rs 470 Cr at 31st March'21 as against Rs 284 Cr as at 31st March'20. Parent Company's Cash and Cash equivalent rises from Rs. 119 Cr in Mar'20 to Rs. 376 Cr in Mar'21, despite investment of Rs. 31 Cr into purchase of Land and Buildings for upcoming projects in 2021/22
- Cash flow From Operations (CFO) at INR 266 Cr in 12MFY21 as against INR 45 Cr in previous year
- Inventory stood at INR 179 Cr as at 31st March 2021 as against INR 238 Cr as at 31st March 2020
- Receivables stable at 95 days as at 31st Mar'21.

MORE INSIGHT INTO THE BUSINESS

Core business to grow at historical pace
Caplin's core business which is focused on Latin America and Francophone Africa is expected to grow at above industry-average pace with margins expected to improve with increased branded generics business

US Business to boost the growth
Aspirations to have exceptional compliance record and focus on niche products which continues to be in shortage in US market, Caplin believes US business to be one of it's primary engines that will drive growth

Backed by enhanced value chain
Backward and forward integration to help save cost, capture more market and control supply chain which is expected to boost earnings

Strong balance sheet
Caplin's DNA of remaining net debt-free and self-sustenance is highlighted by increasing cash surplus over the years. Strong Balance sheet of Caplin acts as an anchor for our long term vision

Expansion into other geographies and widening of the portfolio
Caplin plans to enter more regulated markets such as Canada, Mexico and Australia in the near to medium term horizon as well as expand its products portfolio.

FINANCIAL RATIOS

Below are some of the Key Financial ratios:

Particulars	Consolidated		Standalone	
	FY 2020-21	FY 2019-20	FY 2020-21	FY 2019-20
Debtors Turn Over Ratio	4.18	4.44	3.04	3.07
Inventory Turnover Ratio	2.26	3.00	8.25	10.38
Current Ratio	7.25	5.70	6.89	5.93
Interest Coverage Ratio	NA	NA	NA	NA
Debt Equity Ratio	0.01	0.04	0.00	0.001
Operating Profit Margin %	29.1%	29.8%	41.9%	42.7%
Net Profit Margin %	23.2%	23.8%	31.2%	33.3%
Return on Net worth % (RONW)*	23.6%	28.4%	23.0%	38.3%

* RONW for standalone: As compared to FY 2019-20, RONW for FY 2020-21 is lower by 15.3% mainly due to higher retained earnings.
* RONW for Consolidated: As compared to FY 2019-20, RONW for FY 2020-21 is lower by 4.8% mainly due to higher retained earnings.

> **The pandemic has accelerated several opportunities and challenges for the industry. While the growing trust deficit with China presents an opportunity for India, there is increasing competition from other countries, such as Vietnam and Malaysia.**

RISK MANAGEMENT

In this COVID-19 era, the business environment has become uncertain. The Company is in the second year since the onset of COVID-19, however, despite multiple disruptions due to lock downs and related curbs, the Company has been able to continue reporting strong numbers and registering impressive growth.

The Company has a well - established process of risk management which, inter-alia, includes identification of design gaps, analysis and assessment of various risks, formulation of risk mitigation strategies and implementation of the same to minimise the impact of such risks on the business and operations. The process ensures that new risks, which might arise, or the impact of existing risks which might have increased, are identified and a strategy is put in place for mitigating such risks.

The Company has a robust Enterprise Risk Management (ERM) framework which enables us to manage our risks better. It also tracks significant external developments and internal challenges to recognise new threats and their potential impact on our risk profile.

The major risks identified by the management are regulatory, competition, supply chain disruption, cyber & data security along with economic and political risks. A review of the risk management policy is carried out annually by the Risk Management Committee and the Board of Directors.

The Board of Directors of the Company directly oversee the risk management framework. The Board has formed a Risk Management Committee which periodically examines critical events impacting the risk profile, existing and emerging risks and other uncertainties, and monitors the progress of planned actions.

The Risk Management Committee meets periodically and it includes the CFO, Independent Directors and other important executives of the Company. In addition, the Company's senior leadership team undertakes various risk governance measures at the operational level as per the requirements. While every company, as part of its risk management strategy, tries to put in place mitigation measures to the extent possible, risks cannot be wished away. We have listed a summarised account of some of our key risks and mitigation measures drawn from management reviews and deliberations of RMC.

SOME OF THE IDENTIFIED RISKS AND ITS MITIGATION STRATEGY

Geographical risk
Dependence of the Company on a specific geography can affect balanced growth.

Mitigation strategy
The Company has a strong presence in Latin America. On one hand, the Company is enlarging its presence in Latin America and on the other hand the Company has been gradually stepping up its presence into US and other regulated markets, which will reduce its dependency in Latin America in future.

Currency fluctuation and receivables risk
The Company is exposed to currency fluctuations due to its international presence

Mitigation strategy
Rising costs due to currency fluctuations are passed on to consumers.

Quality risk
The Company's top line and brand could be affected by a decline in product quality

Mitigation strategy
The facilities of the Company are US FDA, EU-GMP, ANVISA and WHO-GMP-approved, strengthening quality assurance. While

there is a robust in- house QC and QA SOPs and teams for ensuring high level of quality adherence, the Company also undertakes periodic audits (external and internal) to benchmark practices in line with global standards.

Liquidity risk
The Company's ability to fund operations or report surpluses could be affected by a global economic slowdown.

Mitigation strategy
The Cash and Bank balance (including liquid investments) of the Company stood at Rs. 470 Cr. cr as on 31st March 2021. Adequate inventory with the Company proved to be an advantage during the pandemic as it enabled the company to provide products on demand.

Competition risk
The Company's prospects can be affected by rising competition

Mitigation strategy
The Company has selected to market products marked by superior quality. It is present in countries with relatively low competition. It has networked pharmacies and medical practitioners to its portal, enhancing their convenience and effectiveness. It is addressing the injectables space within US, an area marked by relatively low competition.

Policy risk
The business of the Company might be hampered due to change in policies regarding generic medicines

Mitigation strategy
Medical needs have witnessed a rapid growth owing to growing population and changing everyday habits. Increase in prices of branded drugs has led to the promotion of generics by various governments, strengthening a case for affordable health care. The Company has reinforced its position in this growing space through the delivery of quality and validated generic products.

INTERNAL CONTROL SYSTEMS AND THEIR ADEQUACY

The Company maintains appropriate systems of internal control, including monitoring procedures, to ensure that all assets are safeguarded against loss from unauthorized use or disposal. Company policies, guidelines and procedures provide for adequate checks and balances and are meant to ensure that all transactions are authorized, recorded and reported correctly.

The Audit Committee approves and reviews audit plans for the year based on internal risk assessment. Audits are conducted on an ongoing basis and significant deviations are brought to the notice of the Audit Committee of the Board of Directors following which corrective action is recommended for implementation. All these measures facilitate timely detection of any irregularities and early remedial steps.

The Audit Committee of the Company also reviews the reports of the internal auditors quarterly and recommends steps for further improvement of the internal controls. The Company has also implemented an Internal Financial Control (IFC) framework to ensure proper internal controls over financial reporting.

INDUSTRIAL RELATION AND HUMAN RESOURCES

Industrial Relations scenario continued to be cordial during the year. The Company regards its employees as one of its great assets and accords high priority to training and development of employees. The employees have also shown their relentless and dedication to the Company even in these tough times. Caplin's employees have supported the management and enabled the Company to fulfil its purpose and achieve its goals over the last many years. This high level of commitment is rooted in their passion for our purpose and a sense of ownership towards it.

The Company is also committed to the wellbeing of its people, it offers a safe working environment that nurtures talent, maintains a culture of openness and transparency, and also fosters ownership among them. The Company's decisions are aligned with professional and personal goals of employees, enhancing pride of association.

To meet the challenges in view of COVID 19 pandemic, the Company also took following measures during the year:

- Ensured preventive measures at workplace and manufacturing by developing and implementing COVID 19 appropriate SOPs
- Vaccinated more than 90% of its workforce on priority basis
- Arrangements with Hospitals for meeting any emergency for employees
- Continued the operations without any major disruption by introducing technology and allowing flexibility of work to the employees

Total number of employees at consolidated level as on March, 31, 2021 stands at 1675

ADHERENCE TO ACCOUNTING STANDARDS.

The Company continues to adhere to standard accounting policies under the Indian Accounting Standards (Ind AS), as applicable.

CAUTIONARY STATEMENT

The statement made in this section describes the Company's objectives, projections, expectation and estimations which may be 'forward looking statements' within the meaning of applicable securities laws and regulations. Forward–looking statements are based on certain assumptions and expectations of future events. The Company cannot guarantee that these assumptions and expectations are accurate or will be realised by the Company. Actual result could differ materially from those expressed in the statement or implied due to the influence of external factors which are beyond the control of the Company. The Company assumes no responsibility to publicly amend, modify or revise any forward-looking statements on the basis of any subsequent developments.

CAPLIN POINT®
Laboratories

MANAGEMENT REPORTS

DIRECTORS' REPORT

To the Members,

The Directors present their 30th Annual Report on the business and operations of the Company and the accounts for the Financial Year ended March 31, 2021.

1. FINANCIAL HIGHLIGHTS

Rs. In Lakhs

Financial Results	Standalone		Consolidated	
Particulars	**2020-21**	**2019-20**	**2020-21**	**2019-20**
Revenue from Operations	48,267.96	52,782.53	1,06,129.04	86,320.17
Other Income	1,861.80	6,597.13	2,354.22	4,133.37
Total Income	**50,129.76**	**59,379.66**	**1,08,483.26**	**90,453.54**
Profit Before Interest, Depreciation and Tax	**23,254.29**	**27,296.37**	**35,217.93**	**30,140.14**
Less: Finance cost	16.67	18.50	158.96	31.97
Less : Depreciation and amortisation expenses	2,244.08	1,965.38	3,697.12	3,161.92
Profit Before Tax	**20,993.53**	**25,312.49**	**31,361.85**	**26,946.25**
Less: Tax Expenses	5,371.55	5,548.64	6,218.82	5,437.88
Profit After Tax	**15,621.98**	**19,763.85**	**25,143.03**	**21,508.37**
Less: Non-controlling Interest	-	-	916.41	7.57
Net profit attributable to the shareholders of the Company	**15,621.98**	**19,763.85**	**24,226.62**	**21,500.80**

2. OPERATIONS REVIEW /PERFORMANCE

The Company has, on standalone basis registered total revenue of Rs. 48,267.96 Lakhs (Total Income Rs. 50,129.76 Lakhs) from operations during the year under review as against Rs. 52,782.53 Lakhs (Total Income Rs. 59,379.66 Lakhs) in the previous Financial Year. The Profit After Tax was Rs. 15,621.98 Lakhs during the year under review as against Rs. 19,763.85 Lakhs in the previous Financial Year.

The Company has on consolidated basis, registered total revenue of Rs. 1,06,129.04 Lakhs (Total Income Rs. 1,08,483.26 Lakhs) from operations during the year under review as against Rs. 86,320.17 Lakhs (Total Income Rs. 90,453.54 Lakhs) in the previous Financial Year.

3. MANAGEMENT DISCUSSION AND ANALYSIS

In compliance with Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (Listing Regulations) separate Section on Management Discussion and Analysis, as approved by the Board, which includes details on the state of affairs of the Company along with operational performance / review, forms part of this Annual Report.

4. DIVIDEND

The Board of Directors at their Meeting held on May 06, 2021, declared an Interim Dividend of Rs. 1.50 (75%) per equity share of Rs.2/- each, for the Financial Year 2020-21 and was paid to those shareholders whose name appeared in the Register of Members and beneficial owners as on the record date May 19, 2021.

Further, the Board of Directors, at their meeting held on August 5, 2021, have recommended a Final Dividend of Rs.1.50 (75%) per equity share of Rs. 2 /- each, for the Financial Year 2020-21, subject to the approval of the shareholders at the ensuing Annual General Meeting (AGM). If approved, the total dividend for the Financial Year 2020-21 would amount to Rs.3/- per equity share (150%) of Rs 2/- each.

In compliance with Regulation 43A of the Listing Regulations, the Dividend Distribution Policy is uploaded on the Company's website at http://www.caplinpoint.net/investor.aspx

5. TRANSFER TO RESERVES

The Board of Directors have decided to retain the entire amount of profits for the Financial Year 2020-21 in profit and loss account.

6. SUBSIDIARIES

Details of subsidiaries have been covered under Extract of Annual Return, which can be accessed on the following link. http://www.caplinpoint.net/investor.aspx

During the Financial Year, there were no material development in the status of subsidiary companies.

Caplin Steriles Limited and Caplin Point Far East Limited, Hongkong are the material subsidiaries of the Company.

Pursuant to Section 129(3) of the Act, 2013, a statement containing the salient features of the financial statements of subsidiaries in the prescribed Form AOC-1 is annexed as *Annexure - I* to this Report.

7. CONSOLIDATED FINANCIAL STATEMENTS

Pursuant to Section 129(3) of the Act, 2013 and Listing Regulations, the Consolidated Financial Statements prepared in accordance with the Indian Accounting Standards prescribed by the Institute of Chartered Accountants of India, are attached to this report.

Pursuant to the provisions of Section 136 of the Act, 2013 the financial statements of the Company, consolidated financial statements along with relevant documents and separate audited financial statements in respect of the subsidiaries are available on the website of the Company.

8. DEPOSITS

The Company did not accept any deposits from the public within the meaning of Chapter V of the Act, 2013, read with the Companies (Acceptance of Deposits) Rules, 2014 for the year ended March 31, 2021.

9. BUSINESS RESPONSIBILITY REPORT

Pursuant to Regulation 34 of the Listing Regulations, a Business Responsibility Report is attached as *Annexure - VII* to this Report.

10. SHARE CAPITAL

The paid up share capital as on March 31, 2021 stood at Rs.15,12,85,500/- consisting of 7,56,42,750 equity shares of Rs.2/- each.

11. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS UNDER SECTION 186 OF THE ACT, 2013

Particulars of loans, guarantees and investments as on March 31, 2021 are given in the Note No. 3, 3A, 4, 6 & 10 to the standalone financial statements.

12. NUMBER OF MEETINGS OF THE BOARD

The number of Board meetings held during the Financial Year 2020-21 are provided as part of Corporate Governance Report prepared in terms of the Listing Regulations.

13. DIRECTORS AND KEY MANAGERIAL PERSONNEL

a. Directors

As on March 31, 2021, the Board consisted of a Non- Executive Chairman, an Executive Director, six Independent Directors and a Non-Executive - Non- Independent Director.

During the year under review, Dr. Sridhar Ganesan (DIN: 06819026) was re-appointed as the Managing Director of the Company for a further period of two years effective August 25, 2020, by the shareholders at their AGM held on September 28, 2020.

Dr. R Ravichandran (DIN: 01920603), Independent Director retired on May 11, 2021 (close of business hours), upon completion of his tenure. The Board wishes to place on record the valuable guidance and directions provided during his tenure as a Director of the Company.

b. Company Secretary and Compliance Officer

During the year, Mr. Vinod Kumar S, Company Secretary, Key Managerial Personnel (KMP) and Compliance Officer of the Company resigned from the services of the Company effective February 5, 2021.

Consequent to Mr. Vinod Kumar's resignation, the Board had appointed Mr. Dinesh R G as the Company Secretary, KMP and Compliance Officer of the Company effective May 6, 2021.

c. Retirement by Rotation

Pursuant to Section 152 (6) of the Act, 2013, Mr. C C Paarthipan (DIN: 01218784), Non-Executive Non-Independent Director retires by rotation and being eligible offers himself for re-appointment.

d. KMP

Pursuant to Sections 2(51) and 203 of the Act, 2013, Dr. Sridhar Ganesan, Managing Director, Mr. D Muralidharan, Chief Financial Officer and Mr. Dinesh R G, Company Secretary are the KMP of the Company.

14. DECLARATION BY INDEPENDENT DIRECTORS

Pursuant to Section 149(7) of the Act, 2013, all Independent Directors have declared that they meet the criteria of independence as provided under Section 149(6) of the Act, 2013 and Regulation 25 of the Listing Regulations and the Board confirms that they are independent of the management.

15. DIRECTORS RESPONSIBILITY STATEMENT

Pursuant to Section 134(5) of the Act, 2013, the Directors confirm that:

a. In the preparation of the annual accounts, the applicable accounting standards (IND AS) had been followed along with proper explanation relating to material departures;

b. The Directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as at March 31, 2021 and of the profit of the Company for that period;

c. The Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act, 2013 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

d. The Directors had prepared the annual accounts on a going concern basis;

e. The Directors had laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and were operating effectively; and

f. The Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

16. MATERIAL CHANGES AND COMMITMENTS, IF ANY AFFECTING THE FINANCIAL POSITION OF THE COMPANY

There were no material changes and commitments, affecting the financial position of the Company, which have occurred between the end of the Financial Year of the Company to which the financial statements relate and the date of the report.

17. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO

Pursuant to Section 134 (3)(m) of the Act, 2013 read with Rule 8 (3) of the Companies (Accounts) Rules, 2014, particulars of conservation of energy, technology absorption, foreign exchange earnings and outgo, as are given as *Annexure - II* to this Directors' Report.

18. ANNUAL EVALUATION OF THE BOARD, ITS COMMITTEES AND INDIVIDUAL DIRECTORS

Pursuant to the provisions of the Act, 2013 and Regulation 4 of the Listing Regulations, the Board of Directors has carried out annual performance evaluation of its own performance, the Directors Individually as well as the evaluation of the working of its Committees.

The manner in which the evaluation was carried out has been explained in the Corporate Governance Report which forms part of this report.

19. CORPORATE SOCIAL RESPONSIBILITY (CSR)

Pursuant to the provisions of Section 135 of the Act, 2013 read with CSR Rules, the Company has constituted CSR Committee and based upon the recommendations of the CSR Committee the Board of Directors have approved CSR Policy.

Disclosure under Companies Corporate Social Responsibility Policy 2014 is annexed as an *Annexure - III* to this report.

20. BOARD COMMITTEES

Pursuant to the Act, 2013 and the Listing Regulations, the Company has formed all the statutory Committees namely, the Audit Committee, the Nomination and Remuneration Committee, the Corporate Social Responsibility Committee, the Stakeholders' Relationship Committee and the Risk Management Committee.

Detailed information about these Committees and relevant information for the year under review are given in the Corporate Governance Report.

There have been no instances where the Board did not accept the recommendations of its Committees including the Audit Committee.

21. INTERNAL FINANCIAL CONTROLS

Details in respect of adequacy of internal financial controls concerning the Financial Statements are stated in the Management Discussion and Analysis section which forms part of this Annual Report.

22. VIGIL MECHANISM

The Company has established a vigil mechanism, through a Whistle Blower Policy, where Directors and employees can voice their genuine concerns or grievances about any unethical or unacceptable business practice. A whistle-blowing mechanism not only helps the Company in detection of fraud, but is also used as a corporate governance tool leading to prevention and deterrence of misconduct. It provides direct access to the employees of the Company to approach the Compliance Officer or the Chairman of the Audit Committee, where necessary. The Company ensures that genuine Whistle Blowers are accorded complete protection from any kind of unfair treatment or victimization.

The Vigil mechanism policy is disclosed on the website of the Company at http://www.caplinpoint.net/investor.aspx

23. AUDITORS

a. Statutory Auditors

The Company at its 26th AGM held on September 21, 2017 had re-appointed M/s. CNGSN & Associates LLP, Chartered Accountants, Chennai, as Statutory Auditors of the Company to hold office, for the second term of five consecutive years from the conclusion of 26th AGM till the conclusion of 31st AGM.

The Statutory Auditors will continue to hold office for the 5th year in the second term of five consecutive years, from the conclusion of this AGM.

The Company has obtained necessary certificate under Section 141 of the Act, 2013 conveying their eligibility for being the Statutory Auditors of the Company for the Financial Year 2021-22.

The Auditors' Report for the Financial Year 2020-21 does not contain any qualification, reservation or adverse remark and the same is attached with the annual financial statements.

b. Secretarial Auditors

Pursuant to Section 204 of the Act, 2013 and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Company is required to appoint a Secretarial Auditor for auditing secretarial and related records of the Company.

The Secretarial Audit Report for the Financial Year 2020-21, given by M/s. G Ramachandran & Associates, Company Secretaries, Chennai is attached as *Annexure - IV* to this Report. The Secretarial Audit Report does not contain any qualification, reservation or other remarks.

Pursuant to Regulation 24A of Listing Regulations, a listed entity shall annex with its Annual Report the Secretarial Audit Report of its material unlisted subsidiary incorporated in India. Caplin Steriles Limited being a material unlisted subsidiary of the Company, the Secretarial Audit Report is annexed as *Annexure - IV-A* to this Directors Report.

c. Internal Auditors

Pursuant to Section 138 of the Act, 2013, the Board at its meeting held on May 6, 2021 had re-appointed M/s. TBL & Associates as Internal Auditors for carrying out internal audit of the Company, for the Financial Year 2021-22. The internal audit for the Financial Year 2020-21 was completed as per the scope defined by the Audit Committee from time to time.

24. REPORTING OF FRAUDS BY AUDITORS

Pursuant to provisions of the Section 143(12) of the Act, 2013, neither the Statutory Auditors nor the Secretarial Auditors has reported any incident of fraud to the Audit Committee during the year under review.

25. CORPORATE GOVERNANCE

Pursuant to Regulation 34 of Listing Regulations, a Report on Corporate Governance is given separately which forms a part of this Annual Report.

26. ANNUAL RETURN

Pursuant to Section 92(3) and 134(3)(a) of the Act, 2013, read with Rule 12 of Chapter VII Rules of the Companies (Management and Administration) Amendment Rules, 2020, Annual Return in Form MGT-7 for FY 2020-21 is uploaded on the website of the Company and can be accessed at http://www.caplinpoint.net/investor.aspx

27. RISK MANAGEMENT

The Company has constituted a Risk Management Committee in compliance with the requirements of Regulation 21 of the Listing Regulations. The details of this Committee and its terms of reference are set out in Corporate Governance Report, which forms part of this Annual Report.

The Company has in place a Risk Management framework to identify, evaluate and monitor business risks and challenges across the Company, that seek to minimise the adverse impact on business objectives and capitalise on opportunities. The Company's success as an organisation largely depends on its ability to identify such opportunities and leverage them while mitigating the risks that arise while conducting its business.

28. EMPLOYEE STOCK OPTION PLAN

The Company has two stock options in force (i.e) Caplin Point Employee Stock Option Plan -2015 and Caplin Point Employee Stock Option Plan – 2017. The Company has granted 2,81,000 options under Caplin Point Employee Stock Option Plan -2015 out of which 92,750 options has been exercised and allotted as on March 31, 2021. The Company has granted 4,90,000 options under Caplin Point Employee Stock Option Plan-2017 as on March 31, 2021. The details required under Rule 12 (9) of Companies (Share Capital and Debentures) Rules, 2014 and as required to be provided under the SEBI Guidelines as on March 31, 2021 forms part of this Report and is available at http://www.caplinpoint.net/investor.aspx

The Company believes that equity based compensation schemes are an effective tool to reward the employees in the growth of the Company to attract new talents, to retain the key resources in the organisation and for the benefit of the present and future employees of the Company. In view of the above, the Board of Directors approved the formulation and implementation of Caplin Point Employee Stock Option Plan - 2021 (ESOP 2021 Plan). Resolution seeking approval of the shareholders for ESOP 2021 Plan, has been incorporated in the Notice of the AGM.

29. PARTICULARS OF EMPLOYEES RELATED DISCLOSURES

The statements required under Section 197, of the Act, 2013 read with Rule 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, as amended, form part of this Report and will be made available to any shareholder on request, as prescribed therein.

The prescribed particulars of employees required under 5(1) of the said Rules are is annexed as an *Annexure - V* to this Report.

Pursuant to Section 197(12) of the Act, 2013 read with the Rule 5 of the Companies (Appointment of Managerial Personnel) Rules, 2014, no employee who drew a remuneration of more than Rs.1.02 crores per annum or Rs. 8.50 lakhs per month, was employed throughout the Financial Year or part of the Financial Year.

30. PARTICULARS OF CONTRACTS OR ARRANGEMENTS WITH RELATED PARTIES

All Related Party Transactions which were entered into during the year under review were on arm's length basis and in the ordinary course of business. There were no materially significant related party transactions made by the Company with the Promoters, Directors and KMP which may have a potential conflict with the interests of the Company at large.

All Related Party Transactions are placed before the Audit Committee for review and approval. Prior omnibus approval of the Audit Committee is obtained on an annual basis for the transactions which are planned/repetitive in nature. Related Party Transactions entered pursuant to the omnibus approval so granted are placed before the Audit Committee for its review on a quarterly basis, specifying the nature, value and terms and conditions of the transactions. All the Related Party Transactions under Ind AS-24 have been disclosed at Note No. 44 to the standalone financial statements forming part of this Annual Report.

Particulars of transactions with related parties, in prescribed form AOC-2 is enclosed as *Annexure - VI* to this Report.

Approval of the shareholders is being sought under Regulation 23 of the Listing Regulations for the material Related Party Transactions and the proposal along with detailed explanatory statement is given as part of the Notice to Shareholders for the ensuing AGM.

The related party transaction policy and material related party transactions have been uploaded on the website of the Company at http://www.caplinpoint.net/investor.aspx

31. DETAILS OF SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS

There are no significant and material orders passed by the Regulators or Courts or Tribunals which would impact the going concern status of the Company.

32. DISCLOSURE UNDER SEXUAL HARASSMENT OF WOMEN AT THE WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

Pursuant to the provisions of Sexual Harassment of Women at the Workplace (Prevention, Prohibition and Redressal) Act, 2013, the Company has put in place a Policy on Prevention of Sexual Harassment at Workplace and Internal Complaints Committees (ICC) has been set up to redress complaints. There were no complaints relating to sexual harassment, pending at the beginning of Financial Year, received during the year and pending as on the end of the Financial Year 2020-21.

33. INVESTOR EDUCATION AND PROTECTION FUND

Pursuant to Sections 124 and 125 of the Act, 2013, the amount of dividends remaining unpaid or unclaimed for a period of seven years from the date of transfer to the unpaid account, is required to be transferred to the Investor Education and Protection Fund (IEPF) of the Central Government.

During the year under review, the Company has credited 2,03,625 unclaimed equity shares of Rs.2/- each to IEPF pertaining to those shareholders who have not encashed/claimed their dividends for a period of seven consecutive years. The voting rights on the shares outstanding in the IEPF Authority as on March 31, 2021 shall remain frozen till the rightful owner of such shares claims the shares.

Pursuant to Sections 124 and 125 of the Act, 2013, the unpaid or unclaimed dividend for the Financial Year 2013-14 has to be transferred to IEPF. Members, who have not yet en-cashed or claimed the dividends that are yet to be transferred to the IEPF, are requested to contact the Company's Registrar and Share Transfer Agent, at the earliest.

Members are requested to take note of the same and claim their unclaimed dividends immediately to avoid transfer of the underlying shares to the IEPF Account. The shares transferred to the IEPF Account can be claimed back by the concerned Members from IEPF Authority after complying with the procedure prescribed under the Rules.

34. SHIFTING OF REGISTERED OFFICE

The Company shifted its registered office of the Company from "Narbavi", No.3, Lakshmanan Street, T Nagar, Chennai-600 017 to "Ashvich Towers", 3rd Floor, No.3, Developed Plots, Industrial Estates, Perungudi, Chennai -600 096 effective July 09,2020.

35. OTHER DISCLOSURES

a. There has been no change in the nature of business of the Company during the year under review.

b. Pursuant to Section 197 (14) of the Act, 2013, the Managing Director of the Company did not receive any remuneration or commission from any of its subsidiaries.

c. The Company maintains cost records as per Companies (Cost Records and Audit) Rules, 2014.

d. The Board confirms the compliance of the provisions of the Secretarial Standards notified by the Institute of Company Secretaries of India, New Delhi.

36. ACKNOWLEDGEMENT

The Board of Directors wishes to place on record its sincere appreciation to the customers, suppliers, business partners and subsidiaries and shareholders for their support. The Directors would like to thank the Bankers and financial Institutions as well. The Directors would take this opportunity to appreciate and sincerely acknowledge the dedication and hard work of the employees for the growth of the Company.

FOR AND ON BEHALF OF THE BOARD

Place: Chennai
Date: August 5, 2021

C C PAARTHIPAN
Chairman

Annexure - I

FORM AOC-1

(Pursuant to first Proviso to Sub-Section (3) of Section 129, of the Act, 2013 read with Rule 5 of Companies (Accounts) Rules, 2014)

STATEMENT CONTAINING SALIENT FEATURES OF THE FINANCIAL STATEMENT OF SUBSIDIARIES/ASSOCIATE COMPANIES/JOINT VENTURES

PART "A": SUBSIDIARIES

(Amount in Rs.)

S. No.	Particulars	Details*				
1	Name of the subsidiary	Caplin Steriles Limited	Argus Salud Pharma LLP	Caplin Point Far East Limited – Hong Kong (Consolidated)**	Caplin Point Laboratories Colombia SAS – Colombia	Caplin Point (S) Pte. Ltd - Singapore
2	Reporting period for the subsidiary concerned, if different from the holding company's reporting period	Not applicable	Not applicable	Not applicable	Not applicable	Not applicable
3	Date of Acquisition	December 12, 2018	April 13, 2010	May 13, 2014	September 15, 2016	October 4, 2019
4	Reporting currency and Exchange rate as on the last date of the relevant Financial year in the case of foreign subsidiaries	Not applicable	Not applicable	1 USD = 73.5	1 Columbia Peso = Rs. 0.020	1 USD = 73.5
5	Share capital	1,79,95,70,750	99,10,000	8,48,484	2,14,17,045	36,75,000
6	Reserves & surplus	1,09,85,80,250	0	3,16,63,49,865	(2,10,58,022)	(10,91,475)
7	Total assets	3,10,66,25,000	1,55,30,162	4,20,46,79,661	25,24,764	27,30,525
8	Total Liabilities	20,84,74,000	56,20,162	1,03,74,81,312	21,65,741	1,47,000
9	Investments #	-	-	-	-	-
10	Turnover	91,67,91,000	1,78,708	7,24,54,04,135	79,40,922	-
11	Profit before taxation	(30,67,07,000)	1,35,640	1,62,08,29,865	(16,68,653)	(6,13,799)
12	Provision for taxation	7,83,31,920	50,000	16,14,10,704	60,000	-
13	Profit after taxation	(22,83,76,000)	85,640	1,45,94,19,161	(17,28,653)	(6,13,799)
14	Proposed Dividend	-	-	-	-	-
15	% of shareholding	99.99%	99.90%	100.00%	85.83%	100.00%

* Indian Rupee equivalent of the foreign currency translated as per exchange rate as at March 31, 2021 as mentioned in Sl No.4 above

Investments other than in subsidiary companies

**Represents details as per consolidated financial statements of Caplin Point Far East Limited which includes the financial statements of its subsidiaries Caplin Point El Salvador, S.A. De C.V., Drogueria Saimed de Honduras S.A, Neoethicals CIA.LTDA - Ecuador, Neo Ethicals S.A - Nicaragua, Nuevos Eticos Neo Ethicals S.A - Guatemala

Notes:

1. Name of subsidiaries which are yet to commence operations: (i) Caplin Point Laboratories Colombia SAS and (ii) Caplin Point (S) Pte. Ltd.
2. Name of subsidiaries which have been liquidated or sold during the year: Nil

Part "B": Associates and Joint Ventures

S.No.	Name of Associates/ Joint ventures	Latest audited balance sheet date	Date on which the Joint venture was acquired	Shares of Associate/Joint ventures held by the company on the year end			Description of how there is significant influence	Reason why the Joint venture is not consolidated	Net worth attributable to shareholding as per latest audited balance sheet	Profit / Loss for the year	
				No of Shares	Amount of Investment in Associates/ Joint Venture	Extent of Holding %				i. Considered in Consolidation	ii. not Considered in Consolidation
1	Hainan Join town Caplin Point Pharmaceutical Company Limited- China	31.03.2021	12.09.2018	17,28,951	1,82,16,900	39	Not applicable	Not applicable	1,73,55,240	(4,57,536)	(7,15,633)

FOR AND ON BEHALF OF THE BOARD

Place: Chennai
Date: August 5, 2021

C C PAARTHIPAN
Chairman

Annexure - II

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE OUTGO

(Pursuant to provisions of Section 134(3) (m) of the Act, 2013 read with Rule 8(3) of the Companies (Accounts) Rules, 2014)

(A) CONSERVATION OF ENERGY

Power and Fuel Consumption	Year ended March 31, 2021	Year ended March 31, 2020
Electricity		
Purchased units	61,73,465	60,84,048
Total amount paid	4,27,44,609	4,14,64,666
Rate per unit	6.92	6.82
Own Generation by		
Diesel Generator (Units)	1,89,578	2,97,204
Amount paid	43,65,581	56,99,758
Rate per unit	23.03	19.18
Third party (units)	1,99,680	2,44,711
Amount paid	12,77,949	15,66,152
Rate per unit	6.40	6.40
Others		
Diesel Consumed for Boiler(in Litres)	-	2,70,984
Total Amount paid	-	1,84,01,524
Rate per Litre	-	67.9
Light Diesel Oil Consumed for Boiler(in Litres)	4,40,786	1,23,828
Total Amount paid	1,52,56,042	47,91,410
Rate per Litre	34.61	38.69

(B) TECHNOLOGY ABSORPTION

i) Efforts made towards technology absorption

- ✓ New products developments, Developments NSAIDs, Anti-Depressants, Anti-emetic, Anti- Coagulants, etc
- ✓ Quality Improvements in Projects for major products
- ✓ FR & D efforts in conducting trails, stabilization of process and optimization of process
- ✓ Company’s R & D initiatives lay emphasis on innovation and continues products improvements to widen the range of products / applications
- ✓ Formulation development and analytical development of injectable and ophthalmic
- ✓ Support to QC in transferring the analytical methods
- ✓ Support to regulatory department in compiling documents required for dossier submission
- ✓ The Company also lays emphasis on technology and innovation in its method of functioning and operations

ii) Benefits derived as a result of R& D

Provides Company an opportunity to widen the range and application of products. Continues process improvements resulting in optimization of products and cost reduction.

iii) Imported Technology (Imported during the Last three years reckoned from the beginning of the Financial Year)

a. **Details of technology imported:** Nil
b. **The year of import:** Not applicable
c. **Whether the technology been fully absorbed:** Not applicable
d. **If not fully absorbed, areas where absorption has not taken place and the reasons thereof:** Not applicable

iv) Expenditure incurred on Research and Development

The Company has incurred an expenditure of Rs. 2600.73 Lakhs towards Research and Development (Rs. 1939.85 Lakhs of Revenue Expenditure and Rs.660.88 Lakhs of Capital Expenditure).

(C) FOREIGN EXCHANGE EARNINGS AND OUTGO

(Amount in Lakhs)

Foreign exchange earned	47,127.85
Foreign exchange used	3,333.67

FOR AND ON BEHALF OF THE BOARD

Place: Chennai
Date: August 5, 2021

C C PAARTHIPAN
Chairman

Annexure - III

ANNUAL REPORT ON CSR ACTIVITIES FOR THE FINANCIAL YEAR 2020-21

(Pursuant to Section 135 of the Act, 2013 and Companies (Corporate Social Responsibility) Rules, 2014, as amended)

1. Brief outline on CSR Policy of the Company

Corporate Social Responsibility is strongly connected with the principles of Sustainability; an organization should make decisions based not only on financial factors, but also on the social and environmental consequences. Therefore, it is the core corporate responsibility of Caplin Point Laboratories Limited to practice its corporate values through its commitment to grow in a socially and environmentally responsible way, while meeting the interests of its stakeholders.

Caplin Point Laboratories Limited recognizes that its business activities have wide impact on the societies in which it operates, and therefore an effective practice is required giving due consideration to the interests of its stakeholders including shareholders, customers, employees, suppliers, business partners, local communities and other organizations. The company endeavours to make CSR a key business process for sustainable development. Caplin Point Laboratories Limited is responsible to continuously enhance shareholders wealth; it is also committed to its other stakeholders to conduct its business in an accountable manner that creates a sustained positive impact on society. Our company is committed towards aligning with nature; and has adopted eco-friendly practices. As a corporate entity, the company is committed towards sustainability.

2. Composition of CSR Committee

S. No.	Name of Director	Designation / Nature of Directorship	No. of meetings of CSR Committee held during the year	Number of meetings attended during the year
1.	Mr. C C Paarthipan	Chairman / Non- Executive Director	1	1
2.	Dr. Sridhar Ganesan	Chairman / Non- Executive Director	1	1
3.	Mr. V Thirumalai	Member / Independent Director	1	1

3. Web-link where Composition of CSR committee, CSR Policy and CSR projects approved by the board are disclosed on the website of the company:

Sr. No.	Particulars	Weblink
1	CSR Committee	http://cmsbox.caplinpoint.net//PDF/List%20of%20Directors%20and%20Committees%20-%20Website.pdf
2.	CSR Policy and Projects	http://cmsbox.caplinpoint.net//PDF/Corporate_Social_Responsibility_Policy.pdf

4. Details of Impact assessment of CSR projects carried out in pursuance of sub-rule (3) of rule 8 of the Companies (Corporate Social Responsibility Policy) Rules, 2014:

Not Applicable

5. Details of the amount available for set off in pursuance of sub-rule (3) of rule 7 of the Companies (Corporate Social Responsibility Policy) Rules, 2014 and amount required for set off for the Financial Year, if any : Nil

6. Average net profit of the company as per Section 135(5) : Rs. 19,878.24 Lakhs

7. a) Two percent of average net profit of the company as per section 135(5): Rs. 397.56 Lakhs

   b) Surplus arising out of the CSR projects or programs or activities of the previous Financial Years: Nil

   c) Amount required to be set off for the Financial Year, if any: Not Applicable

   d) Total CSR obligation for the Financial Year (7(a)+7(b)-7(c): Rs. 397.56 Lakhs

8. a) CSR amount spent or unspent for the Financial Year:

Total amount spent for the Financial Year (Rs. in lakhs)	Amount Unspent (Rs. in lakhs)				
	Total amount transferred to unspent CSR account as per Section 135(6)		Amount transferred to any fund specified under Schedule VII as per second proviso to Section 135(5)		
	Amount	Date of transfer	Name of the Fund	Amount	Date of transfer
9.55	397.56	28.04.2021		Nil	

   b) Details of CSR amount spent against ongoing projects for the Financial Year:

Sl. No.	Name of the Project.	Item from the list of activities in Schedule VII to the Act.	Local area (Yes/No).	Location of the project.		Project duration.	Amount allocated for the project (in Rs. Lakhs).	Amount spent in the current Financial Year (in Rs.).	Amount transferred to Unspent CSR Account for the project as per Section 135(6) (in Rs.).	Mode of Implementation Direct (Yes/No).	Mode of Implementation - Through Implementing Agency	
				State/UT	District.						Name	CSR Registration number.
1	Providing Sanitation facilities	Item no. (i)	Yes	Tamilnadu/ Podicherry	Thiruvallur Pondicherry Chennai	3 years	60	-				
2	Development of Green Belts, Rejuvenation of lakes and water bodies	Item no. (iv)	Yes	Tamilnadu/ Podicherry	Thiruvallur Pondicherry Chennai	3 years	65	-				
3	Setting up Healthcare facilities	Item no. (i)	Yes	Tamilnadu/ Podicherry	Thiruvallur Pondicherry Chennai	3 years	160	-	397.56	No (Through Company owned Trust)	Caplin Point Meenakshi CSR Trust	Under process
4	Setting up / upgrading the Educational Infrastructure	Item no. (ii)	Yes	Tamilnadu/ Podicherry	Thiruvallur Pondicherry Chennai	3 years	60	-				
5	Setting up care homes and hostel for orphans and women	Item no. (iii)	Yes	Tamilnadu/ Pondicherry	Thiruvallur Pondicherry Chennai	3 years	52.56	-				
	TOTAL						397.56	-	397.56			

c) Details of CSR amount spent against other than ongoing projects for the Financial Year:

Sl no.	Name of the Project / Activity	Item from the list of activities in Schedule VII to the Act	Local Area (Yes / No)		Amount spent for the project (in lakhs)	Mode of Implementation	
			State	District		Name	CSR Registration No.
1.	COVID related assistance & relief	Promoting health care including preventive health care	Yes	Chennai	9.55	Direct	NA
	Total				**9.55**	-	-

d) Amount spent in Administrative Overheads: Nil

e) Amount spent on Impact Assessment, if applicable: Nil

f) Total amount spent for the Financial Year (8b+8c+8d+8e): 9.55 Lakhs

g) Excess amount for set off, if any:

Sl No.	Particulars	Amount (in Lakhs.)
(i)	Two percent of average net profit of the company as per section 135(5)	397.56
(ii)	Total amount spent for the Financial Year	9.55
(iii)	Excess amount spent for the Financial Year [(ii)-(i)]	(388.01)
(iv)	Surplus arising out of the CSR projects or programmes or activities of the previous Financial Years, if any	Nil
(v)	Amount available for set off in succeeding Financial Years [(iii)-(iv)]	Nil

9. (a) Details of Unspent CSR amount for the preceding three Financial Year:

Sl. No.	Preceding Financial Year.	Amount transferred to Unspent CSR Account under section 135 (6)	Amount spent in the reporting Financial Year (in Rs. Lakhs).	Amount transferred to any fund specified under Schedule VII as per section 135(6), if any.			Amount remaining to be spent in succeeding Financial Year
				Nameof the Fund	Amount	Date of transfer.	
1.	2019-20	Not applicable	10.45	Not applicable	Not applicable	Not applicable	Not applicable
2.	2018-19	Not applicable	8.56	Not applicable	Not applicable	Not applicable	Not applicable
3.	2017-18	Not applicable	5.85	Not applicable	Not applicable	Not applicable	Not applicable
	TOTAL		**24.86**				

b) Details of CSR amount spent in the Financial Year for ongoing projects of the preceding Financial Year(s):

Sl. No.	Project ID.	Name of the Project.	Financial Year in which the project was commenced.	Project duration.	Total amount allocated for the project (in Rs.).	Amount spent on the project in the reporting Financial Year (in Rs).	Cumulative amount spent at the end of reporting Financial Year. (in Rs.)	Status of the project - Completed/ Ongoing.
1.	Not Applicable							

10. In case of creation or acquisition of capital asset, furnish the details relating to the asset so created or acquired through CSR spent in the Financial Year Nil

11. Specify the reason(s), if the company has failed to spend two per cent of the average net profit as per section 135(5):

Reason for not spending the CSR amount: The Company has identified some long - term projects where the CSR funds shall be utilised during next few years. However, due to ongoing COVID 19 pandemic and resultant disruption, the Company was not able to undertake the identified CSR Projects during the year. The unutilised funds have been transferred to specific CSR Bank account and the same is planned to be utilised during coming years.

FOR AND ON BEHALF OF THE BOARD

Place: Chennai
Date: August 5, 2021

C C PAARTHIPAN
Chairman of CSR Committee

Annexure - IV

Form No. MR-3

SECRETARIAL AUDIT REPORT

FOR THE FINANCIAL YEAR ENDED 31ST MARCH 2021

[Pursuant to section 204(1) of the Companies Act, 2013 and rule No.9 of the Companies (Appointment and Remuneration Personnel) Rules, 2014]

To,
The Members,
Caplin Point Laboratories Limited
CIN# L24231TN1990PLC019053
Ashvich Towers, 3rd Floor,
No.3, Developed Plots, Industrial Estates,
Perungudi, Chennai 600096

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by M/s. Caplin Point Laboratories Limited (hereinafter called the company). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the books, papers, minute books, forms and returns filed and other records maintained by the company and also the information, explanations and clarifications provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit and considering the relaxations granted by the Ministry of Corporate Affairs and Securities and Exchange Board of India warranted due to the spread of the COVID-19 pandemic, we hereby report that in our opinion, the company has, during the audit period covering the Financial Years ended 31st March, 2021 complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records maintained by M/s. Caplin Point Laboratories Limited ("the Company") for the Financial Years ended on 31st March, 2021 according to the provisions of:

(i) The Companies Act, 2013 (the Act) and the rules made thereunder;

(ii) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made thereunder;

(iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;

(iv) Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings;

(v) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):

  (a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
  (b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
  (c) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018;
  (d) The Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014; and
  (e) The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

(vi) Customs Act, 1962; and rules thereunder
(vii) Factories Act, 1948;
(viii) Air (Prevention & Control of Pollution) Act, 1981;
(ix) Water (Prevention & Control of Pollution) Act, 1974;
(x) Environment Protection Act, 1986 and
(xi) Drugs and Cosmetics Act, 1940

We have also examined compliance with the applicable clauses of the following:

(i) Secretarial Standards issued by the Institute of Company Secretaries of India.

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above.

We further report that

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice is given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

Majority decision is carried through while the dissenting members' views are captured and recorded as part of the minutes.

We further report that there are adequate systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

We further report that during the audit period under review:

1) The Company has transferred the unclaimed dividend amount of Rs.20,98,065/- pertaining to the Financial Year 2012-13 to Investor Education and Protection Fund on 27th April, 2021.

2) The company credited the Investor Education and Protection Fund with 2,03,625 unclaimed equity shares of Rs.2/- each, pertaining to the Financial Year 2012-13 on 11th May, 2021.

3) During the year under review, 11,500 equity shares of Rs.2/- each, have been claimed by the shareholders from Investor Education and Protection Fund.

4) The Company has transferred an amount Rs.3,97,56,483/- remaining unspent pursuant to ongoing projects to a separate bank account on 28th April, 2021 as required under Section 135 of the Companies Act, 2013 read with the Companies (Corporate Social Responsibility Policy) Rules, 2014.

5) The company has received a notice from National Stock Exchange Ltd (NSE) vide No. NSE/LIST-SOP/REG-34/FINES/0814 dated 8th January, 2021 regarding non – compliance of Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for Non-uploading of Annual Report for the Financial Years ended 31st March, 2020 on the NSE Website and imposing a fine.

The company has sent its replies dated 18th January, 2021 and 28th January, 2021 stating that the delay in uploading of its annual report for the Financial Years 31st March, 2020 was inadvertence and mainly duly to technical problems, outbreak of Covid-19 pandemic and consequent lockdown. We were informed that in terms of Exchange's policy for exemption of fine, the Company has requested for waiver with NSE, inter-alia, citing aforementioned reasons.

We further report that for the purpose of issuing this secretarial audit report, we have conducted online verification & examination of certain records and documents, as facilitated by the Company, as we could not verify such details physically, in view of COVID-19 and subsequent lockdown restrictions imposed by the Government.

For **G Ramachandran & Associates**
Company Secretaries

G. RAMACHANDRAN
Proprietor
FCS No.9687
CoP No.3056

Date: August 5, 2021
Place: Chennai
UDIN: F009687C000738239

This Report is to be read with our letter of even date which is annexed as Annexure A and forms an integral part of this report.

ANNEXURE-A SECRETARIAL AUDIT REPORT OF EVEN DATE

To,
The Members,
Caplin Point Laboratories Limited
CIN# L24231TN1990PLC019053
Ashvich Towers, 3rd Floor,
No.3, Developed Plots, Industrial Estates,
Perungudi, Chennai 600096

Our Report of even date is to be read along with this letter.

1. Maintenance of Secretarial record is the responsibility of the management of the company. Our responsibility is to express an opinion on these secretarial records based on our audit.

2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.

3. We have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.

4. Wherever required, we have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.

5. The compliance of the provisions of corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on test basis.

6. The Secretarial Audit report is neither an assurance as to future viability of the Company nor of the efficacy of effectiveness with which the management has conducted the affairs of the Company.

For **G Ramachandran & Associates**
Company Secretaries

G. RAMACHANDRAN
Proprietor
FCS No.9687
CoP No.3056

Date: August 5, 2021
Place: Chennai
UDIN: F009687C000738239

Annexure - IVA

Form No. MR-3
SECRETARIAL AUDIT REPORT
FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2021

[Pursuant to section 204(1) of the Companies Act, 2013 and rule No.9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To,
The Members,
M/s. Caplin Steriles Limited
CIN# U24304TN2018PLC126270
3rd Floor, Ashvich Towers, No.3, Developed Plots,
Industrial Estates, Perungudi,
Chennai 600096

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by M/s. Caplin Steriles Limited (hereinafter called the company). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the books, papers, minute books, forms and returns filed and other records maintained by the company and also the information, explanations and clarifications provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit and considering the relaxations granted by the Ministry of Corporate Affairs and Securities and Exchange Board of India warranted due to the spread of the COVID-19 pandemic, we hereby report that in our opinion, the company has, during the audit period covering the financial ended 31st March, 2021 complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records maintained by M/s. Caplin Steriles Limited ("the Company") for the financial ended 31st March, 2021 according to the provisions of:

(i) The Companies Act, 2013 (the Act) and the rules made thereunder;

(ii) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made thereunder;

(iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;

(iv) Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings;

(v) Customs Act, 1962; and rules thereunder

(vi) Factories Act, 1948;

(vii) Air (Prevention & Control of Pollution) Act, 1981;

(viii) Water (Prevention & Control of Pollution) Act, 1974;

(ix) Environment Protection Act, 1986 and

(x) Drugs and Cosmetics Act, 1940

We have also examined compliance with the applicable clauses of the following:

(i) Secretarial Standards issued by the Institute of Company Secretaries of India.

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above.

We report that

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice is given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

Majority decision is carried through while the dissenting members' views are captured and recorded as part of the minutes.

We further report that there are adequate systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

We further report that the following;

1) During the audit period the company allotted 70 equity shares of Rs. 10/- each at a premium of Rs. 19.23/- per share to M/s. Eight Roads Ventures India III L.P. and 30 equity shares of Rs. 10/- each at a premium of Rs. 19.23/- per share to M/s. F-Prime Capital Partners Life Sciences Fund VI LP on 1st April, 2020 on preferential basis. We had also reported the allotment details in our previous secretarial audit report dated 6th August, 2020, as the allotment of shares had been made by the Company before the date of our report.

2) In terms of rule 6 of the Companies (Appointment and Qualifications of Directors) Rules, 2014, read with rule 3 of the Companies (Creation and Maintenance of databank of Independent Directors) Rules, 2019, the independent Directors, Ms. Gariyali Chanderkanta (DIN 08711546) and Mr. Komattu Chacko John (DIN 01067374) have enrolled for inclusion of their names in the Institute of Independent Directors Databank on 23rd March, 2021 and 25th June, 2021 respectively.

We further report that for the purpose of issuing this secretarial audit report, we have conducted online verification & examination of certain records and documents, as facilitated by the Company, as we could not verify such details physically, in view of COVID-19 and subsequent lockdown restrictions imposed by the Government.

For **G Ramachandran & Associates**
Company Secretaries

G. RAMACHANDRAN
Proprietor
FCS No.9687
CoP No.3056

Date: July 12, 2021
Place: Chennai
UDIN: F009687C000616128

This Report is to be read with our letter of even date which is annexed as Annexure A and forms an integral part of this report.

ANNEXURE-A SECRETARIAL AUDIT REPORT OF EVEN DATE

To,
The Members,
M/s. Caplin Steriles Limited
CIN# U24304TN2018PLC126270
3rd Floor, Ashvich Towers, No.3, Developed Plots,
Industrial Estates, Perungudi,
Chennai 600096

Our Report of even date is to be read along with this letter.

1. Maintenance of Secretarial record is the responsibility of the management of the company. Our responsibility is to express an opinion on these secretarial records based on our audit.

2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.

3. We have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.

4. Where ever required, we have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.

5. The compliance of the provisions of corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on test basis.

6. The Secretarial Audit report is neither an assurance as to future viability of the Company nor of the efficacy of effectiveness with which the management has conducted the affairs of the Company.

For **G Ramachandran & Associates**
Company Secretaries

G. RAMACHANDRAN
Proprietor
FCS No.9687
CoP No.3056

Date: July 12, 2021
Place: Chennai
UDIN: F009687C000616128

Annexure - V

PARTICULARS OF EMPLOYEE RELATED DISCLOSURES

(Pursuant to Section 197 of the Act, 2013 read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014)

i. **The ratio of the remuneration of each director to the median remuneration of the employees of the company for the Financial Years and the percentage increase in remuneration of each Director, Chief Financial Officer, Chief Executive Officer, Company Secretary in the Financial Year**

S.No	Name of the Director/KMP	Designation	Ratio to Median in Remuneration	% of increase in Remuneration
1	Mr C C Paarthipan	Chairman	--	
2	Dr Sridhar Ganesan	Managing Director	15.92 Times	2%
3	Mr D P Mishra	Director	0.23 Times	-
4	Mr V Thirumalai	Independent Director	0.40 Times	-
5	Dr K C John	Independent Director	0.62 Times	-
6	Dr R Ravichandran	Independent Director	0.62 Times	-
7	Mr R Viswanathan	Independent Director	0.23 Times	-
8	Mr D Sathyanarayanan	Independent Director	0.45 Times	-
9	Dr C K Gariyali	Independent Director	0.23 Times	-
10	Mr D Muralidharan	Chief Financial Officer	11.25 Times	4%
11	Mr Vinodkumar S, $	Company Secretary	2.84 Times	9%

$ Mr. Vinodkumar S resigned w.e.f. 5th February 2021

ii. **The percentage increase in the median remuneration of employees in the Financial Year:** 0.71%

iii. **Number of Permanent employees in the rolls of the Company as on March 31, 2021:** 613 (Standalone)

iv. **Average percentile increase already made in the salaries of employees other than the managerial personnel in the last Financial Year and its comparison with the percentile increase in the managerial remuneration and justification thereof and point out if there are any exceptional circumstances for increase in the managerial remuneration:** 13.52%

v. **Affirmation that the remuneration is as per the remuneration policy of the Company:** The Company affirms remuneration is as per the remuneration policy of the Company.

FOR AND ON BEHALF OF THE BOARD

Place: Chennai
Date: August 5, 2021

C C Paarthipan
Chairman

Annexure - VI

FORM AOC – 2

(Pursuant to Section 134 (3) (h) of the Act, 2013 read with Rule 8(2) of the Companies (Accounts) Rules, 2014)

Form for disclosure of particulars of contract / arrangements entered in to by the Company with the related parties referred to in sub-Section 188 (1) of the Act, 2013 including certain arm's length transactions under third proviso thereto.

1. Details of contracts or arrangements or transactions not at arm's length basis

There were no contracts or arrangements or transactions entered in to by the Company during the year ended March 31, 2021 which were not at arm's length basis.

2. Details of material contracts or arrangement or transactions at arm's length basis:

Sl. No	Name of the Related party and relationship	Durations	Salient terms	Date approved by Board / Audit Committee	Nature of Transactions	Amount (In Rupees)
1.	Caplin Steriles Limited - Subsidiary	01.04.2020 to 31.03.2021	Normal Course of business	18.06.2020	Purchase and sale of goods and Services	2,47,62,459
2.	Neo Ethicals S.A Nicaragua - Step-down Subsidiary	01.04.2020 to 31.03.2021	Normal course of business	18.06.2020	Sale of goods	33,94,95,842
3.	Neo Ethicals Cia. Ltda-Ecuador - Step-down Subsidiary	01.04.2020 to 31.03.2021	Normal course of business	18.06.2020	Sale of goods	32,95,21,797
4.	Drogueria Saimed De Honduras - Step-down Subsidiary	01.04.2020 to 31.03.2021	Normal course of business	18.06.2020	Sale of goods	33,59,40,209
5.	Ashvich Infotek Private Limited - Directors Interested	01.04.2020 to 31.03.2021	Agreement to Lease	18.06.2020	Lease Rent paid	1,12,62,349
6	Nuevos Eticos Neoethicals, S A – GT - Step-down Subsidiary	01.04.2020 to 31.03.2021	Normal course of business	18.06.2020	Sale of goods.	123,92,28,048

FOR AND ON BEHALF OF THE BOARD

Place: Chennai
Date: August 5, 2021

C C Paarthipan
Chairman

Annexure - VII

BUSINESS RESPONSIBILITY REPORT

(Pursuant to Regulation 34 (2) (f) of Listing Regulations)

SECTION A: GENERAL INFORMATION ABOUT THE COMPANY

S.No.	Details	
01	Corporate Identity Number (CIN) of the Company	L24231TN1990PLC019053
02	Name of the Company	CAPLIN POINT LABORATORIES LIMITED
03	Registered address	Ashvich Tower, No. 3, Developed Plots Industrial Estate, Perungudi, Chennai – 600 096
04	Website	www.caplinpoint.net
05	E-mail id	info@caplinpoint.net
06	Financial Year reported	2020-21
07	Sector(s) that the Company is engaged in (industrial activity code-wise)	NIC code 210
08	List three key products/services that the Company manufactures/provides	Pharmaceutical formulations such as: 1. Propofol Injections 2. Omeprazol Capsules 3. Softgel Vitamins
09	Total number of locations where business activity is undertaken by the Company a) Number of International Locations b) Number of National Locations	The Company has a Branch in China to source its raw materials and finished goods for import/export. The Company has three direct subsidiaries outside India (i) Hongkong (ii) Colombia (iii) Singapore. The Company in Colombia and Singapore are yet to commence operations. The Company has entered into joint venture with Hainan Jointown Caplin Point Pharmaceuticals Company Limited in Hainan Province of China. **Factories** **UNIT I** 85/3, Suthukeny Village, Mannadipet Commune Panchayat, Puducherry - 605 502 **UNIT II** No. 19, Chinnapuliyur Village, Sirupuzhalpettai (Post), Gummidipoondi Taluk, Tamil Nadu – 601 201. **R&D Units** **UNIT III** Plot No.44,8th Avenue Domestic Tariff Area, Mahindra World city, Chengalpattu Taluk, Chengalpattu - 603 004

S.No.	Details	
		UNIT VI 4th Floor, Plot No. 95 & 96, Road no.9, ALEAP Industrial Estates, Gajularamarm Village, Qutbullapur Mandal, Hyderabad - 500 090. **UNIT VII** Module no.307 & 308, 3rd Floor, Ticel Park, Phase II, CSIR Road, Taramani, Chennai - 600 113. **Unit VIII** Ashvich Towers, No. 3, Developed Plots Industrial, Estate, Perungudi, Chennai - 600 096
10	Markets served by the Company - Local/State/National/International	International – Predominantly Latin America and West Africa

SECTION B: FINANCIAL DETAILS OF THE COMPANY

S.No.	Details	
01	Paid up Capital (INR)	Rs. 1,512.86 Lakhs
02	Total Turnover (INR)	Rs. 48,267.96 Lakhs
03	Total profit after taxes (INR)	Rs. 15,621.98 Lakhs
04	Total Spending on Corporate Social Responsibility (CSR) as percentage of profit after tax	Rs. 9.55 Lakhs i.e. 0.06% of profit after tax
05	List of activities in which expenditure in 4 above has been incurred	Please refer the “Annual Report on CSR activities for the FY 2020-21” annexed to this Annual report

SECTION C: OTHER DETAILS

S.No.	Details	
01	Does the Company have any Subsidiary Company/ Companies?	YES
02	Do the Subsidiary Company/Companies participate in the BR (Business Responsibility) Initiatives of the parent company? If yes, then indicate the number of such subsidiary company(s)	The participation by subsidiaries in BR is not necessitated considering the size of the Company.
03	Do any other entity/entities (e.g. suppliers, distributors etc.) that the Company does business with, participate in the BR initiatives of the Company? If yes, then indicate the percentage of such entity/entities? [Less than 30%, 30-60%, More than 60%]	NO

SECTION D: BR INFORMATION

1. Details of Director/Directors responsible for BR

(a) Details of the Director/Director responsible for implementation of the BR policy/policies

DIN	06819026
Name	Dr Sridhar Ganesan
Designation	Managing Director

(b) Details of the BR head

No.	Particulars	Details
1	DIN Number (if applicable)	06819026
2	Name	Dr Sridhar Ganesan
3	Designation	Managing Director
4	Telephone number	044 2496 8000
5	e-mail id	info@caplinpoint.net

2. Principle-wise (as per NVGs) BR Policy/policies

(a) Details of compliance (Reply in Y/N)

No.	Questions	P1 Business Ethics	P 2 Product responsibility	P3 Well being of Employees	P 4 Stakeholder engagement	P5 Human Rights	P 6 Environ-ment	P7 Public policy	P8 CSR	P9 Customer relation
1	Do you have a policy/ policies for....	YES	YES	YES	YES	YES	YES	YES	YES	YES
2	Has the policy being formulated in consultation with the relevant stakeholders?	YES	YES	YES	YES	YES	YES	YES	YES	YES
3	Does the policy conform to any national / international standards? If yes, specify? (50 words)	The policies conform to the guidelines / standards of Companies Act, 2013 and other Statutory Acts, Regulations, Notifications, etc. The policies / standards are at par with generally accepted practices for the respective principles.								
4	Has the policy being approved by the Board? Is yes, has it been signed by MD/ owner/ CEO/ appropriate Board Director?	YES	YES	YES	YES	YES	YES	YES	YES	YES

No.	Questions	P1 Business Ethics	P 2 Product responsibility	P3 Well being of Employees	P 4 Stakeholder engagement	P5 Human Rights	P 6 Environ-ment	P7 Public policy	P8 CSR	P9 Customer relation
5	Does the company have a specified committee of the Board/ Director/ Official to oversee the implementation of the policy?	YES	YES	YES	YES	YES	YES	YES	YES	YES
6	Indicate the link for the policy to be viewed online?	http://www.caplinpoint.net/investor.aspx								
7.	Has the policy been formally communicated to all relevant internal and external stakeholders?	YES	YES	YES	YES	YES	YES	YES	YES	YES
8	Does the Company have in-house structure to implement the policy/ policies	YES	YES	YES	YES	YES	YES	YES	YES	YES
9	Does the Company have a grievance redressal mechanism related to the policy/ policies to address stakeholders' grievances related to the policy/ policies?	YES	YES	YES	YES	YES	YES	YES	YES	YES
10	Has the company carried out independent audit/ evaluation of the working of this policy by an internal or external agency?	YES	YES	YES	YES	YES	YES	YES	YES	YES

(b) If answer to the question at serial number 1 against any principle, is 'No', please explain why: (Tick up to 2 options)

No.	Questions	P 1	P 2	P 3	P 4	P 5	P 6	P 7	P 8	P 9
1	The company has not understood the Principles	--	--	--	--	--	--	--	--	--
2	The company is not at a stage where it finds itself in a position to formulate and implement the policies on specified principles	--	--	--	--	--	--	--	--	--
3	The company does not have financial or manpower resources available for the task	--	--	--	--	--	--	--	--	--
4	It is planned to be done within next 6 months	--	--	--	--	--	--	--	--	--
5	It is planned to be done within the next 1 year	--	--	--	--	--	--	--	--	--
6	Any other reason (please specify)									

3. Governance related to BR (Business Responsibility)

S.No.	Particulars	Details
1	Indicate the frequency with which the Board of Directors, Committee of the Board or CEO to assess the BR performance of the Company. Within 3 months, 3-6 months, Annually, More than 1 year	The BR is assessed annually by the Board of Directors
2	The BR is assessed annually by the Board of Directors	YES

SECTION E: PRINCIPLE-WISE PERFORMANCE

PRINCIPLE 1

S.No.	Particulars	Details
01	Does the policy relating to ethics, bribery and corruption cover only the company? Yes/ No. Does it extend to the Group/Joint Ventures/ Suppliers/ Contractors/NGOs /Others	YES. The Company Strictly adheres to fair, transparent and ethical governance practices. The Company has well defined anti-corruption and anti-bribery systems in place.
02	How many stakeholder complaints have been received in the past Financial Year and what percentage was satisfactorily resolved by the management? If so, provide details thereof, in about 50 words or so.	The Company has received 245 complaints from the shareholders during the year 2020-21 and all the complaints were resolved. No complaint has been received under Whistle Blower Policy.

PRINCIPLE 2

S.No.	Particulars	Details
01	List up to 3 of your products or services whose design has incorporated social or environmental concerns, risks and/or opportunities.	NIL
02	For each such product, provide the following details in respect of resource use (energy, water, raw material etc.) per unit of product(optional): (a) Reduction during sourcing/production/ distribution achieved since the previous year throughout the value chain? (b) Reduction during usage by consumers (energy, water) has been achieved since the previous year?	NIL
03	Does the company have procedures in place for sustainable sourcing (including transportation)? (a) If yes, what percentage of your inputs was sourced sustainably? Also, provide details thereof, in about 50 words or so	NO
04	Has the company taken any steps to procure goods and services from local & small producers, including communities surrounding their place of work? (a) If yes, what steps have been taken to improve their capacity and capability of local and small vendors?	The Company continuously engages itself in identifying local vendors and service providers. The Company guides them on a continuous basis with respect to improvement of quality of products and services provided by them.
05	Does the company have a mechanism to recycle products and waste? If yes what is the percentage of recycling of products and waste (separately as <5%, 5-10%, >10%). Also, provide details thereof, in about 50 words or so	NIL

PRINCIPLE 3

S.No.	Particulars	Details
01	Please indicate the Total number of employees	613
02	Please indicate the Total number of employees hired on temporary/contractual/casual basis	366
03	Please indicate the Number of permanent women employees	100
04	Please indicate the Number of permanent employees with disabilities	2
05	Do you have an employee association that is recognized by management	Nil
06	What percentage of your permanent employees is members of this recognized employee association?	Nil

07. Please indicate the Number of complaints relating to child labour, forced labour, involuntary labour, sexual harassment in the last Financial Years and pending, as on the end of the Financial Year.

No.	Category	No of complaints filed during the Financial Year	No of complaints pending as on the end of Financial Year
1	Child labour / forced labour / involuntary labour	NIl	
2	Sexual harassment	NIL	
3	Discriminatory employment	NIL	

8. What percentage of your under mentioned employees were given safety & skill up- gradation training in the last year?

a)	Permanent Employees	100%
b)	Permanent Women Employees	
c)	Casual/Temporary/Contractual Employees	
d)	Employees with Disabilities	

PRINCIPLE 4

S.No.	Particulars	Details
01	Has the company mapped its internal and external stakeholders?	YES
02	Out of the above, has the company identified the disadvantaged, vulnerable & marginalized stakeholders	YES
03	Are there any special initiatives taken by the company to engage with the disadvantaged, vulnerable and marginalized stakeholders. If so, provide details thereof, in about 50 words or so	NO

PRINCIPLE 5

S.No.	Details	
01	Does the policy of the company on human rights cover only the company or extend to the Group / Joint Ventures / Suppliers / Contractors / NGOs / Others?	The Company's Code of Conduct and HR practices have been developed to respect and protect human rights. It extends only to the Company and its Subsidiaries.
02	How many stakeholder complaints have been received in the past Financial Year and what percent was satisfactorily resolved by the management	NIL

PRINCIPLE 6

S.No.	Particulars	Details
01	Does the policy related to Principle 6 cover only the company or extends to the Group/ Joint Ventures/Suppliers/Contractors/NGOs/others	It extends only to the Company and its Subsidiaries.
02	Does the company have strategies/ initiatives to address global environmental issues such as climate change, global warming, etc? Y/N. If yes, please give hyperlink for webpage etc	NO
03	Does the company identify and assess potential environmental risks	YES
04	Does the company have any project related to Clean Development Mechanism? If so, provide details thereof, in about 50 words or so. Also, if Yes, whether any environmental compliance report is filed?	NO
05	Has the company undertaken any other initiatives on - clean technology, energy efficiency, renewable energy, etc. Y/N. If yes, please give hyperlink for web page etc	YES. The Company focuses on energy conservation. The energy conservation measures include use of alternate source of energy like wind power, solar.
06	Are the Emissions/Waste generated by the company within the permissible limits given by CPCB/SPCB for the Financial Years being reported	Yes. All emissions & wastes are within the permissible limits.
07	Number of show cause/ legal notices received from CPCB/SPCB which are pending (i.e. not resolved to satisfaction) as on end of Financial Year	NIL

PRINCIPLE 7

S.No.	Particulars	Details
01	Is your company a member of any trade and chamber or association? If Yes, Name only those major ones that your business deals with	YES 1. Indian Drug Manufacturers Association 2. Pharmaceuticals Manufacturers Association of Tamil Nadu 3. Pharmaceutical Export Promotion Council 4. Federation of Indian Exports Organization 5. Madras Chamber of Commerce and Industry 6. Confederation of Indian Industries
02	Have you advocated/lobbied through above associations for the advancement or improvement of public good? Yes/No; if yes specify the broad areas (drop box: Governance and Administration, Economic Reforms, Inclusive Development Policies, Energy security, Water, Food Security, Sustainable Business Principles, Others)	YES We have advocated for reforms through these Associations for the advancement of general public.

PRINCIPLE 8

S.No.	Particulars	Details
01	Does the company have specified programmes/initiatives/projects in pursuit of the policy related to Principle 8? If yes details thereof	Yes. Please refer the "Annual Report on CSR activities for the FY 2020-21" annexed to this Annual report
02	Are the programmes/projects undertaken through in-house team/own foundation/external NGO/government structures/any other organization?	All the projects were undertaken directly by the Company.
03	Have you done any impact assessment of your initiative?	NO
04	What is your company's direct contribution to community development projects- Amount in INR and the details of the projects undertaken	Yes. Please refer the "Annual Report on CSR activities for the FY 2020-21" annexed to this Annual report
05	Have you taken steps to ensure that this community development initiative is successfully adopted by the community? Please explain in 50 words, or so	NO

PRINCIPLE 9

S.No.	Particulars	Details
01	What percentage of customer complaints/consumer cases are pending as on the end of Financial Year	NIL
02	Does the company display product information on the product label, over and above what is mandated as per local laws? Yes/No/N.A. /Remarks(additional information)	NO
03	Is there any case filed by any stakeholder against the company regarding unfair trade practices, irresponsible advertising and/or anti-competitive behaviour during the last five years and pending as on end of Financial Year. If so, provide details thereof, in about 50 words or so	NO
04	Did your company carry out any consumer survey/ consumer satisfaction trends?	NO

FOR AND ON BEHALF OF THE BOARD

Place: Chennai
Date: August 5, 2021

C C PAARTHIPAN
Chairman

CORPORATE GOVERNANCE REPORT

1. COMPANY'S PHILOSOPHY ON CODE OF GOVERNANCE

Caplin believes in best Corporate Governance practices which stresses the importance of transparency, excellence, accountability and protection of shareholder's interests and this has been the foundation on which Caplin has been conducting business since inception and it is a continuous and ongoing process. The Company's Corporate Governance Report is produced below.

2. BOARD OF DIRECTORS

a) Composition and category of Board of Directors

As on March 31, 2021, Board comprises of Nine Directors out of which six are Independent Directors including a Independent Woman Director and an Executive Director and two Non-Executive - Non-Independent Directors.

Mr. C C Paarthipan, is the Non-Executive Non-Independent Promoter Chairman and Dr. Sridhar Ganesan is the Managing Director of the Company. Mr. D P Mishra is a Non-Executive Non-Independent Director of the Company.

Mr. V Thirumalai, Mr. R Viswanathan, Dr. R Ravichandran, Dr. K C John, D Sathyanarayanan and Dr. C K Gariyali are the Independent Directors of the Company. Dr. R Ravichandran (DIN: 01920603), Non-Executive Independent Director ceased to be a Director w.e.f. May 11, 2021 (close of business hours), upon completion of his tenure.

The Composition of the Board is in conformity with the requirement of Regulation 17 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) and the Companies Act, 2013 (Act, 2103). In the opinion of the Board, all the Independent Directors have confirmed that they meet the "Independence Criteria" as mentioned under Section 149 of the Act, 2013 and Regulation 16 (1)(b) of Listing Regulations. Every Independent Director, at the first meeting of the Board in which he/she participates as a Director and thereafter at the first meeting of the Board in every Financial Year, gives a declaration under Section 149(7) of the Act, 2013 that he/she meets the criteria of independence as required under Section 149(6) of the Act, 2013.

As required under Regulation 16 of the Listing Regulations, it is also ensured that Independent Directors do not hold Non-Independent Directorship position in another company, where any Non-Independent Director of the Company is an Independent Director.

b) Board Meetings

Board and Committee meetings through video conferencing or other audio visual means, were made available to the Directors. As per the Companies (Meetings of Board and its Powers) Rules, 2014 (Fourth Amendment Rules, 2020) dated 30th December 2020, meetings through Video Conferencing were permitted for approving the restricted items of businesses including financial statements. During the year, information as mentioned in Part A of Schedule II of the Listing Regulations, has been placed before the Board for its consideration. The Board periodically reviews the compliance reports of all Laws applicable to the Company, Company's strategic direction, management policies, performance objectives and effectiveness of Corporate Governance practices.

As a matter of good governance practice, all Board meetings are called by proper notice along with structured agenda papers which is backed by comprehensive background information of the business transaction. The Board has complete unrestricted access to all information with regards to the Company.

During the Financial Year under review, the Board of Directors met four times (i.e.) 18.06.2020, 10.08.2020, 05.11.2020 and 04.02.2021. The maximum time gap between two meetings did not exceed 120 days. The necessary quorum was present for all the meetings.

Besides, the Independent Directors held a separate meeting on 04.02.2021, in compliance with the provisions of the Act, 2013 and Regulation 25(3) of the Listing Regulations. All the Independent Directors were present at the meeting.

The details of Directors seeking re-appointment at the ensuing Annual General Meeting (AGM) is furnished in the Notice convening the meeting of the shareholders.

The composition of the Board, attendance at Board Meetings held during the said period and at the last AGM, number of Directorships, memberships/chairmanships of the Board and Committees of public Companies as on March 31, 2021 in the Company are as under:

Name of the Director & DIN	Category	No. of Board Meetings attended in the year	Attendance at the previous AGM (28.09.2020)	Directorships in other Public Limited Companies	Committee Position(s) in Public Limited Companies (Including Caplin Point Laboratories Limited)		Directorship(s) in other Listed Companies
					Chairman	Member	
Mr. C C Paarthipan DIN : 01218784	Non-Executive Non-Independent Promoter Chairman	4	Yes	1	-	-	-
Dr. Sridhar Ganesan DIN :06819026	Managing Director	4	Yes	-	-	1	-
Mr. D P Mishra DIN : 02032818	Non- Executive - Non-Independent Director	4	Yes	-	-	1	-
Mr. V Thirumalai DIN :03015619	Independent Director	4	Yes	-	1	1	-
Mr. R Viswanathan DIN : 07173713	Independent Director	4	Yes	-	-	-	-
Dr. K C John DIN : 01067374	Independent Director	4	Yes	1	1	2	-
Mr. D Sathyanarayanan DIN : 07650566	Independent Director	4	Yes	-	-	1	-
Dr. C K Gariyali DIN:08711546	Independent Director	4	Yes	1	-	1	-
Dr. R Ravichandran * DIN :01920603	Independent Director	4	Yes	-	1	2	-

***** Retired w.e.f. May 11, 2021

Notes:

i. As required under the Regulation 17A of the Listing Regulations, none of the directors holds directorship in more than 7 (seven) listed companies and as per declarations received, none of the Directors serves as an Independent Director in more than 7 (seven) listed companies, across the directorships held including that in Caplin Point Laboratories Limited.

ii. None of the Directors was a member in more than 10 (ten) Committees, nor a Chairman in more than 5 (five) committees across all companies in which he/she was a Director, including those held in Caplin Point Laboratories Limited. For the purpose of considering the limit of the committees on which a Director can serve, all public limited companies, whether listed or not, have been included and all other companies including private limited companies, foreign companies and companies under Section 8 of the Act, 2013, have been excluded.

iii. Only Audit Committee and Stakeholders' Relationship Committee are considered for the purpose of reckoning committee positions.

iv. None of the Directors of the Company are related to each other.

c) Familiarisation Programme for Independent Directors

Pursuant to the Code of Conduct for Independent Directors specified under the Act, 2013 and requirements of the Listing Regulations, the Company has framed a familiarisation programme for all its Independent Directors. The Company follows a structured orientation programme for the Independent Directors to familiarise them to understand the nature of industry the Company operates into, its business model, updates on the business and operations of the Company and their roles, rights and responsibilities.

The details of familiarisation programme are provided at http://www.caplinpoint.net/investor.aspx

3. KEY SKILLS, EXPERTISE AND COMPETENCIES OF THE BOARD

The Board of the Company comprises of eminent personalities and leaders in their respective fields. These members bring in the required skills, competence and expertise to the Board. These Directors are nominated based on well-defined selection criteria. Nomination and Remuneration Committee considers, inter alia, key skills, qualifications, expertise and competencies, whilst recommending to the Board the candidature for appointment of Director. The Board of Directors have, based on the recommendations of the Nomination and Remuneration Committee, identified the following core key skills/expertise/competencies of Directors as required in the context of business of the Company for its effective functioning which are currently possessed by the Board Members of the Company.

4. MATRIX HIGHLIGHTING CORESKILLS/EXPERTISE/COMPETENCIES OF THE BOARD OF DIRECTORS

The Board of Directors of the Company have identified the following skills required for the Company and availability of such skills with the Board:

Name of the Director	Financial	Governance	People Management and Leadership	Industry Knowledge	Strategic Planning	Risk Management
Mr. C C Paarthipan	√	√	√	√	√	√
Dr. Sridhar Ganesan	√	√	√	√	√	√
Mr. D P Mishra	√	√	√	√	√	√
Mr. V Thirumalai	√	√	√	√	√	√
Mr. R Viswanathan	√	√	√	√	√	√
Dr. K C John	√	√	√	√	√	√
Mr. D Sathyanarayanan	√	√	√	√	√	√
Dr. C K Gariyali	√	√	√	√	√	√
Dr. R Ravichandran	√	√	√	√	√	√

a. **Financial:** Basic understandings in financial management, financial statements, financial controls and experience in accounting principles, auditing and reporting.

b. **Governance:** Ensuring adherence to the Corporate Governance Principles, ability to benchmark with the best governance practices globally, protecting and enhancing stakeholders value and driving corporate ethics and values, ability to understand, assess and manage risk.

c. **People Management and Leadership:** Effective management of business operations, ability to guide on complex business decisions, anticipate changes, setting priorities, aligning resources towards achieving goals, Expertise in developing talent, succession planning, furthering representation and diversity and other strategic human resource advisory.

d. **Industry Knowledge:** Expertise in Pharma Industry

e. **Strategic Planning:** Good business instincts and acumen, ability to get to the crux of the issue, ability to provide guidance and active participation in complex decision making, set priorities and focus energy and resources towards achieving goals.

f. **Risk Management:** In depth knowledge and expertise of risk management, risk framework, adequacy and efficiency of controls, mitigation of risks etc. in respect of the businesses of the Company.

5. COMMITTEES

A. Audit Committee

a) Terms of Reference

In accordance with the provisions of Section 177 of the Act, 2013 and Regulation 18 of the Listing Regulations, the Company has formed its Audit Committee. The composition and terms of reference are in conformity with the said provisions.

The Committee acts as a link between the Management, the Statutory Auditors, Internal Auditors and the Board. The Committee supervises the Company's internal controls, monitors the Company's financial reporting process and inter alia performs the following functions:

- recommending the appointment, remuneration and term of appointment of Statutory Auditors of the Company and approval for availing any other services;
- reviewing and monitoring the Auditor's independence and performance and effectiveness of audit process;
- examining the annual financial statements and auditor's report thereon before submission to the Board for approval;
- overseeing the Company's financial reporting process and disclosure of financial information to ensure that the financial statements are correct, sufficient and creditable;
- reviewing Management Discussion and Analysis of financial condition and results of operations;
- scrutinizing the inter-corporate loans and investments;
- reviewing, approving or subsequently modifying any Related Party Transactions in accordance with the Related Party Transaction Policy of the Company;
- reviewing with the Management, performance of Statutory Auditors and Internal Auditors, adequacy of internal control systems;
- reviewing the adequacy of internal audit function and discussing with Internal Auditors any significant finding and follow-up thereon;
- evaluating internal financial controls and risk management systems, reviewing the functioning of the whistle blower mechanism;
- reviewing the valuation of undertakings or assets of the Company, wherever it is necessary;
- reviewing the utilization of loans and/ or advances from/ investment, by the holding company in the subsidiary exceeding rupees 100 crore or 10% of the asset size of the subsidiary, whichever is lower including existing loans / advances / investments existing as on the date of coming into force of this provision;
- reviewing the functioning of the Whistle Blower mechanism;
- Any other functions as may be decided by the Board from time to time.

b) Composition

The composition of the Audit Committee is given below:

Name of the Members	Category
Dr. K C John*	Chairman, Independent Director
Dr. Sridhar Ganesan	Member, Managing Director
Mr. V Thirumalai**	Member, Independent Director
Mr. D Sathyanarayanan	Member, Independent Director
Dr. R Ravichandran***	Member, Independent Director

* appointed as Chairman w.e.f. May 12, 2021
** appointed as Member w.e.f. May 12, 2021
*** Ceases to be a Member and Chairman w.e.f. May 11, 2021

c) Meetings

The Audit Committee met four times during the year on 18.06.2020, 10.08.2020, 05.11.2020 and 04.02.2021. The maximum time gap between two meetings did not exceed 120 days.

Name of the Members	No. of meetings attended
Dr. K C John	4
Dr. R Ravichandran	4
Dr. Sridhar Ganesan	4
Mr. D Sathyanarayanan	4

Dr. R Ravichandran, the then Chairman of the Audit Committee was present at the AGM held on September 28, 2020. Mr. Dinesh R G, Company Secretary is the Secretary to the Committee.

The Committee invites the Statutory Auditors and the Internal Auditors for discussions at the meeting. Managing Director and Chief Financial Officer are permanent invitees at the Committee meetings. Members of Senior Management team also attend the meetings depending on the agenda.

B. Nomination and Remuneration Committee

a) Terms of Reference

In accordance with the provisions of Section 178 of the Act, 2013 and Regulation 19 of the Listing Regulations, the Company has formed its Nomination and Remuneration Committee. The composition and terms of reference are in conformity with the said provisions.

The brief description of the terms of reference of the Committee are given below:

- Formulate Remuneration Policy and a Policy on Board Diversity;
- Formulate criteria for evaluation of Directors and the Board;
- To ensure that the Remuneration Policy shall also include the criteria for determining qualifications, positive attributes and independence of a Director and recommend to the Board a policy, relating to the remuneration for the Directors, Key Managerial Personnel and other employees and recommend the remuneration to the Board;
- Identify persons who are qualified to become Directors and who may be appointed in Senior Management in accordance with the criteria laid down, recommend to the Board their appointment and removal and shall carry out evaluation of every Director's performance.

The Committee acts as the Compensation Committee for administration of Caplin Point Laboratories Limited ESOP 2015 and Caplin Point Laboratories Limited ESOP 2017.

b) Composition

The composition of the Nomination and Remuneration Committee is given below:

Name of the Members	Category
Mr. V Thirumalai	Chairman, Independent Director
Dr. K C John	Member, Independent Director
Mr. D P Mishra*	Member, Non Executive Non-Independent Director
Dr. R Ravichandran**	Member, Independent Director

* appointed as a Member w.e.f. May 12, 2021

** Ceases to be a Member w.e.f. May 11, 2021

c) Meetings

The Nomination and Remuneration Committee met three times during the year on 18.06.2020, 05.11.2020 and 04.02.2021.

Name of the Members	No. of meetings attended
Mr. V Thirumalai	3
Dr. K C John	3
Dr. R Ravichandran	3

Mr. V Thirumalai, the Chairman of the Nomination and Remuneration Committee was present at the AGM held on

September 28, 2020. Mr. Dinesh R G, Company Secretary is the Secretary to the Committee.

d) Performance evaluation criteria for Independent Directors

Pursuant to the provisions of the Act, 2013 and Regulation 25(4) of the Listing Regulations, the Board has carried out the annual performance evaluation of its own performance, individual Directors and of its Committees. The Company had carried out the said evaluation process in a transparent manner by using the questionnaire considered / approved by the Board after taking into account the Guidance Note issued by SEBI vide its Circular SEBI/HO/CFD/CMD/CIR/2017/004 dated January 5, 2017 and the recommendations of the Nomination and Remuneration Committee, covering various aspects of the Board's functioning such as adequacy of the composition of the Board and its Committees, board culture, execution and performance of specific duties, obligations, compliance and governance etc.

The performance evaluation of the Independent Directors was carried out by the entire Board excluding the Directors being evaluated. The performance evaluation of the Chairman and the Non-Executive Non-Independent Directors was carried out by the Independent Directors. The Directors expressed their satisfaction over the evaluation process.

e) Remuneration Policy

The Remuneration Policy of the Company is designed and framed to attract, motivate and retain available talents. The policy reflects the Company's objectives for good corporate governance as well as sustained long-term value creation for shareholders.

When determining the remuneration policy and arrangements for Executive Directors/ KMP's, the Nomination & Remuneration Committee considers pay, other employee retention benefits such as ESOP etc, and employment conditions with peers / elsewhere in the competitive market to ensure that pay structures are appropriately aligned and that levels of remuneration remain appropriate in this context.

The remuneration paid to Executive Directors as mentioned in this report has been approved by the Board and the details regarding the same are placed at the AGM for approval of the shareholders. No remuneration, other than sitting fees for attending the Board/ Committee meetings were paid to the non-Executive Directors.

The remuneration policy has been uploaded on the website of the Company at http://www.caplinpoint.net/investor.aspx

f) Details of Remuneration Paid to Non-Executive Directors for the Financial Year ended March 31, 2021

(Amount in Rs.)

Name of Director	Remuneration	Commission and performance linked incentive	Sitting Fees	Total	No. of shares held
Mr. C C Paarthipan	--	--	--	--	1,41,67,192
Mr. V Thirumalai	--	--	1,40,000	1,40,000	2,41,635
Dr. K C John	--	--	2,20,000	2,20,000	--
Mr. R Viswanathan	--	--	80,000	80,000	--
Mr. D Sathyanarayanan	--	--	1,60,000	1,60,000	--
Mr. D P Mishra	--	--	80,000	80,000	--
Dr. C K Gariyali	--	--	80,000	80,000	--
Mr. R Ravichandran	--	--	2,20,000	2,20,000	--

g) Details of Remuneration Paid to Executive Directors for the Financial Year Ended March 31,2021

(Amount in Rs. Lakhs)

Name of Director	Gross	Contribution to PF	Total	No. of shares held
Dr. Sridhar Ganesan	54.05	2.33	56.38	80,250

There is no severance fees payable to Executive Directors. The Notice period is bound by the employee contracts.

C. Stakeholders Relationship Committee

a) Terms of Reference

In accordance with the provisions of Section 178 of the Act, 2013 and Regulation 20 of the Listing Regulations, the Company has formed its Stakeholders Relationship Committee. The composition and terms of reference are in conformity with the said provisions.

The Committee inter alia reviews the mechanism of redressal of grievances of the securities holders, service level of Registrar and Transfer Agents and deals with other matters concerning securities holders including dividend.

b) Composition

The composition of the Stakeholders Relationship Committee is given below:

Name of the Members	Category
Mr. V Thirumalai	Chairman, Independent Director
Mr. D Sathyanarayanan*	Member, Independent Director
Mr. D P Mishra	Member, Non Executive Non-Independent Director
Dr. R Ravichandran**	Member, Independent Director

* appointed as a Member w.e.f. May 12, 2021

** Ceases to be a Member w.e.f. May 11, 2021

c) Meetings

The Stakeholders Relationship Committee met four times during the year on 18.06.2020, 10.08.2020, 05.11.2020 and 04.02.2021.

Name of the Members	No. of meetings attended
Mr. V Thirumalai	4
Mr. D P Mishra	4
Dr. R Ravichandran	4

Mr. V Thirumalai, the Chairman of the Stakeholders Relationship Committee was present at the AGM held on September 28, 2020. Mr. Dinesh R G, Company Secretary acts as the Compliance Officer to the Committee and the Company.

The status of Investor Complaints during the year ended March 31, 2021, is as under:

Particulars	No. of Complaints
Complaints as on April 1, 2020	Nil
Complaints received during the year	245
Complaints resolved during the year	245
Complaints pending as on March 31, 2021	Nil

D. Risk Management Committee

a) Terms of Reference

Pursuant to the provisions of Regulation 21 of the Listing Regulations, top 1000 listed entities based on their market capitalisation are required to form a Risk Management Committee. Composition and terms of reference of the Committee are in conformity with the said provisions.

The brief description of the terms of reference of the Committee are given below:

- To assess the Company's risk profile and key areas of risk in particular;
- To recommend the Board and adoption of risk assessment and rating procedures;
- To articulate the Company's policy for the oversight and management of business risks;
- To examine and determine the sufficiency of the Company's internal processes for reporting on and managing key risk areas;
- To assess and recommend the Board acceptable levels of risk;
- To develop and implement a risk management frame work and internal control system;
- To review the nature and level of insurance coverage;
- To have special investigations into areas of corporate risk and break-downs in internal control;
- To report the trends on the Company's risk profile, reports on specific risks and the status of the risk management process;
- To define the risk appetite of the organization;
- To exercise oversight of management's responsibilities and review the risk profile of the organization to ensure that risk is not higher than the risk appetite determined by the board;
- To ensure that the Company is taking appropriate measures to achieve prudent balance between risk and reward· in both ongoing and new business activities;
- To assist the Board in setting risk strategies, policies, frameworks, models and procedures in liaison with management and in the discharge of its duties relating to corporate accountability and associated risk in terms of management assurance and reporting;
- To review and assess the nature, role, responsibility and authority of the risk management function within the Company and outline the scope of risk management work;
- To fulfill its statutory, fiduciary and regulatory responsibilities;
- To ensure that the risk awareness culture is pervasive throughout the organization;
- To review issues raised by Internal Audit that impact the risk management framework;
- To ensure that infrastructure, resources and systems are in place for risk management is adequate to maintain a satisfactory level of risk management discipline;
- The Board shall review the performance of the risk management committee annually;
- Perform other activities related to risk management as requested by the Board of Directors or to address issues related to any significant subject within its term of reference.

b) Composition

The composition of the Risk Management Committee is given below:

Name of the Members	Category
Mr. D Sathyanarayanan*	Chairman, Independent Director
Dr. Sridhar Ganesan	Managing Director
Mr. D Muralidharan**	Member, Chief Financial Officer
Dr. R Ravichandran***	Member, Independent Director

* appointed as Chairman w.e.f. May 12, 2021
** appointed as Member w.e.f. May 12, 2021
*** Ceases to be Chairman and Member w.e.f. May 11, 2021

c) Meetings

The Risk Management Committee met one time during the year on 18.06.2020.

Name of the Members	No. of meetings attended
Dr. Ravichandran	1
Mr. D Sathyanarayanan	1
Dr. Sridhar Ganesan	1

Mr. Dinesh R G, Company Secretary is the Secretary to the Committee.

The Chairman of the Committee will apprise the Board, the most significant risks along with the status of action taken by the Management for mitigating such risks and the effectiveness of the Enterprise Risk Management system. Details of Risk Management measures taken by the Company have been provided in the Management Discussion and Analysis Report which is attached to the Board's Report.

E. Corporate Social Responsibility Committee

The Company has constituted a Corporate Social Responsibility ("CSR") Committee pursuant to the provisions of Section 135 of the Act, 2013, read with Companies (Corporate Social Responsibility) Rules, 2014.

The CSR Committee formulate and recommends to the Board, a CSR Policy indicating the activities to be undertaken by the Company as specified in Schedule VII of the Act, 2013. The Committee recommends the amount of expenditure to be incurred on the activities mentioned in the CSR Policy and monitors the implementation of the CSR Policy.

The composition of the CSR Committee and the details of meetings attended by its members are given below.

a) Composition

The composition of the Corporate Social Responsibility Committee is given below:

Name of the Members	Category
Mr. C C Paarthipan	Chairman
Dr. Sridhar Ganesan	Member, Managing Director
Mr. V Thirumalai	Member, Independent Director

b) Meetings

The Corporate Social Responsibility Committee met one time during the year on 10.08.2020.

Name of the Members	No. of meetings attended
Mr. C C Paarthipan	1
Dr. Sridhar Ganesan	1
Mr. V Thirumalai	1

Mr. Dinesh R G, Company Secretary is the Secretary to the Committee.

The CSR Report as required under the Act, 2013 for the year ended March 31, 2021 is attached as *Annexure - III* to the Board's Report.

6. EMPLOYEE STOCK OPTION

Detailed information about Employee Stock Option and relevant information are given in the Directors Report.

7. GENERAL BODY MEETINGS

Details of AGM held during last three years and the special resolution(s) passed thereat, are as follows:

Year	Date	Time	Location	Special Resolutions Passed
2020	28.09.2020 (29th AGM)	10.00 AM	Through Video Conferencing ("VC") / Other Audio Visual Means ("OVAM").	1. Appointment of Dr. C K Gariyali as an Independent Director
2019	12.09.2019 (28th AGM)	10.00 AM	Sri Thyaga Brahma Gana Sabha (Vani Mahal) No.103, G N Road, T Nagar, Chennai -600 017	1. Amendment of Object Clause of Memorandum of Association 2. Adoption of New Set of Articles of Association
2018	28.09.2018 (27th AGM)	10.00 AM	Sri Thyaga Brahma Gana Sabha (Vani Mahal) No.103, G N Road, T Nagar, Chennai -600 017	1. Re-appointment of Mr. V Thirumalai as an Independent Director for a second term of five consecutive years. 2. Re-appointment of Dr. K Nirmala Prasad as an Independent Director for a second term of five consecutive years. 3. Re-appointment of Mr. R Viswanathan as an Independent Director for a second term of five consecutive years. 4. Grant of options to the employees of the subsidiary Company(ies) of the Company under Caplin Point Employees Stock Option Plan 2017 (ESOP 2017)

During the year under review, no resolution was passed by the Company through Postal Ballot and there is no such proposal to pass any resolution through postal ballot as on the date of this Report.

8. MEANS OF COMMUNICATIONS

a) Results

Quarterly financial results are announced within 45 (forty five) days from the end of the quarter and annual audited results are announced within 60 (sixty) days from the end of the Financial Year as per the Regulation 33 of the Listing Regulations and are published in the newspapers in accordance with Regulation 47 of the Listing Regulations.

Quarterly financial results are announced to stock exchanges within 30 (thirty) minutes from the closure of the Board meeting at which these are considered and approved. Quarterly, half-yearly and annual financial results and other public notices issued to the Members are usually published in various leading dailies, such as The Financial Express and Maalai Malar. These quarterly financial results are also hosted on the website of the Company.

b) Website

The Company's website contains a functional section "Investors" which displays details/information of interest to various stakeholders. Official press releases are sent to the Stock Exchanges and the same is hosted on the website of the Company.

c) Presentations to institutional Investors / Analysts

Detailed presentations are made to institutional investors and analysts on a quarterly basis and the same is hosted on the website of the Company.

9. GENERAL INFORMATION TO THE SHAREHOLDERS

Day, Date, Time & Venue of Annual General Meeting	Tuesday, September 28, 2021 at 10:00 AM through VC/OAVM	
Date of Book Closure	September 22, 2021 to September 28, 2021 (both days inclusive)	
Dividend Payment Date	Dividend as recommended by the Board of Directors, if declared at the meeting, will be paid on or before October 23, 2021	
Financial Year	April 1 to March 31	
Listing of Equity Shares:-	**BSE Limited ("BSE")** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001 **National Stock Exchange of India Ltd. ("NSE")** Exchange Plaza, C-1, Block G, Bandra Kurla Complex Bandra (E), Mumbai - 400 051	
Trading Symbol	NSE	CAPLIPOINT
	BSE	CAPPL (524742)
ISIN number in National Securities Depository Limited (NSDL) and the Central Depository Service (India) Limited (CDSL)	INE475E01026	
Outstanding GDRs/ADRs/ Not issued Warrants or any convertible instruments	Not Issued	
Listing Fees	Annual listing fee for the Financial Year 2020-21 paid to all the Stock Exchanges.	
Depository Fees	Annual custody fee for the Financial Year 2020-21 paid to the Depositories.	
Dematerialization of shares	As on March 31, 2021, 97% of the Company's shares were held in dematerialized form	

Particulars	**No. of Shares**	**%**
Physical	22,72,560	3.00
Demat		
NSDL	6,70,41,322	88.63
CDSL	63,28,868	8.37
TOTAL	7,56,42,750	100.00
Registrar And Share Transfer Agents	M/s. Integrated Registry Management Services Private Limited, II Floor, "Kences Towers" No.1 Ramakrishna Street, North Usman Road T Nagar, Chennai - 600 017 Phone: 044 - 28140801 - 803 Fax: 044 – 28142479	
Share Transfer System	In terms of Regulation 40(1) of Listing Regulations, as amended, securities can be transferred only in dematerialized form, except in case of request received for transmission or transposition of securities. Members holding shares in physical form are requested to consider converting their holdings to dematerialized form. Transfers of equity shares in electronic form are effected through the depositories with no involvement of the Company. The Directors and Company Secretary are authorized by the Board severally to approve transfers, which are noted at subsequent Board Meetings.	
Outstanding GDRs / ADRs / Warrants / Any other Convertible Instruments	The Company does not have any outstanding GDRs / ADRs / Warrants / Any other Convertible Instruments as on March 31, 2021.	
Commodity Price Risk or Foreign exchange Risk and hedging activities	The Company does not involve in hedging activities in foreign exchange and commodity markets.	

10. STOCK MARKET DATA

Month and Year	BSE				NSE			
	Caplin Price in Rs.		S&P BSE Sensex		Caplin Price in Rs.		S&P CNX Nifty	
	High	Low	High	Low	High	Low	High	Low
April, 2020	376.25	**264.00**	33887.25	27500.79	377.00	**263.00**	9889.05	8055.80
May, 2020	351.00	308.00	32845.48	29968.45	351.45	307.00	9598.85	8806.75
June, 2020	421.75	309.15	35706.55	32348.10	421.70	310.05	10553.15	9544.35
July, 2020	442.00	307.00	38617.03	34927.20	441.90	305.10	11341.40	10299.60
August, 2020	**686.00**	435.75	40010.17	36911.23	**686.00**	435.00	11794.25	10882.25
September, 2020	615.00	491.80	39359.51	36495.98	615.00	490.05	11618.10	10790.20
October, 2020	587.75	488.00	41048.05	38410.20	587.40	488.00	12025.45	11347.05
November, 2020	507.90	438.40	44825.37	39334.92	508.30	437.75	13145.85	11557.40
December, 2020	532.00	450.75	47896.97	44118.10	531.75	450.15	14024.85	12962.80
January, 2021	514.40	458.00	50184.01	46160.46	515.10	458.00	14753.55	13596.75
February, 2021	501.45	450.50	52516.76	46433.65	501.20	452.00	15431.75	13661.75
March, 2021	474.00	402.00	51821.24	48236.35	471.90	401.00	15336.30	14264.40

11. SHARE PRICE PERFORMANCE IN COMPARISON TO BROAD BASED INDICES - BSE SENSEX AND NSE NIFTY SHARE PRICE MOVEMENT (NSE AND BSE)





12. DISTRIBUTION OF SHAREHOLDING AS ON MARCH 31, 2021

S.No	Category	No. of Shareholders	No. of Shares	% to Capital
1	Promoters	5	52214192	69.03
2	Mutual Funds	5	337386	0.45
3	Banks/Indian Financial Institutions	2	381404	0.50
4	Foreign Institutional Investors	26	516854	0.68
5	Insurance Companies	1	250123	0.33
6	Individuals	65793	17355519	22.94
7	Bodies Corporate	251	1010128	1.34
8	Clearing Members	115	183817	0.24
9	IEPF	1	1657631	2.19
10	LLP	26	368343	0.49
11	Non-Resident Indians	1423	957738	1.27
12	HUF	426	182015	0.24
13	Overseas Bodies Corporate	1	227500	0.30
14	Trusts	1	100	-
	TOTAL	**68076**	**75642750**	**100.00**

13. DISTRIBUTION SCHEDULE AS ON MARCH 31, 2021

S. No	Category of Shares	No. of Holders	% to Holders	No. of Shares	% to Shares
1	Up to 500	64076	94.12	5690163	7.52
2	501 - 1000	2133	3.13	1731201	2.29
3	1001 – 2000	970	1.43	1455210	1.92
4	2001 – 3000	344	0.51	872053	1.15
5	3001 – 4000	123	0.18	439088	0.58
6	4001 – 5000	130	0.19	616073	0.81
7	5001 – 10000	163	0.24	1176998	1.56
8	Above 10001	137	0.20	63661964	84.16
	Total	**68076**	**100.000**	**75642750**	**100.00**

14. UNCLAIMED DIVIDEND AS ON MARCH 31, 2021

Financial Year	Due Date of transfer to IEPF	(Amount in Rs.)
2013-14	17.01.2022	29,54,608.00
2014-15	05.12.2022	33,67,485.00
2015-16 (Interim)	06.03.2023	17,21,280.00
2015-16 (Final)	12.10.2023	24,41,064.50
2016-17	21.10.2024	46,35,698.50
2017-18	28.10.2025	8,50,574.00
2018-19	20.11.2026	34,64,909.80
2019-20 (Interim)	03.04.2027	39,69,651.00
2019-20 (Final)	27.10.2027	6,19,576.60

PLANT LOCATIONS

a) Factories

Unit I	Unit II
85/3, Suthukeny Village, Mannadipet Commune Panchayat, Puducherry – 605 502 e-mail: cp1@caplinpoint.net Phone : 0413-2674046, 2674047, Fax : 0413-2674044	No.19, Chinnapuliyur Village, Sirupuzhalpettai (Post), Gummidipoondi Taluk, Tamilnadu – 601 201. email: cp2@caplinpoint.net Phone : 9445391317

b) Research & Development Units

Unit III	Unit VI	Unit VII	Unit VIII
Plot No.44, 8th Avenue Domestic Tariff Area, Mahindra World city, Chengalpattu Taluk, Chengalpattu- 603 004	4th Floor, Plot No. 95 & 96, Road No.9, ALEAP Industrial Estates, Gajularamarm Village, Qutbullapur Mandal, Hyderabad- 500 090	Module no.307 & 308, 3rd Floor, Ticel Park, Phase II, CSIR Road, Taramani, Chennai- 600 113	Ashvich Towers, No. 3, Developed Plots Industrial Estate, Perungudi, Chennai - 600 096

c) Address for Correspondence

Registrar and Transfer Agents (Issues relating to shares, dividends and Annual Reports)	M/s. Integrated Registry Management Services Private Limited Unit: Caplin Point Laboratories Ltd II Floor, “Kences Towers” No.1 Ramakrishna Street North Usman Road, T Nagar, Chennai - 600 017 Phone: 044 - 28140801 - 803, Fax: 044 - 28142479. E-mail: csdstd@integratedindia.in
For any other general matters or in case of any difficulties / grievances	The Company Secretary & Compliance officer M/s. Caplin Point Laboratories Limited “Ashvich Towers” 3rd Floor, No.3, Developed Plots Industrial Estates, Perungudi, Chennai- 600 096 Phone: 044 2496 8000 Website: www.caplinpoint.net E-mail: investor@caplinpoint.net

15. OTHER DISCLOSURES

a) Related Party Transactions

There were no materially significant related party transactions made by the Company with its Promoters, their subsidiaries, Directors or Management or relatives etc. that may have potential conflict with the interests of the Company at large. All the related party transactions are at arm's length basis and in the normal course of business and were approved by the Audit Committee. The details of related party transactions entered during the Financial Years under review, is provided in Notes to accounts.

The policy on Related Party Transactions is hosted on the website of the Company at http://www.caplinpoint.net/investor.aspx

b) Details of Non-Compliance

The Company has complied with various rules and regulations prescribed by the Stock Exchanges, Securities and Exchange Board of India or any other statutory authority relating to the capital markets during the last 3 years. No penalties or strictures have been imposed by them on the Company. The Company further confirms that during the year, no material non-compliance was reported.

c) Vigil Mechanism / Whistle Blower Policy

The Company has formulated a Vigil Mechanism / Whistle Blower Policy to enable Directors and employees to report their genuine concerns and grievances. The Policy provides for adequate safeguards against victimization of employees and directors who avail the vigil mechanism. The Company hereby affirms that no director/employee have been denied access to the Chairman of the Audit Committee.

The whistle blower policy is hosted on the website of the Company at http://www.caplinpoint.net/investor.aspx

d) Compliance with Mandatory Requirements

The Company has complied with all the mandatory requirements specified in Regulations 17 to 27 and clauses (b) to (i) of sub – regulation (2) of Regulation 46 of the Listing Regulations.

e) Policy on Material Subsidiaries

The Company has formulated a Policy on Material Subsidiary as required under Listing Regulations and the policy is hosted on the website of the Company at http://www.caplinpoint.net/investor.aspx

f) Utilization of Funds

The Company has not raised any funds through preferential allotment or qualified institutions placement as specified under Regulation 32 (7A) of the Listing Regulations.

g) Certificate on Non-Disqualification of Directors

The Company has obtained a certificate from M/s. G Ramachandran & Associates, Company Secretaries, Chennai, Secretarial Auditors of the Company, confirming that none of the Directors on the Board of the Company have been debarred or disqualified from being appointed or continuing as directors of the Company by the Board/ Ministry of Corporate Affairs or any such Statutory Authority.

h) Recommendations by the Committees

During the Year under review, the Board of Directors had accepted all recommendations of the Committees of the Board of Directors, which are mandatorily required to be made.

i) Total Fees paid to Statutory Auditors

During the Financial Year 2020-21, total fees for all services paid by the Company to M/s. CNGSN & Associates LLP, Chartered Accountants, Chennai, Statutory Auditors and all the entities forming part of the same network, aggregate to Rs. 24.28 Lakhs.

j) Sexual Harassment at workplace

During the year under review, the Company has not received any complaints in terms of Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

k) Compliance on Corporate Governance Report

The Corporate Governance Report of the Company for the

Financial Year 2020-21 is in compliance with the applicable requirements of SEBI as per Listing Regulations.

l) CEO/ CFO Certification

The Managing Director and the CFO of the Company have certified to the Board of Directors, inter-alia, the accuracy of financial statements and adequacy of internal controls for the financial reporting as required under Regulation 17(8) of the Listing Regulations for the Financial Year ended March 31, 2021.

m) Code of Conduct

The Company has received confirmations from the Board (incorporating duties of Independent Directors) and the Senior Management personnel regarding their adherence to the Code of Conduct. The Annual Report of the Company contains a certificate by the Managing Director, on the compliance declarations received from Board of Directors and Senior Management. The Code has been hosted on the Company's website at http://www.caplinpoint.net/investor.aspx

16. NON-MANDATORY REQUIREMENTS

i. The Company maintains an office for the Non-Executive Chairman of the Company at the Company's expense and allows reimbursement of expenses incurred in performance of his duties.

ii. Half-yearly and other quarterly financial statements are published in newspapers and uploaded on Company's website www.caplinpoint.net

iii. The auditors' report on financial statements of the Company are unqualified.

iv. The internal auditors of the Company make presentations to the Audit Committee on their reports on a regular basis.

17. UNCLAIMED SUSPENSE ACCOUNT

There are no unclaimed physical shares till date in the books of the Company and hence the requirements to provide the details as per Regulation 34 (3) read with Schedule V of Part F of Listing Regulations is not applicable.

DECLARATION REGARDING COMPLIANCE BY BOARD MEMBERS AND SENIOR MANAGEMENT PERSONNEL WITH THE COMPANY'S CODE OF CONDUCT

This is to confirm that for the Financial Year ended March 31, 2021 all members of the Board and the Senior Management Personnel have affirmed in writing their adherence to the Code of Conduct adopted by the Company.

FOR CAPLIN POINT LABORATORIES LTD

Dr Sridhar Ganesan
Managing Director

Place: Chennai
Date: August 5, 2021

CERTIFICATE ON COMPLIANCE OF THE PROVISIONS OF THE CODE OF CORPORATE GOVERNANCE

To
The Members
M/s. Caplin Point Laboratories Limited
CIN: L24231TN1990PLC019053
Ashvich Towers, 3rd Floor,
No.3, Developed Plots, Industrial Estates,
Perungudi, Chennai 600096

We have examined all the relevant records of Caplin Point Laboratories Limited ("the Company"), for the purpose of certifying compliance of the conditions of the Corporate Governance, under Securities Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended from time to time, ("the SEBI LODR Regulations"), for the financial year ended 31st March, 2021.

The compliance of conditions of Corporate Governance is the responsibility of the Management including the preparation and maintenance of all the relevant records and documents. Our examination is limited to procedures and implementation process adopted by the Company for ensuring compliance with the conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

In our opinion and to the best of our information and according to the explanations and representations provided by the Management and considering the relaxations granted by the Ministry of Corporate Affairs and Securities and Exchange Board of India warranted due to the spread of the COVID-19 pandemic, we certify that the Company has complied with the conditions of Corporate Governance as stipulated under the SEBI LODR Regulations.

We further state that such compliance is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For **M/s. G Ramachandran & Associates**
Company Secretaries

G Ramachandran
Proprietor
FCS No.: 9687 CoP No.:3056

Date: August 5, 2021
Place: Chennai
UDIN: F009687C000738261

CERTIFICATE OF NON – DISQUALIFICATION OF DIRECTORS

[Pursuant to clause C (10) (i) of Schedule V read with Regulations 34(3) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015]

To
The Members
M/s. Caplin Point Laboratories Limited
CIN: L24231TN1990PLC019053
Ashvich Towers, 3rd Floor,
No.3, Developed Plots, Industrial Estates,
Perungudi, Chennai 600096

We have examined the relevant registers, records, forms, returns and disclosures received from the Directors of M/s. Caplin Point Laboratories Limited having CIN: L24231TN1990PLC019053 and having registered office at Ashvich Towers, 3rd Floor, No.3, Developed Plots, Industrial Estates, Perungudi, Chennai 600096 (hereinafter referred to as 'the Company'), produced before us by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C Sub clause 10(i) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In our opinion and to the best of our information and according to the verifications (including Directors Identification Number (DIN) status at the portal www.mca.gov.in) as considered necessary and explanations furnished to us by the Company & its officers, we hereby certify that none of the Directors on the Board of the Company as stated below for the financial Year ending on 31st March, 2021 have been debarred or disqualified from being appointed or continuing as Directors of companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs or any such other Statutory Authority.

S. No.	DIN	Name of Director	Designation	Date of Appointment
1	01067374	Mr. Komattu Chacko John	Director	25th August, 2014
2	01218784	Mr. Paarthipan Chingelput Chellappan	Director	1st October, 1993
3	02032818	Mr. Durga Prasanna Mishra	Director	18th December, 2014
4	03015619	Mr. V Thirumalai	Director	25th June, 1994
5	06819026	Mr. Sridhar Ganesan	Managing Director	12th February, 2014
6	07173713	Mr. Rengaraj Viswanathan	Director	12th May, 2015
7	07650566	Mr. Damodaran Sathyanarayanan	Director	9th November, 2016
8	08711546	Ms. Gariyali Chanderkanta	Director	4th March, 2020
9	01920603	Dr. Ravichandran Rajagopalan *	Director	12th May, 2014

* Retired with effect from 11th May, 2021

Ensuring the eligibility of for the appointment / continuity of every Director on the Board is the responsibility of the management of the Company. Our responsibility is to express an opinion on these based on our verification. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For **M/s. G Ramachandran & Associates**
Company Secretaries

G RAMACHANDRAN
Proprietor
FCS No.: 9687
CoP No.:3056

Date: August 5, 2021
Place: Chennai
UDIN: F009687C000738283

STANDALONE FINANCIAL STATEMENTS

INDEPENDENT AUDITOR'S REPORT

To
The Members
Caplin Point Laboratories Limited, Chennai
Report on the Audit of the Standalone Financial Statements

Opinion

We have audited the accompanying standalone financial statements of Caplin Point Laboratories Limited ("the Company"), which comprise the Balance Sheet as at 31st March, 2021, the Statement of Profit and Loss (including other comprehensive income), the Statement of Changes in Equity and the Statement of Cash Flows for the year then ended, and notes to the financial statements, including a summary of the significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 ("Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India including Indian Accounting Standards ('Ind AS') specified under Section 133 of the Act, of the state of affairs of the Company as at 31st March 2021, and its profit, total comprehensive income, the changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditors' Responsibilities for the Audit of the Standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('ICAI') together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone financial statements.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the standalone financial statements of the current period. These matters were addressed in the context of our audit of the standalone financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

We have determined the following to be the key audit matters to be communicated in our report.

S.No	Key Audit Matter	How was the matter addressed in our audit
1.	*Accuracy of recognition, measurement, Presentation and disclosures of revenues and other related balances in accordance with Ind AS 115 "Revenue from Contracts with Customers" (revenue recognition standard)* The application of the revenue accounting standard involves certain key judgements relating to identification of distinct performance obligations, determination of transaction price of the identified performance obligations, the appropriateness of the basis used to measure revenue recognized over a period. Additionally, revenue accounting standard contains disclosures which involves collation of information in respect of disaggregated revenue and periods over which the remaining performance obligations will be satisfied subsequent to the balance sheet date.	***Principal Audit Procedures*** We assessed the Company's process to identify the impact of the revenue accounting standard. Our audit approach consisted testing of the design and operating effectiveness of the internal controls and substantive testing as follows: ➢ Evaluated the design of internal controls relating to implementation of the new revenue accounting standard. ➢ Selected a sample of continuing and new contracts, and tested the operating effectiveness of the internal control, relating to identification of the distinct performance obligations and determination of transaction price. We carried out a combination of procedures involving enquiry and observation, re-performance and inspection of evidence in respect of operation of these controls. ➢ Tested the relevant information technology systems' access and change management controls relating to contracts and related information used in recording and disclosing revenue in accordance with the new revenue accounting standard.
	Impact of Covid-19 pandemic on the Company's operations	➢ We assessed the Company's process to identify, assess, and respond to risks of material misstatement considering the uncertainties and the impact of Covid-19 pandemic on the Company's operations and results for the year under consideration. We have designed, planned and performed audit procedures including verification of the source and completeness of data provided for audit. We have considered management's adjustments or disclosures which includes the impact of the changes in the environment on the recognition and measurement of account balances and transactions in the financial statements or other specific disclosures.

Information other than the financial statements and Auditors' Report Thereon

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Management Discussion and Analysis, Board's Report including Annexures to Board's Report, Business Responsibility Report, Corporate Governance and Shareholder's Information, but does not include the Standalone financial statements and our Auditors' report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance and conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Management's Responsibility for the Standalone Financial Statements

The Company's board of directors is responsible for the matters stated in section 134 (5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, cash flows and changes in equity of the Company in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Rules, 2016, as amended from time to time, and other accounting principles generally accepted in India.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial reporting process.

Auditors' Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Standards on Auditing will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with Standards on Auditing, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit

in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our Auditors' report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our Auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the standalone financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the standalone financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the standalone financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards. From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the standalone financial statements of the current period and are therefore the key audit matters. We describe these matters in our Auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by Section 143(3) of the Act, based on our audit we report that:

    a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit.

    b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.

    c) The Balance Sheet, the Statement of Profit and Loss, and the Cash Flow Statement dealt with by this report are in agreement with the books of account;

    d) In our opinion, the aforesaid standalone financial statements comply with the Ind AS specified under section 133 of the Act, read with rule 7 of the Companies (Accounts) Rules, 2015;

    e) On the basis of the written representations received from the directors and taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2021 from being appointed as a director in terms of Section 164(2) of the Act;

    f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure A". Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls over financial reporting.

g) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197 (16) of the Act, as amended, in our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 of the Act; and

h) With respect to the other matters to be included in the Auditors' Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014 (as amended), in our opinion and to the best of our information and according to the explanations given to us:

   i. The Company has disclosed the impact of pending litigations on its financial position in its standalone financial statements.

   ii. The Company has made provision, as required under the applicable law or Accounting Standards, for material foreseeable losses, if any, on long-term contracts including derivative contracts;

   iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.

2. As required by the Companies (Auditors' Report) Order, 2016 ("the Order") issued by the Central Government of India in terms of Section 143(11) of the Act, we give in the "Annexure B" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

for **M/s CNGSN & ASSOCIATES LLP**
CHARTERED ACCOUNTANTS
Firm Registration No: 004915S/S200036

B. Ramakrishnan
Partner
Membership No: 201023
UDIN: 21201023AAAAAE3738

Place: Chennai
Date: 06/05/2021

Annexure "A" – To The Independent Auditors' Report on the Standalone Financial Statements of Caplin Point Laboratories Limited for the year ended 31 March 2021

Report on the internal financial controls over Financial Reporting under section 143(3) (i) of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of **Caplin Point Laboratories Limited ("the Company")** as of 31 March 2021 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") issued by the Institute of Chartered Accountants of India (ICAI). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of the Company's business, including adherence to Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act,2013.

Auditor's Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls with reference to financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and Standards on Auditing, prescribed under Section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to financial statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements were established and maintained and whether such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements included obtaining an understanding of internal financial controls with reference to financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the Auditors' judgment, including the assessment of the risks of material misstatement of the standalone financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls with reference to financial statements

A Company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A Company's internal financial controls with reference to financial statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls with reference to financial statements

Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that internal financial controls with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, to the best of our information and according to the explanation given to us, the Company has, in all material respects, an adequate internal financial controls over financial reporting and such internal financial controls were operating effectively as at 31 March 2021, based on the internal financial control over financial reporting criteria established by the Company considering the essential components of internal controls stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (the "Guidance Note").

for **M/s CNGSN & ASSOCIATES LLP**
CHARTERED ACCOUNTANTS
Firm Registration No: 004915S/S200036

B. Ramakrishnan
Partner
Membership No: 201023
UDIN: 21201023AAAAAE3738

Place: Chennai
Date: 06/05/2021

Annexure "B " –To The Independent Auditors' Report on the Standalone Financial Statements of Caplin Point Laboratories Limited for the year ended 31 March 2021

(Referred to in paragraph 2 under 'Report On Other Legal and Regulatory Requirements' section of our report to the Members of Caplin Point Laboratories Limited of even date)

i. In respect of the Company's fixed assets:

   a. The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets.

   b. The Company has a regular program of physical verification of its fixed assets, by which all fixed assets are verified in a phased manner, which in our opinion, is reasonable having regard to the Size of the company and the nature of its assets. Pursuant to the program, certain fixed assets were physically verified by the management during the year and no material discrepancies were noticed on such verification. According to the information and explanations given to us, no material discrepancies were noticed on such verification.

   c. The title deeds of immovable properties included in fixed assets are held in the name of the Company, except for a land and building for Rs. 17.38 Crores purchased by the Company during the financial year 2020-21 through e-auction from Bank under the SARFAESI Act, 2002 and rules thereof, for which the transfer of title is in progress . In respect of immovable properties taken on lease and disclosed as property, plant and equipment in the standalone Ind AS financial statements, the lease agreements are in the name of the Company.

ii. The inventory has been physically verified by the management during the year. In our opinion, the frequency of such verification is reasonable. The Company has maintained proper records of inventory. The discrepancies noticed on verification between the physical stock and the book records were not material.

iii. According to the information and explanation given to us, the Company has not granted any loans, secured or unsecured to companies, firms, limited liability partnerships or other parties covered in the register maintained under section 189 of the Act, 2013. Accordingly, the provisions of clause 3(iii) (a), (b) and (c) of the Order is not applicable to the Company.

iv. In our opinion and according to information and explanation given to us, in respect of loans, investments, guarantees and security, the Company has complied with the provisions of sections 185 and section 186 of the Companies Act, 2013.

v. In our opinion and according to information and explanation given to us, the Company has not accepted any deposits from the public within the meaning of the directives issued by the Reserve Bank of India, provisions of Section 73 to 76 of the Act, any other relevant provisions of the Act and the relevant rules framed thereunder. Accordingly, paragraph 3(v) of the Order is not applicable to the Company.

vi. We have broadly reviewed the books of account maintained by the Company pursuant to the rules made by the Central Government for the maintenance of cost records under section 148 of the Act, and are of the opinion that prima facie, the prescribed accounts and records have been made and maintained.

vii. a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, amounts deducted/ accrued in the books of account in respect of undisputed statutory dues including provident fund, employees' state insurance, income-tax, sales- tax, service tax, goods and service tax, duty of customs, duty of excise, value added tax, cess and other material statutory dues have been generally regularly deposited during the year by the company with the appropriate Authorities.

   According to the information and explanations given to us, no undisputed amounts payable in respect of provident fund, employees' state insurance, income-tax, sales- tax, service tax, goods and service tax, duty of customs, duty of excise, value added tax, cess and other material statutory dues were in arrears as at March 31, 2021 for a period of more than six months from the date they became payable.

   b) There are no dues of Income-tax or Sales tax or Service tax or Goods and Services tax or duty of Customs or duty of Excise or Value added tax which have not been deposited by the Company on account of disputes, except for the following:

S.No	Name of the statute	Nature of dues	As At 31/3/2021 (Rs. In lakhs)	As At 31/3/2020 (Rs. In lakhs)	Forum where dispute is pending
1.	Income Tax Act, 1961	Income Tax	85.32	25.83	Income Tax Appellate Tribunal/ CIT Appeals

viii. In our opinion and according to the information and explanations given to us, the company has no outstanding dues to any financial institutions or banks or any government or any debenture holders during the year. Accordingly, paragraph 3 (viii) of the order is not applicable.

ix. Company has not raised any money by way of initial public offer or further public offer (including debt instruments) and term loans during the year. Accordingly, the provisions of Clause 3(ix) of the Order is not applicable to the Company.

x. In our opinion and according to the information and explanation given to us, no material fraud by the Company or on the Company by its officers or employees has been noticed or reported during the course of our audit.

xi. In our opinion and according to the information and explanations given to us, the Company has paid/ provided managerial remuneration in accordance with the requisite approvals mandated by the provisions of section 197 read with Schedule V to the Act.

xii. The Company is not a Nidhi Company and accordingly, paragraph 3 (xii) of the order is not applicable to the Company.

xiii. According to the information and explanations given to us and based on our examination of the records of the company, transactions with the related parties are in compliance with section 177 and 188 of the Act. Where applicable, the details of such transactions have been disclosed in the financial statements as required by the applicable accounting standards.

xiv. According to the information and explanations given to us and based on our examination of the records of the company, the company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year. Accordingly, paragraph 3(xiv) of the order is not applicable.

xv. According to the information and explanations given to us and based on our examination of the records of the company, the company has not entered into non-cash transactions with directors or persons connected with them. Accordingly, paragraph 3(xv) of the order is not applicable.

xvi. According to the information and explanations given to us and based on our examination of the records of the company, the company is not required to be registered under section 45-IA of the Reserve Bank of India Act 1934.

for **M/s CNGSN & ASSOCIATES LLP**

CHARTERED ACCOUNTANTS
Firm Registration No: 004915S/S200036

B. Ramakrishnan
Partner
Membership No: 201023
UDIN: 21201023AAAAAE3738

Place: Chennai
Date: 06/05/2021

STANDALONE BALANCE SHEET

AS AT MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

Particulars	Notes	As at March 31, 2021	As at March 31, 2020
ASSETS			
(1) Non-Current Assets			
(a) Property, plant and equipment	2	17,793.38	16,172.13
(b) Capital work-in-progress	2A	136.03	377.31
(c) Intangible assets	2B	360.48	339.24
(d) Right of Use Assets	2C	114.91	181.14
(e) Investments in Subsidiaries and Associate	3	13,798.02	13,520.67
(f) Financial assets			
(i) Investments	3A	66.35	33.04
(ii) Loans & Advances	4	349.45	220.84
(g) Income tax assets (Net)		216.85	214.73
Sub-total-Non current assets		**32,835.47**	**31,059.10**
(2) Current Assets			
(a) Inventories	5	2,486.73	2,236.88
(b) Financial assets			
(i) Investments	6	1,053.50	6,022.98
(ii) Trade receivables	7	9,845.88	21,898.29
(iii) Cash and cash equivalents	8	14,882.21	3,683.94
(iv) Bank balances other than (iii) above	9	21,667.30	2,143.00
(v) Loans & Advances	10	2,509.59	2,045.06
(c) Other current assets	11	819.57	43.48
Sub-total-Current assets		**53,264.78**	**38,073.63**
Total		**86,100.25**	**69,132.73**
EQUITY AND LAIBILITIES			
(1) Equity			
Equity share capital	12	1,512.86	1,512.86
Other equity	13	74,354.48	58,477.68
Sub-total-Equity		**75,867.34**	**59,990.54**
(2) Liabilities			
(A) Non-Current Liabilities			
(a) Financial liabilities			
(i) Borrowings	14	-	1.52
(ii) Lease Liabilities	15	53.32	128.48
(b) Deferred tax liabilities (Net)	16	2,097.13	2,213.94
(c) Other non current liabilities	17	349.15	372.49
Sub-total-Non current liabilities		**2,499.60**	**2,716.43**
(B) Current Liabilities			
(a) Financial liabilities			
(i) Trade payables	18	7,010.24	5,141.28
(ii) Lease Liabilities	19	79.19	84.81
(iii) Borrowings	20	1.19	26.77
(iv) Other current liabilities	21	642.69	1,085.69
(b) Provisions	22	-	87.21
Sub-total-Current liabilities		**7,733.31**	**6,425.76**
Total		**86,100.25**	**69,132.73**

The accompanying notes 1 to 49 form an integral part of these standalone financial statements.

As per our report of even date attached
For **CNGSN & Associates LLP**
Chartered Accountants
Firm Registration No : 4915S/ S200036

For and on behalf of the Board of Directors of Caplin Point Laboratories Limited;
CIN: L24231TN1990PLC019053

B.Ramakrishnan
Partner
ICAI Membership No. 201023

C.C. Paarthipan
Chairman
DIN:01218784

Dr.Sridhar Ganesan
Managing Director
DIN:06819026

Place : Chennai
Date : 6th May, 2021

Muralidharan D
Chief Financial Officer

Dinesh R G
Company Secretary

STANDALONE STATEMENT OF PROFIT AND LOSS

FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

Particulars	Notes	For the Year ended March 31, 2021	For the year ended March 31, 2020
I . INCOME			
(a) Revenue from Operations	23	48,267.96	52,782.53
(b) Other income	24	1,861.80	6,597.13
Total Income		**50,129.76**	**59,379.66**
II . EXPENSES			
(a) Cost of Materials Consumed	25	11,247.53	9,573.49
(b) Purchases of Stock-in-Trade		8,292.46	14,318.47
(c) Changes in inventories of Finished Goods including Stock-in-Trade and Work-in-progress	26	(56.88)	(74.10)
(d) Employee benefits expense	27	2,659.38	2,499.91
(e) Finance costs	28	16.67	18.50
(f) Depreciation and Amortisation Expenses	29	2,244.08	1,965.38
(g) Research and Development Expenses	30	1,939.85	2,435.77
(h) Other expenses	31	2,793.13	3,329.75
Total Expenses		**29,136.23**	**34,067.17**
III . Profit before Exceptional items and tax		20,993.53	25,312.49
IV. Exceptional Items		-	-
V . Profit Before Tax		20,993.53	25,312.49
VI . Tax Expense (Net)			
- Current Tax		5,488.36	5,588.87
- Deferred tax (Benefits)/Charge		(116.81)	(40.23)
VII . Profit After Tax for the Year		**15,621.98**	**19,763.85**
VIII. Other Comprehensive Income (net of tax) Items that will not be reclassified to profit or loss:			
(i) Remeasurement of Defined Benefit Plans		22.00	(33.47)
IX.Total Comprehensive Income for the Year		**15,643.98**	**19,730.38**
Earning Per Equity Share (Nominal value per share Rs.2/-)			
Basic		**20.65**	**26.13**
Diluted		**20.45**	**25.95**

The accompanying notes 1 to 49 form an integral part of these standalone financial statements.

As per our report of even date attached
For **CNGSN & Associates LLP**
Chartered Accountants
Firm Registration No : 4915S/ S200036

For and on behalf of the Board of Directors of Caplin Point Laboratories Limited;
CIN: L24231TN1990PLC019053

B.Ramakrishnan
Partner
ICAI Membership No. 201023

C.C. Paarthipan
Chairman
DIN:01218784

Dr.Sridhar Ganesan
Managing Director
DIN:06819026

Place : Chennai
Date : 6th May, 2021

Muralidharan D
Chief Financial Officer

Dinesh R G
Company Secretary

STANDALONE STATEMENT OF CASH FLOW

FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

Particulars	For the Year Ended March 31, 2021	For the year ended March 31, 2020
A. Cash Flow from Operating Activities		
Profit before tax	**20,993.53**	**25,312.49**
Adjustments for:		
Depreciation and Amortisation expense	2,244.08	1,965.38
Finance costs	16.67	18.50
Government grant	(80.33)	(53.83)
Loss on sale/disposal of property, plant and equipment	6.05	4.26
Employee Stock option Scheme Expense	329.13	148.96
Net Unrealised Foreign Exchange Fluctuation Loss (Gain)	18.64	(1,375.85)
Fair value gain on financial instruments through profit or loss	438.89	(48.78)
Realised gain on Financial Assets	(637.78)	(485.41)
Dividend Income	(304.78)	(3,291.09)
Interest income	(1,255.81)	(139.87)
Operating Profit before Working Capital changes	**21,768.29**	**22,054.76**
Adjustments for :		
(Increase) / Decrease in inventories	(249.85)	115.03
(Increase) / Decrease in Trade receivables	12,052.42	(7,947.73)
(Increase) / Decrease in Loans	(472.98)	321.90
Increase/(Decrease) in Trade payables,Current Liabilities & Provisions-Long and Short Term	1,857.12	(808.34)
Cash Generated from Operations	34,955.00	13,735.62
Income tax Paid	(5,490.48)	(5,035.07)
Net Cash inflow / (outflow) from Operating activities	**29,464.52**	**8,700.55**
B. Cash Flow from Investing Activities		
Sale / (Purchase) of investments	4,497.28	988.38
Investment in Subsidiaries	(37.15)	(3,528.72)
Sale / (Purchase) of property, plant and equipment (Including CWIP)	(4,255.41)	(4,919.07)
Interest received	480.72	152.10
Dividend received	304.78	3,291.09
Income tax on Dividend income	-	(574.78)
Realised gain on Financial Assets	637.78	485.41
Net Cash inflow/(outflow) from Investing activities	**1,628.00**	**(4,105.59)**
C. Cash Flow from Financing Activities		
Proceeds from exercise of employee stock options	-	0.25
Increase/(Decrease) in Long and Short term Borrowings	(27.10)	(25.83)

(All amounts are in ₹ Lakhs unless otherwise stated)

Particulars	For the Year Ended March 31, 2021	For the year ended March 31, 2020
Interest paid (Including interest on Lease liability)	(16.67)	(13.62)
Dividend paid (including Dividend distribution tax paid)	(302.57)	(3,252.64)
Net Cash inflow / (outflow) from Financing activities	**(346.34)**	**(3,291.84)**
Net increase / (decrease) in cash and cash equivalents during the year D=(A+B+C)	**30,746.18**	**1,303.12**
Cash and Cash Equivalents as at the beginning of the year ('E)	**5,560.74**	**4,252.23**
Effect of exchange rate changes on cash and cash equivalents (F)	(18.64)	5.39
Cash and Cash Equivalents as at the end of the year (G=D+E+F)	**36,288.28**	**5,560.74**
Less: Deposit under Lien (H)	35.77	500.00
Net Cash and Cash Equivalents as at the end of the year (I=G-H)	**36,252.51**	**5,060.74**

Notes:

The above Standalone Statement of Cash Flows has been prepared under the “Indirect method’ as set out in Ind AS 7, ‘statement of Cash Flows’.

(All amounts are in ₹ Lakhs unless otherwise stated)

Particulars	For the Year Ended March 31, 2021	For the year ended March 31, 2020
a). Reconcillation of Cash And Cash Equivalents		
Cash And Cash Equivalents As Per Balance Sheet	14,882.21	3,683.94
Other Bank Balances As Per Balance Sheet	21,667.30	2,143.00
Total Cash And Cash Equivalents As Per Balance Sheet	**36,549.51**	**5,826.94**
Less: Balance In Unclaimed Dividend Account	261.23	266.20
Less: Deposit Under Lien	35.77	500.00
Total Cash And Cash Equivalents As Per The Statement Of Cash Flows	**36,252.51**	**5,060.74**

b). Net Cash and Cash Equivalents as at the end of the year includes bank deposits classified under other bank balance considering that such bank deposits are readily convertible to a known amount of cash and subject to an insignificant risk of changes in value, however, deposit under lien has been excluded.

c). Cash and cash equivalents does not include

- Investment in mutual fund of Rs 1053.50 Lakhs classified as current investment (Previous Year Rs 6022.98 Lakhs)

The above Cash Flow Statement has been prepared under the ‘Indirect Method’ as set out in the Indian Accounting Standard 7 (Ind AS -7) “Statement of Cash Flow.

The accompanying notes 1 to 49 form an integral part of these standalone financial statements.

As per our report of even date attached
For **CNGSN & Associates LLP**
Chartered Accountants
Firm Registration No : 4915S/ S200036

B.Ramakrishnan
Partner
ICAI Membership No. 201023

Place : Chennai
Date : 6th May, 2021

For and on behalf of the Board of Directors of Caplin Point Laboratories Limited;
CIN: L24231TN1990PLC019053

C.C. Paarthipan
Chairman
DIN:01218784

Dr.Sridhar Ganesan
Managing Director
DIN:06819026

Muralidharan D
Chief Financial Officer

Dinesh R G
Company Secretary

STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED MARCH 31, 2021

A. EQUITY SHARE CAPITAL (Refer Note 12)

(All amounts are in ₹ Lakhs unless otherwise stated)

Particulars	As at 31 March 2021		As at 31 March 2020	
	NO OF EQUITY SHARES of ₹ 2/-each	AMOUNT	NO OF EQUITY SHARES of ₹ 2/-each	AMOUNT
Balance at the beginning of the reporting period	7,56,42,750	1,512.86	7,56,30,250	1,512.61
Changes in equity share capital during the year	-	-	12,500	0.25
Balance at the end of the reporting period	**7,56,42,750**	**1,512.86**	**7,56,42,750**	**1,512.86**

B. OTHER EQUITY (Refer Note 13)

(All amounts are in ₹ Lakhs unless otherwise stated)

Particulars	Reserves and Surplus					Total Other Equity
	Capital Reserve	Securities Premium Reserve	General Reserve	Employee Stock Option Outstanding (Net)	Retained Earnings	
Balance as at 31 March 2019	**40.98**	**162.75**	**1,128.78**	**685.67**	**39,673.71**	**41,691.89**
Profit for the year					19,763.85	19,763.85
Final Dividend on equity shares for FY 18-19					(1,664.14)	(1,664.14)
Interim Dividend on equity shares for FY 19-20					(1,588.49)	(1,588.49)
Movement in the comprehensive income for the year - actuarial gain/(loss) on employee benefit obligation					(33.47)	(33.47)
Movement in security premium		49.54				49.54
Share- based payment expenses (Net)				258.50		258.50
Balance as at 31 March 2020	**40.98**	**212.29**	**1,128.78**	**944.17**	**56,151.46**	**58,477.68**
Profit for the year					15,621.98	15,621.98
Final Dividend on equity shares for FY 19-20					(302.57)	(302.57)
Interim Dividend on equity shares for FY 20-21					-	-
Movement in the comprehensive income for the year - actuarial gain/(loss) on employee benefit obligation					22.00	22.00
Movement in security premium		-				-
Share- based payment expenses (Net)				535.39		535.39
Balance as at 31 March 2021	**40.98**	**212.29**	**1,128.78**	**1,479.56**	**71,492.87**	**74,354.48**

The accompanying notes 1 to 49 form an integral part of these standalone financial statements.

As per our report of even date attached
For **CNGSN & Associates LLP**
Chartered Accountants
Firm Registration No : 4915S/ S200036

For and on behalf of the Board of Directors of Caplin Point Laboratories Limited;
CIN: L24231TN1990PLC019053

B.Ramakrishnan
Partner
ICAI Membership No. 201023

C.C. Paarthipan
Chairman
DIN:01218784

Dr.Sridhar Ganesan
Managing Director
DIN:06819026

Place : Chennai
Date : 6th May, 2021

Muralidharan D
Chief Financial Officer

Dinesh R G
Company Secretary

1: SIGNIFICANT ACCOUNTING POLICIES AND KEY ACCOUNTING ESTIMATES AND JUDGEMENTS

1A. Company Background:

Caplin Point Laboratories Limited (“Caplin Point” or “the Company”) incorporated in 1990, headquartered and having its registered office in Chennai, Tamil Nadu, India. The Company is into the business of pharmaceuticals - producing, developing and marketing wide range of generic formulations and branded products and exporting to overseas market. The Company’s principal research and development facilities are located in Tamil Nadu, India; its principal manufacturing facility is located in Puducherry, India. The Company’s shares are listed on the Bombay Stock Exchange and the National Stock Exchange in India.

1B. SIGNIFICANT ACCOUNTING POLICIES AND KEY ACCOUNTING ESTIMATES AND JUDGEMENTS:

a) Basis of accounting and preparation of Standalone Financial Statements:

i) *Basis of accounting*

These standalone financial statements of the Company have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (hereinafter referred to as the ‘Ind AS’) as notified under section 133 of the Companies Act, 2013 (‘the Act’) read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 as amended and other relevant provisions of the Act and accounting principles generally accepted in India. These standalone financial statements were authorized for issue by the Company’s Board of Directors on May 6, 2021

Accounting Policies have been consistently applied except where a newly issued Accounting Standard is initially adopted or a revision to an existing Accounting Standard requires a change in the accounting policy hitherto in use.

These standalone financial statements are prepared under the historical cost convention unless otherwise indicated.

ii) *Current / Non-Current Classification*

Any asset or liability is classified as current if it satisfies any of the following conditions:

i. the asset/liability is expected to be realized/settled in the Company’s normal operating cycle;

ii. the asset is intended for sale or consumption;

iii. the asset/liability is held primarily for the purpose of trading;

iv. the asset/liability is expected to be realized/settled within twelve months after the reporting period;

v. the asset is cash or cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting date;

vi. in the case of a liability, the Company does not have an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

All other assets and liabilities are classified as non-current.

For the purpose of current/non-current classification of assets and liabilities, the Company has ascertained its normal operating cycle as twelve months. This is based on the nature of services and the time between the acquisition of assets or inventories for processing and their realization in cash and cash equivalents.

iii) *Functional and Presentation Currency*

These standalone financial statements are presented in Indian rupees, which is the functional currency of the Company. All financial information presented in Indian rupees (₹) has been rounded off to the nearest thousands, except otherwise indicated.

iv) *Use of Estimates and Judgements*

The preparation of the Standalone Financial Statements in conformity with Ind AS requires the Management to make estimates and assumptions considered in the reported amounts of assets and liabilities (including contingent liabilities) and the reported income and expenses during the year. The Management believes that the estimates used in preparation of the Standalone Financial Statements are prudent and reasonable.

Future results could differ due to these estimates and the differences between the actual results and the estimates are recognised in the periods in which the results are known/ materialize. Estimates and underlying assumptions are reviewed on an ongoing basis.

Information about critical judgments in applying accounting policies, as well as estimates and assumptions that have the most significant effect to the carrying amounts of assets and liabilities within the next financial year, are included in the accounting policies, given as under:

- Measurement of defined benefit obligations (Refer note 'l')
- Measurement and likelihood of occurrence of provisions and contingencies (Refer note 'n')
- Recognition of deferred tax assets (Refer note 'i')
- Useful lives of property, plant, equipment and Intangibles (Refer note 'b & c')
- Impairment of Assets (Refer note 'f')
- Impairment of financial assets (Refer note 'h')

v) *Application of New Accounting Pronouncements:*

Ministry of Corporate Affairs ("MCA") through Companies (Indian Accounting Standards) Amendment Rules, 2019 and Companies (Indian Accounting Standards) Second Amendment Rules, had notified Ind AS 116 Leases which replaced the existing lease standard, Ind AS 17 Leases, and other interpretations. The Company had adopted the same and the same is detailed in note (m) below.

b) Property, Plant and Equipment:

i) *Recognition and Measurement*

Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses, if any. The cost of an item of property, plant and equipment comprises:

- Its purchase price, including import duties and non-refundable purchase taxes, after deducting trade discounts and rebates.
- Any costs directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.
- -the initial estimate of the costs of dismantling and removing the item and restoring the site on which it is located, the obligation for which the Company incurs either when the item is acquired or as a consequence of having used the item during a particular period for purposes other than to produce inventories during that period.
- Income and expenses related to the incidental operations, not necessary to bring the item to the location and condition necessary for it to be capable of operating in the manner intended by management, are recognized in Statement of Profit and Loss. If significant parts of an item of property, plant and equipment have different useful lives, then they are accounted for as separate items (major components) of property, plant and equipment.

The Company has elected to continue with the carrying value of all its property, plant and equipment as recognized in the standalone financial statements as at the date of transition to Ind AS, measured as per the previous GAAP and use that as the deemed cost as at the transition date pursuant to the exemption under Ind AS 101.

Assets to be disposed off are reported at the lower of the carrying value or the fair value less cost to sell.

Capital work-in-progress in respect of assets which are not ready for their intended use are carried at cost, comprising of direct costs, related incidental expenses and attributable interest if any.

(All amounts are in ₹ Lakhs unless otherwise stated)

ii) *Subsequent Expenditure*

Subsequent expenditure is capitalized only if it is probable that the future economic benefits associated with the expenditure will flow to the Company.

iii) *Depreciation*

Depreciation on tangible assets is provided on a straight line method over the useful lives of the assets.

The estimated useful lives of tangible assets and the amortization period are reviewed at the end of each financial year and the amortization method is revised to reflect the changed pattern, if any.

Estimated useful lives of the assets, based on technical assessment, which are different in certain cases from those prescribed in Schedule II to the Companies Act, 2013, are as follows:

Asset Category	Estimated useful life (Years)
Factory Building	30
Building other than factory building	60
Plant & Machinery	5 -15
Furniture & Fixtures	10
Office Equipment	5
Computers	3
Electrical Fittings and Installation	10
Motor Vehicles	6
Motor Cycle	10

Depreciation is provided on pro-rata basis for the number of days available for use. Depreciation on sale/ disposal of assets is provided on pro-rata up to the date of sale / disposal.

An asset purchased where the actual cost does not exceed Rs 5,000 is depreciated at the rate of 100%.

Advances given towards acquisition of property, plant and equipment outstanding at each balance sheet date are disclosed as Capital Advance under Loans & Advances.

iv) *Derecognition:*

The carrying amount of an item of property, plant and equipment is derecognised on disposal or when no future economic benefits are expected from its use or disposal. The gain or loss arising from the derecognition of an item of property, plant and equipment is measured as the difference between the net disposal proceeds and the carrying amount of the item and is recognized in the Statement of Profit and Loss when the item is derecognized.

c) Intangible Assets:

i) *Recognition and Measurement:*

Intangible assets are carried at cost less accumulated amortisation and impairment losses, if any. The cost of an intangible asset comprises of its purchase price, including any import duties and other taxes (other than those subsequently recoverable from the taxing authorities), and any directly attributable expenditure on making the asset ready for its intended use. Intangible assets arising on acquisition of business are measured at fair value as at date of acquisition.

Expenditure on research and development eligible for capitalization are carried as Intangible assets underdevelopment where such assets are not yet ready for their intended use.

The Company has elected to continue with the carrying value of all its intangible assets as recognized in the standalone financial statements as at the date of transition to Ind AS, measured as per the previous GAAP and use that as the deemed cost as at the transition date pursuant to the exemption under Ind AS 101.

ii) *Subsequent Expenditure*

Subsequent expenditure is capitalized only if it is probable that the future economic benefits associated with the expenditure will flow to the Company.

(All amounts are in ₹ Lakhs unless otherwise stated)

iii) *Amortisation*

Intangible assets are amortised over their estimated useful economic life on Straight Line Method as follows:

Particulars	Estimated useful life
Computer Software	6 Years or useful life whichever is lower

The estimated useful lives of intangible assets and the amortisation period are reviewed at the end of each financial year and the amortisation method is revised to reflect the changed pattern, if any.

iv) *Derecognition:*

The carrying amount of an intangible asset is derecognised on disposal or when no future economic benefits are expected from its use or disposal. The gain or loss arising from the derecognition of an intangible asset is measured as the difference between the net disposal proceeds and the carrying amount of the intangible asset and is recognized in the Statement of Profit and Loss when the asset is derecognized.

d) Lease Accounting (Right of Use Assets and Lease Liabilities):

The Company had adopted Ind AS 116 “Leases” and applied the same to the lease contracts existing on April 01, 2019 using the modified retrospective approach. This had resulted in recognizing “Right of Use Assets and Lease Liability”.

The Company recognizes right-of-use asset representing its right to use the underlying asset for the lease term at the lease commencement date. The cost of the right-of-use asset measured at inception shall comprise of the amount of the initial measurement of the lease liability adjusted for any lease payments made at or before the commencement date less any lease incentives received, plus any initial direct costs incurred, if any. The right-of-use assets is subsequently measured at cost less accumulated depreciation and adjusted for any remeasurement of the lease liability. The right-of-use assets is depreciated using the straight-line method from the commencement date over the shorter of lease term or useful life of right-of-use asset.

The Company measures the lease liability at the present value of the lease payments that are not paid at the commencement date of the lease. The lease payments are discounted using the interest rate implicit in the lease, if that rate can be readily determined. If that rate cannot be readily determined, the Company uses incremental borrowing rate. For leases with reasonably similar characteristics, the Company, on a lease by lease basis, may adopt either the incremental borrowing rate specific to the lease or the incremental borrowing rate for the portfolio as a whole. The lease liability is subsequently remeasured by increasing the carrying amount to reflect interest on the lease liability, reducing the carrying amount to reflect the lease payments made and remeasuring the carrying amount to reflect any reassessment or lease modifications. The Company has elected not to apply the requirements of Ind AS 116 Leases to short-term leases of all assets that have a lease term of 12 months or less and leases for which the underlying asset is of low value. The lease payments associated with these leases are recognized as an expense on a straight-line basis over the lease term.

Operating leases are mainly in the nature of lease of office premises with no restrictions and are renewable / cancellable at the option of either of the parties. There are no sub-leases. There are no restrictions imposed by the lease arrangements. On application of Ind AS 116, the nature of expenses has changed from lease rent in previous periods to depreciation cost for the right-of-use asset, and finance cost for interest accrued on lease liability.

e) Research and development:

Revenue expenditure pertaining to research is charged to the Statement of Profit and Loss. Development costs of products are also charged to the Statement of Profit and Loss in the year it is incurred. Fixed assets utilized for research and development are capitalized and depreciated in accordance with the policies stated for Tangible Fixed Assets and Intangible Assets.

Expenditure on in-licensed development activities, whereby research findings are applied to a plan or design for the production of new or substantially improved products and processes, is capitalized, if the cost can be reliably measured, the product or process is technically and commercially feasible and the company has sufficient resources to complete the development and to use and sell the asset.

f) Impairment of Assets:

Intangible assets and property, plant and equipment are evaluated for recoverability whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. For the purpose of impairment testing, the recoverable amount (i.e. the higher of the fair value less cost to sell and the value-in-use) is determined on an individual asset basis unless the asset does not generate cash flows that are largely independent of those from other assets. In such cases, the recoverable amount is determined for the CGU to which the asset belongs.

If such assets are considered to be impaired, the impairment to be recognized in the Statement of Profit and Loss is measured by the amount by which the carrying value of the assets exceeds the estimated recoverable amount of the asset. An impairment loss is reversed in the Statement of Profit and Loss if there has been a change in the estimates used to determine the recoverable amount. The carrying amount of the asset is increased to its revised recoverable amount, provided that this amount does not exceed the carrying amount that would have been determined (net of any accumulated amortization or depreciation) had no impairment loss been recognized for the asset in prior years.

g) Foreign Currency transactions / translations:

Initial Recognition:

On initial recognition, transactions in foreign currencies entered into by the Company are recorded in the functional currency (i.e. Indian Rupees), by applying to the foreign currency amount, the spot exchange rate between the functional currency and the foreign currency at the date of the transaction. Exchange differences arising on foreign exchange transactions settled during the year are recognized in the Statement of Profit and Loss.

Measurement of foreign currency items at reporting date:

Foreign currency monetary items of the Company are translated at the closing exchange rates. Nonmonetary items that are measured at historical cost in a foreign currency, are translated using the exchange rate at the date of the transaction. Exchange differences arising out of these translations are recognized in the Statement of Profit and Loss.

h) Financial Instruments:

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

I. Financial Assets

Classification

On initial recognition, the Company classifies financial assets at amortized cost or fair value through other comprehensive income or fair value through profit or loss on the basis of its business model for managing the financial assets and the contractual cash flow characteristics of the financial asset.

Initial recognition and measurement

All financial assets (not measured subsequently at fair value through profit or loss) are recognised initially at fair value plus transaction costs that are attributable to the acquisition of the financial asset. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trades) are recognised on the trade date, i.e., the date that the Company commits to purchase or sell the asset.

Financial assets measured at amortized cost:

A 'financial asset' is measured at the amortised cost if both the following conditions are met:

i. the asset is held within a business model whose objective is to hold assets for collecting contractual cash flows, and

ii. Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

After initial measurement, such financial assets are subsequently measured at amortised cost using the effective interest rate (EIR) method. Amortised cost is calculated by taking into account any discount or premium and fees or costs that are an integral part of the EIR. The EIR amortisation is included in finance income in the Statement of Profit and Loss. The losses arising from impairment are recognised in the Statement of Profit and Loss. This category generally applies to trade and other receivables.

Financial assets included within the fair value through profit and loss (FVTPL) category are measured at fair value with all changes recognized in the Statement of Profit and Loss.

All equity investments in scope of Ind AS 109 are measured at fair value. Equity instruments which are held for trading are classified as at FVTPL. For all other equity instruments, the Company decides to classify the same either as at fair value through other comprehensive income (FVTOCI) or FVTPL. The Company makes such election on an instrument-by-instrument basis. The classification is made on initial recognition and is irrevocable.

If the Company decides to classify an equity instrument as at FVTOCI, then all fair value changes on the instrument, excluding dividends, are recognized in other comprehensive income (OCI). There is no recycling of the amounts from OCI to Statement of Profit and Loss, even on sale of such investments.

Equity instruments included within the FVTPL category are measured at fair value with all changes recognized in the Statement of Profit and Loss.

The Company has elected to continue with the carrying value of all its equity investments as recognized in the standalone financial statements as at the date of transition to Ind AS, measured as per the previous GAAP and use that as the deemed cost as at the transition date pursuant to the exemption under Ind AS 101.

Derecognition

A financial asset (or, where applicable, a part of a financial asset or part of a Company of similar financial assets) is primarily derecognised (i.e. removed from the Company's balance sheet) when:

- The rights to receive cash flows from the asset have expired, or
- The Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement; and either:

i. The Company has transferred substantially all the risks and rewards of the asset, or

ii. The Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Company has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Company continues to recognize the transferred asset to the extent of the Company's continuing involvement. In that case, the Company also recognizes an associated liability.

Impairment of financial assets

In accordance with Ind AS 109, the Company applies Expected Credit Loss (ECL) model for measurement and recognition of impairment loss on the following financial assets and credit risk exposure:

i. Financial assets that are debt instruments, and are measured at amortised cost e.g., loans, debt securities, deposits, and bank balance.

ii. Trade receivables: The Company follows 'simplified approach' for recognition of impairment loss allowance on trade receivables, which do not contain a significant financing component.

The application of simplified approach does not require the Company to track changes in credit risk. Rather, it recognizes impairment loss allowance based on lifetime ECLs at each reporting date, right from its initial recognition.

II. Financial Liabilities

Classification

The Company classifies all financial liabilities as subsequently measured at amortised cost, except for financial liabilities measured at fair value through profit or loss. Such liabilities, including derivatives that are liabilities, are subsequently measured at fair value with changes in fair value being recognised in the Statement of Profit and Loss.

Initial recognition and measurement

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss or at amortized cost (loans, borrowings and payables).

All financial liabilities are recognised initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

The Company's financial liabilities include trade and other payables, borrowings.

Financial liabilities at fair value through profit or loss

Financial liabilities at fair value through profit or loss include financial liabilities held for trading and financial liabilities designated upon initial recognition as at fair value through profit or loss. Financial liabilities are classified as held for trading if they are incurred for the purpose of repurchasing in the near term.

Gains or losses on liabilities held for trading are recognised in the Statement of profit and loss.

Financial liabilities designated upon initial recognition at fair value through profit or loss are designated at the initial date of recognition, and only if the criteria in Ind AS 109 are satisfied. For liabilities designated as FVTPL, fair value gains/ losses attributable to changes in own credit risk are recognized in OCI. These gains/ loss are not subsequently transferred to Statement of Profit and Loss. However, the Company may transfer the cumulative gain or loss within equity. All other changes in fair value of such liability are recognised in the Statement of Profit and Loss.

Loans and borrowings

After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortised cost using the EIR method. Gains and losses are recognised in Statement of Profit and Loss when the liabilities are derecognised.

Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included as finance costs in the Statement of Profit and Loss.

This category generally applies to interest-bearing loans and borrowings.

Derecognition

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the Statement of Profit and Loss.

Offsetting of financial instruments

Financial assets and financial liabilities are offset and the net amount is reported in the balance sheet if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on net basis, to realise the assets and settle the liabilities simultaneously.

i) Income tax:

Income tax expense comprises current and deferred tax. It is recognised in Statement of Profit and Loss except to the extent that it relates items recognised directly in equity in which case, it is recognised in OCI.

Current tax

Current tax comprises the expected tax payable or receivable on the taxable income or loss for the year and any adjustment to the tax payable or receivable in respect of previous years. It is measured using tax rates enacted or substantively enacted at the reporting date. Current tax also includes any tax arising from dividends.

Current tax assets and liabilities are offset only if, the Company:

i. has a legally enforceable right to set off the recognised amounts; and

ii. Intends either to settle on a net basis, or to realize the asset and settle the liability simultaneously.

Deferred tax

Deferred tax is recognised in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes.

Deferred tax assets are recognised for unused tax losses, unused tax credits and deductible temporary differences to the extent that it is probable that future taxable profits will be available, against which they can be used. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized; such reductions are reversed when the probability of future taxable profits improves.

Unrecognized deferred tax assets are reassessed at each reporting date and recognised to the extent that it has become probable that future taxable profits will be available against which they can be used.

Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, using tax rates enacted or substantively enacted at the reporting date are expected to apply to taxable income in the years in which the temporary differences are expected to be recovered or settled.

The measurement of deferred tax reflects the tax consequences that would follow from the manner in which the Company expects, at the reporting date, to recover or settle the carrying amount of its assets and liabilities.

Deferred tax assets and liabilities are offset only if:

i. the Company has a legally enforceable right to set off current tax assets against current tax liabilities; and

ii. the deferred tax assets and the deferred tax liabilities relate to income taxes levied by the same taxation authority on the same taxable entity.

j) Inventories:

i. Inventories are valued at lower of cost or net realizable value

ii. Raw materials, Packing materials, stores and spares are valued at cost including duties and taxes, exclusive of tax credit. The cost is arrived at FIFO basis.

iii. In respect of finished goods and work in progress, cost includes raw materials, packing materials, labour cost and other appropriate allocable overhead.

k) Revenue Recognition:

Revenue is recognized when the significant risks and rewards of ownership have been transferred to the buyer, recovery of the consideration is probable, the associated costs and possible return of goods can be estimated reliably, the entity retains no continuing managerial involvement or effective control over the goods usually associated with ownership and the amount of revenue can be measured reliably.

Revenue from the sale of goods is measured at the fair value of the consideration received or receivable (after including fair value allocations related to multiple deliverable and/or linked arrangements), net of returns, sales tax, excise duty/ goods and service tax and applicable trade discounts and allowances. The timing of the transfer of risks and rewards varies depending on the individual terms of the sales agreements.

Service income is recognised in accordance with the terms of the contract with customers when the related performance obligation is completed, or when risks and rewards of ownership are transferred, as applicable.

Interest income is recognized on time proportionate basis with reference to the Effective Interest Rate method. Dividend from investments is recognised as revenue when right to receive is established.

l) Employee benefits:

i) Short term employee benefits

All employee benefits payable wholly within twelve months of rendering the service are classified as short term employee benefits and they are recognized in the period in which the employee renders the related service. The Company recognizes the undiscounted amount of short term employee benefits expected to be paid in exchange for services rendered as a liability (accrued expense) after deducting any amount already paid.

ii) Post-Employment Benefits:

Defined contribution plans

Obligations for contributions to defined contribution plans are expensed as the related service is provided and the Company will have no legal or constructive obligation to pay further amounts. Prepaid contributions are recognised as an asset to the extent that a cash refund or a reduction in future payments is available.

Defined benefit plans

The Company's net obligation in respect of defined benefit plans is calculated separately for each plan by estimating the amount of future benefit that employees have earned in the current and prior periods, discounting that amount and deducting the fair value of any plan assets.

The calculation of defined benefit obligations is performed periodically by an independent qualified actuary using the projected unit credit method. When the calculation results in a potential asset for the Company, the recognised asset is limited to the present value of economic benefits available in the form of any future refunds from the plan or reductions in future contributions to the plan. To calculate the present value of economic benefits, consideration is given to any applicable minimum funding requirements.

Remeasurement of the net defined benefit liability, which comprise actuarial gains and losses and the return on plan assets (excluding interest) and the effect of the asset ceiling (if any, excluding interest), are recognized immediately in other comprehensive income (OCI). The actual return of the portfolio of plan assets, in excess of the yields computed by applying the discount rate used to measure the defined benefit obligation is recognized in other comprehensive income. Net interest expense (income) on the net defined liability(assets) is computed by applying the discount rate, used to measure the net defined liability (asset). Net interest expense and other expenses related to defined benefit plans are recognised in Statement of Profit and Loss.

When the benefits of a plan are changed or when a plan is curtailed, the resulting change in benefit that relates to past service or the gain or loss on curtailment is recognised immediately in Statement of Profit and Loss. The Company recognises gains and losses on the settlement of a defined benefit plan when the settlement occurs. Other long-term employee benefits

The Company's s net obligation in respect of long-term employee benefits is the amount of future benefit that employees have earned in return for their service in the current and prior periods. The obligation is measured on the basis of a periodical independent actuarial valuation using the projected unit credit method. Remeasurement are recognised in Statement of Profit and Loss in the period in which they arise.

m) Share-based payment transactions:

Employees Stock Options Plans ("ESOPs"): The grant date fair value of options granted to employees is recognized as an employee expense, with a corresponding increase in equity, over the period that the employees become unconditionally entitled to the options. The expense is recorded for each separately vesting portion of the award as if the award was, in substance, multiple awards. The increase in equity recognized in connection with share based payment transaction is presented as a separate component in equity under "Employee Stock Options Outstanding Reserve". The amount recognized as an expense is adjusted to reflect the actual number of stock options that vest.

n) Provisions and Contingent liabilities:

A provision is recognised when the Company has a present obligation as a result of past events and it is probable that an outflow of resources will be required to settle the obligation in respect of which a reliable estimate can be made. If effect of the time value of money is material, provisions are discounted using an appropriate discount rate that reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost.

Contingent liabilities are disclosed in the Notes to the Standalone Financial Statements.

Contingent liabilities are disclosed for:

i) Possible obligations which will be confirmed only by future events not wholly within the control of the Company, or

ii) Present obligations arising from past events where it is not probable that an outflow of resources will be required to settle the obligation or a reliable estimate of the amount of the obligation cannot be made.

A Contingent Asset is disclosed where an inflow of economic benefits is probable.

o) Borrowing costs:

Borrowing costs are interest and other costs that the Company incurs in connection with the borrowing of funds and is measured with reference to the effective interest rate (EIR) applicable to the respective borrowing.

Borrowing costs include interest costs measured at EIR and exchange differences arising from foreign currency borrowings to the extent they are regarded as an adjustment to the interest cost.

Borrowing costs, allocated to qualifying assets, pertaining to the period from commencement of activities relating to construction / development of the qualifying asset up to the date of capitalisation of such asset are added to the cost of the assets. Capitalisation of borrowing costs is suspended and charged to the Statement of Profit and Loss during extended periods when active development activity on the qualifying assets is interrupted.

All other borrowing costs are recognised as an expense in the period which they are incurred.

p) Government Grants and Assistance:

Government grants are initially recognised as deferred income at fair value if there is reasonable assurance that they will be received and the Company will comply with the conditions associated with the grant;

- In case of capital grants, they are then recognised in Statement of Profit and Loss as other income on a systematic basis over the useful life of the asset.

- In case of grants that compensate the Company for expenses incurred are recognised in Statement of Profit and Loss on a systematic basis in the periods in which the expenses are recognised.

Export benefits available under prevalent schemes are accrued in the year in which the goods are exported and there is no uncertainty in receiving the same.

q) Earnings per share:

Basic earnings per share is computed by dividing the profit / (loss) after tax by the weighted average number of equity shares outstanding during the year. The weighted average number of equity shares outstanding during the year is adjusted for the events for bonus issue, bonus element in a rights issue to existing shareholders, share split and reverse share split (consolidation of shares) including for changes effected prior to the approval of the financial statements by the Board of Directors. Diluted earnings per share is computed by dividing the profit / (loss) after tax as adjusted for dividend, interest and other charges to expense or income (net of any attributable taxes) relating to the dilutive potential equity shares, by the weighted average number of equity shares considered for deriving basic earnings per share and the weighted average number of equity shares which could have been issued on conversion of all dilutive potential equity shares.

Dilutive potential equity shares are deemed converted as of the beginning of the period, unless issued at a later date. Dilutive potential equity shares are determined independently for each period presented.

r) Insurance claims:

Insurance claims are accounted for on the basis of claims admitted / expected to be admitted and to the extent that the amount recoverable can be measured reliably and it is reasonable to expect the ultimate collection.

s) Goods and Service tax (‘GST’) input credit:

GST input credit is accounted for in the books in the period in which the underlying service received is accounted and when there is reasonable certainty in availing / utilizing the credits.

t) Segment reporting:

The Company operates in one reportable business segment i.e. “Pharmaceuticals”.

u) Operating cycle:

Based on the nature of products / activities of the Company and the normal time between acquisition of assets and their realisation in cash or cash equivalents, the Company has determined its operating cycle as 12 months for the purpose of classification of its assets and liabilities as current and non-current.

v) Cash Flow Statement:

Cash flows are reported using the indirect method, whereby profit for the period is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future operating cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the Company are segregated.

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

NOTE 2: PROPERTY, PLANT AND EQUIPMENT

(All amounts are in ₹ Lakhs unless otherwise stated)

Particulars	Gross block				Depreciation Reserve				Net Block	
	As at 01-04-2020	Additions during the year	Deletions during the year	As at 31-03-2021	As at 01-04-2020	Additions during the year	Deletions during the year	As at 31-03-2021	As at 31-03-2021	As at 31-03-2020
Tangible Assets										
Land	993.41	605.57	-	1,598.98	-			-	1,598.98	993.41
Leasehold Land	137.10	1,267.39	-	1,404.49	3.05	8.52		11.57	1,392.92	134.05
Factory Buildings	4,604.80	1,151.01	-	5,755.81	593.99	179.10		773.09	4,982.72	4,010.81
Buildings - Others	451.10	-	-	451.10	98.86	6.89		105.75	345.35	352.24
Plant & Machinery (i)	7,043.05	109.11	33.91	7,118.25	2,620.49	579.75	25.49	3,174.75	3,943.50	4,422.56
Air Conditioner	318.77	7.92	-	326.69	41.17	32.06		73.23	253.46	277.60
Furniture & Fixtures	1,638.83	17.14	-	1,655.96	414.39	177.08		591.47	1,064.50	1,224.44
Office Equipment	569.74	16.11	-	585.86	360.40	65.03		425.43	160.42	209.34
Computers	581.77	28.83	-	610.60	307.34	125.67		433.01	177.59	274.43
Electrical Fittings	1,324.93	9.46	-	1,334.38	348.67	125.20		473.87	860.51	976.26
Motor Vehicles	516.28	14.50	7.91	522.87	359.61	47.10	7.91	398.79	124.08	156.67
Tools & Spares	51.56	-	-	51.56	40.25	11.31		51.56	0.00	11.31
Lab Equipment (i)	3,904.20	500.87	-	4,405.07	775.85	740.46		1,516.31	2,888.76	3,128.35
Motor Cycle	0.73	-	-	0.73	0.07	0.07		0.15	0.59	0.66
Total Tangible Assets	**22,136.27**	**3,727.92**	**41.82**	**25,822.37**	**5,964.14**	**2,098.23**	**33.40**	**8,028.98**	**17,793.38**	**16,172.13**

(i) Gross Block for 31st March 2021 includes Rs. 486.08 Lacs (PY: Rs. 433.41 Lacs) of government grant in the nature of waiver of duty on purchase of plant and machinery & lab equipments. Accumulated Depreciation for Plant & Machinery as at 31st March 2021 includes Rs. 136.93 Lacs (PY: Rs. 60.92 Lacs) on such government grant.

Particulars	Gross block				Depreciation Reserve				Net Block	
	As at 01-04-2019	Additions during the year	Deletions during the year	As at 31-03-2020	As at 01-04-2019	Additions during the year	Deletions during the year	As at 31-03-2020	As at 31-03-2020	As at 31-03-2019
Tangible Assets										
Land	993.41	-	-	993.41	-	-		-	993.41	993.41
Leasehold Land	137.10	-	-	137.10	1.56	1.49		3.05	134.05	135.52
Factory Buildings	4,067.54	537.26	-	4,604.80	435.02	158.97		593.99	4,010.81	3,622.59
Buildings - Others	451.10	-	-	451.10	91.45	7.41		98.86	352.24	359.65
Plant & Machinery	6,306.04	773.89	36.88	7,043.05	2,035.00	610.70	25.21	2,620.49	4,422.56	4,251.90
Air Conditioner	168.43	150.34	-	318.77	19.70	21.47		41.17	277.60	167.84

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

Particulars	Gross block				Depreciation Reserve				Net Block	
	As at 01-04-2019	Additions during the year	Deletions during the year	As at 31-03-2020	As at 01-04-2019	Additions during the year	Deletions during the year	As at 31-03-2020	As at 31-03-2020	As at 31-03-2019
Furniture & Fixtures	1,114.93	523.90	-	1,638.83	272.84	141.55		414.39	1,224.44	842.10
Office Equipment	473.13	96.61	-	569.74	277.85	82.55		360.40	209.34	195.28
Computers	338.53	243.24	-	581.77	198.01	109.33		307.34	274.43	138.03
Electrical Fittings	1,056.95	267.98	-	1,324.93	237.19	111.48		348.67	976.26	819.77
Motor Vehicles	452.78	69.93	6.43	516.28	316.28	49.12	5.79	359.61	156.67	137.25
Tools & Spares	51.56	-	-	51.56	38.54	1.71		40.25	11.31	13.02
Lab Equipment	2,147.42	1,756.78	-	3,904.20	206.33	569.52		775.85	3,128.35	1,941.09
Motor Cycle	0.73	-	-	0.73	-	0.07		0.07	0.66	-
Total Tangible Asset	**17,759.65**	**4,419.93**	**43.31**	**22,136.27**	**4,129.77**	**1,865.37**	**31.00**	**5,964.14**	**16,172.13**	**13,617.46**

Note 2A Capital Work-in-Progress

Particulars	As at March 31, 2021	As at March 31, 2020
Opening Balance	377.31	861.99
Additions	3,532.37	3,960.67
Less:		
Capitalisation	(3,773.65)	(4,445.35)
Assets held for sale		-
Closing Balance	**136.03**	**377.31**

Note : 2B Intangible Assets

Particulars	Gross block				Depreciation Reserve				Net Block	
	As at 01-04-2020	Additions during the year	Deletions during the year	As at 31-03-2021	As at 01-04-2020	Additions during the year	Deletions during the year	As at 31-03-2021	As at 31-03-2021	As at 31-03-2020
Computer Software	473.76	100.86	-	574.62	134.52	79.62	-	214.14	360.48	339.24
Total Intangible Assets	**473.76**	**100.86**	**-**	**574.62**	**134.52**	**79.62**	**-**	**214.14**	**360.48**	**339.24**

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

Particulars	Gross block				Depreciation Reserve				Net Block	
	As at 01-04-2019	Additions during the year	Deletions during the year	As at 31-03-2020	As at 01-04-2019	Additions during the year	Deletions during the year	As at 31-03-2020	As at 31-03-2020	As at 31-03-2019
Computer Software	225.21	248.55	-	473.76	78.48	56.04	-	134.52	339.24	159.16
Total Intangible Assets	**225.21**	**248.55**	**-**	**473.76**	**78.48**	**56.04**	**-**	**134.52**	**339.24**	**159.16**

Note : 2C ROU Assets

Particulars	Gross block				Depreciation Reserve				Net Block	
	As at 01-04-2020	Additions during the year	Deletions during the year	As at 31-03-2021	As at 01-04-2020	Additions during the year	Deletions during the year	As at 31-03-2021	As at 31-03-2021	As at 31-03-2020
ROU Assets	225.11		-	225.11	43.97	66.23	-	110.21	114.91	181.14
Total ROU Assets	**225.11**	**-**	**-**	**225.11**	**43.97**	**66.23**	**-**	**110.21**	**114.91**	**181.14**

Particulars	Gross block				Depreciation Reserve				Net Block	
	As at 01-04-2019	Additions during the year	Deletions during the year	As at 31-03-2020	As at 01-04-2019	Additions during the year	Deletions during the year	As at 31-03-2020	As at 31-03-2020	As at 31-03-2019
ROU Assets		225.11	-	225.11		43.97	-	43.97	181.14	-
Total ROU Assets	**-**	**225.11**	**-**	**225.11**	**-**	**43.97**	**-**	**43.97**	**181.14**	**-**

NOTE 3 NON-CURRENT INVESTMENTS

	As at March 31, 2021	As at March 31, 2020
A. Fully paid Ordinary / Equity shares/Share in LLP - Unquoted - at cost		
(i) Subsidiaries		
88,000 (88,000) Caplin Point Far East Limited, (Hong Kong) of HKD 1/- each	7.68	7.68
9,69,814 (7,86,417) Caplin Point laboratories Colombia, SAS, (Colombia) of COP 1,000/- each	212.43	175.27
Argus Salud Pharma LLP 99.90% (99.90%) of capital contribution and 99.90% (99.90%) share of profit	99.00	99.00
10,53,74,113 (10,53,74,113) equity shares of Caplin Steriles Limited of ₹ 10/- each fully paid up (i)	13,259.04	13,052.78
50,000 (5,000) Equity Shares in CAPLIN POINT (S) PTE Ltd of USD 1/- each	37.70	3.77
(ii) Associate		
17,28,951 (17,28,951) equity shares of Hainan Jointown Caplinpoint Pharmaceutical Company Limited of ₹ 10/- each fully paid up	182.17	182.17
Total	**13,798.02**	**13,520.67**

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

(i) On 12th December 2018, the Company has incorporated Caplin Steriles Ltd as a Wholly Owned Subsidiary with an initial Paid up capital of 100,000 equity shares of Rs 10 each.

Pursuant to the Business Transfer Agreement executed by the Company on 18th January, 2019, the regulated markets injectable business (including USFDA approved injectable plant and DSIR recognized R&D Units CP4 & CP5) have been transferred to Caplin Steriles Limited for which the Company has been issued 9,32,99,782 equity shares of Rs.10/-each fully paid up as a consideration for this Slump Sale.

Pursuant to the Investment Agreement dated 18th January 2019, the company was allotted 1,19,74, 331 Equity Shares of face value of ₹ 10/- at a premium of Rs. 19.23 each in Caplin Sterils Ltd on 27th March, 2020 by way of rights issue against consideration in cash.

The ESOP's issued by the Company to the employees of its subsidiary is considered as part of its cost of investment.

NOTE 3A : NON-CURRENT INVESTMENTS

	As at March 31, 2021	As at March 31, 2020
A. Fully paid Ordinary / Equity shares - Quoted - fair value through profit or loss account		
26,800 (26,800) shares of The Catholic Syrian Bank Ltd of ₹ 10/- each fully paid up	62.42	29.17
4,400 (4,400) shares of Karnataka Bank Ltd of ₹10/- each fully paid up	2.69	2.40
4,800 (4,800) shares of Indian Overseas Bank of ₹ 10/- each fully paid up	0.77	1.15
700 (700) shares of Bank of India of ₹ 10/- each fully paid up	0.47	0.32
Total	**66.35**	**33.04**

NOTE 4 : LONG-TERM LOANS AND ADVANCES

	As at March 31, 2021	As at March 31, 2020
Unsecured, considered good		
Security Deposits	55.48	50.81
Other Deposits	97.32	93.55
Advance for Capital expenditure	196.65	76.48
Total	**349.45**	**220.84**
*** Break up:**		
Loan Receivable considered good- Secured	-	-
Loan Receivable considered good- Unsecured	349.45	220.84
Loan Receivable which have significant increase in credit risk	-	-
Loan Receivable - credit impaired	-	-
Total	**349.45**	**220.84**
Less:Allowance for doubtful Loans	-	-
Total Loans	**349.45**	**220.84**

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

NOTE 5: INVENTORIES (LOWER OF COST OR NET REALISABLE VALUE)

	As at March 31, 2021	As at March 31, 2020
Raw Materials	870.42	648.12
Packing Materials	508.52	545.06
Work-in-Progress	157.63	176.81
Stock In Trade	456.92	114.78
Finished Goods	436.48	702.56
Stores and Spares	56.76	49.55
Total	**2,486.73**	**2,236.88**

NOTE 6 : CURRENT INVESTMENT

	As at March 31, 2021	As at March 31, 2020
Investment in Mutual Fund - fair value through Profit or Loss (i)	1,053.50	6,022.98
Total	**1,053.50**	**6,022.98**

(i) Investment in Mutual Fund at fair value through profit or loss

FUND NAME	As at March 31, 2021		As at March 31, 2020	
	Units	Amount ₹ in lakhs	Units	Amount ₹ in lakhs
ICICI Prudential Liquid Plan - D -G	-	-	138,988.30	408.32
ICICI Prudential Savings Fund - Growth	-	-	26,564.82	102.90
ICICI Prudential Short Term - Growth	-	-	1,694,333.86	714.49
Kotak Flexi Debt - Regular Plan - Growth	-	-	2,739,946.51	736.29
Reliance Short Term Fund - Growth	-	-	1,726,439.40	652.16
UTI Liquid Cash Plan	-	-	12,462.97	403.48
Axis Triple Advantage fund - equity	-	-	100,000.00	17.52
Franklin India Flexi Cap fund	-	-	5,000.00	2.63
Aditya Birla Sun Life Floating Rate Fund	-	-	139,481.73	349.98
Aditya Birla Sun Life Liquid Fund	-	-	372,674.56	1,212.19
Aditya Birla Sun Life Savings Fund	-	-	27,147.07	107.92
- Franklin India Fixed Maturity Plan B Series - 5 - Plan B1244 days - Growth	2,000,000.00	250.81	2,000,000.00	229.55
Franklin India Fixed Maturity Plans - Series 4 - Plan E 1098 days - Growth - Direct	2,000,000.00	251.36	2,000,000.00	233.45
ICICI Prudential Money Market Fund	-	-	154,001.88	429.39
ICICI Prudential Ultra Short Term Fund	-	-	2,024,199.49	422.71
Aditya Birla Sun Life Overnight Fund - Growth	18,065.00	200.45	-	-
Aditya Birla Sun Life Overnight Fund– Growth - Direct	31,528.00	350.88	-	-
Total		**1,053.50**		**6,022.98**

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

Particulars	As at March 31, 2021	As at March 31, 2020
Aggregate book value of quoted investments	983.61	5,480.90
Aggregate Market value of quoted investments	1,119.85	6,056.02
Aggregate value of un-quoted investments	13,798.02	13,520.67
Aggregate amount of impairment in value of investment	-	-

NOTE 7 : TRADE RECEIVABLES

	As at March 31, 2021	As at March 31, 2020
(Unsecured considered good unless otherwise stated)		
Trade Receivables	7,698.96	11,431.01
Receivables from related parties	2,146.92	10,467.28
Trade receivables which have significant increase in credit risk	-	-
Trade receivables - Credit impaired	-	-
Less: Allowance for doubtful trade receivables	-	-
Total receivables	**9,845.88**	**21,898.29**

NOTE 8 : CASH AND CASH EQUIVALENTS

	As at March 31, 2021	As at March 31, 2020
Cash on Hand	4.58	9.87
Balance with Banks		
- Current accounts	3,567.29	3,674.07
In Bank Deposit Accounts		
- Bank Deposit accounts less than 3 months maturity	11,310.34	-
Total	**14,882.21**	**3,683.94**

NOTE 9 : OTHER BANK BALANCES

		As at March 31, 2021	As at March 31, 2020
-	Unpaid Dividend account	261.23	266.20
	In Bank Deposit Accounts		
-	Bank Deposit accounts maturity (more than 3 months but less than 12 months) [Refer Note 35]	19,406.07	1,876.80
-	Bank Deposit accounts maturity (more than 12 months)	2,000.00	-
Total		**21,667.30**	**2,143.00**

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

NOTE 10 : SHORT TERM LOANS AND ADVANCES *

	As at March 31, 2021	As at March 31, 2020
Unsecured, considered good		
Advances recoverable in cash or kind for the value to be received	260.48	414.91
Export Incentives Receivable	1,011.94	988.30
Balance with Statutory Authorities	1,237.17	641.85
Total	**2,509.59**	**2,045.06**
*** Break up:**		
Loans considered good- Secured	-	-
Loans considered good- Unsecured	2,509.59	2,045.06
Loans which have significant increase in credit risk	-	-
Loans - credit impaired	-	-
Total	**2,509.59**	**2,045.06**
Less:Allowance for doubtful Loans	-	-
Total Loans	**2,509.59**	**2,045.06**

NOTE 11 : OTHER CURRENT ASSETS

	As at March 31, 2021	As at March 31, 2020
Interest Accrued on Deposits	817.51	43.48
Employee Benefits Asset(Net of provision)	2.06	-
Total	**819.57**	**43.48**

NOTE 12 EQUITY SHARE CAPITAL

	As at March 31, 2021	As at March 31, 2020
8,50,00,000 (31st March, 2020: 8,50,00,000) equity shares of ₹ 2/- each	1,700.00	1,700.00
ISSUED, SUBSCRIBED AND PAID UP		
7,56,42,750 (31st March, 2020:7,56,42,750) equity shares of ₹ 2/- each fully paid up	1,512.86	1,512.86
Total	**1,512.86**	**1,512.86**

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

a) Reconciliation of equity shares outstanding at the beginning and at the end of the Year

Fund Name	As at March 31, 2021		As at March 31, 2020	
	NO OF EQUITY SHARES of ₹ 2/- each	Amount	NO OF EQUITY SHARES of ₹ 2/- each	Amount
Equity shares outstanding at the beginning of the Year	7,56,42,750	1,512.86	7,56,30,250	1,512.61
Add: Equity shares allotted pursuant to employee stock option plan*	-	-	12,500	0.25
Less: Equity shares bought back during the Year	-	-	-	-
Equity shares outstanding at the end of the Year	**7,56,42,750**	**1,512.86**	**7,56,42,750**	**1,512.86**

*During the financial year 2020-21 (2019-20), Nil (12,500) equity shares under ESOP Scheme vested were exercised

b) Rights, preference & restrictions attached to shares

Equity Shares

The Company has only one class of equity shares having a par value of ₹ 2/- per share. Each holder of equity share is entitled to one Vote per Share.

The Dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting.

In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

c) Details of shares in the company held by each shareholder holding more than 5% shares:

Name of Shareholder	As at March 31, 2021 (of ₹ 2/- each)		As at March 31, 2020 (of ₹ 2/- each)	
	No. of Shares held	% of Holding	No. of Shares held	% of Holding
P. Vijayalakshmi	1,78,80,000	23.64%	1,78,80,000	23.64%
C.C. Paarthipan	1,41,67,192	18.73%	1,41,67,192	18.73%
P. Ashok Gorkey	90,50,000	11.96%	90,50,000	11.96%
P. Vivek Siddarth	90,00,000	11.90%	90,00,000	11.90%

d) Shares reserved for issuance under Employee Stock Options Plans of the Company

Particulars	As at March 31, 2021		As at March 31, 2020	
	No. of Shares of ₹ 2/- each	Amount	No. of Shares of ₹ 2/- each	Amount
Caplin Point Employee Stock Option Plan 2015	2,81,000	5.62	3,74,250	7.49
Caplin Point Employee Stock Option Plan 2017	4,90,000	9.80	2,88,000	5.76

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

e) Aggregate number of shares issued pursuant to Stock Option Plans of the Company

Particulars	**Aggregate No. of Shares**
Issued in FY 2016-17	26,750
Issued in FY 2017-18	26,750
Issued in FY 2018-19	26,750
Issued in FY 2019-20	12,500
Total	**92,750**

f) No shares have been allotted without payment being received in cash or by way of bonus shares during the period of five years immediately preceding the balance sheet date.

NOTE 13 : RESERVES & SURPLUS

		As at March 31, 2021	**As at March 31, 2020**
a)	Capital Reserve		
	Opening and closing balance as per last balance sheet	40.98	40.98
b)	Securities Premium		
	Opening balance as per last balance sheet	212.29	162.75
	Add:Additions during the year	-	49.54
	Balance at the end of the Year	**212.29**	**212.29**
c)	General Reserve		
	Opening and closing balance as per last balance sheet	1,128.78	1,128.78
d)	*Employee Stock Options Out*standing		
	- Employee Stock options outstanding		
	Opening balance as per last balance sheet	2,503.49	1,733.55
	Add: Options granted during the year	377.42	819.48
	Less: Exercised during the year	-	49.54
	Less: Lapsed during the year	-	-
	Balance at the end of the Year (A)	**2,880.91**	**2,503.49**
	- Deferred Employees Stock Options Cost		
	Opening balance as per last balance sheet	1,559.32	1,047.88
	Add: Options granted during the year	377.42	819.48
	Less: Amortised during the year in statement of P&L account	(329.13)	(148.96)
	Less: Amortised during the year in Cost of investment	(206.26)	(159.08)
	Balance at the end of the Year (B)	**1401.34**	**1,559.32**
	(A-B)	**1,479.56**	**944.17**
e)	Surplus in the Statement of Profit & Loss		
	Balance at the beginning of the Period	56,164.10	39,652.88
	Add : Profit during the Period	15,621.98	19,763.85

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

	As at March 31, 2021	As at March 31, 2020
Final Dividend paid	(302.57)	(1,664.14)
Interim Dividend Paid	-	(1,588.49)
Balance at the end of the Year	**71,483.51**	**56,164.10**
f) Other Comprehensive Income		
i) Actuarial Gain/ (Loss) on employee benefit obligation		
Opening balance as per last balance sheet	(12.64)	20.83
Add/(Less); Additions during the year	22.00	(33.47)
Balance at the end of the Year	**9.36**	**(12.64)**
Total	**74,354.48**	**58,477.68**

Nature of Reserve

a) Capital Reserve

The Capital Reserve has been created on restructuring of the Capital of the Company under a scheme of amalgamation.

b) Securities Premium

Securities Premium account has been created on issue of shares under employee stock option scheme.

c) General Reserve

The General Reserve is created by time to time transfer of profits from retained earnings for appropriation purposes. As the General Reserve is created by transfer from one component of equity to another and is not an item of other comprehensive income, items included in the General Reserve will not be reclassified subsequently to the statement of profit and loss.

NOTE 14 : LONG TERM BORROWINGS

	As at March 31, 2021	As at March 31, 2020
Secured		
Loan from others (i)	1.19	28.29
Less : Current maturities of long term debt	1.19	26.77
Total	**-**	**1.52**

i) Obligations under Hire purchase are secured against relevant fixed assets obtained under Hire Purchase Finance

Terms of Repayments

a) Vehicle loans from Banks and other financial institutions are repayable in equal monthly instalments.

b) The rate of interest on vehicle loans vary between 8% to 10% per annum.

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

NOTE 15 : LEASE LIABILITY

	As at March 31, 2021	As at March 31, 2020
Lease Liability (Refer Note 39)	53.32	128.48
Total	**53.32**	**128.48**

NOTE 16 : DEFERRED TAX LIABILITIES (NET)

	As at March 31, 2021	As at March 31, 2020
Deferred Tax Liabilities on account of timing differences	2,097.13	2,213.94
Total	**2,097.13**	2,213.94

NOTE 17 : OTHER NON CURRENT LIABILITIES

	As at March 31, 2021	As at March 31, 2020
Govt Grant [Refer Note 2(i)]	349.15	372.49
Others	-	-
Total	**349.15**	**372.49**

NOTE 18 : TRADE PAYABLES

	As at March 31, 2021	As at March 31, 2020
Total outstanding dues of micro enterprises and small enterprises (Refer Note- 34)	22.72	-
Total outstanding dues of creditors other than micro enterprises and small enterprises	6,987.52	5,141.28
Total	**7,010.24**	**5,141.28**

NOTE 19 : LEASE LIABILITY (CURRENT LIABILITY)

	As at March 31, 2021	As at March 31, 2020
Lease Liability	79.19	84.81
Total	**79.19**	**84.81**

NOTE 20 : CURRENT BORROWING

	As at March 31, 2021	As at March 31, 2020
Current maturities of long term debt	1.19	26.77

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

NOTE 21 : OTHER CURRENT LIABILITIES

	As at March 31, 2021	As at March 31, 2020
Statutory Dues payable	64.12	74.60
Creditors for Capital Goods	73.19	542.54
Unclaimed Dividend (Ref Note :43)	261.23	266.20
Salary and bonus payable	128.00	104.58
Provision for Gratuity(Net)	116.15	97.77
Total	**642.69**	**1,085.69**

NOTE 22 : SHORT TERM PROVISIONS

	As at March 31, 2021	As at March 31, 2020
Provision for Employee Benefits	-	87.21
Total	**-**	**87.21**

NOTE 23 : REVENUE FROM OPERATIONS

	For the Year ended March 31, 2021	For the year ended March 31, 2020
Revenue from Operations	**47,105.09**	**51,053.13**
Sale of products	46,816.03	51,044.58
Sale of Services	289.06	8.55
Other operating revenues		
Export Incentives	1,162.87	1,729.40
Total	**48,267.96**	**52,782.53**

NOTE 24 : OTHER INCOME

	For the Year ended March 31, 2021	For the year ended March 31, 2020
Interest Income	1,255.81	139.87
Dividend on Non Current investment from subsidiary Company (a)	304.78	3,291.09
Share of Profit/ (loss) in LLP from Non Current investment from Subsidiary LLP (b)	0.86	2.99
Gain on sale of financial instruments	637.78	485.41
Fair value gain on financial instruments through profit or loss	(438.89)	48.78
Gain on Foreign exchange (net)	17.23	2,561.67
Govt Grant (c)	80.33	53.83
Miscellaneous Income	3.90	13.49
Total	**1,861.80**	**6,597.13**

(a) Dividend received from Caplin Point Far East Limited, Hong Kong, a Wholly owned subsidiary, on equity shares held by the Company

(b) Share of profit/ (loss) of the Company with respect to 99.90% share in Argus Salud Pharma LLP.

(c) Systematic recognition of Government grant, in the nature of waiver of duty on depreciable tangible assets, over the useful life of the such assets.

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

NOTE 25 : COST OF MATERIALS CONSUMED

	For the Year ended March 31, 2021	For the year ended March 31, 2020
Opening Stock	1,242.74	1,431.87
Add : Purchases (Net)	11,440.50	9,384.36
Less : Closing Stock	1,435.70	1,242.74
Total	**11,247.53**	**9,573.49**

NOTE 26 : CHANGES IN INVENTORIES OF FINISHED GOODS INCLUDING STOCK -IN-TRADE AND WORK-IN-PROGRESS

	For the Year ended March 31, 2021	For the year ended March 31, 2020
Inventories at the end of the year		
Work in Progress	157.63	176.81
Finished Goods	436.48	702.56
Stock-in-Trade	456.92	114.78
(A)	**1,051.03**	**994.15**
Inventories at the beginning of the year		
Work in Progress	176.81	320.72
Finished Goods	702.56	100.48
Stock-in-Trade	114.78	498.85
(B)	**994.15**	**920.05**
Net (Increase) / Decrease in Inventories (B- A)	**(56.88)**	**(74.10)**

NOTE 27 : EMPLOYEE BENEFITS EXPENSE

	For the Year ended March 31, 2021	For the year ended March 31, 2020
Salaries,wages, bonus and allowances	1,946.82	2,011.21
Contribution to Provident and Other funds	166.10	125.16
Employee share based expense	329.13	148.96
Staff Welfare Expenses	217.33	214.58
Total	**2,659.38**	**2,499.91**

NOTE 28 : FINANCE COSTS

	For the Year ended March 31, 2021	For the year ended March 31, 2020
Interest Expense	1.51	3.93
Interest Expense on Lease (Refer Note 39)	15.16	14.57
Total	**16.67**	**18.50**

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

NOTE 29 : DEPRECIATION AND AMORTISATION

	For the Year ended March 31, 2021	For the year ended March 31, 2020
Depreciation on property, plant and equipment (Refer note: 2)	2,098.23	1,865.37
Amortisation of Intangible Assets	79.62	56.04
Depreciation on ROU Asset	66.23	43.97
Total	**2,244.08**	**1,965.38**

NOTE 30 : RESEARCH AND DEVELOPMENT EXPENSES

	For the Year ended March 31, 2021	For the year ended March 31, 2020
R & D Expenses	1,939.85	2,435.77
Total	**1,939.85**	**2,435.77**

NOTE 31 : OTHER EXPENSES

	For the Year ended March 31, 2021	For the year ended March 31, 2020
Loss on Sale of Asset	6.05	4.26
Power and Fuel	636.44	719.23
Contract Labour charges	390.70	452.19
Other Manufacturing Expenses	77.61	77.67
Communication Expenses	43.25	47.71
Donations	19.34	9.45
Corporate Social Responsibility	410.37	0.25
Professional and Consultancy charges	240.12	320.75
Rates & taxes	56.57	59.05
Travelling Expenses	96.10	213.93
Auditors' Remuneration -(Refer note:41)	17.18	16.83
Insurance	54.50	27.20
Repairs and Maintenance		
a) Plant and Machinery	139.75	156.74
b) Building	130.33	160.19
c) Others	35.57	51.51
Rent & Amenities	87.41	108.49
Freight outwards	276.98	589.10
Sundry Expenses	74.86	315.20
Total	**2,793.13**	**3,329.75**

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

NOTE 32 : COMMITMENT (TO THE EXTENT NOT PROVIDED FOR)

Particulars	As at March 31, 2021	As at March 31, 2020
Estimated amount of contracts remaining to be executed on capital account	189.61	480.11
Other Commitments (Raw material, Packing Material, Finished Goods, Other services)	3,035.06	1,745.39
Interim dividend of Rs 1.50 (75%) per equity share of Rs.2 each for the Financial Year 2020-21 payable on or after 27th May' 2021, not recognized as a liability in the financial statements for the year ended 31st March' 2021	1,134.64	-
Final Dividend proposed for F.Y 2019-20 of Rs 0.40 per equity share (Previous Year Rs. 2.20) before the financial statements approved for issue, but not recognised as a liability in the financial statements for the year ended 31st March' 2020	Nil	302.57
Dividend Tax	Nil	Nil

NOTE 33 : CONTINGENT LIABILITIES (TO THE EXTENT NOT PROVIDED FOR)

Disputed statutory dues:

Name of the statute	Nature of dues	As at March 31, 2021	As at March 31, 2020	Forum where dispute is pending
Income Tax Act, 1961	Income tax	102.02	127.95	Income Tax Appellate Tribunal/ CIT Appeals

NOTE 34 : DUES TO MICRO, SMALL AND MEDIUM ENTERPRISES

DISCLOSURE UNDER THE MICRO, SMALL AND MEDIUM ENTERPRISES DEVELOPMENT ACT, 2006 ARE PROVIDED AS UNDER FOR THE YEAR 2020-21, TO THE EXTENT THE COMPANY HAS RECEIVED INTIMATION FROM THE "SUPPLIERS" REGARDING THEIR STATUS UNDER THE ACT

Particulars	As at March 31, 2021	As at March 31, 2020
(i) Principal amount and the interest due thereon remaining unpaid to each supplier at the end of each accounting year		-
Principal amount due to micro and small enterprise	22.72	-
Interest due on above	-	-
(ii) Interest paid by the Company in terms of Section 16 of the Micro, Small and Medium Enterprises Development Act, 2006, along-with the amount of the payment made to the supplier beyond the appointed day during the period	-	-
(iii) Interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the period) but without adding interest specified under the Micro, Small and Medium Enterprises Act, 2006	-	-
(iv) The amount of interest accrued and remaining unpaid at the end of each accounting year	-	-
(v) Interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprises	-	-

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

Dues to Micro and Small Enterprises have been determined to the extent such parties have been identified on the basis of information collected by the Management. This has been relied upon by the auditors.

NOTE 35 : BALANCES WITH SCHEDULED BANKS IN DEPOSIT ACCOUNTS INCLUDES:

(a) Bank Deposit Accounts under Note no: 9 for the current year include ₹ 35.77 lakhs (as at 31.03.2020 ₹500 lakhs) earmarked as lien towards Margin for Letter of Credit and Bank Guarantee .

NOTE 36 : EMPLOYEE BENEFITS

(i) Defined Contribution Plan:

The Company makes monthly contributions for qualifying employees towards provident/retirement fund administered and managed by the Government of India under defined contribution plans .

The Company recognized ₹ 147.76 lakhs (Previous year ₹ 151.43 lakhs) towards provident and pension fund contributions in the Statement of Profit and Loss.

(ii) Defined Benefit Plan:

The Company makes contributions to the group gratuity scheme administered by the LIC of India, a funded defined benefit plan for qualifying employees.

The following table sets out the status of the gratuity plan and reconciliation of opening and closing balances of the present value of defined benefit obligation.

		As at 31.03.2021	As at 31.03.2020
i)	Reconciliation in present value of obligations ('PVO') - defined benefit obligation:		
	Current service cost	88.86	65.07
	Past service cost	-	
	Interest cost	20.92	18.09
	Actuarial loss/ (gain)		
	- Due to demographic assumption	-	-
	- Due to finance assumption	(8.63)	22.26
	- Due to experience assumption	(26.03)	11.22
	Benefits paid	(25.84)	(38.09)
	PVO at the beginning of the year	288.45	209.90
	PVO at the end of the year	337.73	288.45
ii)	Change in fair value of plan assets:		
	Actuarial Gains/(Losses)	(12.66)	(6.77)
	Interest Income	13.50	16.40

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

		As at 31.03.2021	As at 31.03.2020
	Contribution by the employer	55.90	6.47
	Benefits paid	(25.84)	(38.09)
	Fair Value of the plan assets at the beginning of the year	190.67	212.66
	Fair Value of the plan assets at the end of the year	221.58	190.67
iii)	Reconciliation of PVO and fair value of plan assets:		
	PVO at the end of the year	337.73	288.45
	Fair Value of plan assets at the end of the year	221.58	190.67
	Funded status	(116.15)	(97.77)
	Un recognised actuarial gain/ (loss)	-	-
	Net Asset/(liability) recognised in the balance sheet	(116.15)	(97.77)
iv)	Expense recognised in the Statement of Profit and Loss:		
	Current Service cost	88.86	65.07
	Past Service cost	-	-
	Net Interest cost	7.42	1.69
	Total expense recognised in the Statement of Profit and loss	96.28	66.76
v)	Other Comprehensive Income:		
	Actuarial loss/ (gain)		
	- Due to demographic assumption	-	-
	- Due to finance assumption	(8.63)	22.26
	- Due to experience assumption	(26.03)	11.22
	Return on plan assets excluding net interest	12.66	6.77
	Total amount recognised as OCI	(22.00)	40.25
vi)	Category of assets as at the end of the year:		
	Insurer Managed Funds (100%)	221.58	190.67
	(Fund is managed by Life Insurance Corporation of India as per IRDA guidelines, category-wise composition of the plan assets is not available)		
vii)	Actual Return on plan Assets:	0.84	9.62
viii)	Assumption used in accounting for the gratuity plan		
	Mortality (%)	Rates stipulated in Indian Assured Lives Mortality 2012-14	Rates stipulated in Indian Assured Lives Mortality 2012-14
	Discount Rate (%)	7.03	6.73
	Salary Escalation Rate	7	7
	Employee Attrition Rate (%)	7	7

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

NOTE 37 : INCOME TAXES

	Particulars	For the Financial Year ended March 31, 2021	For the Financial Year ended March 31, 2020
a	Tax expenses recognised in profit and loss:		
	Current Tax Expense for the year	5,488.36	5,588.87
	Deferred income tax liability/ (asset), net	(116.81)	(40.23)
	Tax expense for the year	**5,371.55**	**5,548.64**
b	Reconciliation of effective tax rate:		
	Profit before Tax	20,993.53	25,312.49
	Tax using the Company's domestic tax rate	5,283.65	6,370.65
	(March 31, 2021:25.168%, March 31, 2020: 25.168%)		
	Tax effect of :		
	Tax impact on Donation & CSR expenses disallowance	108.15	-
	Impact of foreign dividend taxed at special rate	(76.71)	(253.18)
	Tax incentive on additional employment	(19.60)	(12.58)
	Tax impact on Actual Gain on Mutual fund & shares	(7.47)	(21.11)
	Tax impact on fair value of Mutual fund & shares (Disallowance)	110.46	-
	Tax impact - Timing difference on R&D capital asset, book and tax depreciation and others	(26.94)	(535.14)
	Current and Deferred Tax expenses as per note (a) above	**5,371.55**	**5,548.64**

c	Movement in deferred tax balances			
	Deferred Tax Liability	**As at 31st March' 2020**	**For the year ended 31st March 2021**	**As at 31st March' 2021**
	Property, plant and equipment	2213.94	(116.81)	2097.13
	Total	**2213.94**	**(116.81)**	**2,097.13**

NOTE 38 : REMUNERATION TO MANAGING DIRECTOR/WHOLE-TIME DIRECTORS

Particulars	For the Financial Year ended March 31, 2021	For the Financial Year ended March 31, 2020
Salaries	54.05	58.3
Contribution to provident and other funds	2.33	2.71
Total *	**56.38**	**61.01**

* Refer note 44 (C)

NOTE 39 : OPERATING LEASES

Transition to IND AS 116

Ministry of Corporate Affairs ("MCA") through Companies (Indian Accounting Standards) Amendment Rules, 2019 and Companies (Indian Accounting Standards) Second Amendment Rules, had notified Ind AS 116 Leases which replaces the existing lease standard, Ind AS 17 Leases, and other interpretations. Ind AS 116 sets out the principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. It introduces a single, on-balance sheet lease accounting model for lessees.

Company as a Lessee (Operating Leases)

Effective April 01,2019 the company had adopted Ind AS 116 "Leases" and applied the same to the lease contracts existing on April 01,2019 using the modified retrospective approach. This has resulted in recognizing Right of Use Assets and Lease Liability as on 1st April, 2019 to the extent of Rs. 1.10 Crs each. The adoption of this Standard does not have any material impact on the financial results for the year and there is no impact on the opening retained earnings on adopting this approach. The Company has used a single discount rate to a portfolio of leases with similar characteristics. Operating leases are mainly in the nature of lease of office premises with no restrictions and are renewable / cancellable at the option of either of the parties. There are no sub-leases. There are no restrictions imposed by the lease arrangements.

The Company recognises right-of-use asset representing its right to use the underlying asset for the lease term at the lease commencement date. The cost of the right-of-use asset measured at inception shall comprise of the amount of the initial measurement of the lease liability adjusted for any lease payments made at or before the commencement date less any lease incentives received, plus any initial direct costs incurred, if any. The right-of-use assets is subsequently measured at cost less any accumulated depreciation and adjusted for any remeasurement of the lease liability. The right-of-use assets is depreciated using the straight-line method from the commencement date over the shorter of lease term or useful life of right-of-use asset.

The Company measures the lease liability at the present value of the lease payments that are not paid at the commencement date of the lease. The lease payments are discounted using the interest rate implicit in the lease, if that rate can be readily determined. If that rate cannot be readily determined, the Company uses incremental borrowing rate. For leases with reasonably similar characteristics, the Company, on a lease by lease basis, may adopt either the incremental borrowing rate specific to the lease or the incremental borrowing rate for the portfolio as a whole. The lease liability is subsequently remeasured by increasing the carrying amount to reflect interest on the lease liability, reducing the carrying amount to reflect the lease payments made and remeasuring the carrying amount to reflect any reassessment or lease modifications. The Company has elected not to apply the requirements of Ind AS 116 Leases to short-term leases of all assets that have a lease term of 12 months or less and leases for which the underlying asset is of low value. The lease payments associated with these leases are recognized as an expense on a straight-line basis over the lease term.

On application of Ind AS 116, the nature of expenses has changed from lease rent in previous periods to depreciation cost for the right-of-use asset, and finance cost for interest accrued on lease liability.

Company as a Lessee (Finance Leases)

The Company has entered into long term leasing arrangements for land which are in the nature of finance lease. These arrangements do not involve any material recurring payments.

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

NOTE 40 : RESEARCH AND DEVELOPMENT EXPENDITURE

Particulars	For the Financial Year ended March 31, 2021	For the Financial Year ended March 31, 2020
Capital expenditure included in Fixed Assets	660.88	2,829.91
Revenue expenditures incurred during the Financial Year	1,939.85	2,435.77
Total	**2,600.73**	**5,265.68**

NOTE 41 : AUDITORS' REMUNERATION COMPRISES OF FEES: (EXCLUDING APPLICABLE TAX)

Particulars	For the Financial Year ended March 31, 2021	For the Financial Year ended March 31, 2020
For Statutory Audit	13.00	13.00
For Tax Audit	3.50	3.50
For Others	0.68	0.33
Total	**17.18**	**16.83**

NOTE 42 : EARNINGS PER SHARE IS CALCULATED AS UNDER

Particulars	For the Financial Year ended March 31, 2021	For the Financial Year ended March 31, 2020
Basic		
Net Profit attributable to Equity Shareholders (₹ in Lakhs)	15,621.98	19,763.85
Weighted average number of equity shares of ₹2/- each outstanding during the year (in Nos.)	7,56,42,750	7,56,42,750
Earnings per share (in Rs)	20.65	26.13
Diluted		
Net Profit attributable to Equity Shareholders (₹ in Lakhs)	15,621.98	19,763.85
Weighted average number of equity shares of ₹2/- each outstanding during the year (in Nos.)	7,63,21,000	7,62,34,250
Earnings per share (in Rs.)	20.45	25.95

NOTE 43 : AMOUNT DUE TO INVESTOR EDUCATION AND PROTECTION FUND

The due amount of ₹ 20.98 lakhs (PY : ₹ 16.48 lakhs) were transferred to investor education and protection fund and there is no outstanding due amount to be transferred to investor education and protection fund.

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

NOTE 44 : RELATED PARTY DISCLOSURES, AS REQUIRED BY INDIAN ACCOUNTING STANDARD 24 (IND AS 24) ARE GIVEN BELOW.

(a) Related parties and nature of relationship

Name of the Related parties	Nature of Relationship	Percentage of Shares held by Caplin point laboratories limited As at March 31, 2021	Percentage of Shares held by Caplin point laboratories limited As at March 31, 2020
Mr. Vivek Siddharth,	Relative of Chairman	Not Applicable	Not Applicable
Argus Salud Pharma LLP, (India)	Subsidiary LLP	99.90%	99.90%
Caplin Point Laboratories Colombia SAS, (Colombia)	Subsidiary Company	85.83%	83.33%
Caplin Point Far East Limited, (Hong Kong)	Wholly owned Subsidiary Company	100.00%	100.00%
Caplin Point (S) PTE Ltd*	Wholly owned Subsidiary Company	100.00%	100.00%
Caplin Steriles Limited, (India)	Subsidiary Company	99.999%	100.00%
Caplin Point El Salvador, S.A. DE C.V.,(El Salvador)	Step down subsidiary Company	100.00%	99.96%
Nuevos Eticos Neo Ethicals S.A - Guatemala	Step down subsidiary Company (w.e.f. 31st March, 2020)	69.00%	69.00%
Neoethicals CIA.LTDA - Ecuador	Step down subsidiary Company (w.e.f. 1st Feb, 2020)	100.00%	99.00%
Drogueria Saimed de Honduras S.A.	Step down subsidiary Company (w.e.f. 30th Sep, 2019)	100.00%	99.996%
Neo Ethicals S.A - Nicaragua	Step down subsidiary Company (w.e.f. 22nd Apr, 2019)	100.00%	98.00%
Ashvich Infotek Private Limited	Director's relatives are interested	Not Applicable	Not Applicable
Hainan Jointown Caplin point Pharmaceutical Company Limited, (China)	Associate	39.00%	39.00%

* Incorporated during the Financial Year 2019-20

(b) Key Managerial Personnel

Dr. Sridhar Ganesan	– Managing Director from 28.03.2015
Dr. B. Philip Ashok Karunakaran	– Whole Time Director from 07.08.2017 to 10.04.2019
Mr. D Muralidharan	– Chief Financial Officer from 19.02.2016
Mr. Vinod Kumar S	– Company Secretary from 13.04.2015 to 05.02.2021
Mr. Dinesh R G	– Company Secretary from 06.05.2021

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

(c) Details of Transactions that have taken place during the Financial Year with Key Management Personnel/Related Party:

Particulars	For the Financial Year ended March 31, 2021	For the Financial Year ended March 31, 2020
Remuneration*		
Salary paid to Mr.Vivek Siddharth	12.45	18.66
Salary paid to Dr. Sridhar Ganesan	56.38	56.86
Salary paid to Dr. B. Philip Ashok Karunakaran (i)	-	4.15
Salary paid to Mr. D Muralidharan	39.83	38.31
Salary paid to Mr. Vinod Kumar S (ii)	8.58	9.44

* Provision for contribution to gratuity fund, leave encashment on retirement and other defined benefits which are made based on actuarial valuation on an overall Company basis are not included in remuneration to key management personnel.

(i) Dr. B. Philip Ashok Karunakaran, Whole-time Director, resigned w.e.f 10.04.2019

(ii) Mr. Vinod Kumar S, Company secretary, resigned w.e.f 05.02.2021

(d) Details of Transactions that have taken place during the Financial Year with Subsidiary Companies/LLP:

Particulars	For the Financial Year ended March 31, 2021	For the Financial Year ended March 31, 2020
Share of profit (Loss) in Argus Salud Pharma LLP	0.86	2.99
Purchase by Argus Salud Pharma LLP from Caplin Point Laboratories Limited	-	2.87
Sales by Argus Salud Pharma LLP to Caplin Point Laboratories Limited	-	0.53
Investment in Caplin Point (S) PTE Ltd	33.93	3.77
Investment in Caplin point Laboratories Colombia SAS	37.15	28.72
Investment in Equity Shares of Caplin Steriles Limited (i)	206.27	3,659.09
Sale of MEIS Licence and recovery of expenses from Caplin Steriles Limited	66.32	82.41
R&D expense reimbursement & corporate office common expense sharing from Caplin Steriles Limited	52.12	631.28
Sale of Assets and Materials to Caplin Steriles Limited	64.84	51.52
Purchase of Assets and Materials from Caplin Steriles Limited	64.33	30.99
Sale of goods to DROGUERIA SAIMED DE HONDURAS - HS	3,359.40	2,423.19
Sale of goods to Nuevos Eticos Neoethicals, S A - GT	12,392.28	-
Sale of goods to Neo Ethicals S.A Nicaragua	3,394.96	4,959.67
Sale of goods to Neo Ethicals CIA.LTDA-Ecuador	3,295.22	412.68
Rent & Consultancy charges paid to Ashvich Infotek Private Limited	99.18	227.20
Purchase of Asset from Ashvich Infotek Private Limited by Caplin Point Laboratories Ltd	13.45	-
Dividend income received from Caplin point Far East Limited	304.78	3,291.09

(i) Includes Rs. 206.27 Lakhs (PY: Rs. 159.09 Lakhs) pertaining to ESOP issued to employees of CSL by the company.

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

(e) Outstanding Balances

Particulars	As at March 31, 2021	As at March 31, 2020
Amount receivable/ (Payable) to Argus Salud Pharma LLP	(26.52)	(27.37)
Amount receivable/ (Payable) from Nuevos Eticos Neo Ethicals S.A - Guatemala	447.57	6,576.03
Amount receivable/ (Payable) from DROGUERIA SAIMED DE HONDURAS - HS	(95.15)	2,493.70
Amount receivable/ (Payable) from Neo Ethicals S.A Nicaragua	1,841.03	(568.67)
Amount receivable/ (Payable) from Neo Ethicals CIA.LTDA-Ecuador	(46.52)	1,966.21
Amount receivable/ (Payable) from Caplin Steriles Ltd	-	-

NOTE 45. Total Share Capital of Argus Salud Pharma LLP is Rs. 99.10 Lakhs (Rs. 99.10 Lakhs) out of which 99.90% of shares is held by the Company and 0.10% is held by May India Property Private Limited and their profit sharing ratio is 99.90% and 0.10% respectively (Previous year 99.90% and 0.10% respectively).

FINANCIAL INSTRUMENTS:

NOTE 46. Financial Instruments - Fair value and risk management

A. Accounting classification and fair values:

Carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy, are presented below. It does not include the fair value information for financial assets and financial liabilities not measured at fair value if the carrying amount is a reasonable approximation of fair value.

Fair value hierarchy

Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices).

Level 3 - Inputs for the assets or liabilities that are not based on observable market data (unobservable inputs).

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

Particulars	As at 31 March 2021			As at 31 March 2020		
	Carrying Amount			Carrying Amount		
	FVTPL	Amortised Cost	Total	FVTPL	Amortised Cost	Total
Financial Assets						
Non - Current Investments - Mutual fund and equity	66.35	-	66.35	33.04		33.04
Non - Current Loans and advances						
- Security Deposit	-	55.48	55.48		50.81	50.81
- Others	-	97.32	97.32		93.55	93.55
Current Investments	1,053.50	-	1,053.50	6,022.98		6,022.98
Trade Receivable		9,845.88	9,845.88		21,898.29	21,898.29
Current Loans and advances		2,509.59	2,509.59		2,045.06	2,045.06
Cash and Cash Equivalents		14,882.21	14,882.21		3,683.94	3,683.94
Other Bank Balances other than Cash and Cash Equivalents		21,667.30	21,667.30		2,143.00	2,143.00
Other Current Assets		819.57	819.57		43.48	43.48
Total	**1,119.85**	**49,877.35**	**50,997.20**	**6,056.02**	**29,958.13**	**36,014.15**
Financial Liabilities						
Non - Current Borrowings		-	-	-	1.52	1.52
Non - Current Lease Liability		53.32	53.32		128.48	128.48
Trade Payables		7,010.24	7,010.24	-	5,141.28	5,141.28
Current -Lease Liability		79.19	79.19		84.81	84.81
Current Borrowings		1.19	1.19		26.77	26.77
Other Current Liabilities		642.69	642.69	-	1,085.69	1,085.69
Total	**-**	**7,786.63**	**7,786.63**	**-**	**6,468.55**	**6,468.55**

(i) The Company estimates that the fair value of these investments are not materially different as compared to its cost

B. Measurement of fair values:

Valuation techniques and significant unobservable inputs:

The following tables show the valuation techniques used in measuring Level 2 and Level 3 fair values, for financial instruments measured at fair value in the statement of financial position, as well as the significant unobservable inputs used:

(All amounts are in ₹ Lakhs unless otherwise stated)

Type	Valuation Technique	Significant unobservable input	Inter-relationship between significant unobservable inputs and fair value measurement
Non - Current Financial Assets (other than investments in mutual fund) and Liability measured at amortised cost	Discounted cash flows: The valuation model considers the present value of expected receipt / payment discounted using appropriate discounting rate	Not applicable	Not applicable

C. Financial risk management:

The Company has exposure to the following risks arising from financial instruments:

- Credit risk;
- Liquidity risk; and
- Market risk

The Company's board of directors have overall responsibility for the establishment and oversight of the Company's risk management framework. The board of directors has established the risk management framework. The Company's risk management policies are established to set appropriate risk limits and to monitor risks and adherence to limits. risk management policies and systems are reviewed periodically to reflect changes in market condition and the Company's activities. The Company through its training, standards and procedures, aims to maintain a disciplined and constructive control environment in which all employees understand their roles and obligations.

The audit committee oversees how management monitors compliance with the Company's risk management policies and procedures, and reviews the adequacy of the risk management framework in relation to the risks faced by the Company. The audit committee is assisted in its oversight role by internal audit. Internal audit undertakes both regular and adhoc reviews of risk management controls and procedures, the results of which are reported to the audit committee.

i. Credit Risk:

Credit Risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company's receivables from customers and investment securities. Credit risk is managed through credit approvals, establishing credit limits and continuously monitoring the credit worthiness of the customers to which the Company grants credit terms in the normal course of business.

Trade Receivables

Summary of the Company's exposure to credit	As at 31.03 2021	As at 31.03 2020
Neither past due nor impaired	9,845.88	21,898.29
Total	**9,845.88**	**21,898.29**

Expected credit loss assessment

The Company allocates each exposure to a credit risk grade based on a variety of data that is determined to be predictive of the risk of loss (e.g timeliness of payments, available information, etc) and applying experienced credit judgement.

Exposures to the customers outstanding at the end of each reporting period are reviewed by the Company to determine incurred and expected credit losses, if any. Historical trends of impairment of trade receivables reflects no credit losses. Given that the macroeconomic indicators affecting customers of the Company have not undergone any substantial change, the Company expects the historical trend of “no credit loss” to continue.

No allowance for impairment in respect trade and other receivables was provided during the year and immediate preceding year.

Cash and cash equivalents

As at the year end, the Company held cash and cash equivalents of ₹ 14,882.21 lakhs (31.03.2020 ₹ 3683.94 lakhs). The cash and cash equivalents are held with banks with good credit rating.

Other Bank balances

Other bank balances are held with bank with good credit rating.

Investment in mutual funds

The Company limits its exposure to credit risk by generally investing in liquid securities and only with counterparties that have a good credit rating. The Company does not expect any losses from non - performance by these counter-parties.

Other financial asset

Other financial assets are neither past due nor impaired.

ii. Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations with its financial liabilities that are settled by delivering cash or another financial asset. The Company’s approach to managing liquidity is to ensure that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company’s reputation.

The Company has not availed any fund based working capital facilities from banks and financial institutions. The Company has obtained non-fund based working capital lines from banks. The Company invests its surplus funds in bank fixed deposit and liquid and liquid plus schemes of mutual funds which carry no/low mark to market risks. The Company monitors funding options available in the debt and capital markets with a view to maintain financial flexibility.

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

Exposure to liquidity risk

The following are the remaining contractual maturities of financial liabilities at the reporting date. The amounts are gross and undiscounted.

As at 31 March 2021	Carrying amount	Contractual cash flow					
		Total	0-12 months	1-2 years	2-3 Years	3-5 Years	More than 5 Years
Non - derivative financial liabilities							
Borrowing	1.19	1.19	1.19	-	-	-	-
Interest Payable on non-current borrowing	-	-	-	-	-	-	-
Lease Liability	132.50	132.50	79.18	36.97	16.35	-	-
Trade payables	7,010.24	7,010.24	7,010.24	-	-	-	-
Other current Financial Liabilities	642.69	642.69	642.69	-	-	-	-
Total	**7,786.62**	**7,786.62**	**7,733.30**	**36.97**	**16.35**	**-**	**-**

As at 31 March 2020	Carrying amount	Contractual cash flow					
		Total	0-12 months	1-2 years	2-3 Years	3-5 Years	More than 5 Years
Non - derivative financial liabilities							
Borrowing	28.29	28.29	26.77	1.52	-	-	-
Interest Payable on non-current borrowing	-	0.02	0.02	-	-	-	-
Lease Liability	213.29	213.29	84.81	79.19	49.30		
Trade payables	5,141.28	5,141.28	5,141.28	-	-	-	-
Other current Financial Liabilities	1,085.69	1,085.69	1,085.69	-	-	-	-
Total	**6,468.55**	**6,468.57**	**6,338.57**	**80.71**	**49.30**	**-**	**-**

iii) Market Risk

Market risk is the risk that changes in market prices - such as foreign exchange rates, interest rates and equity prices - will affect the Company's income or the value of its holdings of financial instruments. Market risk is attributable to all market risk sensitive financial instruments including foreign currency receivable and payable. We are exposed to market risk primarily related to foreign exchange rate risk as the Company's product is exported to various countries and a certain portion of its export is sourced thorough import. Thus our exposure to market risk is a function of revenue generating and operating activities in foreign currency. The objective of market risk management is to avoid excessive exposure in our foreign currency revenues and costs. The Company does not use any derivative to manage market risk since certain degree of a natural hedge available in the form of foreign currency realised from exports are paid against imports.

Currency risk

The Company is exposed to currency risk on account of its exoprt and import of pharmaceuticals and import of raw material, capital goods,etc . The functional currency of the Company is Indian Rupee, where as majority of its export and imports are settled through USD($).

Exposure to Currency risk

Following is the currency profile of non-derivative finnacial assets and financial liabilities

Particulars	As at March h 31, 2021		As at March 31, 2020	
	USD in Lakhs	₹ in Lakhs	USD in Lakhs	₹ in Lakhs
Export Debtors	133.96	9,845.88	290.48	21,898.29
Cash and cash equivalents	35.57	2,614.31	15.74	1,186.60
Total	**169.53**	**12,460.19**	**306.22**	**23,084.89**
Creditors	1.94	142.28	8.20	617.91
Total	**1.94**	**142.28**	**8.20**	**617.91**
Net statement of financial position exposure	**167.59**	**12,317.91**	**298.02**	**22,466.98**

Sensitivity analysis

A reasonable strengthening (weakening) of the Indian Rupee against US dollars as at March 31 would have affected the measurement of financial instruments denominated in US dollars and affected equity and profit or loss by the amount shown below. This analysis assumes that all other variables, in particular interest rates, remain constant and ignores any impact of forecast sales and purchases.

1% appreciation / depreciation of the respective foreign currencies with respect to functional currency of the Company would result in increase / decrease in the profit before taxes by approximately ₹ 123.18 Lakhs for the year ended March 31, 2021 (₹ 224.67 Lakhs for the year ended March 31, 2020)

Interest rate risk

Interest rate risk can be either fair value interest rate risk or cash flow interest rate risk. Fair value interest rate risk is the risk of changes in fair values of fixed interest bearing financial assets or borrowings because of fluctuations in the interest rates, if such assets/ borrowings are measured at fair value through profit or loss. Cash flow interest rate risk is the risk that the future cash flows of floating interest bearing borrowings will fluctuate because of fluctuations in the interest rates.

Exposure to interest rate risk

As on 31 March 2021 and 31 March 2020, the Company has not availed any long term borrowings except for loans on certain vehicles on fixed rate basis. Further, the Company has not availed any fund based working capital lines.

Fair value sensitivity analysis for fixed rate instruments

The Company does not account for any fixed-rate borrowings at fair value through profit or loss. Therefore, change in interest rates at the reporting date would not affect profit or loss.

Commodity rate risk

The Company's operating activity involve purchase of Active Pharmaceutical Ingredients (API) and other direct materials, whose prices are exposed to the risk of fluctuation over short period of time. The commodity price risk exposure is evaluated and managed through procurement and other related operating policies. As on 31 March 2021, 31 March 2020, the Company had not entered into any material derivative contracts to hedge exposure to fluctuations in commodity prices.

Risk due to outbreak of COVID 19 pandemic

The Company has considered the possible effects that may result from the pandemic relating to COVID-19 on the carrying amounts of receivables, inventories and investments. In developing the assumptions relating to the possible future uncertainities in the global economic conditions because of this pandemic, the Company has used internal and external sources of information and based on the current estimates arrived at using the said assumptions, the Company expects to recover the carrying amount of receivables, inventories and investments. As the outbreak continues to evolve, the company will continue to closely monitor any material changes to future economic conditions.

NOTE 47 : CAPITAL MANAGEMENT

The Company's policy is to maintain a strong capital base so as to maintain investor, creditor and market confidence and to sustain future development of the business. Management monitors the return on the capital as well as the level of dividends to ordinary shareholders.

NOTE 48 : The Company operates in one segment only viz., pharmaceutical formulations.

NOTE 49 : Previous year's figures have been regrouped / reclassified wherever necessary to correspond with the current year's classification / disclosure.

As per our report of even date attached

For **CNGSN & Associates LLP**
Chartered Accountants
Firm Registration No : 4915S/ S200036

B.Ramakrishnan
Partner
ICAI Membership No. 201023

Place : Chennai
Date : 6th May, 2021

For and on behalf of the Board of Directors of Caplin Point Laboratories Limited;
CIN: L24231TN1990PLC019053

C.C. Paarthipan
Chairman
DIN:01218784

Dr.Sridhar Ganesan
Managing Director
DIN:06819026

Muralidharan D
Chief Financial Officer

Dinesh R G
Company Secretary

CAPLIN POINT®
Laboratories

CONSOLIDATED FINANCIAL STATEMENTS

INDEPENDENT AUDITOR'S REPORT

To
The Members
Caplin Point Laboratories Limited, Chennai

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the accompanying consolidated financial statements of **Caplin Point Laboratories Limited** (hereinafter referred to as the "Holding Company") and its subsidiaries (the Holding Company, its subsidiaries and its associate, together referred to as 'the Group'), which comprise the consolidated balance sheet as at 31 March 2021, the consolidated statement of profit and loss (including other comprehensive income), consolidated statement of changes in equity and consolidated statement of cash flows for the year then ended, and notes to the consolidated financial statements, including a summary of the significant accounting policies and other explanatory information (hereinafter referred to as "the consolidated financial statements").

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of the other auditor on separate financial statements of the subsidiaries and associates referred to in the Other Matters Section below, the aforesaid consolidated financial statements give the information required by the Companies Act, 2013 ('Act') in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the consolidated state of affairs of the Group as at 31 March 2021, its consolidated profit including other comprehensive income, consolidated changes in equity and consolidated cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements (CFS) section of our report.We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('ICAI') together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the consolidated financial statements.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements for the financial year ended March 31, 2021.These matters were addressed in the context of our audit of the consolidated financial statements as a whole and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined the matters described below to be the key audit matter to be communicated in our report. We have fulfilled the responsibilities described in the 'Auditor's responsibilities for the audit of the consolidated financial statements' section of our report, including in relation to these matters. Accordingly, our audit included the performance of procedures designed to respond to our assessment of the risks of material misstatement of the consolidated financial statements. The results of our audit procedures, including the procedures performed to address the matters below, provide the basis for our audit opinion on the accompanying consolidated financial statements. The results of audit procedures performed by us and by other auditors of components not audited by us, as reported by them in their audit reports furnished to us, including those procedures performed to address the matters below, provide the basis for our audit opinion on the accompanying consolidated financial statements.

	Key Audit Matter	How was the matter addressed in our audit
	Accuracy of recognition, measurement, presentation and disclosures of revenues and other related balances in accordance with Ind AS 115 "Revenue from Contracts with Customers " (revenue recognition standard) The application of the revenue accounting standard involves certain key judgements relating to identification of distinct performance obligations, determination of transaction price of the identified performance obligations, the appropriateness of the basis used to measure revenue recognized over a period. Additionally, revenue accounting standard contains disclosures which involves collation of information in respect of disaggregated revenue and periods over which the remaining performance obligations will be satisfied subsequent to the balance sheet date. *Impact of Covid-19 pandemic on the operations of the Group*	***Principal Audit Procedures*** We assessed the Group's process to identify the impact of the revenue accounting standard. Our audit approach consisted testing of the design and operating effectiveness of the internal controls and substantive testing as follows: ➢ Evaluated the design of internal controls relating to implementation of the revenue accounting standard. ➢ Selected a sample of continuing and new contracts, and tested the operating effectiveness of the internal control, relating to identification of the distinct performance obligations and determination of transaction price. We carried out a combination of procedures involving enquiry and observation, re-performance and inspection of evidence in respect of operation of these controls. ➢ Tested the relevant information technology systems' access and change management controls relating to contracts and related information used in recording and disclosing revenue in accordance with the revenue accounting standard. ➢ We assessed the Group's process to identify, assess, and respond to risks of material misstatement considering the uncertainties and the impact of Covid-19 pandemic on the Group's operations and results for the year under consideration. We have designed, planned and performed audit procedures, including verification of the source and completeness of data provided for audit. We have considered management's adjustments or disclosures which includes the impact of the changes in the environment on the recognition and measurement of account balances and transactions in the financial statements or other specific disclosures.

Information Other than the Financial Statements and Auditor's Report Thereon

The Holding Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Management Discussion and Analysis, Board's Report including Annexures to Board's Report, Business Responsibility Report, Corporate Governance and Shareholder's Information, but does not include the Consolidated financial statements, Standalone financial statements and our Auditors' report thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

The Holding Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these consolidated financial statements that give a true and fair view of the consolidated state of affairs, consolidated profit or loss and other comprehensive income, consolidated statement of changes in equity and consolidated cash flows of the Group including its associate in accordance with the accounting principles generally accepted in India, including the Ind AS specified under Section 133 of the Act. The respective Board of Directors /management of the companies included in the Group, are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of each company and for preventing and detecting frauds and other irregularities; the selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error which have been used for the purpose of preparation of the consolidated financial statements by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial statements, the respective Board of Directors of the companies included in the Group and of its associate are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are also responsible for overseeing the Group's financial reporting process.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Standards on Auditing will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with Standards on Auditing, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

- Conclude on the appropriateness of management's use of the going concern basis of accounting in preparation of consolidated financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

- Obtain sufficient appropriate audit evidence regarding the financial information of such entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the audit of the financial statements of such entities included in the consolidated Ind AS financial statements of which we are the independent auditors. For other entities included in the consolidated Ind AS financial statements, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the Consolidated financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Consolidated financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Consolidated financial statements.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion on the consolidated financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our Auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Other Matters

The consolidated annual financial results include the audited financial results of eight subsidiaries whose financial statements reflect total assets (before consolidation adjustments) of Rs. 761.77 Crore as at 31 March 2021, total revenue (before consolidation adjustments) of Rs. 868.38 Crore and total net profit after tax (before consolidation adjustments) of Rs. 179.10 Crore and the Group's share of net loss after tax (before consolidation adjustments) of Rs. 0.04 Crore of one associate for the year ended on that date, as considered in the consolidated annual financial results, which have been audited by their respective independent auditors. The independent auditors' reports on financial statements of these entities have been furnished to us by the management and our opinion on the consolidated annual financial results, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the report of such auditors and the procedures performed by us are as stated in paragraph above.

Our opinion on the consolidated annual financial results is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the financial results certified by the Board of Directors.

Report on other Legal and Regulatory Requirements

As required by Section 143(3) of the Act, based on our audit and on the consideration of the reports of other auditors on separate financial statements of subsidiary and associate companies incorporated in India, referred in the Other Matters paragraph above we report, to the extent applicable, that:

a) We have sought and obtained all the information and explanations, which to the best of our knowledge and belief were necessary for the purpose of our audit of the aforesaid consolidated financial statements.

b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books and the reports of the other auditors.

c) The Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss including Other Comprehensive Income, the Consolidated Cash Flow Statement and the Consolidated Statement of Changes in Equity dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of preparation of the consolidated financial statements.

d) In our opinion, the aforesaid consolidated financial statements comply with Ind AS specified under Section 133 of the Act;

e) On the basis of the written representations received from the directors and taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2021 from being appointed as a director in terms of Section 164(2) of the Act;

f) With respect to the adequacy of the internal financial controls with reference to financial statements of the Holding Company and its subsidiary companies incorporated in India and the operating effectiveness of such controls, refer to our separate Report in “Annexure A”.

g) With respect to the other matters to be included in the Auditor’s Report in accordance with the requirements of section 197 (16) of the Act, as amended, in our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Holding Company to its directors during the year is in accordance with the provisions of section 197 of the Act;

h) With respect to the other matters to be included in the Auditors’ Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014 (as amended), in our opinion and to the best of our information and according to the explanations given to us:

   i. The consolidated financial statements disclose the impact of pending litigations as at 31 March 2021 on the consolidated financial position of the Group.

   ii. The Group has made provision, as required under the applicable law or Ind AS, for material foreseeable losses, if any, on long-term contracts including derivative contracts.

   iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company during the year ended 31 March 2021.

for **M/s CNGSN & ASSOCIATES LLP**
CHARTERED ACCOUNTANTS
Firm Registration No: 004915S/S200036

B. Ramakrishnan
Partner
Membership No: 201023
UDIN:21201023AAAAAD5983

Place: Chennai
Date: 06.05.2021

Annexure A - To The Independent Auditors' Report of even date To The Members of Caplin Point Laboratories Limited, on the consolidated Ind AS financial statements as of and for the year ended 31st March 2021

Report on the Internal financial Controls with reference to financial statements under Clause (i) of sub-section 3 of section 143 of the Companies Act, 2013 (the "Act")

In conjunction with our audit of the Consolidated financial statements of **Caplin Point Laboratories Limited** (hereinafter referred to as "the Holding Company") as of and for the year ended 31 March 2021, we have audited the internal financial controls with reference to consolidated financial statements of the Holding Company and such companies incorporated in India under the Companies Act, 2013 which are its subsidiary companies as of that date.

Management's Responsibility for Internal financial Controls

The Holding Company's Board of Directors is responsible for establishing and maintaining internal financial controls with reference to consolidated financial statements based on the internal control over financial reporting criteria established by the respective Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") issued by the Institute of Chartered Accountants of India (ICAI). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of the Company's business, including adherence to Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act,2013 (hereinafter referred to as "Act").

Auditor's Responsibility

Our responsibility is to express an opinion on the internal financial controls with reference to consolidated financial statements based on our audit.We conducted our audit in accordance with Guidance Note and the Standards on Auditing, prescribed under Section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to consolidated financial statements.

Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to consolidated financial statements were established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to consolidated financial statements and their operating effectiveness. Our audit of internal financial controls with reference to consolidated financial statements included obtaining an understanding of internal financial controls with reference to consolidated financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the Auditors' judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls with reference to consolidated financial statements.

Meaning of Internal financial Controls over Financial Reporting

A Company's internal financial controls with reference to the consolidated financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A Company's internal financial controls with reference to consolidated financial statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorisations of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal financial Controls with reference to consolidated financial statements

Because of the inherent limitations of internal financial controls with reference to consolidated financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to consolidated financial statements to future periods are subject to the risk that internal financial controls with reference to consolidated financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Holding Company and its subsidiary which is incorporated in India, have, in all material respects, an adequate internal financial controls with reference to consolidated financial statements and such internal financial controls were operating effectively as at 31 March 2021, based on the internal controls with reference to the consolidated financial statements criteria established by the respective company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (the "Guidance Note").

for **M/s CNGSN & ASSOCIATES LLP**
CHARTERED ACCOUNTANTS
Firm Registration No: 004915S/S200036

B. Ramakrishnan
Partner
Membership No: 201023
UDIN:21201023AAAAAD5983

Place: Chennai
Date: 06.05.2021

CONSOLIDATED BALANCE SHEET

As at March 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

Particulars	Notes	As at March 31, 2021	As at March 31, 2020
ASSETS			
(1) Non-Current Assets			
(a) Property, Plant and Equipment	2	29,695.51	26,562.55
(b) Capital work-in-progress	2A	1,382.42	2,011.82
(c) Intangible assets	2B	729.23	506.74
(d) Right of Use Assets	2C	114.91	181.14
(e) Financial Assets			
(i) Investments	3	66.35	55.54
(ii) Loans & Advances	4	791.86	537.74
(f) Income tax assets (Net)		-	467.04
Sub-total-Non current assets		**32,780.28**	**30,322.57**
(2) Current Assets			
(a) Inventories	5	17,900.19	23,823.17
(b) Financial Assets			
(i) Investments	6	1,053.50	6,022.98
(ii) Trade Receivables	7	27,936.07	22,896.49
(iii) Cash and Cash equivalents	8	23,157.48	4,992.91
(iv) Bank balances other than (iii) above	9	22,800.14	17,349.98
(v) Loans & Advances	10	9,889.62	6,829.98
(c) Other Current Assets	11	843.56	337.62
Sub-total-Current assets		**103,580.56**	**82,253.13**
Total		**136,360.84**	**112,575.70**
Equity and Liabilities			
(1) Equity			
Equity Share capital	12	1,512.86	1,512.86
Other Equity	13	117,069.30	93,278.56
Equity attributable to shareholders of the company		**118,582.16**	**94,791.42**
Non controlling interest		1,753.85	865.69
Sub-total-Equity		**120,336.01**	**95,657.11**
(2) Liabilities			
(A) Non-Current Liabilities			
(a) Financial Liabilities			
(i) Borrowings	14	-	1.52
(ii) Lease Liabilities	15	53.32	128.48
(b) Deferred Tax Liabilities (Net)	16	115.65	1,011.24
(c) Income tax Liability (Net)		33.42	-
(d) Other non current liabilities	17	1,537.09	1,344.88
Sub-total-Non current liabilities		**1,739.48**	**2,486.12**
(B) Current Liabilities			
(a) Financial Liabilities			
(i) Borrowings	18	1,706.70	3,646.29
(ii) Lease Liabilities	19	79.19	84.81
(iii) Trade Payables	20	8,850.01	6,413.62
(iv) Other Current Liabilities	21	3,640.95	4,196.89
(b) Provisions	22	8.50	90.86
Sub-total-Current liabilities		**14,285.35**	**14,432.47**
Total		**136,360.84**	**112,575.70**

The accompanying notes 1 to 49 form an integral part of these consolidated financial statements.

As per our report of even date attached
For **CNGSN & Associates LLP**
Chartered Accountants
Firm Registration No : 4915S/ S200036

For and on behalf of the Board of Directors of Caplin Point Laboratories Limited;
CIN: L24231TN1990PLC019053

B.Ramakrishnan
Partner
ICAI Membership No. 201023

C.C. Paarthipan
Chairman
DIN:01218784

Dr.Sridhar Ganesan
Managing Director
DIN:06819026

Place : Chennai
Date : 6th May, 2021

Muralidharan D
Chief Financial Officer

Dinesh R G
Company Secretary

CONSOLIDATED STATEMENT OF PROFIT AND LOSS

FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

Particulars	Notes	For the Year ended March 31, 2021	For the Year Ended March 31, 2020
I. INCOME			
(a) Revenue from Operations	23	1,06,129.04	86,320.17
(b) Other income	24	2,354.22	4,133.37
Total Income		**1,08,483.26**	**90,453.54**
II. EXPENSES			
(a) Cost of Materials Consumed	25	12,981.58	10,812.02
(b) Purchase of Stock-in-Trade		25,957.29	50,014.35
(c) Changes in inventories of Finished Goods including Stock-in-Trade and Work-in-progress	26	8,235.21	(19,510.10)
(d) Employee benefits expense	27	10,252.82	6,775.88
(e) Finance costs	28	158.96	31.97
(f) Depreciation and Amortisation Expenses	29	3,697.12	3,161.92
(g) Research and Development Expenses	30	5,369.47	5,301.43
(h) Other expenses	31	10,468.95	6,919.82
Total Expenses		**77,121.41**	**63,507.29**
III . Profit before Exceptional Items and tax		31,361.85	26,946.25
IV. Exceptional Items		-	-
V. Profit Before Tax		31,361.85	26,946.25
VI. Tax Expense (Net)			
- Current Tax		7,114.42	6,183.93
- Deferred tax (Benefits)/Charge		(895.60)	(746.05)
VII. Profit After Tax for the Year		**25,143.03**	**21,508.37**
VIII. Other Comprehensive Income (net of tax) **Items that will not be reclassified to profit or loss:**			
(i) Remeasurement of Defined Benefit Plans		31.53	(70.40)
(ii) Surplus on acquisition of subsidiary		-	198.69
(iii) Exchange difference in translating the financial statements of foreign operations		(748.14)	1,538.73
IX. Total Comprehensive Income for the Year		**24,426.42**	**23,175.39**
X. Profit attributable to:			
Owners of the Company		24,226.62	21,500.80
Non - Controlling Interests		916.41	7.57
		25,143.03	**21,508.37**

(All amounts are in ₹ Lakhs unless otherwise stated)

Particulars	Notes	For the Year ended March 31, 2021	For the Year Ended March 31, 2020
XI. Total Comprehensive Income For the Period attributable to :			
Owners of the Company		23,510.01	23,167.82
Non - Controlling Interests		916.41	7.57
		24,426.42	**23,175.39**
Earning Per Equity Share (Nominal value per share Rs.2/-)			
Basic EPS		**32.03**	**28.42**
Diluted EPS		**31.71**	**28.20**

The accompanying notes 1 to 49 form an integral part of these consolidated financial statements.

As per our report of even date attached
For **CNGSN & Associates LLP**
Chartered Accountants
Firm Registration No : 4915S/ S200036

B.Ramakrishnan
Partner
ICAI Membership No. 201023

Place : Chennai
Date : 6th May, 2021

For and on behalf of the Board of Directors of Caplin Point Laboratories Limited;
CIN: L24231TN1990PLC019053

C.C. Paarthipan
Chairman
DIN:01218784

Dr.Sridhar Ganesan
Managing Director
DIN:06819026

Muralidharan D
Chief Financial Officer

Dinesh R G
Company Secretary

CAPLIN POINT®
Laboratories

CONSOLIDATED STATEMENT OF CASH FLOW

FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

Particulars		For the year ended March 31, 2021	For the year ended March 31, 2020
A.	**Cash Flow from Operating Activities**		
	Profit before tax	**31,361.85**	**26,946.25**
	Adjustments for:		
	Depreciation and Amortisation expense	3,697.12	3,161.92
	Finance costs	158.96	31.97
	Government grant	(106.24)	(75.69)
	Loss on sale/disposal of property, plant and equipment	60.05	4.26
	Employee Stock option Scheme Expense	535.39	308.05
	Net Unrealised Foreign Exchange Fluctuation Loss (Gain)	23.82	(1,431.24)
	Fair value gain on financial instruments through profit or loss	438.89	(48.78)
	Realised gain on Financial Assets	(637.78)	(496.81)
	Interest income	(1,860.72)	(744.51)
	Operating Profit before Working Capital changes	**33,671.34**	**27,655.42**
	Adjustments for :		
	(Increase) / Decrease in inventories	5,922.98	(703.15)
	(Increase) / Decrease in Trade receivables	(5,039.58)	(23,066.67)
	(Increase) / Decrease in Loans	(3,313.77)	1,395.36
	Increase/(Decrease) in Trade payables, Current Liabilities & Provisions-Long and Short Term	2,698.38	3,124.44
	Impact of Foreign currency translation	(748.14)	1,538.72
	CASH GENERATED FROM OPERATIONS	33,191.21	9,944.12
	Income tax Paid (Net)	(6,613.96)	(5,476.42)
	Net Cash inflow / (outflow) from Operating activities (A)	**26,577.25**	**4,467.70**
B.	**Cash Flow from Investing Activities**		
	Payment for Acquisition of subsidiaries(Net)	-	910.65
	Sale / (Purchase) of investments	4,497.28	988.37
	Proceeds from sale of Equity shares/(Investment in Equity shares)	22.50	(22.50)
	Sale / (Purchase) of property, plant and equipment (Including CWIP)	(7,048.31)	(7,673.81)
	Interest received	1,354.78	424.78
	Income tax on Dividend income	-	(574.78)
	Realised gain on Financial Assets	637.78	496.81
	Net Cash inflow / (outflow) from Investing activities (B)	**(535.97)**	**(5,450.48)**
C.	**Cash Flow from Financing Activities**		
	Proceeds from exercise of employee stock options	-	0.25
	Proceeds from issue of CCPS (Net of Cost)	-	11,299.97
	Expenses for Increasing the Authorised share capital	-	(22.45)

(All amounts are in ₹ Lakhs unless otherwise stated)

Particulars	For the year ended March 31, 2021	For the year ended March 31, 2020
Increase/(Decrease) in Long and Short term Borrowings	(1,941.11)	(21.53)
Interest paid (Including interest on Lease liability)	(154.08)	(27.09)
Dividend paid(including Dividend distribution tax paid)	(302.57)	(3,252.63)
Net Cash inflow / (outflow) from Financing activities ('C)	**(2,397.76)**	**7,976.52**
Net increase / (decrease) in cash and cash equivalents during the year (D=A+B+C)	**23,643.52**	**6,993.74**
Cash and Cash Equivalents as at the beginning of the year (E')	**22,076.69**	**15,065.47**
Effect of exchange rate changes on cash and cash equivalents (F)	(23.82)	17.48
Cash and Cash Equivalents as at the end of the year (G=D+E+F)	**45,696.39**	**22,076.69**
Less: Deposit under Lien (H)	460.82	913.04
Net Cash and Cash Equivalents as at the end of the year (I=G-H)	**45,235.57**	**21,163.65**

Notes:

The above Consolidated Statement of Cash Flows has been prepared under the “Indirect method’ as set out in Ind AS 7, ‘statement of Cash Flows’.

a). Reconciliation of Cash And Cash Equivalents

(All amounts are in ₹ Lakhs unless otherwise stated)

Particulars	For the year ended March 31, 2021	For the year ended March 31, 2020
Cash And Cash Equivalents As Per Balance Sheet	23,157.48	4,992.91
Other Bank Balances As Per Balance Sheet	22,800.14	17,349.98
Total Cash And Cash Equivalents As Per Balance Sheet	**45,957.62**	**22,342.89**
Less: Balance In Unpaid Dividend Account	261.23	266.20
Less: Deposit Under Lien	460.82	913.04
Total Cash And Cash Equivalents As Per The Statement Of Cash Flows	**45,235.57**	**21,163.65**

b). Net Cash and Cash Equivalents as at the end of the year includes bank deposits classified under other bank balance considering that such bank deposits are readily convertible to a known amount of cash and subject to an insignificant risk of changes in value, however, deposit under lien has been excluded.

c). Cash and cash equivalents does not include

- Investment in mutual fund of Rs 1053.50 Lakhs classified as current investment (Previous Year Rs 6022.98 Lakhs)

The above Cash Flow Statement has been prepared under the ‘Indirect Method’ as set out in the Indian Accounting Standard 7 (Ind AS -7) “ Statement of Cash Flow.

The accompanying notes 1 to 49 form an integral part of these consolidated financial statements.

As per our report of even date attached
For **CNGSN & Associates LLP**
Chartered Accountants
Firm Registration No : 4915S/ S200036

For and on behalf of the Board of Directors of Caplin Point Laboratories Limited;
CIN: L24231TN1990PLC019053

B.Ramakrishnan
Partner
ICAI Membership No. 201023

C.C. Paarthipan
Chairman
DIN:01218784

Dr.Sridhar Ganesan
Managing Director
DIN:06819026

Place : Chennai
Date : 6th May, 2021

Muralidharan D
Chief Financial Officer

Dinesh R G
Company Secretary

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED MARCH 31, 2021

A. EQUITY SHARE CAPITAL (Refer Note 12)

Particulars	As at 31 March 2021		As at 31 March 2020	
	NO OF EQUITY SHARES of ₹ 2/- each	AMOUNT (in Lakhs)	NO OF EQUITY SHARES of ₹ 2/- each	AMOUNT (in Lakhs)
Balance at the beginning of the reporting period	7,56,42,750	1,512.86	7,56,30,250	1,512.61
Changes in equity share capital during the year	-	-	12,500	0.25
Balance at the end of the reporting period	7,56,42,750	1,512.86	7,56,42,750	1,512.86

B. OTHER EQUITY (Refer Note 13)

AMOUNT ₹ in lakhs

Particulars	Reserves and Surplus									
	Capital Reserve	Securities Premium on equity shares	Securities Premium on Preference shares	General Reserve	Employee Stock Option Outstanding (Net)	Preference share capital Series A Compulsorily Convertible Preference Shares of ₹ 10/- each fully paid up	Foreign Exchange Translation Reserve	Cost of Equity Transactions	Retained Earnings	Total Other Equity
Balance as at 31 March 2019	**40.98**	**162.75**	**6,907.70**	**1,128.78**	**685.14**	**3,592.30**	**104.45**	**(121.00)**	**49,277.23**	**61,778.33**
Profit for the year									21,508.37	21,508.37
Final Dividend on equity shares for FY 18-19									(1,664.14)	(1,664.14)
Interim Dividend on equity shares for FY 19-20									(1,588.49)	(1,588.49)
Movement in the comprehensive income for the year - actuarial gain/(loss) on employee benefit obligation									(70.40)	(70.40)
Movement in Foreign Exchange Translation Reserve							1,538.72			1,538.72
Movement in security premium	(1.05)	49.54	7,434.00							7,482.49
Cost incurred for increasing Authorised Share Capital								(22.45)		(22.45)
Surplus on Acquisition of subsidiary	198.69									198.69
Transfer to Security premium on exercise of ESOPs					(49.54)					(49.54)
Share- based payment expenses (Net)					308.56					308.56
Add/ (Transfer) to non-controlling interest									(7.57)	(7.57)
Preference share capital Series A Compulsorily Convertible Preference Shares of ₹ 10/- each fully paid up						3,865.99				3,865.99
Balance as at 31 March 2020	**238.62**	**212.29**	**14,341.70**	**1,128.78**	**944.16**	**7,458.29**	**1,643.17**	**(143.45)**	**67,455.00**	**93,278.56**
Profit for the year									25,143.03	25,143.03
Final Dividend on equity shares for FY 19-20									(302.57)	(302.57)
Movement in the comprehensive income for the year - actuarial gain/(loss) on employee benefit obligation									31.53	31.53
Movement in Foreign Exchange Translation Reserve							(748.14)			(748.14)
Gain on derecognition of Non Controlling Interest	47.88									47.88
Movement in security premium		0.02	-							0.02
Share- based payment expenses (Net)					535.40					535.40
Add/ (Transfer) to non-controlling interest									(916.41)	(916.41)
Balance as at 31 March 2021	**286.50**	**212.31**	**14,341.70**	**1,128.78**	**1,479.56**	**7,458.29**	**895.03**	**(143.45)**	**91,410.58**	**117,069.30**

The accompanying notes 1 to 49 form an integral part of these consolidated financial statements.

As per our report of even date attached
For **CNGSN & Associates LLP**
Chartered Accountants
Firm Registration No : 4915S/ S200036

B.Ramakrishnan
Partner
ICAI Membership No. 201023

Place : Chennai
Date : 6th May, 2021

For and on behalf of the Board of Directors of Caplin Point Laboratories Limited;
CIN: L24231TN1990PLC019053

C.C. Paarthipan
Chairman
DIN:01218784

Dr.Sridhar Ganesan
Managing Director
DIN:06819026

Muralidharan D
Chief Financial Officer

Dinesh R G
Company Secretary

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

1. SIGNIFICANT ACCOUNTING POLICIES AND KEY ACCOUNTING ESTIMATES AND JUDGEMENTS:

a) Basis of accounting and preparation of Consolidated Financial Statements:

Basis of accounting

i) These Consolidated Financial Statements (hereinafter referred to as 'Consolidated Financial Statements') of Caplin Point Laboratories Limited ('the Company') and its subsidiaries (hereinafter referred to as 'the Group'), have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (hereinafter referred to as the 'Ind AS') as notified under section 133 of the Companies Act, 2013 ('the Act') read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 as amended and other relevant provisions of the Act and accounting principles generally accepted in India.

Accounting Policies have been consistently applied except where a newly issued Accounting Standard is initially adopted or a revision to an existing Accounting Standard requires a change in the accounting policy hiterto in use.

These consolidated financial statements are prepared under the historical cost convention unless otherwise indicated.

Current / Non-Current Classification:

Any asset or liability is classified as current if it satisfies any of the following conditions:

- the asset/liability is expected to be realized/settled in the Company's normal operating cycle;
- the asset is intended for sale or consumption;
- the asset/liability is held primarily for the purpose of trading;
- the asset/liability is expected to be realized/settled within twelve months after the reporting period;
- the asset is cash or cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting date;
- in the case of a liability, the Company does not have an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

All other assets and liabilities are classified as non-current.

For the purpose of current/non-current classification of assets and liabilities, the Company has ascertained its normal operating cycle as twelve months. This is based on the nature of services and the time between the acquisition of assets or inventories for processing and their realization in cash and cash equivalents

Functional and Presentation Currency

ii) These consolidated financial statements are presented in Indian rupees, which is the functional currency of the parent Company. All financial information presented in Indian rupees has been rounded off to the nearest thousands, except otherwise indicated.

Use of Estimates and Judgements

iii) The preparation of the Consolidated Financial Statements in conformity with Ind AS requires the Management to make estimates and assumptions considered in the reported amounts of assets and liabilities (including contingent liabilities) and the reported income and expenses during the year. The Management believes that the estimates used in preparation of the Consolidated Financial Statements are prudent and reasonable.

Future results could differ due to these estimates and the differences between the actual results and the estimates are recognised in the periods in which the results are known/ materialize. Estimates and underlying assumptions are reviewed on an ongoing basis.

Information about critical judgments in applying accounting policies, as well as estimates and assumptions that have the most significant effect to the carrying amounts of assets and liabilities within the next financial year, are included in the accounting policies, given as under:

- Measurement of defined benefit obligations (Refer note 'o')
- Measurement and likelihood of occurrence of provisions and contingencies (Refer note 'q')
- Recognition of deferred tax assets (Refer note 'l')
- Measurement of consideration and assets acquired as part of business combination (Refer note 'c')
- Useful lives of property, plant, equipment and Intangibles (Refer note 'e&f')
- Impairment of Intangibles (Refer note 'i')
- Impairment of financial assets (Refer note 'k')

iv) *Application of New Accounting Pronouncements:*

Ministry of Corporate Affairs ("MCA") through Companies (Indian Accounting Standards) Amendment Rules, 2019 and Companies (Indian Accounting Standards) Second Amendment Rules, had notified Ind AS 116 Leases which replaced the existing lease standard, Ind AS 17 Leases, and other interpretations. The Company had adopted the same and the policy is detailed **in note (g) below.**

b) Principles of Consolidation:

Subsidiaries

Subsidiaries are all entities that are controlled by the Company. Control exists when the Company is exposed to, or has rights, to variable returns from its involvement with the entity, and has the ability to affect those returns through power over the entity. In assessing control, potential voting rights are considered only if the rights are substantive. The financial statements of subsidiaries are included in these consolidated financial statements from the date that control commences until the date that control ceases. The financial statements of the Company and its subsidiaries and jointly controlled entity have been consolidated using uniform accounting policies for like transactions and other events in similar circumstances as mentioned in those policies.

Upon loss of control, the Group derecognizes the assets and liabilities of the subsidiary, any non-controlling interests and the other components of equity related to the subsidiary.

Transactions eliminated on consolidation

Intra-group balances and transactions, and any unrealized income and expenses arising from intra-group transactions, are eliminated in full while preparing these consolidated financial statements. Unrealized gains or losses arising from transactions with equity accounted investees are eliminated against the investment to the extent of the Company's interest in the investee.

Non-controlling interests ("NCI")

NCI are measured at their proportionate share of the acquiree's net identifiable assets at the date of acquisition. Changes in the Group's equity interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions.

c) Business Combinations:

Business combinations are accounted for using the acquisition method. At the acquisition date, identifiable assets acquired and liabilities assumed are measured at fair value. For this purpose, the liabilities assumed include contingent liabilities representing present obligation and they are measured at their acquisition date fair values irrespective of the fact that outflow of resources embodying economic benefits is not probable. The consideration transferred is measured at fair value at acquisition date and includes the fair value of any contingent consideration.

Where the consideration transferred exceeds the fair value of the net identifiable assets acquired and liabilities assumed, the excess is recorded as goodwill. Alternatively, in case of a bargain purchase wherein the consideration transferred is lower than the fair value of the net identifiable assets acquired and liabilities assumed, the difference is recorded as a gain in other comprehensive income and accumulated in equity as capital reserve.

d) Goodwill:

Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Goodwill is initially measured at cost, being the excess of the consideration transferred over the net identifiable assets acquired and liabilities assumed, measured in accordance with Ind AS 103, Business Combinations. Goodwill is considered to have indefinite useful life and hence is not subject to amortization but tested for impairment at least annually. After initial recognition, goodwill is measured at cost less any accumulated impairment losses.

e) Property, Plant and Equipment:

I. Recognition and Measurement

Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses, if any. The cost of an item of property, plant and equipment comprises:

- its purchase price, including import duties and non-refundable purchase taxes, after deducting trade discounts and rebates.
- any costs directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.
- the initial estimate of the costs of dismantling and removing the item and restoring the site on which it is located, the obligation for which the Company incurs either when the item is acquired or as a consequence of having used the item during a particular period for purposes other than to produce inventories during that period.
- income and expenses related to the incidental operations, not necessary to bring the item to the location and condition necessary for it to be capable of operating in the manner intended by management, are recognised in Statement of Profit and Loss. If significant parts of an item of property, plant and equipment have different useful lives, then they are accounted for as separate items (major components) of property, plant and equipment.

The Company has elected to continue with the carrying value of all its property, plant and equipment as recognized in the standalone financial statements as at the date of transition to Ind AS, measured as per the previous GAAP and use that as the deemed cost as at the transition date pursuant to the exemption under Ind AS 101.

Assets to be disposed off are reported at the lower of the carrying value or the fair value less cost to sell.

Capital work-in-progress in respect of assets which are not ready for their intended use are carried at cost, comprising of direct costs, related incidental expenses and attributable interest.

II. Subsequent Expenditure

Subsequent expenditure is capitalised only if it is probable that the future economic benefits associated with the expenditure will flow to the Company.

(All amounts are in ₹ Lakhs unless otherwise stated)

III. Depreciation

Depreciation on tangible assets is provided on a straight line method over the useful lives of the assets.

The estimated useful lives of tangible assets and the amortisation period are reviewed at the end of each financial year and the amortisation method is revised to reflect the changed pattern, if any.

Estimated useful lives of the assets, based on technical assessment, which are different in certain cases from those prescribed in Schedule II to the Companies Act, 2013, are as follows:

Asset Category	Estimated Useful life (Years)
Factory Building	30
Building other than factory building	60
Plant & Machinery	5 -15
Furniture & Fixtures	10
Office Equipment	5
Computers	3
Electrical Fittings and Installation	10
Motor Vehicles	6
Motor Cycle	10

Depreciation is provided pro-rata for the number of days availability for use. Depreciation on sale / disposal of assets is provided pro-rata up to the date of sale / disposal.

An asset purchased where the actual cost does not exceed Rs 5,000 is depreciated at the rate of 100%.

Advances given towards acquisition of property, plant and equipment outstanding at each balance sheet date are disclosed as Capital Advance under Loans & Advances.

IV. Derecognition:

The carrying amount of an item of property, plant and equipment is derecognised on disposal or when no future economic benefits are expected from its use or disposal. The gain or loss arising from the derecognition of an item of property, plant and equipment is measured as the difference between the net disposal proceeds and the carrying amount of the item and is recognized in the Statement of Profit and Loss when the item is derecognized.

f) Intangible Assets:

I. Recognition and Measurement

Intangible assets are carried at cost less accumulated amortisation and impairment losses, if any. The cost of an intangible asset comprises of its purchase price, including any import duties and other taxes (other than those subsequently recoverable from the taxing authorities), and any directly attributable expenditure on making the asset ready for its intended use. Intangible assets arising on acquisition of business are measured at fair value as at date of acquisition.

Expenditure on research and development eligible for capitalisation are carried as Intangible assets under development where such assets are not yet ready for their intended use.

The Company has elected to continue with the carrying value of all its intangible assets as recognized in the standalone financial statements as at the date of transition to Ind AS, measured as per the previous GAAP and use that as the deemed cost as at the transition date pursuant to the exemption under Ind AS 101.

II. Subsequent Expenditure

Subsequent expenditure is capitalized only if it is probable that the future economic benefits associated with the expenditure will flow to the Company.

III. Amortisation

Intangible assets are amortised over their estimated useful life on Straight Line Method as follows:

Particulars	Estimated useful Life
Computer Software	6 Years or use full life which-ever is lower

The estimated useful lives of intangible assets and the amortisation period are reviewed at the end of each financial year and the amortisation method is revised to reflect the changed pattern, if any.

IV. Derecognition:

The carrying amount of an intangible asset is derecognised on disposal or when no future economic benefits are expected from its use or disposal. The gain or loss arising from the derecognition of an intangible asset is measured as the difference between the net disposal proceeds and the carrying amount of the intangible asset and is recognized in the Statement of Profit and Loss when the asset is derecognized.

g) Lease Accounting (Right of Use Assets and Lease Liabilities):

The Company has adopted Ind AS 116 “Leases” and applied the same to the lease contracts existing on April 01, 2019 using the modified retrospective approach. This has resulted in recognizing Right of Use Assets and Lease Liability.

The Company recognises right-of-use asset representing its right to use the underlying asset for the lease term at the lease commencement date. The cost of the right-of-use asset measured at inception shall comprise of the amount of the initial measurement of the lease liability adjusted for any lease payments made at or before the commencement date less any lease incentives received, plus any initial direct costs incurred, if any. The right-of-use assets is subsequently measured at cost less any accumulated depreciation and adjusted for any remeasurement of the lease liability. The right-of-use assets is depreciated using the straight-line method from the commencement date over the shorter of lease term or useful life of right-of-use asset.

The Company measures the lease liability at the present value of the lease payments that are not paid at the commencement date of the lease. The lease payments are discounted using the interest rate implicit in the lease, if that rate can be readily determined. If that rate cannot be readily determined, the Company uses incremental borrowing rate. For leases with reasonably similar characteristics, the Company, on a lease by lease basis, may adopt either the incremental borrowing rate specific to the lease or the incremental borrowing rate for the portfolio as a whole. The lease liability is subsequently remeasured by increasing the carrying amount to reflect interest on the lease liability, reducing the carrying amount to reflect the lease payments made and remeasuring the carrying amount to reflect any reassessment or lease modifications. The Company has elected not to apply the requirements of Ind AS 116 Leases to short-term leases of all assets that have a lease term of 12 months or less and leases for which the underlying asset is of low value. The lease payments associated with these leases are recognized as an expense on a straight-line basis over the lease term.

Operating leases are mainly in the nature of lease of office premises with no restrictions and are renewable / cancellable at the option of either of the parties. There are no sub-leases. There are no restrictions imposed by the lease arrangements. On application of Ind AS 116, the nature of expenses has changed from lease rent in previous periods to depreciation cost for the right-of-use asset, and finance cost for interest accrued on lease liability.

Leases under which the Company assumes substantially all the risks and rewards of ownership are classified as finance leases. When acquired, such assets are capitalized at fair value or present value of the minimum lease payments at the inception of the lease, whichever is lower.

h) Research and Development:

Revenue expenditure pertaining to research is charged to the Statement of Profit and Loss. Development costs of products are also charged to the Statement of Profit and Loss in the year it is incurred, unless a product's technological feasibility has been established, in which case such expenditure is capitalised. These costs are charged to the respective heads in the Statement of Profit and Loss in the year it is incurred. The amount capitalised comprises of expenditure that can be directly attributed or allocated on a reasonable and consistent basis for creating, producing and making the asset ready for its intended use. Fixed assets utilised for research and development are capitalised and depreciated in accordance with the policies stated for Tangible Fixed Assets and Intangible Assets.

Expenditure on in-licensed development activities, whereby research findings are applied to a plan or design for the production of new or substantially improved products and processes, is capitalised, if the cost can be reliably measured, the product or process is technically and commercially feasible and the Company has sufficient resources to complete the development and to use and sell the asset.

i) Impairment of Assets:

Intangible assets and property, plant and equipment are evaluated for recoverability whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. For the purpose of impairment testing, the recoverable amount (i.e. the higher of the fair value less cost to sell and the value-in-use) is determined on an individual asset basis unless the asset does not generate cash flows that are largely independent of those from other assets. In such cases, the recoverable amount is determined for the CGU to which the asset belongs.

If such assets are considered to be impaired, the impairment to be recognized in the Statement of Profit and Loss is measured by the amount by which the carrying value of the assets exceeds the estimated recoverable amount of the asset. An impairment loss is reversed in the Statement of Profit and Loss if there has been a change in the estimates used to determine the recoverable amount. The carrying amount of the asset is increased to its revised recoverable amount, provided that this amount does not exceed the carrying amount that would have been determined (net of any accumulated amortization or depreciation) had no impairment loss been recognized for the asset in prior years.

j) Foreign Currency Transactions / Translations:

Initial Recognition:

On initial recognition, transactions in foreign currencies entered into by the Company are recorded in the functional currency (i.e. Indian Rupees), by applying to the foreign currency amount, the spot exchange rate between the functional currency and the foreign currency at the date of the transaction. Exchange differences arising on foreign exchange transactions settled during the year are recognized in the Statement of Profit and Loss.

Measurement of foreign currency items at reporting date:

Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated into the functional currency at the exchange rate at that date. Non-monetary assets and liabilities that are measured based on historical cost in a foreign currency are translated at the exchange rate at the date of the transaction.

Exchange differences arising on the settlement of monetary items or on translating monetary items at rates different from those at which they were translated on initial recognition during the period or in previous financial statements are recognized in the Consolidated Statement of Profit and Loss in the period in which they arise.

In case of foreign operations whose functional currency is different from the parent company's functional currency, the assets and liabilities of such foreign operations and fair value adjustments arising upon acquisition, are translated to the reporting currency at exchange rates at the reporting date. The income and expenses of such foreign operations are translated to the reporting currency at the monthly average exchange rates prevailing during the year. Resulting foreign currency differences are recognized in other comprehensive income/ (loss) and presented within equity as part of FCTR.

k) Financial Instruments:

I. Financial Assets

Classification

On initial recognition, the Company classifies financial assets at amortized cost, fair value through other comprehensive income or fair value through profit or loss on the basis of its business model for managing the financial assets and the contractual cash flow characteristics of the financial asset.

Initial recognition and measurement

All financial assets (not measured subsequently at fair value through profit or loss) are recognised initially at fair value plus transaction costs that are attributable to the acquisition of the financial asset. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trades) are recognised on the trade date, i.e., the date that the Company commits to purchase or sell the asset.

Financial assets measured at amortized cost

A 'financial asset' is measured at the amortised cost if both the following conditions are met:

i) The asset is held within a business model whose objective is to hold assets for collecting contractual cash flows, and

ii) Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

After initial measurement, such financial assets are subsequently measured at amortised cost using the effective interest rate (EIR) method. Amortised cost is calculated by taking into account any discount or premium and fees or costs that are an integral part of the EIR. The EIR amortisation is included in finance income in the Statement of Profit and Loss. The losses arising from impairment are recognised in the Statement of Profit and Loss. This category generally applies to trade and other receivables.

Financial assets included within the fair value through profit and loss (FVTPL) category are measured at fair value with all changes recognized in the Statement of Profit and Loss.

All equity investments in scope of Ind AS 109 are measured at fair value. Equity instruments which are held for trading are classified as at FVTPL. For all other equity instruments, the Company decides to classify the same either as at fair value through other comprehensive income (FVTOCI) or FVTPL. The Company makes such election on an instrument-by-instrument basis. The classification is made on initial recognition and is irrevocable.

If the Company decides to classify an equity instrument as at FVTOCI, then all fair value changes on the instrument, excluding dividends, are recognized in other comprehensive income (OCI). There is no recycling of the amounts from OCI to Statement of Profit and Loss, even on sale of such investments.

Equity instruments included within the FVTPL category are measured at fair value with all changes recognized in the Statement of Profit and Loss.

The Company has elected to continue with the carrying value of all its equity investments as recognized in the standalone financial statements as at the date of transition to Ind AS, measured as per the previous GAAP and use that as the deemed cost as at the transition date pursuant to the exemption under Ind AS 101.

Derecognition

A financial asset (or, where applicable, a part of a financial asset or part of a Company of similar financial assets) is primarily derecognised (i.e. removed from the Company's balance sheet) when:

- The rights to receive cash flows from the asset have expired, or
- The Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement; and either:

i) The Company has transferred substantially all the risks and rewards of the asset, or

ii) The Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Company has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Company continues to recognise the transferred asset to the extent of the Company's continuing involvement. In that case, the Company also recognises an associated liability.

Impairment of financial assets

In accordance with Ind AS 109, the Company applies Expected Credit Loss (ECL) model for measurement and recognition of impairment loss on the following financial assets and credit risk exposure:

i) Financial assets that are debt instruments, and are measured at amortised cost e.g., loans, debt securities, deposits, and bank balance.

ii) trade receivables.

The Company follows 'simplified approach' for recognition of impairment loss allowance on trade receivables which do not contain a significant financing component.

The application of simplified approach does not require the Company to track changes in credit risk.

Rather, it recognises impairment loss allowance based on lifetime ECLs at each reporting date, right from its initial recognition.

II. *Financial Liabilities*

Classification

The Company classifies all financial liabilities as subsequently measured at amortised cost, except for financial liabilities measured at fair value through profit or loss. Such liabilities, including derivatives that are liabilities, are subsequently measured at fair value with changes in fair value being recognised in the Statement of Profit and Loss.

Initial recognition and measurement

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, at amortised cost (loans, borrowings and payables).

All financial liabilities are recognised initially at fair value and, in the case of loans and borrowings and Payables, net of directly attributable transaction costs.

The Company's financial liabilities include trade and other payables, borrowings.

Financial liabilities at fair value through profit or loss

Financial liabilities at fair value through profit or loss include financial liabilities held for trading and financial liabilities designated upon initial recognition as at fair value through profit or loss. Financial liabilities are classified as held for trading if they are incurred for the purpose of repurchasing in the near term.

Gains or losses on liabilities held for trading are recognised in the Statement of Profit and Loss.

Financial liabilities designated upon initial recognition at fair value through profit or loss are designated at the initial date of recognition, and only if the criteria in Ind AS 109 are satisfied. For liabilities designated as FVTPL, fair value gains/ losses attributable to changes in own credit risk are recognized in OCI. These gains/loss are not subsequently transferred to Statement of Profit and Loss. However, the Company may transfer the cumulative gain or loss within equity. All other changes in fair value of such liability are recognised in the Statement of Profit and Loss.

Loans and borrowings

After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortised cost using the EIR method. Gains and losses are recognised in Statement of Profit and Loss when the liabilities are derecognised.

Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included as finance costs in the Statement of Profit and Loss.

This category generally applies to interest-bearing loans and borrowings.

Derecognition

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the Statement of Profit and Loss.

Offsetting of financial instruments

Financial assets and financial liabilities are offset and the net amount is reported in the balance sheet if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously.

l) Income tax:

Income tax expense comprises current and deferred tax. It is recognised in Statement of Profit and Loss except to the extent that it relates items recognised directly in equity in which case, it is recognized in OCI.

Current tax

Current tax comprises the expected tax payable or receivable on the taxable income or loss for the year and any adjustment to the tax payable or receivable in respect of previous years. It is measured using tax rates enacted or substantively enacted at the reporting date. Current tax also includes any tax arising from dividends.

Current tax assets and liabilities are offset only if, the Company:

i) Has a legally enforceable right to set off the recognised amounts; and

ii) Intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Deferred tax

Deferred tax is recognised in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes.

Deferred tax assets are recognised for unused tax losses, unused tax credits and deductible temporary differences to the extent that it is probable that future taxable profits will be available against which they can be used. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realised; such reductions are reversed when the probability of future taxable profits improves.

Unrecognised deferred tax assets are reassessed at each reporting date and recognised to the extent that it has become probable that future taxable profits will be available against which they can be used.

Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, using tax rates enacted or substantively enacted at the reporting date are expected to apply to taxable income in the years in which the temporary differences are expected to be recovered or settled.

The measurement of deferred tax reflects the tax consequences that would follow from the manner in which the Company expects, at the reporting date, to recover or settle the carrying amount of its assets and liabilities.

Deferred tax assets and liabilities are offset only if:

i) The Company has a legally enforceable right to set off current tax assets against current tax liabilities; and

ii) The deferred tax assets and the deferred tax liabilities relate to income taxes levied by the same taxation authority on the same taxable entity.

m) Inventories:

a. Inventories are valued at lower of cost or net realizable value

b. Raw materials, Packing materials, stores and spares are valued at cost including duties and taxes, exclusive of tax credit. The cost is arrived at FIFO basis.

c. In respect of finished goods and work in progress cost includes raw materials, packing materials, labour cost and other appropriate allocable overhead.

n) Revenue Recognition:

Revenue is recognized when the significant risks and rewards of ownership have been transferred to the buyer, recovery of the consideration is probable, the associated costs and possible return of goods can be estimated reliably, the entity retains no continuing managerial involvement or effective control over the goods usually associated with ownership and the amount of revenue can be measured reliably.

Revenue from the sale of goods is measured at the fair value of the consideration received or receivable (after including fair value allocations related to multiple deliverable and/or linked arrangements), net of returns, sales tax, excise duty/ goods and service tax and applicable trade discounts and allowances. Revenue includes shipping and handling costs billed to the customer. The timing of the transfer of risks and rewards varies depending on the individual terms of the sales agreements.

Service income is recognised in accordance with the terms of the contract with customers when the related performance obligation is completed, or when risks and rewards of ownership are transferred, as applicable.

Interest income is recognized on time proportionate basis with reference to the Effective Interest Rate method.

Dividend from investments is recognised as revenue when right to receive is established.

o) Employee Benefits:

Short term employee benefits

All employee benefits payable wholly within twelve months of rendering the service are classified as short term employee benefits and they are recognized in the period in which the employee renders the related service. The Company recognizes the undiscounted amount of short term employee benefits expected to be paid in exchange for services rendered as a liability (accrued expense) after deducting any amount already paid.

Defined contribution plans

Obligations for contributions to defined contribution plans are expensed as the related service is provided and the Company will have no legal or constructive obligation to pay further amounts. Prepaid contributions are recognised as an asset to the extent that a cash refund or a reduction in future payments is available.

Defined benefit plans

The Company's net obligation in respect of defined benefit plans is calculated separately for each plan by estimating the amount of future benefit that employees have earned in the current and prior periods, discounting that amount and deducting the fair value of any plan assets.

The calculation of defined benefit obligations is performed periodically by an independent qualified actuary using the projected unit credit method. When the calculation results in a potential asset for the Company, the recognised asset is limited to the present value of economic benefits available in the form of any future refunds from the plan or reductions in future contributions to the plan. To calculate the present value of economic benefits, consideration is given to any applicable minimum funding requirements.

Remeasurement of the net defined benefit liability, which comprise actuarial gains and losses and the return on plan assets (excluding interest) and the effect of the asset ceiling (if any, excluding interest), are recognized immediately in other comprehensive income (OCI). The actual return of the portfolio of plan assets, in excess of the yields computed by applying the discount rate used to measure the defined benefit obligation is recognized in other comprehensive income. Net interest expense (income) on the net defined liability (assets) is computed by applying the discount rate, used to measure the net defined liability (asset). Net interest expense and other expenses related to defined benefit plans are recognised in Statement of Profit and Loss.

When the benefits of a plan are changed or when a plan is curtailed, the resulting change in benefit that relates to past service or the gain or loss on curtailment is recognised immediately in Statement of Profit and Loss. The Company recognises gains and losses on the settlement of a defined benefit plan when the settlement occurs.

Other long-term employee benefits

The Company's s net obligation in respect of long-term employee benefits is the amount of future benefit that employees have earned in return for their service in the current and prior periods. The obligation is measured on the basis of a periodical independent actuarial valuation using the projected unit credit method. Remeasurement are recognised in Statement of Profit and Loss in the period in which they arise.

p) Share-based payment transactions:

Employees Stock Options Plans ("ESOPs"): The grant date fair value of options granted to employees is recognized as an employee expense, with a corresponding increase in equity, over the period that the employees become unconditionally entitled to the options. The expense is recorded for each separately vesting portion of the award as if the award was, in substance, multiple awards. The increase in equity recognized in connection with share based payment transaction is presented as a separate component in equity under "Employee Stock Options Outstanding Reserve". The amount recognized as an expense is adjusted to reflect the actual number of stock options that vest.

q) Provisions and Contingent Liabilities:

A provision is recognised when the Company has a present obligation as a result of past events and it is probable that an outflow of resources will be required to settle the obligation in respect of which a reliable estimate can be made. If effect of the time value of money is material, provisions are discounted using an appropriate discount rate that reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost.

Contingent liabilities are disclosed in the Notes to the Standalone Financial Statements. Contingent liabilities are disclosed for:

i) Possible obligations which will be confirmed only by future events not wholly within the control of the Company, or

ii) Present obligations arising from past events where it is not probable that an outflow of resources will be required to settle the obligation or a reliable estimate of the amount of the obligation cannot be made.

A Contingent Asset is disclosed where an inflow of economic benefits is probable.

r) Borrowing costs:

Borrowing costs are interest and other costs that the Company incurs in connection with the borrowing of funds and is measured with reference to the effective interest rate (EIR) applicable to the respective borrowing.

Borrowing costs include interest costs measured at EIR and exchange differences arising from foreign currency borrowings to the extent they are regarded as an adjustment to the interest cost.

Borrowing costs, allocated to qualifying assets, pertaining to the period from commencement of activities relating to construction / development of the qualifying asset up to the date of capitalisation of such asset are added to the cost of the assets. Capitalisation of borrowing costs is suspended and charged to the Statement of Profit and Loss during extended periods when active development activity on the qualifying assets is interrupted.

All other borrowing costs are recognised as an expense in the period which they are incurred.

s) Government Grants and Assistance:

Government grants are initially recognised as deferred income at fair value if there is reasonable assurance that they will be received and the Company will comply with the conditions associated with the grant;

- In case of capital grants, they are then recognised in Statement of Profit and Loss as other income on a systematic basis over the useful life of the asset.

- In case of grants that compensate the Company for expenses incurred are recognised in Statement of Profit and Loss on a systematic basis in the periods in which the expenses are recognised.

  Export benefits available under prevalent schemes are accrued in the year in which the goods are exported and there is no uncertainty in receiving the same.

t) Earnings per share:

Basic earnings per share is computed by dividing the profit / (loss) after tax by the weighted average number of equity shares outstanding during the year. The weighted average number of equity shares outstanding during the year is adjusted for the events for bonus issue, bonus element in a rights issue to existing shareholders, share split and reverse share split (consolidation of shares) including for changes effected prior to the approval of the financial statements by the Board of Directors. Diluted earnings per share is computed by dividing the profit / (loss) after tax as adjusted for dividend, interest and other charges to expense or income (net of any attributable taxes) relating to the dilutive potential equity shares, by the weighted average number of equity shares considered for deriving basic earnings per share and the weighted average number of equity shares which could have been issued on conversion of all dilutive potential equity shares.

Dilutive potential equity shares are deemed converted as of the beginning of the period, unless issued at a later date. Dilutive potential equity shares are determined independently for each period presented.

u) Insurance claims:

Insurance claims are accounted for on the basis of claims admitted / expected to be admitted and to the extent that the amount recoverable can be measured reliably and it is reasonable to expect the ultimate collection.

v) Goods and Service Tax ('GST') input credit:

GST input credit is accounted for in the books in the period in which the underlying service received is accounted and when there is reasonable certainty in availing / utilising the credits.

w) Segment reporting:

The Company operates in one reportable business segment i.e. "Pharmaceuticals".

x) Operating cycle:

Based on the nature of products / activities of the Company and the normal time between acquisition of assets and their realisation in cash or cash equivalents, the Company has determined its operating cycle as 12 months for the purpose of classification of its assets and liabilities as current and non-current.

y) Cash Flow Statement:

Cash flows are reported using the indirect method, whereby profit for the period is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future operating cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the Company are segregated.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

NOTE: 2 PROPERTY, PLANT AND EQUIPMENT

Particulars	Gross block					Depreciation Reserve					Net Block	
	As at 01-04-2020	Translation Difference	Additions during the year	Deletions during the year	As at 31-03-2021	As at 01-04-2020	Translation Difference	Additions during the year	Deletions during the year	As at 31-03-2021	As at 31-03-2021	As at 31-03-2020
Tangible Assets												
Land	1,340.25	(11.89)	605.57		1,933.94	-				-	1,933.94	1,340.25
Leasehold Land	137.10		1,267.39		1,404.49	3.04		8.52		11.57	1,392.93	134.05
Factory Buildings	8,578.44		1,232.36		9,810.80	788.72		332.56		1,121.28	8,689.52	7,789.72
Buildings - Others	1,296.48	(36.70)	104.18	352.41	1,011.55	226.02	(3.78)	112.19	91.47	242.95	768.60	1,070.46
Plant & Machinery (i)	10,578.41	1.99	2,457.47	41.10	12,996.77	3,164.60	(10.30)	1,068.32	27.01	4,195.61	8,801.16	7,406.09
Air Conditioner	478.92		8.27		487.20	62.63		43.44		106.07	381.13	416.29
Furniture & Fixtures	2,261.87	(6.38)	39.35	9.77	2,285.07	604.03	(6.07)	262.48		860.44	1,424.64	1,657.85
Office Equipment	861.62	(1.76)	30.33		890.19	495.81	(1.09)	96.45		591.16	299.03	365.82
Computers	796.14	(3.20)	60.50	0.74	852.70	417.61	(0.86)	175.82		592.57	260.14	378.53
Electrical Fittings	1,779.75		19.85		1,799.59	422.88		190.77		613.65	1,185.94	1,356.87
Motor Vehicles	897.44	(14.44)	128.36	87.52	923.83	487.76	6.28	112.91	32.52	574.43	349.41	417.39
Tools & Spares	52.86		-		52.86	40.58		11.31		51.89	0.97	12.28
Lab Equipment	5,404.45		1,107.88	22.99	6,489.34	1,188.16		1,099.65	6.00	2,281.80	4,207.54	4,216.29
Motor Cycle	0.73		-		0.73	0.07		0.07		0.15	0.59	0.66
Total Tangible Assets	**34,464.46**	**(72.38)**	**7,061.52**	**514.52**	**40,939.07**	**7,901.91**	**(15.83)**	**3,514.48**	**157.00**	**11,243.56**	**29,695.51**	**26,562.55**

(i) Gross Block for 31st March 2021 includes Rs. 914.47 Lacs (PY: Rs. 628 Lacs) of government grant in the nature of waiver of duty on purchase of plant and machinery & lab equipments. Accumulated Depreciation for Plant & Machinery as at 31st March 2021 includes Rs. 213.63 Lacs (PY: Rs. 111.66 Lacs) on such government grant.

Particulars	Gross block				Depreciation Reserve				Net Block	
	As at 01-04-2019	Additions/ Adjustments/ Translation Difference	Deletions during the year	As at 31-03-2020	As at 01-04-2019	Additions/ Adjustments/ Translation Difference	Deletions during the year	As at 31-03-2020	As at 31-03-2020	As at 31-03-2019
Tangible Assets										
Land	1,098.36	241.89	-	1,340.25	-	-		-	1,340.25	1,098.36
Leasehold Land	137.10	-	-	137.10	1.56	1.49		3.05	134.05	135.54
Factory Buildings	7,788.33	790.11	-	8,578.44	479.74	308.97		788.71	7,789.72	7,308.59
Buildings - Others	451.10	845.38	-	1,296.48	91.45	134.57		226.02	1,070.46	359.66
Plant & Machinery	9,400.13	1,207.44	36.88	10,570.69	2,125.50	1,064.31	25.21	3,164.60	7,406.09	7,255.53
Air Conditioner	313.50	165.42	-	478.92	30.16	32.47		62.63	416.29	302.45
Furniture & Fixtures	1,435.16	826.72	-	2,261.88	285.10	318.93		604.03	1,657.85	1,150.05
Office Equipment	536.51	333.19	8.08	861.62	288.17	207.64		495.81	365.81	248.34

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

Particulars	Gross block				Depreciation Reserve				Net Block	
	As at 01-04-2019	Additions/ Adjustments/ Translation Difference	Deletions during the year	As at 31-03-2020	As at 01-04-2019	Additions/ Adjustments/ Translation Difference	Deletions during the year	As at 31-03-2020	As at 31-03-2020	As at 31-03-2019
Computers	392.32	403.82	-	796.14	203.50	214.11		417.61	378.53	182.99
Electrical Fittings	1,383.60	396.15	-	1,779.75	254.74	168.14		422.88	1,356.87	1,128.86
Motor Vehicles	492.12	424.96	11.93	905.15	321.84	174.32	8.40	487.76	417.39	169.55
Tools & Spares	52.86	-	-	52.86	38.87	1.71		40.58	12.28	13.99
Lab Equipment	3,391.62	2,040.38	27.54	5,404.46	273.56	916.28	1.68	1,188.16	4,216.30	3,118.06
Motor Cycle	0.73	-	-	0.73	-	0.07		0.07	0.66	1.48
Total Tangible Assets	**26,873.44**	**7,675.45**	**84.43**	**34,464.46**	**4,394.19**	**3,543.01**	**35.29**	**7,901.91**	**26,562.55**	**22,473.45**

Note 2A Capital Work-in-Progress

Particulars	As at March 31, 2021	As at March 31, 2020
Opening Balance	2,011.82	970.35
Additions	6,513.21	6,859.28
Less:		
Capitalisation	7,142.61	(5,817.81)
Assets held for sale	-	-
Closing Balance	**1,382.42**	**2,011.82**

Note : 2B Intangible Assets

Particulars	Gross block					Depreciation Reserve					Net Block	
	As at 01-04-2020	Translation Difference	Additions during the year	Deletions during the year	As at 31-03-2021	As at 01-04-2020	Translation Difference	Additions during the year	Deletions during the year	As at 31-03-2021	As at 31-03-2021	As at 31-03-2020
Computer Software	784.40	-1.31	327.62	23.33	1,087.38	283.03	(12.91)	116.41	23.01	363.52	723.86	501.37
GoodWill (acquisition)	5.37				5.37	-					5.37	5.37
Total Intangible Assets	**789.77**	**-1.31**	**327.62**	**23.33**	**1,092.74**	**283.03**	**(12.91)**	**116.41**	**23.01**	**363.52**	**729.23**	**506.74**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

Particulars	Gross block				Depreciation Reserve				Net Block	
	As at 01-04-2019	Additions/ Adjustments/ Translation Difference	Deletions during the year	As at 31-03-2020	As at 01-04-2019	Additions/ Adjustments/ Translation Difference	Deletions during the year	As at 31-03-2020	As at 31-03-2020	As at 31-03-2019
Computer Software	277.37	507.03	-	784.40	72.37	210.65	-	283.03	501.37	210.84
Goodwill on Consolidation	-	5.37	-	5.37	-	-	-		5.37	-
Total Intangible Assets	**277.37**	**512.40**	**-**	**789.77**	**72.37**	**210.65**	**-**	**283.03**	**506.74**	**210.84**

Note : 2C ROU Assets

Particulars	Gross block					Depreciation Reserve					Net Block	
	As at 01-04-2020	Translation Difference	Additions during the year	Deletions during the year	As at 31-03-2021	As at 01-04-2020	Translation Difference	Additions during the year	Deletions during the year	As at 31-03-2021	As at 31-03-2021	As at 31-03-2020
ROU Assets	225.11	-	-	-	225.11	43.97	-	66.23	-	110.21	114.91	181.14
Total ROU Assets	**225.11**	**-**	**-**	**-**	**225.11**	**43.97**	**-**	**66.23**	**-**	**110.21**	**114.91**	**181.14**

Particulars	Gross block				Depreciation Reserve				Net Block	
	As at 01-04-2019	Additions/ Adjustments/ Translation Difference	Deletions during the year	As at 31-03-2020	As at 01-04-2019	Additions/ Adjustments/ Translation Difference	Deletions during the year	As at 31-03-2020	As at 31-03-2020	As at 31-03-2019
ROU Assets		225.11		225.11		43.97		43.97	181.14	-
Total ROU Assets	**-**	**225.11**		**225.11**	**-**	**43.97**		**43.97**	**181.14**	**-**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

NOTE 3 : NON CURRENT INVESTMENTS

	As at March 31, 2021	As at March 31, 2020
A. Fully paid Ordinary / Equity shares (unquoted)		
(i) Others		
Investment in Equity Share of Mytrah Vayu Manjira	-	22.50
(2,25,000 Equity shares of Rs. 10/- each sold during the year)		
B. Fully paid Ordinary / Equity shares - Quoted		
26,800 (26,800) shares of The Catholic Syrian Bank Ltd of ₹ 10/- each fully paid up	62.42	29.17
4,400 (4,400) shares of Karnataka Bank Ltd of ₹10/- each fully paid up	2.69	2.40
4,800 (4,800) shares of Indian Overseas Bank of ₹ 10/- each fully paid up	0.77	1.15
700 (700) shares of Bank of India of ₹ 10/- each fully paid up	0.47	0.32
Total	**66.35**	**55.54**

NOTE 4 : LONG-TERM LOANS AND ADVANCES

	As at March 31, 2021	As at March 31, 2020
Unsecured, considered good		
Security Deposits	65.23	104.40
Other Deposits	179.89	171.86
Advance for Capital expenditure	546.74	261.48
Gratuity Fund Net of Provision	-	-
Total	**791.86**	**537.74**
*** Break up:**		
Loan Receivable considered good- Secured	-	-
Loan Receivable considered good- Unsecured	791.86	537.74
Loan Receivable which have significant increase in credit risk	-	-
Loan Receivable - credit impaired	-	-
Total	**791.86**	**537.74**
Less:Allowance for doubtful Loans	-	-
Total Loans	**791.86**	**537.74**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

NOTE 5 : INVENTORIES (LOWER OF COST OR NET REALISABLE VALUE)

	As at March 31, 2021	As at March 31, 2020
Raw Materials	2,191.27	981.35
Packing Materials	2,026.85	1,262.68
Work-in-Progress	308.61	230.27
Stock In Trade	12,169.87	20,236.41
Finished Goods	472.88	719.89
Stores and Spares	730.71	392.57
Total	**17,900.19**	**23,823.17**

NOTE 6 : CURRENT INVESTMENT

	As at March 31, 2021	As at March 31, 2020
Investment in Mutual Fund - fair value through Profit or Loss (i)	1,053.50	6,022.98
Total	**1,053.50**	**6,022.98**

(i) Investment in Mutual Fund at fair value through profit or loss

FUND NAME	As at March 31, 2021		As at March 31, 2020	
	Units	Amount ₹ in lakhs	Units	Amount ₹ in lakhs
ICICI Prudential Liquid Plan - D -G	-	-	1,38,988.30	408.32
ICICI Prudential Savings Fund - Growth	-	-	26,564.82	102.90
ICICI Prudential Short Term - Growth	-	-	16,94,333.86	714.49
Kotak Flexi Debt - Regular Plan - Growth	-	-	27,39,946.51	736.29
Reliance Short Term Fund - Growth	-	-	17,26,439.40	652.16
UTI Liquid Cash Plan	-	-	12,462.97	403.48
Axis Triple Advantage fund - equity	-	-	1,00,000.00	17.52
Franklin India Flexi Cap fund	-	-	5,000.00	2.63
Aditya Birla Sun Life Floating Rate Fund	-	-	1,39,481.73	349.98
Aditya Birla Sun Life Liquid Fund	-	-	3,72,674.56	1,212.19
Aditya Birla Sun Life Savings Fund	-	-	27,147.07	107.92
Franklin India Fixed Maturity Plan B Series - 5 - Plan B1244 days	20,00,000.00	250.81	20,00,000.00	229.55
Franklin India Fixed Maturity Plans - Series 4 - Plan E 1098 days - Direct - Growth	20,00,000.00	251.36	20,00,000.00	233.45
Aditya Birla Sun Life Overnight Fund - Growth	18,065.00	200.45	-	-
Aditya Birla Sun Life Overnight Fund– Growth - Direct	31,528.00	350.88	-	-
ICICI Prudential Money Market Fund	-	-	1,54,001.88	429.39
ICICI Prudential Ultra Short Term Fund	-	-	20,24,199.49	422.71
Total		**1,053.50**		**6,022.98**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

	As at March 31, 2021	As at March 31, 2020
Aggregate book value of quoted investments	983.61	5,480.90
Aggregate Market value of quoted investments	1,119.85	6,056.02
Aggregate value of un-quoted investments	-	22.50
Aggregate amount of impairment in value of investment	-	-

NOTE 7 : TRADE RECEIVABLES

	As at March 31, 2021	As at March 31, 2020
(Unsecured considered good unless otherwise stated)		
Trade Receivables	27,936.07	22,896.49
Receivables from related parties	-	-
Trade receivables which have significant increase in credit risk	-	-
Trade receivables - Credit impaired	-	-
Less: Allowance for doubtful trade receivables	-	-
Total receivables	27,936.07	22,896.49
Total	**27,936.07**	**22,896.49**

NOTE 8 : CASH AND CASH EQUIVALENTS

	As at March 31, 2021	As at March 31, 2020
Cash on Hand	266.04	331.16
Balance with Banks		
- Current accounts	5,783.56	4,661.75
In Bank Deposit Accounts		
- Bank Deposit accounts less than 3 months maturity	17,107.88	-
Total	**23,157.48**	**4,992.91**

NOTE 9 : OTHER BANK BALANCES

		As at March 31, 2021	As at March 31, 2020
-	Unpaid Dividend account	261.23	266.20
	In Bank Deposit Accounts		
-	Bank Deposit accounts maturity (more than 3 months but less than 12 months)	20,414.82	17,083.78
-	Bank Deposit accounts maturity (more than 12 months)	2,124.09	
Total		**22,800.14**	**17,349.98**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

NOTE 10 : LOANS *

	As at March 31, 2021	As at March 31, 2020
Unsecured, considered good		
Advances recoverable in cash or kind for the value to be received	4,194.11	2,783.82
Export Incentives Receivable	1,181.25	1,148.97
Balance with Statutory Authorities	4,514.26	2,897.19
Total	**9,889.62**	**6,829.98**
*** Break up:**		
Loans considered good- Secured	-	-
Loans considered good- Unsecured	9,889.62	6,829.98
Loans which have significant increase in credit risk	-	-
Loans - credit impaired	-	-
Total	**9,889.62**	**6,829.98**
Less:Allowance for doubtful Loans	-	-
Total Loans	**9,889.62**	**6,829.98**

NOTE 11 : OTHER CURRENT ASSETS

	As at March 31, 2021	As at March 31, 2020
Interest Accrued on Deposits	843.56	337.62
Total	**843.56**	**337.62**

NOTE 12 : EQUITY SHARE CAPITAL

	As at March 31, 2021	As at March 31, 2020
AUTHORISED		
8,50,00,000 (31st March, 2020: 8,50,00,000) equity shares of ₹ 2/- each	**1,700.00**	**1,700.00**
ISSUED, SUBSCRIBED AND PAID UP		
7,56,42,750 (31st March, 2020:7,56,42,750) equity shares of ₹ 2/- each fully paid up	1,512.86	1,512.86
Total	**1,512.86**	**1,512.86**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

a) Reconciliation of equity shares outstanding at the beginning and at the end of the Year

	As at March 31, 2021		As at March 31, 2020	
	NO OF EQUITY SHARES of ₹ 2/- each	Amount	NO OF EQUITY SHARES of ₹ 2/- each	Amount
Equity shares outstanding at the beginning of the Year	7,56,42,750	1,512.86	7,56,30,250	1,512.61
Add: Equity shares allotted pursuant to employee stock option plan*	-	-	12,500	0.25
Equity shares outstanding at the end of the Year	**7,56,42,750**	**1,512.86**	**7,56,42,750**	**1,512.86**

*During the financial year 2020-21 (2019-20), Nil (12,500) equity shares under ESOP Scheme vested were exercised

b) Rights, preference & restrictions attached to shares

Equity Shares

The Company has only one class of equity shares having a par value of ₹ 2/- per share. Each holder of equity share is entitled to one Vote per Share.

The Dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting.

In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

c) Details of shares in the company held by each shareholder holding more than 5% shares:

Name of Shareholder	As at Marchr 31, 2021 (of ₹ 2/- each)		As at Marchr 31, 2020 (of ₹ 2/- each)	
	No. of Shares held	% of Holding	No. of Shares held	% of Holding
P. Vijayalakshmi	1,78,80,000	23.64%	1,78,80,000	23.64%
C.C. Paarthipan	1,41,67,192	18.73%	1,41,67,192	18.73%
P. Ashok Gorkey	90,50,000	11.96%	90,50,000	11.96%
P. Vivek Siddarth	90,00,000	11.90%	90,00,000	11.90%

d) Shares reserved for issuance under Employee Stock Options Plans of the Company

Particulars	As at March 31, 2021		As at March 31, 2020	
	No. of Shares of ₹ 2/- each	Amount	No. of Shares of ₹ 2/- each	Amount
Caplin Point Employee Stock Option Plan 2015	2,81,000	5.62	3,74,250	7.49
Caplin Point Employee Stock Option Plan 2017	4,90,000	9.80	2,88,000	5.76

(All amounts are in ₹ Lakhs unless otherwise stated)

e) Aggregate number of shares issued pursuant to Stock Option Plans of the Company

Particulars	
Issued in FY 2016-17	26,750
Issued in FY 2017-18	26,750
Issued in FY 2018-19	26,750
Issued in FY 2019-20	12,500
Total	**92,750**

f) No shares have been allotted without payment being received in cash or by way of bonus shares during the period of five years immediately preceding the balance sheet date.

NOTE 13 : RESERVES & SURPLUS

		As at March 31, 2021	As at March 31, 2020
a)	**Capital Reserve**		
	Opening balance as per last balance sheet	238.62	40.98
	Add: Gain on derecognition of Non Controlling Interest	47.88	-
	Add: Additions during the year	-	(1.05)
	Add: Surplus on Acquisition of subsidiary	-	198.69
	Balance as at year end	**286.50**	**238.62**
b)	**Securities Premium**		
	Opening balance as per last balance sheet	212.29	162.75
	Add: Additions during the year	0.02	49.54
	Balance as at year end	**212.31**	**212.29**
c)	**General Reserve**		
	Opening and closing balance as per last balance sheet	1,128.78	1,128.78
d)	**Employee Stock Options Outstanding**		
	- Employee Stock options outstanding		
	Opening balance as per last balance sheet	2,503.49	1,733.55
	Add: Options granted during the year	377.42	819.48
	Less: Exercised during the year	-	49.54
	Less: Lapsed during the year	-	
	Balance as at year end (A)	**2,880.91**	***2,503.49***
	- Deferred Employees Stock Options Cost		
	Opening balance as per last balance sheet	1,559.33	1,048.41
	Add: Options granted during the year	377.42	819.48
	Less: Amortised during the year	(535.40)	(308.56)
	Balance as at year end (B)	***1401.34***	***1,559.33***
	(A-B)	**1,479.56**	**944.16**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

		As at March 31, 2021	As at March 31, 2020
e)	**Retained Earnings / Surplus in the Statement of Profit & Loss**		
	Balance at the beginning of the Year	67,517.07	49,268.90
	Add : Profit during the Year	24,226.62	21,500.80
	Final Dividend paid	(302.57)	(1,664.14)
	Interim Dividend Paid	-	(1,588.49)
	Balance at the end of the year	**91,441.12**	**67,517.07**
f)	**Other Comprehensive Income**		
	i) Foreign currency Translation Reserve		
	Balance at the beginning of the Period	1,643.17	104.45
	Profit/ (Loss) on foreign currency translation	(748.14)	1,538.72
	Balance at the end of the year	**895.03**	**1,643.17**
	ii) Actuarial Gain/ (Loss) on employee benefit obligation		
	Opening balance as per last balance sheet	(62.07)	8.33
	Add/(Less); Additions during the year	31.53	(70.40)
	Balance as at the end of the year	**(30.54)**	**(62.07)**
	Securities Premium-Preference Shares	14,341.70	14,341.70
	Cost of Equity Transactions	(143.45)	(143.45)
	Preference share capital Series A Compulsorily Convertible Preference Shares of ₹ 10/- each fully paid up *	7,458.29	7,458.29
	Closing Balance	**1,17,069.30**	**93,278.56**

*Preference Shares

Pursuant to the approval granted by members at the Extra ordinary General Meeting held on 26th February 2019, the company's subsidiary Caplin Steriles Ltd had issued and allotted 3,59,22,993 Series A Compulsorily Convertible Preference Shares of face value of ₹ 10/- at a premium of Rs. 19.23 each to M/s. Eight Road Ventures India IIILP carrying a coupon rate of 0.001% p.a. on 7th March, 2019 and allotted 1,53,95,568 Series A Compulsorily Convertible Preference Shares of face value of ₹ 10/- at a premium of Rs. 19.23 each to M/s. F-Prime Capital Partners Life Sciences Fund VI LP carrying a coupon rate of 0.001% p.a. on 23rd April, 2019 both having a term of 19 years from the date of allotment

As at 31st March 2020, pursuant to the approval granted by members at the Extra ordinary General Meeting held on 12th March 2020, the company's subsidiary Caplin Steriles Ltd had issued and allotted 1,62,85,020 Series A Compulsorily Convertible Preference Shares of face value of ₹ 10/- at a premium of Rs. 19.23 each to M/s. Eight Road Ventures India IIILP carrying a coupon rate of 0.001% p.a. on 27th March' 2020 and allotted 69,79,294 Series A Compulsorily Convertible Preference Shares of face value of ₹ 10/- at a premium of Rs. 19.23 each to M/s. F-Prime Capital Partners Life Sciences Fund VI LP carrying a coupon rate of 0.001% p.a. on 27th March' 2020 both having a term of 19 years from the date of allotment

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

NOTE 14 : LONG TERM BORROWINGS

	As at March 31, 2021	As at March 31, 2020
Secured		
Borrowings from Bank (i)	1,705.51	1,504.77
Loan from others (ii)	1.19	28.29
Unsecured		
Borrowings from Bank	-	2,114.75
Less : Current maturities of long term debt	1,706.70	3,646.29
Total	**-**	**1.52**

(i) Borrowing pertaining to subsidiaries acquired during FY 19-20,Secured against the relevant assets and carries an interest rate between 5.25% and 7.0% per annum.

ii) Obligations under Hire purchase are secured against relevant fixed assets obtained under Hire Purchase Finance repayable in equal monthly instalments carries an interest rate between 8% and 10% per annum.

NOTE 15 : LEASE LIABILITY (Non Current)

	As at March 31, 2021	As at March 31, 2020
Lease Liability (Refer Note-39)	53.32	128.48
Total	**53.32**	**128.48**

NOTE 16 : DEFERRED TAX LIABILITIES (Net)

	As at March 31, 2021	As at March 31, 2020
a) Deferred Tax Liabilities on account of timing differences	2,097.13	2,213.94
b) Deferred Tax Asset on account of timing differences	(1,981.48)	(1,202.70)
Total	**115.65**	**1,011.24**

NOTE 17 : Other Non Current liabilities

	As at March 31, 2021	As at March 31, 2020
Govt Grant	700.84	522.39
Provision for Gratuity(Net)	536.25	522.53
Others	300.00	299.96
Total	**1,537.09**	**1,344.88**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

NOTE 18 CURRENT BORROWINGS

	As at March 31, 2021	As at March 31, 2020
Current Borrowings (Refer Note 14)	1,706.70	3,646.29

NOTE 19 : LEASE LIABILITY (CURRENT)

	As at March 31, 2021	As at March 31, 2020
Lease Liability (Refer Note-39)	79.19	84.81

NOTE 20 : TRADE PAYABLES

	As at March 31, 2021	As at March 31, 2020
Total outstanding dues of micro enterprises and small enterprises	61.56	-
Total outstanding dues of creditors other than micro enterprises and small enterprises	8,788.45	6,413.62
Total	**8,850.01**	**6,413.62**

NOTE 21 : OTHER CURRENT LIABILITIES

	As at March 31, 2021	As at March 31, 2020
Statutory Dues payable	414.45	313.89
Creditors for Capital Goods	329.36	875.02
Unclaimed Dividend (Ref Note :43)	261.23	266.20
Salary and bonus payable	601.67	709.39
Provision for Gratuity(Net)	239.26	201.99
Amount payable towards investment in subsidiary	1.15	1.15
Amount Payable to subsidiary on Acquisition	1,793.82	1,829.25
Total	**3,640.95**	**4,196.89**

NOTE 22 : SHORT TERM PROVISIONS

	As at March 31, 2021	As at March 31, 2020
Provision for Employee Benefits	8.50	90.86
Total	**8.50**	**90.86**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

NOTE 23 : REVENUE FROM OPERATIONS

	For the Year ended March 31, 2021	For the year ended March 31, 2020
Revenue form Operations	**104,825.75**	**84,451.81**
Sale of products	101,077.41	81,431.00
Sale of Services	3,748.34	3,020.81
Other operating revenues		
Export Incentives	1,303.29	1,868.36
Total	**106,129.04**	**86,320.17**

NOTE 24 : OTHER INCOME

	For the Year ended March 31, 2021	For the year ended March 31, 2020
Interest Income	1,860.72	744.51
Dividend Income	-	1.26
Gain on sale of financial instruments	637.78	496.81
Fair value gain on financial instruments through profit or loss	(438.89)	48.78
Foreign exchange, net	71.94	2,737.01
Govt Grant	106.24	75.69
Miscellaneous Income	116.43	29.31
Total	**2,354.22**	**4,133.37**

NOTE 25 : COST OF MATERIALS CONSUMED

	For the Year ended March 31, 2021	For the year ended March 31, 2020
Opening Stock	2,636.60	2,068.05
Add : Purchases (Net)	15,293.82	11,380.57
Less Closing Stock	4,948.84	2,636.60
Total	**12,981.58**	**10,812.02**

NOTE 26 : CHANGES IN INVENTORIES OF FINISHED GOODS INCLUDING STOCK -IN-TRADE AND WORK-IN-PROGRESS

	For the Year ended March 31, 2021	For the year ended March 31, 2020
Inventories at the end of the year		
Work in Progress	308.61	230.27
Finished Goods	472.88	719.89
Stock-in-Trade	12,169.87	20,236.42
(A)	**12,951.36**	**21,186.57**
Inventories at the beginning of the year		
Work in Progress	230.27	366.66

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

	For the Year ended March 31, 2021	For the year ended March 31, 2020
Finished Goods	719.89	102.35
Stock-in-Trade	20,236.42	1,207.45
(B)	**21,186.57**	**1,676.47**
Net (Increase) / Decrease in Inventories (B- A)	**8,235.21**	**(19,510.10)**

NOTE 27 : EMPLOYEE BENEFITS EXPENSE

	For the Year ended March 31, 2021	For the year ended March 31, 2020
Salaries,wages, bonus and allowances	8,372.12	5,730.30
Contribution to Provident and Other funds	746.97	295.68
Employee Compensation Expense -ESOP	535.39	308.05
Staff Welfare Expenses	598.34	441.85
Total	**10,252.82**	**6,775.88**

NOTE 28 : FINANCE COSTS

	For the Year ended March 31, 2021	For the year ended March 31, 2020
Interest Expense	143.80	17.40
Interest Expense on Lease (Refer Note-39)	15.16	14.57
Total	**158.96**	**31.97**

NOTE 29 : DEPRECIATION AND AMORTISATION

	For the Year ended March 31, 2021	For the year ended March 31, 2020
Depreciation on property, plant and equipment (Refer note: 2)	3,514.48	3,042.03
Amortisation of Intangible Assets	116.41	75.92
Depreciation on ROU Asset (Refer Note-39)	66.23	43.97
Total	**3,697.12**	**3,161.92**

NOTE 30 : RESEARCH AND DEVELOPMENT EXPENSES

	For the Year ended March 31, 2021	For the year ended March 31, 2020
R & D Expenses	5,369.47	5,301.43
Total	**5,369.47**	**5,301.43**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

NOTE 31 : OTHER EXPENSES

	For the Year ended March 31, 2021	For the year ended March 31, 2020
Power and Fuel	1,636.37	1,480.93
Contract Labour charges	390.70	452.19
Other Manufacturing Expenses	336.40	332.59
Communication Expenses	163.98	102.02
Donations	48.19	10.03
Corporate Social Responsibility	410.37	-
Professional and Consultancy charges	1,260.60	830.24
Rates & taxes including ANDA Application fees	1,050.01	629.33
Travelling Expenses	272.13	337.54
Auditors' Remuneration (Refer Note-41)	53.91	41.27
Insurance	181.79	65.13
Repairs and Maintenance		
a) Plant and Machinery	536.06	415.76
b) Building	173.98	213.77
c) Others	178.80	107.54
Rent & Amenities	675.86	323.90
Freight outwards	714.33	705.14
Other Selling Expenses	1,088.91	289.64
Software maintenance charges	139.36	159.39
Loss on Sale of Asset	60.05	4.26
Sundry Expenses	1,097.15	419.15
Total	**10,468.95**	**6,919.82**

NOTE 32 : COMMITMENT (TO THE EXTENT NOT PROVIDED FOR)

Particulars	As at March 31, 2021	As at March 31, 2020
Estimated amount of contracts remaining to be executed on capital account	610.30	1,749.12
Other Commitments (Raw material, Packing Material, Finished Goods, Other services)	4,368.37	3,322.04
Interim dividend of Rs 1.50 (75%) per equity share of Rs.2 each for the Financial Year 2020-21 payable on or after 27th May' 2021, not recognized as a liability in the financial statements for the year ended 31st March' 2021	1,134.64	-
Final Dividend proposed for F.Y 2019-20 of Rs 0.40 per equity share (Previous Year Rs. 2.20) before the financial statements approved for issue, but not recognised as a liability in the financial statements for the year ended 31st March' 2020	Nil	302.57

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

NOTE 33: CONTINGENT LIABILITIES (TO THE EXTENT NOT PROVIDED FOR)

Disputed statutory dues:

Name of the statute	Nature of dues	2020-2021 (₹ In lakhs)	2019-2020 (₹ In lakhs)	Forum where dispute is pending
Income Tax Act, 1961	Income tax	102.02	127.95	High Court / Income Tax Appellate Tribunal/ CIT Appeals

NOTE 34: DUES TO MICRO, SMALL AND MEDIUM ENTERPRISES

DISCLOSURE UNDER THE MICRO, SMALL AND MEDIUM ENTERPRISES DEVELOPMENT ACT, 2006 ARE PROVIDED AS UNDER FOR THE YEAR 2020-21, TO THE EXTENT THE COMPANY HAS RECEIVED INTIMATION FROM THE "SUPPLIERS" REGARDING THEIR STATUS UNDER THE ACT

	Particulars	As at March 31, 2021	As at March 31, 2020
(i)	Principal amount and the interest due thereon remaining unpaid to each supplier at the end of each accounting year		-
	Principal amount due to micro and small enterprise	61.56	-
	Interest due on above	-	-
(ii)	Interest paid by the Company in terms of Section 16 of the Micro, Small and Medium Enterprises Development Act, 2006, along-with the amount of the payment made to the supplier beyond the appointed day during the period	-	-
(iii)	Interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the period) but without adding interest specified under the Micro, Small and Medium Enterprises Act, 2006	-	-
(iv)	The amount of interest accrued and remaining unpaid at the end of each accounting year	-	-
(v)	Interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprises	-	-

Dues to Micro and Small Enterprises have been determined to the extent such parties have been identified on the basis of information collected by the Management. This has been relied upon by the auditors.

NOTE 35 : Balances with Scheduled banks in deposit accounts includes:

(a) Bank Deposit Accounts under Note no: 8 for the current year include ₹ 460.82 lakhs (as at 31.03.2020 ₹ 913.04 lakhs) earmarked as lien towards Margin for Letter of Credit and Bank Guarantee

NOTE 36 : Employee Benefits

(i) Defined Contribution Plan:

The Company makes monthly contribution for qualifying employee towards provident/ retirement fund administered and managed by the Government of India under defined contribution plans .

The Company recognized ₹334.16 lakhs (previous year ₹302.39 Lakhs) towards provident and pension fund contributions in the Statement of Profit and Loss.

(ii) Defined Benefit Plan:

The Company makes contributions to the group gratuity scheme administered by the LIC, a funded defined benefit plan for qualifying employees.

The following table sets out the status of the gratuity plan and reconciliation of opening and closing balances of the present value of defined benefit obligation.

Particulars		As at 31.03.2021	As at 31.03.2020
i)	**Reconciliation in present value of obligations ('PVO') - defined benefit obligation:**		
	Current service cost	159.57	113.10
	Past service cost	-	-
	Interest cost	38.50	31.35
	Actuarial loss/ (gain)		
	- Due to demographic assumption		
	- Due to finance assumption	(17.30)	43.57
	- Due to experience assumption	(32.57)	30.55
	Benefits paid	(48.51)	(58.24)
	PVO at the beginning of the year	522.95	362.63
	PVO at the end of the year	622.63	522.95
ii)	**Change in fair value of plan assets:**		
	Actuarial Gains/(Losses)	(21.24)	(8.22)
	Interest Income	22.27	26.96
	Contribution by the employer	109.90	11.12
	Benefits paid	(48.51)	(58.24)
	Fair Value of the plan assets at the beginning of the year	320.95	349.33
	Fair Value of the plan assets at the end of the year	383.37	320.95
iii)	**Reconciliation of PVO and fair value of plan assets:**		
	PVO at the end of the year	622.63	522.95

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

	Particulars	As at 31.03.2021	As at 31.03.2020
	Fair Value of plan assets at the end of the year	*383.37*	320.95
	Funded status	(239.26)	(201.99)
	Un recognised actuarial gain/ (loss)	-	-
	Net Asset/(liability) recognised in the balance sheet	(239.26)	(201.99)
iv)	**Expense recognised in the Statement of Profit and Loss:**		
	Current Service cost	159.57	113.10
	Past Service cost	-	-
	Interest cost	*16.23*	4.39
	Total expense recognised in the Statement of Profit and loss	175.81	117.48
v)	**Other Comprehensive Income:**		
	Actuarial loss/ (gain)		
	- Due to demographic assumption		
	- Due to finance assumption	*(17.30)*	43.57
	- Due to experience assumption	*(32.57)*	30.55
	Return on plan assets excluding net interest	*21.24*	8.22
	Total amount recognised as OCI	(28.64)	82.34
vi)	**Category of assets as at the end of the year:**		
	Insurer Managed Funds (100%)	383.37	320.95
	(Fund is managed by Life Insurance Corporation of India as per IRDA guidelines, category-wise composition of the plan assets is not available)		
vii)	**Actual Return on plan Assets:**	1.03	18.74
viii)	**Assumption used in accounting for the gratuity plan**		
	Mortality (%)	Rates stipulated in Indian Assured Lives Mortality 2012-14	Rates stipulated in Indian Assured Lives Mortality 2012-14
	Discount Rate (%)	7.03	6.73
	Salary Escalation Rate	7	7
	Employee Attrition Rate (%)	7	7

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

NOTE 37 : INCOME TAXES

a Tax expenses recognised in profit and loss:

Particulars	For the Financial Year ended March 31, 2021	For the Financial Year ended March 31, 2020
Current Tax Expense for the year	7,114.42	6,183.93
Deferred income tax liability/ (asset), net	(895.60)	(746.05)
Tax expense for the year	**6,218.82**	**5,437.88**

b Reconciliation of effective tax rate:

Particulars	For the Financial Year ended March 31, 2021	For the Financial Year ended March 31, 2020
Profit before Tax	31,361.85	26,946.25
Tax using the Company's dometsic tax rate	7,893.15	6,781.83
(March 31, 2021: 25.168%, March 31, 2020: 25.168%)		
Tax effect of :		
Tax impact on Donation & CSR expenses disallowance	108.15	-
Impact of foreign dividend taxed at special rate	-	253.18
Differences in tax rates of subsidiary companies	(1,840.07)	(1,069.72)
Tax incentive on additional employement	(19.60)	(12.58)
Tax impact on Actual Gain on Mutual fund & shares	(7.47)	(21.11)
Tax impact on fair value of Mutual fund & shares (Disallowance)	110.46	
Tax impact - timing diferance on R&D capital asset, book and tax depreciation and other	(25.81)	(493.72)
Current and Deferred Tax expenses as per note (a) above	**6,218.82**	**5,437.88**

c Movement in deferred tax balances

Particulars	As at 31st March' 2020	For the year ended 31st March 2021	As at 31st March' 2021
Deferred Tax Liability/(Asset)			
Property, plant and equipment	2,361.27	(82.93)	2,278.34
Business Loss	(1,350.02)	(812.67)	(2,162.69)
Total	**1011.25**	**(895.60)**	**115.65**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

NOTE 38 : REMUNERATION TO MANAGING DIRECTOR/WHOLE-TIME DIRECTORS OF THE PARENT COMPANY

Particulars	For the Financial Year ended March 31, 2021	For the Financial Year ended March 31, 2020
Salaries	54.05	58.30
Contribution to provident and other funds	2.33	2.71
Total *	**56.38**	**61.01**

* Refer note 44 (c)

NOTE 39 : OPERATING LEASES

Transition to IND AS 116

Ministry of Corporate Affairs (“MCA”) through Companies (Indian Accounting Standards) Amendment Rules, 2019 and Companies (Indian Accounting Standards) Second Amendment Rules, had notified Ind AS 116 Leases which replaces the existing lease standard, Ind AS 17 Leases, and other interpretations. Ind AS 116 sets out the principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. It introduces a single, on-balance sheet lease accounting model for lessees.

Comapny as a Lessee (Operating Leases)

Effective April 01,2019 the company had adopted Ind AS 116 “Leases” and applied the same to the lease contracts existing on April 01,2019 using the modified retrospective approach. This has resulted in recognizing Right of Use Assets and Lease Liability as on 1st April, 2019 to the extent of Rs. 1.10 Crs each. The adoption of this Standard does not have any material impact on the financial results for the year and there is no impact on the opening retained earnings on adopting this approach. The Company has used a single discount rate to a portfolio of leases with similar characteristics. Operating leases are mainly in the nature of lease of office premises with no restrictions and are renewable / cancellable at the option of either of the parties. There are no sub-leases. There are no restrictions imposed by the lease arrangements.

The Company recognises right-of-use asset representing its right to use the underlying asset for the lease term at the lease commencement date. The cost of the right-of-use asset measured at inception shall comprise of the amount of the initial measurement of the lease liability adjusted for any lease payments made at or before the commencement date less any lease incentives received, plus any initial direct costs incurred, if any. The right-of-use assets is subsequently measured at cost less any accumulated depreciation and adjusted for any remeasurement of the lease liability. The right-of-use assets is depreciated using the straight-line method from the commencement date over the shorter of lease term or useful life of right-of-use asset.

The Company measures the lease liability at the present value of the lease payments that are not paid at the commencement date of the lease. The lease payments are discounted using the interest rate implicit in the lease, if that rate can be readily determined. If that rate cannot be readily determined, the Company uses incremental borrowing rate. For leases with reasonably similar characteristics, the Company, on a lease by lease basis, may adopt either the incremental borrowing rate specific to the lease or the incremental borrowing rate for the portfolio as a whole. The lease liability is subsequently remeasured by increasing the carrying amount to reflect interest on the lease liability, reducing the carrying amount to reflect the lease payments made and remeasuring the carrying amount to reflect any reassessment or lease modifications. The Company has elected not to apply the requirements of Ind AS 116 Leases to short-term leases of all assets that have a lease term of 12 months or less and leases for which the underlying asset is of low value. The lease payments associated with these leases are recognized as an expense on a straight-line basis over the lease term.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

On application of Ind AS 116, the nature of expenses has changed from lease rent in previous periods to depreciation cost for the right-of-use asset, and finance cost for interest accrued on lease liability.

Comapny as a Lessee (Finance Leases)

The Company has entered into longterm leasing arrangements for land which are in the nature of finance lease. These arrangements do not involve any material recurring payments.

NOTE 40 : RESEARCH AND DEVELOPMENT EXPENDITURE

Particulars	For the Financial Year ended March 31, 2021	For the Financial Year ended March 31, 2020
Capital expenditure included in Fixed Assets	972.39	3,232.76
Revenue expenditures incurred during the Financial Year	5,369.47	5,301.43
Total	**6,341.86**	**8,534.19**

NOTE 41 : AUDITORS' REMUNERATION COMPRISES OF FEES: (EXCLUDING APPLICABLE TAX)

Particulars	For the Financial Year ended March 31, 2021	For the Financial Year ended March 31, 2020
For Statutory Audit	41.83	31.35
For Tax Audit	5.50	5.50
For Others	6.58	4.88
Total	**53.91**	**41.73**

NOTE 42 : EARNINGS PER SHARE IS CALCULATED AS UNDER

Particulars	For the Financial Year ended March 31, 2021	For the Financial Year ended March 31, 2020
Basic		
Net Profit after minority interest attributable to equity shareholders (Rs. in Lakhs)	24,226.62	21,500.80
Weighted average number of equity shares of ₹2/- each outstanding during the year (in Nos.)	7,56,42,750	7,56,42,750
Earnings per share (in Rs.)	32.03	28.42
Diluted		
Net Profit after minority interest attributable to equity shareholders (Rs. in Lakhs)	24,226.62	21,500.80
Weighted average number of equity shares of ₹2/- each outstanding during the year (in Nos.)	7,63,21,000	7,62,35,750
Earnings per share (in Rs.)	31.71	28.20

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

NOTE 43 : AMOUNT DUE TO INVESTOR EDUCATION AND PROTECTION FUND

The due amount of ₹ 20.98 lakhs (PY : ₹ 16.48 lakhs) were credited to investor education and protection fund and there is no outstanding due amount to be credited to investor education and protection fund.

NOTE 44 : RELATED PARTY DISCLOSURES, AS REQUIRED BY INDIAN ACCOUNTING STANDARD 24 (IND AS 24) ARE GIVEN BELOW.

(a) Related parties and nature of relationship

Name of the Related parties	Nature of Relationship	Percentage of Shares held by Caplin point laboratories limited As at March 31, 2021	Percentage of Shares held by Caplin point laboratories limited As at March 31, 2020
Mr. Vivek Siddharth,	Relative of Chairman	Not Applicable	Not Applicable
Argus Salud Pharma LLP, (India)	Subsidiary LLP	99.90%	99.90%
Caplin Point Laboratories Colombia SAS, (Colombia)	Subsidiary Company	85.83%	83.33%
Caplin Point Far East Limited, (Hong Kong)	Wholly owned Subsidiary Company	100.00%	100.00%
Caplin Point (S) PTE Ltd*	Wholly owned Subsidiary Company	100.00%	100.00%
Caplin Steriles Limited, (India)	Subsidiary Company	99.999%	100.00%
Caplin Point El Salvador, S.A. DE C.V.,(El Salvador)	Step down wholly owned subsidiary Company	100.00%	99.96%
Nuevos Eticos Neo Ethicals S.A - Guatemala	Step down subsidiary Company (w.e.f. 31st March, 2020)	69.00%	69.00%
Neoethicals CIA.LTDA - Ecuador	Step down wholly owned subsidiary Company (w.e.f. 1st Feb, 2020)	100.00%	99.00%
Drogueria Saimed de Honduras S.A.	Step down wholly owned subsidiary Company (w.e.f. 30th Sep, 2019)	100.00%	99.996%
Neo Ethicals S.A - Nicaragua	Step down wholly owned subsidiary Company (w.e.f. 22nd Apr, 2019)	100.00%	98.00%
Ashvich Infotek Private Limited	Director's relatives are interested	Not Applicable	Not Applicable
Hainan Jointown Caplin point Pharmaceutical Company Limited, (China)	Associate	39.00%	39.00%

* Incorporated during the Financial Year 2019-20

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

(b) Key managerial personnel

Dr. Sridhar Ganesan	– Managing Director from 28.03.2015
Dr. B. Philip Ashok Karunakaran	– Whole Time Director from 07.08.2017 to 10.04.2019
Mr. D Muralidharan	– Chief Financial Officer from 19-02-2016
Mr. Vinod Kumar S	– Company Secretary from 13.04.2015 to 05.02.2021
Mr. Dinesh R G	– Company Secretary from 06.05.2021

(c) Details of Transactions that have taken place during the Financial Year with Key Management Personnel:

Particulars	For the Financial Year ended March 31, 2021	For the Financial Year ended March 31, 2020
Remuneration*		
Salary paid to Mr.Vivek Siddharth	12.45	18.66
Salary paid to Dr. Sridhar Ganesan	56.38	56.86
Salary paid to Dr. B. Philip Ashok Karunakaran (i)	-	4.15
Salary paid to Mr. D Muralidharan	39.83	38.31
Salary paid to Mr. Vinod Kumar S (ii)	8.58	9.44

* Provision for contribution to gratuity fund, leave encashment on retirement and other defined benefits which are made based on acturial valuation on an overall Company basis are not included in remuneration to key management personnel.

(i) Mr.Dr. B. Philip Ashok Karunakaran, Whole-time Director, resigned w.e.f 10.04.2019

(ii) Mr. Vinod Kumar S,Company secretary, resigned w.e.f 05.02.2021

(d) Details of related party transactions during the year ended 31st March, 2021:

Particulars	For the Financial Year ended March 31, 2021	For the Financial Year ended March 31, 2020
Rent paid & sale of asset to Ashvich Infotek Private Limited by Caplin Steriles Ltd.	117.00	71.22
Rent & Consultancy charges paid to Ashvich Infotek Private Limited by Caplin Point Laboratories Ltd	99.18	227.20
Purchase of Asset from Ashvich Infotek Private Limited by Caplin Point Laboratories Ltd	13.45	-

Note:- Transactions & Balances with companies own subsidiaries are eleminated on consolidation.

(e) Outstanding balances:

Particulars	For the Financial Year ended March 31, 2021	For the Financial Year ended March 31, 2020
Amount receivable/(Payable) to Ashvich Infotech Private Ltd.	(5.95)	(5.10)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

NOTE 45 : FINANCIAL INSTRUMENTS:

Financial Instruments - Fair value and risk management

A. Accounting classification and fair values:

Carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy, are presented below. It does not include the fair value information for financial assets and financial liabilities not measured at fair value if the carrying amount is a reasonable approximation of fair value.

Fair value hierarchy

Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices).

Level 3 - Inputs for the assets or liabilities that are not based on observable market data (unobservable inputs).

Particulars	As at 31 March 2021			As at 31 March 2020		
	Carrying Amount			Carrying Amount		
	FVTPL	Amortised Cost	Total	FVTPL	Amortised Cost	Total
Financial Assets						
Non - Current Investments - others (i)						
Non - Current Investments - Mutual fund and equity	66.35		66.35	55.54	-	55.54
Non - Current Loans and advances			-			-
- Security Deposit	-	65.23	65.23	-	104.40	104.40
- Others	-	179.89	179.89	-	171.86	171.86
Current Investments	1,053.50		1,053.50	6,022.98	-	6,022.98
Trade Receivable		27,936.07	27,936.07	-	22,896.49	22,896.49
Current Loans and advances		9,889.62	9,889.62	-	6,829.98	6,829.98
Cash and Cash Equivalents		23,157.48	23,157.48	-	4,992.91	4,992.91
Other Bank Balances other than Cash and Cash Equivalents		22,800.14	22,800.14	-	17,349.98	17,349.98
Other Current Assets		843.56	843.56	-	337.62	337.62
Total	**1,119.85**	**84,871.99**	**85,991.84**	**6,078.52**	**52,683.24**	**58,761.76**
Financial Liabilities						
Non - Current Borrowings	-	-	-	-	1.52	1.52
Non - Current Lease Liability	-	53.32	53.32		128.48	128.48
Trade Payables	-	8,850.01	8,850.01	-	6,413.62	6,413.62
Current -Lease Liability	-	79.19	79.19	-	84.81	84.81
Current Borrowings	-	1,706.70	1,706.70		3,646.29	3,646.29
Other Current Liabilities	-	3,640.95	3,640.95	-	4,196.89	4,196.89
Total	**-**	**14,330.17**	**14,330.17**	**-**	**14,471.62**	**14,471.62**

(i) The Company estimates that the fair value of these investments are not materially different as compared to its cost

B. Measurement of fair values:

Valuation techniques and significant unobservable inputs:

The following tables show the valuation techniques used in measuring Level 2 and Level 3 fair values, for financial instruments measured at fair value in the statement of financial position, as well as the significant unobservable inputs used:

Type	Valuation Technique	Significant unobservable input	Inter-relationship between significant unobservable inputs and fair value measurement
Non - Current Financial Assets and Liability measured at amortised cost	Discounted cash flows: The valuation model considers the present value of expected receipt / payment discounted using appropriate discounting rate	Not applicable	Not applicable

C. Financial risk management:

The Company has exposure to the following risks arising from financial instruments:

- Credit risk;
- Liquidity risk; and
- Market risk

The Company's board of directors have overall responsibility for the establishment and oversight of the Company's risk management framework. The board of directors has established the risk management framework. The Company's risk management policies are established to set appropriate risk limits and to monitor risks and adherence to limits. risk management policies and systems are reviewed periodically to reflect changes in market condition and the Company's activities. The Company through its training, standards and procedures, aims to maintain a disciplined and constructive control environment in which all employees understand their roles and obligations.

The audit committee oversees how management monitors compliance with the Company's risk management policies and procedures, and reviews the adequacy of the risk management framework in relation to the risks faced by the Company. The audit committee is assisted in its oversight role by internal audit. Internal audit undertakes both regular and adhoc reviews of risk management controls and procedures, the results of which are reported to the audit committee.

i. Credit Risk:

Credit Risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company's receivables from customers and investment securities. Credit risk is managed through credit approvals, establishing credit limits and continuously monitoring the credit worthiness of the customers to which the Company grants credit terms in the normal course of business.

Trade Receivables

The Company's exposure to credit risk is influenced mainly by the individual characteristics of each customer. The demographics of the customer, including the default risk of the industry and country in which the customer operates, also has an influence on credit risk assessment. Credit risk is managed through credit approvals, establishing credit limits and continuously monitoring the credit worthiness of customers to which the Company grants the credit terms in the normal course of business.

Summary of the Company's exposure to credit	As at 31.03 2021	As at 31.03 2020
Neither past due nor impaired	27,936.07	22,896.49
Total	**27,936.07**	**22,896.49**

Expected credit loss assessment

The Company allocates each exposure to a credit risk grade based on a variety of data that is determined to be predictive of the risk of loss (e.g timelines of payments, available information, etc) and applying experienced credit judgement.

Exposures to the customers outstanding at the end of each reporting period are reviewed by the Company to determine incurred and expected credit losses, if any. Historical trends of impairment of trade receivables reflects no credit losses. Given that the macroecomic indicators affecting customers of the Company have not undergone any substantial change, the Company expects the historical trend of "no credit loss" to continue.

No allowance for impairment in respect trade and other receivables was provided during the year and immediate preceding year.

Cash and cash equivalents

As at the year end, the Company held cash and cash equivalents of ₹23,157.48 lakhs (31.03.2020 ₹ 4992.91 lakhs). The cash and cash equivalents are held with banks with good credit rating.

Other Bank balances

Other bank balances are held with bank with good credit rating.

Investment in mutual funds

The Company limits its exposure to credit risk by generally investing in liquid securities and only with counterparties that have a good credit rating. The Company does not expect any losses from non - performance by these counter-parties.

Other financial asset

Other financial assets are neither past due nor impaired.

(All amounts are in ₹ Lakhs unless otherwise stated)

ii. Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations with its financial liabilities that are settled by delivering cash or another financial asset. The Company's approach to managing liquidity is to ensure that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation.

The Company has not availed any fund based working capital facilities from banks and financial institutions. The Company has obtained non-fund based working capital lines from banks. The Company invests its surplus funds in bank fixed deposit and liquid and liquid plus schemes of mutual funds which carry no/low mark to market risks. The Company monitors funding options available in the debt and capital markets with a view to maintain financial flexibility.

Exposure to liquidity risk

The following are the remaining contractual maturities of financial liabilities at the reporting date. The amounts are gross and undiscounted.

As at 31 March 2021	**Carrying amount**	**Contractual cash flow**					
		Total	**0-12 months**	**1-2 years**	**2-3 Years**	**3-5 Years**	**More than 5 Years**
Non - derivative financial liabilities							
Borrowing	1,706.70	1,706.70	1,706.70				
Interest Payable on non-current borrowing	-	-	-				
Lease Liability	132.51	132.51	79.19	36.97	16.35		
Trade payables	8,850.01	8,850.01	8,850.01				
Other current liabilities	3,640.95	3,640.95	3,640.95				
Total	**14,330.17**	**14,330.17**	**14,276.85**	**36.97**	**16.35**	**-**	**-**

As at 31 March 2020	**Carrying amount**	**Contractual cash flow**					
		Total	**0-12 months**	**1-2 years**	**2-3 Years**	**3-5 Years**	**More than 5 Years**
Non - derivative financial liabilities							
Borrowing	3,647.81	3,647.81	3,646.29	1.52	-	-	-
Interest Payable on non-current borrowing	-	0.02	0.02		-	-	-
Lease Liability	213.29	213.29	84.81	79.19	49.30	-	-
Trade payables	6,413.62	6,413.62	6,413.62	-	-	-	-
Other current liabilities	4,196.89	4,196.89	4,196.89	-	-	-	-
Total	**14,471.61**	**14,471.63**	**14,341.63**	**80.71**	**49.30**	**-**	**-**

iii) **Market Risk**

Market risk is the risk that changes in market prices - such as foreign exchange rates, interest rates and equity prices - will affect the Company's income or the value of its holdings of financial instruments. Market risk is attributable to all market risk sensitive financial instruments including foreign currency receivable and payable. We are exposed to market risk primarily related to foreign exchange rate risk as the Comapny's product is exported to variuos countries and a certain portion of its export is sourced thorough import. Thus our exposure to market risk is a function of revenue generating and operating activities in foreign currency. The objective of market risk management is to avoid excessive exposure in our foreign currency revenues and costs. The Company does not use any derivative to manage market risk since certain degree of a natural hedge available in the form of foregin currency realised from exports are paid against imports.

Currency risk

The Company is exposed to currency risk on account of its exoprt and import of pharmaceuticals and import of raw material, capital goods,etc . The functional currency of the Company is Indian Rupee, where as majority of its export and imports are settled through USD($).

Exposure to Currency risk

Following is the currency profile of non-derivative financial assets and financial liabilities

Particulars	**As at March 31, 2021**		**As at March 31, 2020**	
	USD in Lakhs	**₹ in Lakhs**	**USD in Lakhs**	**₹ in Lakhs**
Export Debtors	380.08	27,936.07	303.72	22,896.49
Cash and cash equivalents	43.10	3,167.91	20.01	1,508.53
Total	**423.18**	**31,103.98**	**323.73**	**24,405.02**
Creditors	2.81	206.39	12.89	972.09
Total	**2.81**	**206.39**	**12.89**	**972.09**
Net statement of financial position exposure	**420.38**	**30,897.60**	**310.84**	**23,432.93**

Sensitivity analysis

A reasonable strengthening (weakening) of the Indian Rupee against US dollars as at March 31 would have affected the measurement of financial instruments denominated in US dollars and affected equity and profit or loss by the amount shown below. This analysis assumes that all other variables, in particular interest rates, remain constant and ignores any impact of forecast sales and purchases.

1% appreciation / depreciation of the respective foreign currencies with respect to functional currency of the Company would result in decrease / increase in the profit before taxes by approximately ₹ 308.98 Lakhs for the year ended March 31, 2021 (₹ 234.33 Lakhs for the year ended March 31, 2020)

Interest rate risk

Interest rate risk can be either fair value interest rate risk or cash flow interest rate risk. Fair value interest rate risk is the risk of changes in fair values of fixed interest bearing financial assets or borrowings because of fluctuations in the interest rates, if such assets/ borrowings are measured at fair value through profit or loss. Cash flow interest rate risk is the risk that the future cash flows of floating interest bearing borrowings will fluctuate because of fluctuations in the interest rates.

Exposure to interest rate risk

As on 31 March 2021 and 31 March 2020, the Company has not availed any long term borrowings except for loans on certain vehicles on fixed rate basis. Further, the Company has not availed any fund based working capital lines.

Fair value sensitivity analysis for fixed rate instruments

The Company does not account for any fixed-rate borrowings at fair value through profit or loss. Therefore, change in interest rates at the reporting date would not affect profit or loss.

Commodity rate risk

The Company's operating activity involve purchase of Active Pharmaceutical Ingredients (API) and other direct materials, whose prices are exposed to the risk of fluctuation over short period of time. The commodity price risk exposure is evaluated and managed through procurement and other related operating policies. As on 31 March 2021 and 31 March 2020, the Company had not entered into any material derivative contracts to hedge exposure to fluctuations in commodity prices.

Risk due to outbreak of COVID 19 pandemic

The Company has considered the possible effects that may result from the pandemic relating to COVID-19 on the carrying amounts of receivables, inventories and investments. In developing the assumptions relating to the possible future uncertainities in the global economic conditions because of this pandemic, the Company has used internal and external sources of information and based on the current estimates arrived at using the said assumptions, the Company expects to recover the carrying amount of receivables, inventories and investments. As the outbreak continues to evolve, the company will continue to closely monitor any material changes to future economic conditions.

NOTE 46 : CAPITAL MANAGEMENT

The Company's policy is to maintain a strong capital base so as to maintain investor, creditor and market confidence and to sustain future development of the business. Management monitors the return on the capital as well as the level of dividends to ordinary shareholders.

As on date the Company has no borrowings except for certain vehicle loans.

NOTE 47 : The Company operates in one segment only viz., pharmaceutical formulations.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

(All amounts are in ₹ Lakhs unless otherwise stated)

NOTE 48 : Additional information as required by Paragraph 2 of the General Instructions for the Preparation of Consolidated Financial Statements to Schedule III to the Companies Act, 2013

Name of the Entity	Net Assets, i.e., total assets minus total liabilities				Share in Profit / (Loss)			
	As % of consolidated net assets		Amount ₹ Lakhs		As % of consolidated profit/ Loss		Amount ₹ Lakhs	
	2020-21	2019-20	2020-21	2019-20	2020-21	2019-20	2020-21	2019-20
Parent								
Caplin Point Laboratories Limited	63.05	62.71	75,867.34	59,990.54	62.13	91.89	15,621.98	19,763.85
Subsidiaries								
Indian								
1.Argus Salud Pharma LLP	0.07	0.08	79.78	78.92	0.00	0.01	0.86	2.34
2.Caplin Steriles Limited	24.08	32.46	28,981.51	31,052.35	(9.08)	(11.21)	(2,283.76)	(2,410.67)
Foreign subsidiaries						-		
1.Caplin Point Far East Limited **(Refer Note)**	26.31	19.64	31,663.50	18,782.41	58.60	43.33	14,733.18	9,319.36
2.Caplin Point laboratories Colombia, SAS	0.00	(0.02)	3.59	(15.80)	(0.07)	(0.33)	(17.29)	(71.52)
3. Caplin Point (S) PTE. LTD*	0.02	(0.00)	25.84	(1.13)	(0.02)	(0.02)	(6.20)	(4.89)
Foreign Associate								
1. Hainan Jointown Caplin point Pharmaceuticals Co Ltd	0.14	0.19	173.55	178.13	(0.02)	0.06	(4.58)	12.30
Minority interest in subsidiary	1.46	0.90	1,753.85	865.69				
Total Eliminations / Consolidation Adjustments	(15.14)	(15.97)	(18,212.94)	(15,273.99)	(11.54)	(23.72)	(2,901.17)	(5,102.40)
Total	**100.00**	**100.00**	**1,20,336.01**	**95,657.11**	**100.00**	**100.00**	**25,143.03**	**21,508.37**

Note: Represents details as per consolidated financial statements of Caplin Point Far East Limited which includes the financial statements of its subsidiaries Caplin Point El Salvador, S.A. De C.V., Drogueria Saimed de Honduras S.A (acquired on 30th Sep'2019), Neoethicals CIA.LTDA - Ecuador (acquired on 1st Feb' 2020), Neo Ethicals S.A - Nicaragua (acquired on 22nd Apr' 2019) & Nuevos Eticos Neo Ethicals S.A - Guatemala (acquired on 31st March' 2020).

NOTE 49 : Previous year's figures have been regrouped / reclassified wherever necessary to correspond with the current year's classification / disclosure.

As per our report of even date attached
For **CNGSN & Associates LLP**
Chartered Accountants
Firm Registration No : 4915S/ S200036

For and on behalf of the Board of Directors of Caplin Point Laboratories Limited;
CIN: L24231TN1990PLC019053

B.Ramakrishnan
Partner
ICAI Membership No. 201023

C.C. Paarthipan
Chairman
DIN:01218784

Dr.Sridhar Ganesan
Managing Director
DIN:06819026

Place : Chennai
Date : 6th May, 2021

Muralidharan D
Chief Financial Officer

Dinesh R G
Company Secretary

CAPLIN POINT®
Laboratories

AGM NOTICE

CAPLIN POINT LABORATORIES LIMITED
CIN: L24231TN1990PLC019053
Regd. Office: "Ashvich Towers" 3rd Floor, No.3, Developed Plots Industrial Estates,
Perungudi, Chennai-600 096
PH: 044 2496 8000 | E-mail:info@caplinpoint.net | website: www.caplinpoint.net

NOTICE

NOTICE is hereby given that the 30th Annual General Meeting ("AGM") of the members of Caplin Point Laboratories Limited ("the Company") will be held on Tuesday, September 28, 2021 at 10.00 A.M. through Video Conferencing ("VC") or other Audio Visual Means ("OAVM") to transact the following businesses:

ORDINARY BUSINESS

1. ADOPTION OF FINANCIAL STATEMENTS

To receive, consider and adopt the Audited Standalone and Consolidated Financial Statements of the Company for the Financial Year ended March 31, 2021, together with the Reports of the Board of Directors and the Auditors thereon.

2. DECLARATION OF FINAL DIVIDEND AND RATIFICATION OF INTERIM DIVIDEND

To declare a final dividend of Rs.1.50 (75%) per equity share of Rs. 2/- each and ratify interim dividend of Rs. 1.50 (75%) per equity share of Rs. 2/- each, already paid, aggregating to Rs. 3/- (150%) for the Financial Year ended March 31, 2021.

3. APPOINTMENT OF MR C C PAARTHPAN AS A DIRECTOR LIABLE TO RETIRE BY ROTATION

To appoint a Director in place of Mr. C C Paarthipan (DIN: 01218784), who retires by rotation and being eligible, offers himself for reappointment.

SPECIAL BUSINESS

4. APPROVAL FOR RELATED PARTY TRANSACTIONS

To consider and if thought fit to pass the following resolution as an **Ordinary Resolution**:

"RESOLVED THAT pursuant to Regulation 23(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, approval of members be and is hereby accorded to the Board of Directors of the Company to enter into contracts/ arrangements/ transactions with related party as mentioned in the below table within the meaning of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 on such terms and conditions as the Board may deem fit, for the Financial year 2021-22, provided that the said contract/ arrangements/ transactions shall be so carried out on Arm's length basis and in normal course of business.

Name of the Related Party	Nature of Transactions	Duration	Maximum Value of Transactions p.a.
Nuevos Eticos NeoEthicals S.A-Guatemala	Sale of Goods	01.04.2021 to 31.03.2022	Rs. 250 Crores

RESOLVED FURTHER THAT the Board of Directors be and is hereby authorised to delegate all or any of the powers conferred on it by or under this resolution to any Committee of Directors of the Company and to do all acts and take such steps as may be considered necessary or expedient to give effect to the aforesaid resolution."

5. CAPLIN POINT LABORATORES LIMITED EMPLOYEES STOCK OPTION PLAN, 2021 AND GRANT OF EMPLOYEE STOCK OPTIONS TO THE ELIGIBLE EMPLOYEES

To consider and if thought fit to pass the following resolution as a **Special Resolution**:

"RESOLVED THAT pursuant to the applicable provisions of the Companies Act, 2013, the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 ("SEBI Regulations") (including any statutory modification(s) or re-enactment(s) thereof for the time being in force), and other rules, regulations, circulars and guidelines of any/various statutory/ regulatory authority(ies) that are or may become applicable and subject to any approvals, permissions and sanctions of any/various authority(ies) as may be required and subject to such conditions and modifications as may be prescribed or imposed while granting such approvals, permissions and sanctions which may be agreed to by the Board of Directors of the Company (hereinafter referred to as the ***"Board of Directors"*** which term shall be deemed to include any Committee, including the Nomination and Remuneration Committee, which the Board of Directors has constituted to exercise its powers, including the powers, conferred by this resolution) the approval of the shareholders be and is hereby accorded for the approval of Caplin Point Laboratories Limited Employees Stock Option Plan, 2021 **(Caplin Point ESOP 2021" or 'Plan')** and to authorise the Board of Directors of the Company, to offer, issue, grant and provide Employee Stock Options ("Options") under the Plan, the salient features of which are furnished in the explanatory statement to this notice and to grant such options, to and for benefit of such Person(s) who are:

(i) an employee as designated by the company, who is exclusively working in India or outside India; or

(ii) a director of the company, whether a whole time director or not, including a non-executive director who is not a promoter or member of the promoter group, but excluding an independent director; or

(iii) an employee as defined in sub-clauses (i) or (ii), of a group company including subsidiary or its associate company, in India or outside India, of the company, but does not include:-

(a) an employee who is a promoter or a person belonging to the promoter group; or

(b) a director who, either himself or through his relative or through any body corporate, directly or indirectly, holds more than ten per cent of the outstanding equity shares of the company

and to such other persons as may from time to time be allowed to be eligible for the benefits of the Scheme under applicable laws and regulations prevailing from time to time, (all such persons are hereinafter collectively referred to as "Eligible Employees") at such price or prices, in one or more tranches and on such terms and conditions as may be fixed or determined by the Board of Directors in accordance with the Plan.

RESOLVED FURTHER THAT the maximum number of Options to be granted under the Plan shall not exceed 5,00,000 (Five Lakhs) Options (or such other adjusted figure for any bonus, stock splits or consolidations or other reorganization of the capital structure of the Company as may be applicable from time to time) convertible into 5,00,000 (Five Lakhs) Equity Shares (or such other adjusted figure for any bonus, stock splits or consolidations or other reorganization of the capital structure of the Company as may be applicable from time to time).

RESOLVED FURTHER THAT in case of any corporate action(s) such as rights issues, bonus issues, merger, or sale of division(s) of the Company or other similar events, the Board of Directors and/or the Nomination and Remuneration Committee (as the case may be) be and are hereby authorized to do all such acts, deeds, matters and things as it may deem fit in its absolute discretion and as permitted under applicable laws, so as to ensure that fair and equitable benefits under the ESOP 2021 are passed on to the Eligible Employees.

RESOLVED FURTHER THAT the Plan shall be administered by the Nomination and Remuneration Committee of the Company who shall have all necessary powers as defined in the Plan and is hereby designated as Compensation Committee in pursuance of the SEBI Regulations for the purpose of administration and superintendence of the Plan.

RESOLVED FURTHER THAT the Plan shall be implemented through direct route for extending the benefits to the eligible Employees by the way of fresh allotment and will follow cash mechanism.

RESOLVED FURTHER THAT the new Equity Shares to be issued and allotted by the Company shall rank pari passu in all respects with the then existing Equity Shares of the Company.

RESOLVED FURTHER THAT the Company shall conform to the applicable Accounting Policies, Guidelines or Accounting Standards as may be applicable from time to time, including the disclosure requirements prescribed therein.

RESOLVED FURTHER THAT the Board of Directors be and is hereby authorized to make any modification(s), change(s), variation(s), alteration(s) or revision(s) in the terms and conditions of the Plan from time to time including, but not limited to, amendment(s) with respect to vesting period and schedule, exercise price, exercise period, eligibility criteria or to suspend, withdraw, terminate or revise the Plan.

RESOLVED FURTHER THAT the Board of Directors and/or the Nomination and Remuneration Committee (as the case may be) be and are hereby authorized to take necessary steps for listing of the equity shares allotted under the Plan on the stock exchanges as per the provisions of applicable laws and any listing-related requirements of the stock exchanges concerned.

RESOLVED FURTHER THAT in case the Equity Shares of the Company are either sub-divided or consolidated, then the number of Shares to be allotted and the exercise price payable by the Employees under the Plan shall automatically stand reduced or augmented, as the case may be, in the same proportion as the present face value of Rs. 2/- per Equity Share shall bear to the revised face value of the Equity Shares of the Company after such sub-division or consolidation, without affecting any other rights or obligations of the said allottees.

RESOLVED FURTHER THAT the Board of Directors be and are hereby authorized to do all such acts, deeds, and things, as it may, in its absolute discretion deem necessary including but not limited to appoint Advisors, Merchant Bankers, Consultants or Representatives, being incidental for the effective implementation and administration of the Plan and to make applications to the appropriate Authorities, for their requisite approvals and take all necessary actions and to settle all such questions, difficulties or doubts whatsoever that may arise while implementing this resolution."

6. **EXTENSION OF CAPLIN POINT LABORATORIES LIMITED EMPLOYEES STOCK OPTION PLAN, 2021 TO THE ELIGIBLE EMPLOYEES OF THE GROUP COMPANY, SUBSIDIARIES INCLUDING STEP-DOWN SUBSIDIARIES AND ASSOCIATES OF THE COMPANY.**

To consider and if thought fit to pass the following resolution as a **Special Resolution**:

"RESOLVED THAT pursuant to the applicable provisions of the Companies Act, 2013 read with the rules framed thereunder, the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 ("SEBI Regulations"), the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the circulars/ guidelines issued by SEBI, the Memorandum and Articles of Association of the Company and all other applicable regulations, rules and circulars/guidelines in force, from time to time (including any statutory modification or re-enactment thereof for the time being in force), approval of the members of the Company be and is hereby accorded to extend the benefits of the Caplin Point Laboratories Limited Employees Stock Option Plan, 2021 ("Plan") as referred to in resolution no. 5 of this Notice to the eligible employees of the group companies, subsidiaries including step-down subsidiaries and associates of the Company whether established in India or outside India. *(as specified in the Plan)*"

RESOLVED FURTHER THAT the new Equity Shares to be issued and allotted by the Company shall rank pari passu in all respects with the then existing Equity Shares of the Company.

RESOLVED FURTHER THAT the Company shall conform to the applicable Accounting Policies, Guidelines or Accounting Standards as may be applicable from time to time, including the disclosure requirements prescribed therein.

RESOLVED FURTHER THAT the Board of Directors be and are hereby authorized to do all such acts, deeds, and things, as it may, in its absolute discretion deem necessary that may arise while implementing this resolution."

By order of the Board
Dinesh R G
Company Secretary

Place: Chennai
Date: August 23, 2021

Registered Office:
"Ashvich Towers" 3rd Floor,
No.3, Developed Plots Industrial Estates,
Perungudi,Chennai -600 096
CIN : L24231TN1990PLC019053

NOTES:

1. The statement pursuant to Section 102(1) of the Companies Act, 2013 (Act, 2013) setting out material facts regarding the items of special businesses specified above is annexed hereto.

2. In view of the situation arising due to COVID-19, Ministry of Corporate Affairs ("MCA") vide its Circular No. 20/2020 dated May 05, 2020 w.r.t. clarification on holding of Annual General Meeting ("AGM") through video conferencing ("VC")or other audio visual means ("OAVM") read with Circular No.14/2020 dated April 08, 2020, Circular No.17/2020 dated April13, 2020 Circular No. 20/2020 dated May 5, 2020 and Circular No. 02/2021 dated January 13, 2021 (collectively referred to as "MCA Circulars") and Securities and Exchange Board of India vide its Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/79 dated May 12, 2020 and SEBI/HO/CFD/ CMD2/CIR/P/2021/11 dated January 15 2021 ("SEBI Circulars"), has permitted the holding of the AGM through video conferencing ("VC") or other audio visual means ("OAVM") and dispensed personal presence of the Members at the common venue during AGM. In compliance with the provisions of the Act, 2013, SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), MCA Circulars and SEBI Circular, the AGM of the Company shall thus be held through VC/ OAVM. Hence, the Members can attend and participate in the ensuing AGM through VC/OAVM. The deemed venue for 30th AGM shall be the Registered Office of the Company.

3. Pursuant to the aforesaid Circulars, the facility to appoint proxy by Members under Section 105 of the Act, 2013 to attend and cast vote for the Members is not available for this AGM as the physical attendance of Members has been dispensed with. However, Body Corporates / Institutional shareholders (i.e. other than Individuals, HUF, NRI etc.) are entitled to appoint authorised representatives for the purpose of voting through remote e-voting and participation in the AGM through VC/OAVM and cast their votes through e-voting during the AGM.

4. The Register of Members and Share Transfer Books of the Company will be closed from September 22,2021 to September 28, 2021 (both days inclusive) for the purpose of AGM and final dividend.

5. The final dividend as recommended by the Board of Directors, if declared at the AGM, will be paid on or before October 23, 2021 to those members, whose names appear in the Register of Members on September 21, 2021 and in respect of shares held in dematerialized form, dividend will be paid to members whose names are furnished by National Securities Depository Limited and Central Depository Services (India) Limited as beneficial owners as on that date.

6. Members holding shares in physical forms are requested to notify and change in their address to the Company / Share Transfer Agents quoting Register Folio number. Members holding shares in electronic form are requested to intimate any change in their address or bank mandates to their respective Depository Participants. Members are encouraged to utilize the Electronic Clearing System (ECS) for receiving dividend.

7. The Securities and Exchange Board of India (SEBI) has mandated the submission of Permanent Account Number (PAN) by every participant in securities market. Members holding shares in electronic form are, therefore, requested to submit their PAN to their Depository Participants with whom they are maintaining their demat accounts. Members holding shares in physical form can submit their PAN to the Company / Integrated Registry Management Services Private Limited.

8. Members holding shares in physical form and desirous of making a nomination in respect of their shareholding in the Company as permitted under Section 72 of the Act, 2013 read with Rules made there under are requested to send the prescribed Form SH.13 to M/s. Integrated Registry Management Services Private Limited. The Form SH.13 for the purpose would be available for download on the Company's website www.caplinpoint.net under the section 'Investor'.

9. Members wishing to claim dividends, which remain unclaimed, are requested to correspond with Company Secretary at the Company's Registered Office or the Registrar and Share Transfer Agents, Integrated Registry Management Services Private Limited. Members are requested to note that dividends not encashed or claimed within seven years from the date of transfer to the Company's Unpaid Dividend Account, will, as per Section 124(5) of the Act, 2013 be transferred to the Investor Education and Protection Fund.

10. The Board has appointed G Ramachandran & Associates, (FCS 9687 CoP 3056) Practicing Company Secretaries as the scrutinizers for conducting the e-voting in a fair and transparent manner. The scrutinizers will submit the report to the Chairman of the Company or to any person authorized by the Chairman after completing the scrutiny of the e-voting (votes cast during the AGM and votes cast through remote e-voting), not later than two working days from

the conclusion of the AGM. The results declared along with the Scrutinizer's report shall be communicated to the Stock Exchanges, NSDL, and RTA and also be displayed on the Company's website www.caplinpoint.net.

11. In compliance with the provisions of Section 108 of the Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 as amended from time to time, and pursuant to Regulation 44 of the Listing Regulations, the Company is pleased to offer e-voting facility to its Members to exercise their right to vote at the 30th AGM by electronic means in respect of the businesses to be transacted at the AGM, through the remote e-Voting platform provided by National Securities Depository Limited (NSDL).

12. In view of the situation arising due to COVID-19, owing to difficulties involved in printing and dispatching of physical copies of Annual Report for Financial Year 2020-21 & Notice of 30th AGM and pursuant to MCA and SEBI Circulars, the Annual Report for Financial Year 2020-21 along with the Notice of the 30th AGM is being sent to the Members of the Company only by email. Further, the Members holding shares in physical form or other Members who have not registered their email address with the Company can get the same registered by approaching the Registrar and Transfer Agents, (RTA) Integrated Registry Management Services Private Limited, II Floor, "Kences Towers", No.1 Ramakrishna Street, North Usman Road, T Nagar, Chennai - 600 017, Phone: 044 - 28140801 – 803, e-mail: corpserv@integratedindia.in.

13. Members holding shares in demat form are requested to update their email address with their Depository Participants. Annual Report for the Financial Year 2020-21 will be available on Company's website for download and the Notices and Annual Report can be accessed from Stock Exchange websites (i.e) BSE Limited and National Stock Exchange of India Limited at www.bseindia.com. and www.nseindia.com.

14. The attendance of the members attending the AGM through VC/OAVM will be counted for the purpose of ascertaining the quorum under Section 103 of the Act, 2013.

15. The Members can join the AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the AGM by following the procedure mentioned in this Notice. The facility of participation at the AGM through VC/OAVM will be made available atleast to 1000 members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders' Relationship Committee, Auditors etc. who are allowed to attend the AGM without restriction on account of first come first served basis.

16. The Register of Directors and Key Managerial Personnel and their shareholding, maintained under Section 170 of the Act, 2013, will be available electronically for inspection by the members at the AGM.

17. Pursuant to Finance Act, 2020, dividend income will be taxable in the hands of the shareholders w.e.f. April 1, 2020 and the Company is required to deduct tax at source ("TDS") from dividend paid to the Members at rates prescribed in the Income Tax Act, 1961 ("the IT Act"). In general, to enable compliance with TDS requirements, Members are requested to complete and / or update their Residential Status, PAN, Category as per the IT Act with their Depository Participants or in case shares are held in physical form, with the Company by sending email corpserv@integratedindia.in.

VOTING THROUGH ELECTRONIC MEANS

I. In Compliance with provisions of Section 108 of the Act, 2013 and Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended by the Companies (Management and Administration) Amendment Rules, 2015 and Regulation 44 of Listing Regulations the Company is pleased to provide members facility to exercise their right to vote at the 30th AGM of the Company by electronic means and the business may be transacted through e-Voting Services to Members holding shares as on September 21 2021 being the "Cut-off Date"("CutOff" for the purpose of Rule 20(4)(vii) of the Rules) fixed for determining voting rights of Members entitled to participate in the remote e-Voting process through the platform provided by NSDL viz., www.evoting.nsdl.com.

II. The remote e-voting period commences on Saturday, September 25,2021 at 9.00 A.M. (IST) and ends on Monday, September 27, 2021 at 5.00 P.M. (IST). During this period members of the Company, holding the shares either in physical from or in dematerialised form, may cast their vote by remote e-voting. The remote e-voting module shall be disabled by NSDL for voting thereafter. Members who have not cast their vote on any of the resolutions using the remote e-Voting facility can vote on those resolutions during the AGM. Once the vote on a resolution is cast by the Member, the Member shall not be allowed to change it subsequently.

How do I vote electronically using NSDL e-Voting system?

The way to vote electronically on NSDL e-Voting system consists of "Two Steps" which are mentioned below:

Step 1: Access to NSDL e-Voting system

A) Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode

In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Login method for Individual shareholders holding securities in demat mode is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in demat mode with NSDL.	1. Existing **IDeAS** user can visit the e-Services website of NSDL Viz. https://eservices.nsdl.com either on a Personal Computer or on a mobile. On the e-Services home page click on the "**Beneficial Owner"** icon under **"Login"** which is available under **'IDeAS'** section, this will prompt you to enter your existing User ID and Password. After successful authentication, you will be able to see e-Voting services under Value added services. Click on **"Access to e-Voting"** under e-Voting services and you will be able to see e-Voting page. Click on company name or **e-Voting service provider i.e. NSDL** and you will be re-directed to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 2. If you are not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select **"Register Online for IDeAS Portal"** or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp 3. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or **e-Voting service provider i.e. NSDL** and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

Type of shareholders	Login Method
Individual Shareholders holding securities in demat mode with CDSL	1. Existing users who have opted for Easi / Easiest, they can login through their user id and password. Option will be made available to reach e-Voting page without any further authentication. The URL for users to login to Easi / Easiest are https://web.cdslindia.com/myeasi/home/login or www.cdslindia.com and click on New System Myeasi. 2. After successful login of Easi/Easiest the user will be also able to see the E Voting Menu. The Menu will have links of **e-Voting service provider i.e. NSDL.** Click on **NSDL** to cast your vote. 3. If the user is not registered for Easi/Easiest, option to register is available at https://web.cdslindia.com/myeasi/Registration/EasiRegistration 4. Alternatively, the user can directly access e-Voting page by providing demat Account Number and PAN No. from a link in www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the demat Account. After successful authentication, user will be provided links for the respective ESP i.e. **NSDL** where the e-Voting is in progress.
Individual Shareholders (holding securities in demat mode) login through their depository participants	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. upon logging in, you will be able to see e-Voting option. Click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.

Login type	Helpdesk details
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at toll free no.: 1800 1020 990 and 1800 22 44 30
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at 022- 23058738 or 022-23058542-43

B) Login Method for e-Voting and joining virtual meeting for shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode.

How to Log-in to NSDL e-Voting website?

Step 2: Cast your vote electronically and join General Meeting on NSDL e-Voting system.

How to cast your vote electronically and join General Meeting on NSDL e-Voting system?

1. After successful login at Step 1, you will be able to see all the companies "EVEN" in which you are holding shares and whose voting cycle and General Meeting is in active status.

2. Select "EVEN" of Caplin Point Laboratories Limited for which you wish to cast your vote during the remote e-Voting period and casting your vote during the General Meeting. For joining virtual meeting, you need to click on "VC/OAVM" link placed under "Join General Meeting".

3. Now you are ready for e-Voting as the Voting page opens.

4. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on "Submit" and also "Confirm" when prompted.

5. Upon confirmation, the message "Vote cast successfully" will be displayed.

6. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.

7. Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

General Guidelines for shareholders

1. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail ramgcs@gmail.com with a copy marked to evoting@nsdl.co.in.

2. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the "Forgot User Details/Password?" or "Physical User Reset Password?" option available on www.evoting.nsdl.com to reset the password.

3. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on toll free no.: 1800 1020 990 and 1800 22 44 30 or send a request to Ms. Pallavi Mhatre, Manager at evoting@nsdl.co.in

Process for those shareholders whose email ids are not registered with the depositories for procuring user id and password and registration of e mail ids for e-voting for the resolutions set out in this notice:

1. In case shares are held in physical mode please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by email to corpserv@integratedindia.in.

2. In case shares are held in demat mode, please provide DPID-CLID (16 digit DPID + CLID or 16 digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) to corpserv@integratedindia.in.

3. If you are an Individual shareholders holding securities in demat mode, you are requested to refer to the login method explained at step 1 (A) i.e. Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode.

4. Alternatively members may send a request to evoting@nsdl.co.in for procuring user id and password for e-voting by providing above mentioned documents.

5. In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are required to update their mobile number and email ID correctly in their demat account in order to access e-Voting facility.

THE INSTRUCTIONS FOR MEMBERS FOR e-VOTING ON THE DAY OF THE AGM ARE AS UNDER:-

1. The procedure for e-Voting on the day of the AGM is same as the instructions mentioned above for remote e-voting.

2. Only those Members/ shareholders, who will be present in the AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system in the EGM/AGM.

3. Members who have voted through Remote e-Voting will be eligible to attend the EGM/AGM. However, they will not be eligible to vote at the AGM.

4. The details of the person who may be contacted for any grievances connected with the facility for e-Voting on the day of the AGM shall be the same person mentioned for Remote e-voting.

INSTRUCTIONS FOR MEMBERS FOR ATTENDING THE AGM THROUGH VC/OAVM ARE AS UNDER:

1. Members will be provided with a facility to attend the AGM through VC/OAVM through the NSDL e-Voting system. Members may access by following the steps mentioned above for Access to NSDL e-Voting system. After successful login, you can see link of "VC/OAVM link" placed under "Join General meeting" menu against company name. You are requested to click on VC/OAVM link placed under Join General Meeting menu. The link for VC/OAVM will be available in Shareholder/ Member login where the EVEN of Company will be displayed. Please note that the members who do not have the User ID and Password for e-Voting or have forgotten the User ID and Password may retrieve the same by following the remote e-Voting instructions mentioned in the notice to avoid last minute rush.
2. Members are encouraged to join the Meeting through Laptops for better experience.
3. Further Members will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
4. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
5. Shareholders who would like to express their views/have questions may send their questions in advance mentioning their name, demat account number/folio number, email id, mobile number at compliance.officer@caplinpoint.net from September 22 2021 (9.00 A.M. (IST)) to September 25 2021 (5.00 P.M. (IST)). The same will be replied by the company suitably.
6. Those shareholders who have registered themselves as a speaker will only be allowed to express their views/ask questions during the meeting. The Company reserves the right to restrict the number of speakers depending on the availability of time for the AGM.

   Brief resume, details of Directors shareholding and Directors inter-se relationship of Directors seeking appointment and reappointment as required under Regulation 36 (3) of Listing Regulations and Secretarial Standards on General Meetings are provided as Annexure to this Notice.

EXPLANATORY STATEMENT PURSUANT TO SECTION 102(1) OF THE ACT, 2013

The following Statement sets out all material facts relating to Special Business mentioned in the accompanying Notice.

ITEM NO.4

Pursuant to Regulation 23 (4) of Listing Regulations provide that all material Related Party Transaction will require prior approval of shareholders through ordinary resolution, if the aggregate value of transaction(s) amounts to or exceeds 10 % of the Annual consolidated turnover of the listed entity as per the last audited financial statements of listed entity. The transactions to be entered with related parties as set out in the resolutions are within the ambit of Regulation 23(4) of Listing Regulations.

Accordingly, approval of the shareholders of the Company is sought for the proposed material related party transactions to be entered with Caplin Point Laboratories Limited for the Financial Year 2021-22.

The particulars of the transaction(s) with related parties as set out in the resolution are as follows:

Particulars	Remarks
Name of the Related Party	Nuevos Eticos NeoEthicals S.A-Guatemala
Name of the Director or Key Managerial Personnel who is related	None of the Directors of the Company is related
Nature of Relationship	Step Down Subsidiary
Nature, material terms, monetary value and particulars of the contract or arrangement	Sale of goods for an aggregate value of Rs. 250 crores for the Financial Year 2021-22 2021-22
Any other information relevant or important for the members to take a decision on the proposed resolution	Transactions to be done at arm's length basis and in normal course of business.

None of the Directors and Key Managerial Personnel of the Company or their respective relatives are concerned or interested, financially or otherwise, in the above resolution.

The Board of Directors, therefore, recommend this ordinary resolution as set out in Item No.4 of this notice for the approval of members.

ITEM NOS.5 & 6

Employee Stock Option Plans (ESOPs) are considered as an effective tool to attract and retain the best talent in the Industry. ESOPs inter alia serves to attract, motivate, reward and retain specialists / senior professionals, recognize and reward exceptional performance and facilitate continued building of co-created organization. The Company has instituted "Caplin Point Employee Stock Option Plan – 2015" and "Caplin Point Employee Stock Option Plan – 2017" pursuant to the Special Resolutions approved by the members at the 24th Annual General Meeting held on November 05, 2015 and at the 26th AGM held on September 21, 2017 respectively.

In order to continue to attract and retain better talents, it is proposed to roll out a new Employee Stock Option scheme to eligible employees of the Company, its Group Company(ies), Associate Company(ies) and Subsidiary Company(ies) including Step-Down Subsidiary Company(ies) . The main objective will be to retain and reward employees by providing opportunity to such of those employees to participate in the growth of the Company through owning equity shares.

Accordingly the Board of Directors of the Company on August 23, 2021 approved introduction of Caplin Point Laboratories Limited Employees Stock Option Plan, 20211 ("Plan"), subject to the approval of the shareholders and in terms of the provisions of the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 **("SEBI Regulations")** as amended from time to time. the Board also, inter-alia authorized the Nomination & Remuneration Committee to formulate the detailed terms and conditions of the Plan and to administer and implement the Plan in accordance with the provisions of the SEBI Regulations.

The information as required under Regulation 6(2) of the SEBI Regulations, setting out the salient features of ESOP 2021 and further explaining the proposal is given below:

1	Brief Description of the Plan	The Plan shall be called the Caplin Point Laboratories Limited Employees Stock Option Plan, 2021. The main objective of the Plan will be to attract, retain and reward employees by providing opportunity to participate in the growth of the Company through owning equity shares.
2	Total Number of Options to be granted	The maximum number of Options that may be granted pursuant to this Plan shall not exceed 5,00,000 (Five Lakhs) Options which shall be convertible into equal number of Equity Shares. Further, the maximum number of Options that can be granted and the Shares arise upon exercise of these Options shall stand adjusted in case of corporate action (as defined in the Plan).
3	Identification of Classes of Employees entitled to participate and be beneficiaries in the scheme	(i) an employee as designated by the company, who is exclusively working in India or outside India; or (ii) a director of the company, whether a whole time director or not, including a non-executive director who is not a promoter or member of the promoter group, but excluding an independent director; or (iii) an employee as defined in sub-clauses (i) or (ii), of a group company including subsidiary or its associate company, in India or outside India, of the company, but does not include:- (a) an employee who is a promoter or a person belonging to the promoter group; or (b) a director who, either himself or through his relative or through any body corporate, directly or indirectly, holds more than ten per cent of the outstanding equity shares of the company

4	Requirements of vesting and period of vesting	The Options granted shall vest so long as an employee continues to be in the employment of the Company or the group companies, subsidiaries including step-down subsidiaries and associates as the case may be. The options granted under the Scheme shall vest in 3 equal tranches commencing from completion of 5th year from the date of grant of options, unless otherwise specified by the ESOP Committee (i.e. Nomination and Remuneration Committee). In any event, the vesting period shall not be less than 1 year and not more than 8 years from the date of grant of options. Vesting may happen in one or more tranches. The Vesting schedule as decided will be stipulated in the Option letter to be issued to Individual Grantees. The ESOP Committee shall be entitled to make the Vesting of any or all of the Options granted to an Eligible Employee conditional upon the fulfillment of such performance criteria whether of the Eligible Employee and/ or any team or group of which he is a part and/ or of the Company, as may be determined by the ESOP Committee or determine a Vesting schedule
5	Maximum period (subject to regulation 18(1) and 24(1) of the regulations, as the case may be) within which the options shall be vested	All the options granted on any date shall vest not later than 8 years from the date of grant of options
6	Exercise Price or Pricing Formula	The Options granted to the Employees under this Plan shall carry an Exercise Price, which shall be at a discount to the Market Price, if and as may be determined by the ESOP Committee. However, the Exercise Price shall not be less than the par value of the Equity Shares of the Company. For the above purpose Market Price means the latest available closing price on a recognized stock exchange on which the shares of the company are listed on the date immediately prior to the Relevant Date. If such shares are listed on more than one recognized stock exchange, then the closing price on the recognized stock exchange having higher trading volume shall be considered as the market price. "Relevant date" means a) in the case of grant, the date of meeting of the Nomination and Remuneration committee on which the grant is made or b) in the case of exercise, the date on which the notice of exercise is given to the Company by the Employee.
7	Exercise Period and Process of Exercise	All Vested Options shall be respectively exercised in one or more tranches within a period of 7 years from the respective dates of Vesting, failing which the Options shall lapse. The Employee may Exercise the Options by submitting a written application to the Company expressing his/her desire to exercise such Options in such manner and on such format as may be prescribed by the ESOP Committee from time to time, accompanied by payment of an amount equivalent to the Exercise Price in respect of such Shares and such other writing, if any, as the ESOP Committee may specify to confirm extinguishment of the rights comprising in the Options then exercised.

8	Appraisal process for determining the eligibility of employees for the Plan	The ESOP Committee may on the basis of all or any of the following criteria, decide on the Employees who are eligible for the grant of Options under the Plan and the terms and conditions thereof. i Work related or academic performance of the employee. ii Length of service / Position Held. iii Potential of the employee to contribute to the Company's / group companies, subsidiaries including step-down subsidiaries and associates performance. iv The extent of contribution made by the employee towards business results, achievement of medium to long term performance plans and processes, and customer satisfaction or Employee satisfaction. vi High market value /difficulty in replacement. vii High risk of losing the employee to competition.
9	Maximum number of options to be issued per employee and in aggregate and the maximum quantum of benefits to be provided per employee under the Plan	The maximum number of Options that may be granted pursuant to this Plan shall not exceed 5,00,000 (Five Lakhs) Options which shall be convertible into equal number of Equity Shares. The maximum number of Options that may be granted to one eligible Employee shall not be more than 25,000 options.
10	Maximum quantum of benefits to be provided per employee under Plan	The maximum quantum of benefits that will be provided to every eligible Employee under the Plan will be the difference between the market value of Company's Share on the Recognized Stock Exchanges as on the date of Exercise of Options and the exercise price paid by the Employee.
11	Whether the Plan is to be implemented and administered directly by the company or through a trust	The Plan shall be implemented through direct route for extending the benefits to the eligible Employees by the way of fresh allotment and will follow cash mechanism. The Scheme will be administered by the Nomination and Remuneration Committee of the Company.
12	Whether the Plan involves new issue of shares by the company or secondary acquisition by the trust or both	The Plan involves new issue of shares of the Company
13	The amount of loan to be provided for implementation of the Plan by the Company to the Trust, its tenure, utilization, repayment terms, etc.	Not applicable, since the Plan is proposed to be implemented by direct route.
14	The Maximum percentage of secondary acquisition (subject to limits specified under the regulations) that can be made by the Trust for the purposes of the Plan.	Not applicable, since the Plan is proposed to be implemented by direct route.
15	Confirmation with accounting policies	The Company shall comply with the disclosures requirements and the accounting policies prescribed under the SEBI Regulations, or any other policy(es) that may be prescribed under law with respect to accounting for stock options.

16	The method which the company shall use to value its options.	The Company shall adopt 'fair value method' for valuation of options as prescribed under guidance note or under any accounting standard, as applicable, notified by appropriate authorities from time to time.
17	Statement with regard to Disclosure in Director's Report.	As the company is adopting fair value method, presently there is no requirement for disclosure in Director's report. However, if in future, the Company opts for expensing of share based employee benefits using the intrinsic value, then the difference between the employee compensation cost so computed and the employee compensation cost that shall have been recognized if it had used the fair value, shall be disclosed in the Directors' report and the impact of this difference on profits and on earnings per share ("EPS") of the company shall also be disclosed in the Directors; report.
18	Period of lock in.	The Shares so allotted to the Employees pursuant to exercise of Options will not be subject to a lock-in period and can be freely sold by the Employee thereafter.
19	Terms & conditions for buyback, if any, of specified securities covered under these regulations.	The Board of Directors / ESOP Committee will specify the procedure for buy-back of Options granted, if to be undertaken at any time by the company, and the applicable terms and conditions, including: (i) permissible sources of financing for such buy-back; (ii) minimum financial thresholds to be maintained by the company as per its last financial statements; and (iii) quantum of options that the company may buy-back in a Financial Years.
20	Other disclosures.	The Plan does not involve acquisition of shares from the Secondary Market and no loan is proposed to be provided by the Company.

Separate special resolution is required to be passed by the members if the benefits of Plan as set out in the Resolution No. 5 of this Notice is extended to the employees of the group company, subsidiaries including step-down subsidiaries and associates.

Accordingly, separate special resolution seeking the approval of the members for extending the benefits of Plan to the employees of group company, subsidiaries, including step-down subsidiaries and associates is placed before the members.

None of the Directors and Key Managerial Personnel of the Company or their respective relatives are concerned or interested, financially or otherwise, in the above resolutions.

The Board of Directors recommends the resolutions set out in Item Nos. 5 & 6 of the Notice for the approval of the members by means of special resolutions.

Caplin Point Laboratories Limited Employees Stock Option Plan, 2021 and other documents referred to in the aforesaid resolutions are available for inspection electronically.

By order of the Board
Dinesh R G
Company Secretary

Place: Chennai
Date: August 23, 2021

Registered Office:
"Ashvich Towers" 3rd Floor,
No.3, Developed Plots Industrial Estates,
Perungudi,Chennai -600 096
CIN : L24231TN1990PLC019053

ANNEXURE TO THE NOTICE

Details of Director seeking re-appointment at the ensuing AGM pursuant to Regulation 36 (3) of the Listing Regulations and Secretarial Standards on General Meetings issued by the Institute of Company Secretaries of India.

Name of the Director	Mr. C C Paarthipan
DIN	01218784
Date of Birth	02.08.1952
Date of Appointment on the Board	01.10.1993
Qualifications	B.A.
Expertise in Specific Functional Area	• Mr. C C Paarthipan is the Chairman of Caplin Point Laboratories Limited and has been in the Board since the Company's inception. • He has about three decades of rich experience in the Pharmaceutical Industry. • A good business acumen with exceptional abilities in identifying and exploring business opportunities both in domestic and global markets. • He has been the guiding force of the Company in achieving business targets/ enduring goals.
Number of shares held in the Company	1,41,67,192
List of Directorship or other position held in other Listed Companies	NIL
Chairman/member in the committees of the boards of other listed companies in which he is a Director	Chairman: NIL Member : NIL
Relationships, if any, with other Directors and KMP	None

Notes

Corporate Information

BOARD OF DIRECTORS

Mr. C C Paarthipan, Chairman
Dr. Sridhar Ganesan, Managing Director
Mr. D P Mishra, Director

INDEPENDENT DIRECTORS

Mr. V Thirumalai
Mr. R Viswanathan
Dr. K C John
Mr. D Sathyanarayanan
Dr. C K Gariyali
Dr. R Ravichandran*

CHIEF FINANCIAL OFFICER

Mr. D Muralidharan

COMPANY SECRETARY

Mr. R G Dinesh

STATUTORY AUDITORS

M/s. CNGSN & Associates LLP
Chartered Accountants, Chennai

BANKERS

The CSB Bank Ltd.
Axis Bank Ltd.

REGISTERED & CORPORATE OFFICE

3rd Floor, "Ashvich Towers", No.3, Developed Plots Industrial Estate, Perungudi, Chennai - 600 096.

FACTORIES

UNIT I
85/3, Suthukeny Village, Mannadipet Commune Panchayat, Puducherry - 605 502.

UNIT II
No. 19, Chinnapuliyur Village, Sirupuzhalpettai (Post), Gummidipoondi Taluk, Tamil Nadu – 601 201.

UNIT IV (Caplin Steriles Ltd.)
Survey No.895 & 897, Guruvarajakandigai, Sirupuzhalpettai (post), Gummudipoondi Taluk, Thiruvallur - 601201

R&D

UNIT III
Plot No.44,8th Avenue Domestic Tariff Area, Mahindra World City, Chengalpattu Taluk, Chengalpattu - 603 004

UNIT V (Caplin Steriles Ltd.)
AshvichTower, 2nd Floor, No 3 Developed Plots Industrial Estate, Perungudi, Chennai - 600096

UNIT VI
4th Floor, Plot No. 95 & 96, Road no.9, ALEAP Industrial Estates, Gajularamarm Village, Qutbullapur Mandal, Hyderabad - 500 090.

UNIT VII
Module no.307 & 308, 3rd Floor, Ticel Park, Phase II, CSIR Road, Taramani, Chennai - 600 113.

UNIT VIII
Ashvich Towers, No. 3, Developed Plots, Industrial Estates, Perungudi, Chennai – 600 096

STOCK EXCHANGES WHERE SHARES OF THE COMPANY ARE LISTED

National Stock Exchange of India Limited (NSE)
BSE Limited (BSE)

REGISTRAR AND TRANSFER AGENT

M/s. Integrated Registry Management Services Private Limited
Unit: Caplin Point Laboratories Ltd.
IInd Floor, "Kences Towers"No.1
Ramakrishna Street, North Usman Road, T Nagar, Chennai - 600 017.

Phone: 044 2814 0801 - 803
Fax: 044 2814 2479
E-mail: csdstd@integratedindia.in

WEBSITE & E-MAIL

www.caplinpoint.net
investor@caplinpoint.net
info@caplinpoint.net

CORPORATE IDENTIFICATION NUMBER (CIN)

L24231TN1990PLC019053

*Retired as a director w.e.f. May 11, 2021

Pitchcraft communications info@pitchcraft.in

CAPLIN POINT® Laboratories

CAPLIN POINT LABORATORIES LIMITED
CIN: L24231TN1990PLC019053
Regd. Office: “Ashvich Towers” 3rd Floor, No.3, Developed Plots Industrial Estates,
Perungudi, Chennai-600 096
PH: 044 2496 8000 | E-mail:info@caplinpoint.net | website: www.caplinpoint.net